<SEC-DOCUMENT>0001513162-20-000185.txt : 20200831
<SEC-HEADER>0001513162-20-000185.hdr.sgml : 20200831
<ACCEPTANCE-DATETIME>20200831170335
ACCESSION NUMBER:		0001513162-20-000185
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20200531
FILED AS OF DATE:		20200831
DATE AS OF CHANGE:		20200831

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		201152240

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<head><title>Form 10-K</title> </head> <body bgcolor=white lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><br>&nbsp;<b><font style=COLOR:black>SECURITIES AND EXCHANGE COMMISSION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style=COLOR:black>WASHINGTON, D.C. 20549</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">FORM 10-K</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">[X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">For The Fiscal Year Ended May 31, 2020 </font></b><font style="FONT-SIZE:10pt; COLOR:black">or</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">[ ] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">For The Transition Period From ______ To ______</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">Commission File Number: 001-37863</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><u><font style="FONT-SIZE:14pt; COLOR:black">BIOMERICA, INC.</font></u></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">(Exact Name of registrant as specified in its charter)</font>&nbsp;&nbsp; </p> <div align=center> <table width=800 bordercolor=transparent style=WIDTH:600pt cellpadding=0> <tr style=HEIGHT:51.75pt> <td width=49% style="HEIGHT:51.75pt; WIDTH:49.62%; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">Delaware</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">(State or other jurisdiction of</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Incorporation of organization)</font></p></td> <td width=49% style="HEIGHT:51.75pt; WIDTH:49.62%; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt 1.5pt; TEXT-INDENT:-1.5pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">95-2645573</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt 1.5pt; TEXT-INDENT:-1.5pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">(I.R.S. Employer <br>Identification No.)</font></p></td></tr> <tr style=HEIGHT:28.25pt> <td width=49% style="HEIGHT:28.25pt; WIDTH:49.62%; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN-LEFT:0in; MARGIN-RIGHT:0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">17571 Von Karman Avenue, Irvine, CA</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">(Address of principal executive offices)</font></p></td> <td width=49% style="HEIGHT:28.25pt; WIDTH:49.62%; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN-LEFT:0in; MARGIN-RIGHT:0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt 1.5pt; TEXT-INDENT:-1.5pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">92614</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt 1.5pt; TEXT-INDENT:-1.5pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">(Zip Code)</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> </p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">REGISTRANT'S TELEPHONE NUMBER:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">(<b>949) 645-2111</b></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Securities registered under Section 12(b) of the Exchange Act:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">None</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Securities registered under Section 12(g) of the Exchange Act:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><u><font style="FONT-SIZE:10pt; COLOR:black">(Title of each class)</font></u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">COMMON STOCK, PAR VALUE $0.08</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><u><font style="FONT-SIZE:10pt; COLOR:black">(Name of each exchange on which registered)</font></u></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-FAMILY:"Times New Roman","serif"'>NASDAQ Capital Market</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-FAMILY:"Times New Roman","serif"'>(Trading symbol)</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-FAMILY:"Times New Roman","serif"'>BMRA</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act &nbsp;&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Yes [ &nbsp;&nbsp;]&nbsp; No [X]</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Act. &nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Yes [X] &nbsp;No [ &nbsp;]</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Note - Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange Act from their obligations under those Sections.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Indicate by check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Yes [X]&nbsp; No [ ]</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation (paragraph 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Yes [X]&nbsp; No [ &nbsp;]</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;<font style="FONT-SIZE:10pt; COLOR:black">Indicate by check mark whether the registrant is a large accelerated, an accelerated filer, a non-accelerated filer, or a smaller reporting company. &nbsp;See definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <table width=667 bordercolor=transparent style="WIDTH:500pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=157 style="HEIGHT:15pt; WIDTH:118pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Large Accelerated Filer [ &nbsp;]</font></p></td> <td width=243 style="HEIGHT:15pt; WIDTH:182pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" /> <td width=176 style="HEIGHT:15pt; WIDTH:132pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Accelerated Filer&nbsp;&nbsp;&nbsp; [ &nbsp;]</font></p></td></tr> <tr style=HEIGHT:15pt> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Non-Accelerated Filer &nbsp;&nbsp;[X&nbsp;]</font></p></td> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" /> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Smaller Reporting Company [X]</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act).</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Yes [ &nbsp;]&nbsp; No [X]</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was sold, or the average bid and asked price of such common equity, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter (based upon 7,747,639 shares held by non-affiliates and the closing price of $3.02 per share for Common Stock in the over-the-counter market as of November 30, 2019): $23,397,870. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Indicate the number of shares outstanding of each of the registrant's common stock, par value $0.08, outstanding as of August 31, 2020: </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&nbsp;11,752,589.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">DOCUMENTS INCORPORATED BY REFERENCE: Part III contains information incorporated by reference to the Company's proxy statement for its 2020 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2020. The Exhibit Index incorporates by reference various documents previously filed with the Securities and Exchange Commission.<b> &nbsp;</b></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>2</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">PART I</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 1. &nbsp;&nbsp;&nbsp;&nbsp; BUSINESS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">BUSINESS OVERVIEW</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">THE COMPANY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Biomerica, Inc. ("Biomerica", the "Company", "we", &#8220;us&#8221; or "our") was incorporated in Delaware in September 1971 as Nuclear Medical Systems, Inc., and later changed its name to Biomerica, Inc. The Company has two wholly owned subsidiaries, Biomerica de Mexico, which is used for assembly/manufacturing and BioEurope GmbH, which acts as a distributor of Biomerica products in certain markets. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><a name=_Hlk48290852><font style=FONT-SIZE:10pt>We are a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><a name=_Hlk48290916><font style="FONT-SIZE:10pt; COLOR:black">Our primary focus is the research and development of revolutionary, patented diagnostic guided therapy (&#8220;DGT&#8221;) products to treat gastrointestinal diseases, such as irritable bowel syndrome (&#8220;IBS&#8221;), and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. If these DGT products prove effective in their clinical trials, and are ultimately cleared for sale by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), we believe the revenues potential to the Company is significant. </font></a><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Our medical diagnostic products are sold worldwide in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter drugstores). The diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient&#8217;s body, stools, or blood, often in extremely small concentrations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><a name=_Hlk48293512><font style=FONT-SIZE:10pt>Due to the global 2019 SARS-CoV-2 novel coronavirus (&#8220;COVID-19&#8221;) pandemic, in March 2020 we began redirecting and focusing a majority of our resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been infected by COVID-19. These diagnostic tests use a patient&#8217;s blood sample to detect if the patient has certain antibodies to COVID-19 that were created as part of their body&#8217;s immune response to a COVID-19 infection, even if the infection was asymptomatic. During the fourth quarter of fiscal 2020 we began marketing and selling outside of the U.S. a disposable rapid finger-prick blood test, which detects COVID-19 IgG/IgM antibodies within 10 minutes. </font></a><font style="FONT-SIZE:10pt; COLOR:black">This test is designed to be performed by trained professionals anywhere (e.g. airports, schools, work, pharmacies and doctors&#8217; offices). </font><font style=FONT-SIZE:10pt>Following fiscal 2020 year-end we submitted to the FDA an application under an Emergency Use Authorization (&#8220;EUA&#8221;) to sell in the U.S.</font><font style="FONT-SIZE:10pt; COLOR:black"> a lab-scale, high throughput ELISA COVID-19 antibody test kit that would be sold to labs and hospitals to perform COVID-19 antibody testing. The Company also anticipates selling this test kit outside of the U.S. under a CE Mark (European Conformity). Initial sales for this product are expected during the Company&#8217;s second quarter of fiscal 2021 upon EUA clearance. The Company manufactures this COVID-19 ELISA test on its automated equipment at the Company&#8217;s California facility that is also used to produce serology antibody tests for other diseases.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Aside from the current focus on COVID-19 products in research, development and clinical trials, the products we continue to sell are primarily focused on gastrointestinal diseases, food intolerances, diabetes and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Our products are CE marked and/or sold for diagnostic use where they are registered by each country&#8217;s regulatory agency.&nbsp; In addition, some products are cleared for sale in the U.S. by the FDA.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Technological advances in medical diagnostics have made it possible to perform diagnostic tests within the home and the physician's office (the point-of-care), rather than in the clinical laboratory. One of our objectives has also been to develop and market rapid diagnostic tests that are accurate, employ easily obtained specimens, and are simple to perform without instrumentation. &nbsp;Our over-the-counter (home use) and professional use (doctor&#8217;s office, clinics, etc.) rapid diagnostic products help to manage existing medical conditions and may save lives through early detection and prompt diagnosis. Typically, tests of this kind required the services of medical technologists and sophisticated instrumentation. &nbsp;Further, results are often not available until at least the following day. We believe that rapid point-of-care tests can be as accurate as laboratory tests when used properly, require limited to no instrumentation, give reliable results in minutes and can be performed with confidence in the home or the physician's office.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>3</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Biomerica maintains its headquarters in Irvine, California, where it houses administration, product development, sales and marketing, customer services and its primary manufacturing operations. Biomerica also maintains manufacturing and assembly operations in Mexicali, Mexico, in order to reduce the cost of manufacturing and compete more effectively worldwide. The Company expends considerable funds in research and development of certain new products that diagnose and, in certain cases, are designed to be used as a therapy for several major medical diseases. These products are both internally developed and licensed from others. &nbsp;We employ experienced and highly trained technical personnel (including Ph.D.&#8217;s and scientists) to develop new products and evaluate and implement technology technical transfer activities. Our technical staff, many of whom have been previously employed at large diagnostic manufacturing companies, has extensive industry experience. We also rely on our Scientific Advisory Board of leading medical doctors and clinicians to assist in guiding our clinical studies and product development.&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Additional information about Biomerica is available on our website at www.biomerica.com. The content on any website referred to in this Form 10-K is not a part of or incorporated by reference in this Form 10-K unless expressly noted. Our Annual Report on Form 10-K, Quarterly Reports on Forms 10-Q, Current Reports on Forms 8-K, Proxy Statements and all other filings we make with the Securities and Exchange Commission (&#8220;SEC&#8221;) are available on our website, free of charge, as soon as reasonably practical after we file them with or furnish them to the SEC and are also available online at the SEC&#8217;s website at www.sec.gov.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">PRODUCTION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Most of our diagnostic test kits are manufactured and/or assembled at our facilities in Irvine, California and in Mexicali, Mexico. We established our manufacturing facility in Mexicali, Mexico in fiscal 2003 and moved a significant portion of our diagnostic packaging and assembly to that facility. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Production of diagnostic tests can involve formulating component antibodies and antigens in specified concentrations, attaching a tracer to the antigen, filling components into vials, packaging and labeling. We continually engage in quality control procedures to assure the consistency and quality of our products and to comply with applicable FDA and international regulations. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Our manufacturing operations and facilities are regulated by the FDA Good Manufacturing Practices for medical devices. We have an internal quality department that monitors and evaluates product quality and output. We also have an internal Quality Systems department whose goal is to ensure that our operating procedures are in compliance with current FDA, CE Mark and </font><font style=FONT-SIZE:10pt>International Organization for Standardization</font><font style="FONT-SIZE:8pt; COLOR:black">&nbsp;</font><font style="FONT-SIZE:10pt; COLOR:black">(&#8220;ISO&#8221;) regulations. We either produce our own antibodies and antigens or purchase these materials from qualified vendors. We have alternate, approved sources for most critical raw materials and are working to procure alternate sources for the few that we do not have. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">RESEARCH AND DEVELOPMENT</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">We are currently focused on developing several COVID-19 diagnostic tests, as discussed in this section below, and developing and pursuing the regulatory approval of two tests for the gastrointestinal market.&nbsp; Our increase in research and development spending is due to our focus on these tests and outside clinical studies intended to demonstrate the feasibility of FDA clearance for such tests. The Company also utilizes technical personnel, with Ph.D. and other degrees and extensive experience in development and production of health diagnostic tests, to conduct other development activities and improve existing products, as well as explore potential new technologies that the Company may wish to develop and commercialize. Research and development expenses include the costs of materials, supplies, personnel, consultants, legal fees, facilities, outside clinical trial sites and equipment as well as outside contract services. Consolidated research and development expenses incurred by Biomerica for the years ended May 31, 2020 and 2019 aggregated $1,910,209, and $1,679,098, respectively. As Biomerica begins to validate and commercialize additional key products that address diseases with large market opportunities, research and development expenses are expected to increase during upcoming quarters. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The Company has developed a unique diagnostic guided therapy that is designed to allow physicians to identify patient-specific foods (e.g. pork, milk, onions, sugar, chickpeas, etc.), that when removed from the diet, may alleviate or improve an individual's symptoms of IBS. This product is called <a name=_Hlk48896532>InFoods&reg; IBS </a>and is currently in clinical studies at the Mayo Clinics in Florida and Arizona, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, University of Texas Health Science Center at Houston, Houston Methodist and at the University of Michigan. The United States Patent and Trademark Office (&#8220;USPTO&#8221;) has issued the Company two patents with broad claims that protect the InFoods&reg; IBS product. Patents have also been issued in the countries of Japan and Korea. Additional patents for this product have been filed in the U.S. and in other countries. We are also developing, and have filed patents for other diseases that utilize the InFoods&reg; DGT technology platform which include:&nbsp; Functional Dyspepsia, Crohn&#8217;s Disease, Ulcerative Colitis, Gastroesophageal reflux disease (&#8220;GERD&#8221;), Migraine Headaches, and Osteoarthritis. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>4</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We are also in clinical studies to evaluate the performance of our new and proprietary </font><font style="FONT-SIZE:10pt; TEXT-DECORATION:none; COLOR:windowtext">Helicobacter pylori </font><font style=FONT-SIZE:10pt>(&#8220;H. pylori&#8221;) test.&nbsp; The clinical studies are being conducted at the University of Southern California (&#8220;USC&#8221;), a European University and several other U.S. locations. The Company is working to complete the analytical studies needed to prepare for submission to the FDA and plans to utilize a 510(k) clearance pathway for this test. Biomerica&#8217;s test is designed to provide highly accurate sensitivity and specificity for H. pylori testing and for monitoring of treatment. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We are planning to pursue a de novo 510(k) clearance with the FDA rather than a Premarket Approval Application (&#8220;PMA&#8221;) for the InFoods&reg; IBS product. De novo clearance is typically faster and less expensive than the PMA route, which is the most stringent type of device marketing application required by the FDA. We are planning to submit the H. pylori product using a 510(k) application if validation testing proves effective.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Since March 2020, we have dedicated a majority of resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been infected by COVID-19. These diagnostic tests use a patient&#8217;s blood sample to determine if the patient has certain antibodies to COVID-19 that were created as part of their body&#8217;s immune response to a COVID-19 infection. Following the end of fiscal 2020, we have also dedicated resources to developing a COVID-19 antigen test that is intended to use a patient&#8217;s nasal or saliva sample to determine if the patient has a current and ongoing COVID-19 infection. We submitted to the FDA an application under and Emergency Use Authorization (&#8220;EUA&#8221;) to sell in the U.S. a lab-scale high throughput ELISA COVID-19 antibody test kit that would be sold to labs and hospitals to perform COVID-19 antibody testing.&nbsp; As part of this test we developed and are testing a whole blood collection system to allow simple whole blood sample collection from a finger stick.&nbsp; We anticipate that upon FDA EUA clearance, this collection system will be marketed in the U.S. and internationally.&nbsp; We also are developing and working on other COVID-19 test technologies. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Since the beginning of March 2020, the majority of our research and development resources and our regulatory clearance resources have been focused on developing, validating and registering for sale both point of care (finger-prick rapid tests), and ELISA high throughput laboratory COVID-19 antibody tests in that our primary InFoods product, InFoods&reg; IBS , is now in clinical trials and as such requires limited research and development or regulatory resources. We expect that the majority of these Company resources will continue to be used in the foreseeable future for the development of COVID-19 tests. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;<b><font style="FONT-SIZE:10pt; COLOR:black">MARKETS AND METHODS OF DISTRIBUTION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Biomerica has approximately 400 current customers for its diagnostic business, of which approximately 75 are foreign distributors, 40 are domestic distributors and the balance are primarily domestic hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, physicians' offices and e-commerce customers.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We employ a director of sales and marketing for Europe and South America who is headquartered in Germany.&nbsp; She has 23 years of experience selling and marketing diagnostic and life science products across multiple diagnostics technologies and disciplines. She possesses broad international business experience, with communication skills in German, English, Spanish, French and Portuguese, and scientific and technical understanding of gastrointestinal diagnostic products. She also has strong relationships with key strategic entities in Europe, Eastern Europe, Latin America, Canada and the U.S. who we believe will help Biomerica add new distributors for existing products, and add new product-lines for future distribution by the Company. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">We rely on affiliated and unaffiliated distributors, advertising in medical and trade journals, exhibitions at trade shows, direct mailings and an internal sales staff to market our diagnostic products. We target two main markets: (a) clinical laboratories and (b) point-of-care testing (physicians' offices and over-the-counter drug stores).</font>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Subsequent to February 29, 2020, the Company&#8217;s fiscal third quarter end, </font><b></b><font style=FONT-SIZE:10pt>the Coronavirus pandemic, which</font><b></b><font style=FONT-SIZE:10pt> started in China at the end of </font><b></b><font style=FONT-SIZE:10pt>2019, has</font><b></b><font style=FONT-SIZE:10pt> spread throughout the world, including </font><b></b><font style=FONT-SIZE:10pt>the U.S.</font><b><font style=FONT-SIZE:10pt>&nbsp; </font></b><font style=FONT-SIZE:10pt>The impact it will have on the Company&#8217;s operations is unknown at this time. <font style=COLOR:black>The Company has faced disruptions in certain of the following areas, and may face further challenges from supply chain disruptions, loss of contracts and/or customers, closure of the Company&#8217;s manufacturing or distribution facilities or of the facilities of the Company&#8217;s partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These pandemic related disruptions can materially negatively impact the Company&#8217;s operations and financial performance and may continue to have significant material negative impacts on the Company.&nbsp;&nbsp; </font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 11.7pt 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 11.7pt 0pt 0in' align=center><font style=FONT-SIZE:10pt>5</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 11.7pt 0pt 0in" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 11.7pt 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On March 17, 2020, the Company announced it had&nbsp;commenced shipping initial samples of its <a name=_Hlk47614306>COVID-19 IgG/IgM Rapid Test </a>(qualitative membrane-based immunoassay for the detection of IgG and IgM antibodies to SARS-CoV-2 in whole blood or serum) to countries outside the U.S. for evaluation.&nbsp; The test is a finger-prick blood test that is designed to show results in approximately 10 minutes and can be performed by trained professionals at any location, including airports, schools, work, pharmacies and doctors&#8217; offices.&nbsp;On March 16, 2020, the Company commenced shipping and fulfilling commercial orders for this Rapid Test to customers outside of the U.S primarily through distributors.&nbsp; The Company has also filed for EUA clearance with the FDA to sell its ELISA COVID-19 test kit in the U.S.&nbsp; Once approved, we will market this ELISA COVID-19 product directly to hospitals and clinical labs, as well as sell it through distributors. The Company continues to sell its COVID-19 IgG/IgM Rapid Tests outside of the U.S.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt 1.5pt; TEXT-INDENT:-1.5pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">For the fiscal years ended May 31, 2020 and 2019, the Company had three distributors and two distributors, respectively, which accounted for a total of 57.2% and 46.3% of our net consolidated sales, respectively. Of this, for the fiscal years ended May 31, 2020 and 2019, the largest of the distributors mentioned above accounted for 25.7% and 36.3%, respectively, of net consolidated sales.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">At May 31, 2020 and 2019, the Company had three distributors and two distributors, respectively, which accounted for a total of 80.0% and 68.1%, respectively, of gross accounts receivable. Of the 80.0% as of May 31, 2020, 43.9% was owed by a distributor in Ecuador. Total gross receivables for fiscal 2020 and 2019 were $1,836,852 and $1,527,762, respectively.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">BACKLOG</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">At May 31, 2020 and 2019, Biomerica had a backlog of unshipped orders of approximately $727,000 and $207,000 respectively. At May 31, 2020 this consisted primarily of orders to our distributor in Asia as well as some contract manufacturing work.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">RAW MATERIALS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The principal raw materials utilized by Biomerica consist of various chemicals, serums, reagents and packaging supplies. Almost all of our raw materials are available from several sources, and we are not dependent upon any single source of supply or a few suppliers. &nbsp;&nbsp;However, due to the limited number of suppliers of some materials, especially those such as antibodies, there is always the possibility that the Company may encounter difficulty in the future obtaining key raw materials for its manufacturing processes or that such materials may be exceedingly costly. For the year ended May 31, 2020, one vendor accounted for 59.3% of our purchases of raw materials. For the year ended May 31, 2019, one vendor accounted for 23.8% of our purchases of raw materials. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Our inventory consists of various types of materials including antibodies, antigens, bottles, boxes, various chemicals and reagents utilized in the manufacture of our test kits as well as products in various stages of completion.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Our sourcing and receiving of raw materials have been negatively impacted due to the global COVID-19 pandemic. Many of our suppliers have been impacted by plant shut-downs, state or national mandates or recommended shut-downs, restrictions on distribution channels including ship freight, air freight and trucking, among other things. These suppliers are also experiencing their own disruptions in sourcing raw materials.&nbsp; It is unclear to what extent raw material availability will be impacted in the foreseeable future, and how that will impact our production and sales. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">COMPETITION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Immunodiagnostic products, including COVID-19 products are currently produced globally by hundreds of companies. Biomerica is not a significant player in the overall market.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Our competitors vary greatly in size. Many are divisions or subsidiaries of well-established medical and pharmaceutical companies which are much larger than Biomerica and expend substantially greater amounts than we do for research and development, manufacturing, advertising and marketing.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>6</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The primary competitive factors affecting the sale of diagnostic products are uniqueness, technology, quality of product, performance, price, service and marketing. We believe we compete primarily on the basis of the uniqueness of our products, the quality of our products, the speed of our test results, our patent position, our pricing and our prompt shipment of orders. We offer a broad range of products, but have had limited marketing capability. We are working on expanding this capability through marketing and strategic cooperation with larger companies and distributors as well as hiring new marketing and sales expertise. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">GOVERNMENT REGULATION OF OUR DIAGNOSTIC BUSINESS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Our primary business consists of selling products that are generally legally defined to be in vitro diagnostic and medical devices. As a result, we are considered to be an in vitro diagnostic and medical device manufacturer, and as such are subject to the regulations of numerous governmental entities. These agencies include the FDA, Environmental Protection Agency, Federal Trade Commission, Occupational Safety and Health Administration, U.S. Department of Agriculture ("USDA"), and Consumer Product Safety Commission. These activities are also regulated by various agencies of the states and localities in which our products are sold. These regulations govern the introduction of new medical devices, the observance of certain standards with respect to the manufacture and labeling of medical devices, the maintenance of certain records, the reporting of potential product problems, and other matters.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Food, Drug &amp; Cosmetic Act of 1938 (the "FDCA") regulates medical devices in the United States by classifying them into one of three classes based on the extent of regulation believed necessary to ensure safety and effectiveness. Class I devices are those devices for which safety and effectiveness can reasonably be assured through general controls, such as device listing, adequate labeling, and adherence to the Quality System Regulation ("QSR") as well as Medical Device Reporting (&#8220;MDR&#8221;), labeling and other regulatory requirements. Some Class I medical devices are exempt from the requirement of Pre-Market Notification or clearance. Class II devices are those devices for which safety and effectiveness can reasonably be ensured through the use of special controls, such as performance standards, post-market surveillance and patient registries, as well as adherence to the general controls provisions applicable to Class I devices. Class III devices are devices that generally must receive clearance prior to marketing by the FDA pursuant to a pre-market approval to ensure their safety and effectiveness. Generally, Class III devices are limited to life-sustaining, life-supporting or implantable devices. However, this classification can also apply to novel technology or new intended uses or applications for existing devices. The Company's products are primarily either Class I or Class II medical devices. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Pursuant to FDA requirements, we have registered our manufacturing facility with the FDA as a medical device manufacturer, and listed the medical devices we manufacture. We are also subject to inspection on a routine basis for compliance with FDA regulations. This includes the QSR, which requires that we manufacture our products and maintain our documents in a prescribed manner with respect to issues such as design controls, manufacturing, testing and validation activities. Further, we are required to comply with other FDA requirements with respect to labeling and MDR regulation which requires that we provide information to the FDA on deaths or serious injuries alleged to have been associated with the use of our products, as well as product malfunctions that are likely to cause or contribute to death or serious injury if the malfunction were to recur. We believe that we are currently in material compliance with all relevant QSR and MDR requirements.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In addition, our facility is required to have a California Medical Device Manufacturing License. The license is not transferable and must be renewed biannually. Approval of the license requires that we be in compliance with QSR, labeling and MDR regulations. Our current license expires on December 31, 2020. These licenses are renewed periodically, and to date we have never failed to obtain a renewal.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Through compliance with FDA and California regulations, we can market some of our medical devices throughout the United States. International sales of medical devices are also subject to the regulatory requirements of each country. In Europe, the directives of the European Union (&#8220;EU&#8217;) require that a device have a CE Mark in order to be sold in EU countries. The directive went into effect beginning December 7, 2003. The Company has completed the process for complying with the CE Mark directives; and In Vitro Diagnostics Directive 98/79/EC. We also comply with ISO 13485 for medical devices Quality Management Systems. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">At present, outside the EU the regulatory international review process varies from country to country. We, in general, rely upon our distributors and sales representatives in the foreign countries in which we market our products to ensure that we comply with the regulatory laws of those countries. We believe that our international sales to date have been in compliance with the laws of all foreign countries in which we have made sales. Exports of most medical devices are also subject to certain FDA regulatory controls.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>7</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The designing, development, manufacturing, marketing, post-market surveillance, distribution, advertising and labeling of Biomerica&#8217;s immunoassay in vitro diagnostic (&#8220;IVD&#8221;) medical device products are subject to regulation in the United States by the Center for Devices and Radiological Health of the FDA and state agencies.&nbsp; FDA regulations require that some new products have pre-marketing clearance or approval by the FDA and require certain products to be manufactured in accordance with the FDA&#8217;s &#8220;Good Manufacturing Practice&#8221; regulations, to be extensively tested and to be properly labeled to disclose test results and performance claims and limitations.&nbsp; After a product that is subject to FDA regulation is placed on the market, numerous regulatory requirements apply, including, for example, the requirement that we comply with recordkeeping and reporting requirements, such as the FDA&#8217;s medical device reporting regulations and reporting of corrections and removals.&nbsp; The FDA enforces these requirements by inspection and market surveillance.&nbsp; The last FDA announced inspection was in November 2019 and no observations were noted. Biomerica is currently registered and licensed with the State of California's Department of Health Services. The Company believes that all Biomerica products sold in the U.S. comply with the FDA and state regulations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Management believes that Biomerica's Quality Management System is in material compliance with the EN ISO 13485:2016. EN ISO 13485:2016 is an internationally recognized standard in which companies establish their methods of operation and commitment to quality.</font><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;</font>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We are an FDA regulated and ISO 13485:2016 certified In Vitro Diagnostic (&#8220;IVD&#8221;) Medical Devices company. Our goal is to provide high quality medical diagnostic products that generally meet or exceed customer requirements and comply with all applicable regulatory requirements: FDA 21 CFR Part 820 Quality Management System, EN ISO 13485:2016, Medical Devices Quality Management Systems - Requirements for Regulatory Purposes, In Vitro Diagnostic Medical Devices Directive (&#8220;IVDD&#8221;) 98/79/EC &amp; and Medical Device Directive 93/42/EEC, Guidelines related to Medical Devices Directives and Guidance on CE Marking, etc.&nbsp; Biomerica involve its employees in a continuous improvement process to increase productivity, improve quality and maintain the suitability, adequacy, and effectiveness of our quality management system. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The new EU Medical Device Regulation (&#8220;MDR&#8221;) 2017/745 entered into force on May 25, 2017. The MDR transition period ends May 26, 2021 and will replace Medical Device Directive (&#8220;MDD&#8221;) 93/42/EEC. Manufacturers have less than one year to update their technical documentation and processes to meet the new, more stringent regulatory requirements of the European Union. Notified Bodies can begin certifying devices to the new MDR requirements once they have been designated under MDR by their Competent Authority. Our Notified Body recently became designated against MDR in July 2020. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The new EU In Vitro Diagnostic Medical Device Regulation (&#8220;IVDR&#8221;) 2017/746 entered into force on May 25, 2017. The IVDR transition period ends May 26, 2022 and will replace IVDD 98/79/EC. Manufacturers have less than two years to update their technical documentation and processes to meet the new, more stringent regulatory requirements of the European Union. Notified Bodies can begin certifying devices to the new IVDR requirements once they have been designated under IVDR by their Competent Authority. The application process for Notified Bodies to be designated against IVDR takes 12-18 months. Our Notified Body is currently in the process of being designated under IVDR.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">SEASONALITY OF BUSINESS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The businesses of the Company and its subsidiaries have not been subject to significant seasonal fluctuations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">INTERNATIONAL BUSINESS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The following table sets forth the dollar volume of revenue attributable to sales to domestic customers and foreign customers during the last two fiscal years for Biomerica:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=70% style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Year Ended May 31</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td style="HEIGHT:15pt; WIDTH:0.18%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>2020</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>2019</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Europe </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:0.18%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>2,434,000/36.4%</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>1,694,000/32.6%</font></p></td></tr> <tr style=HEIGHT:0.2in> <td width=70% style="HEIGHT:0.2in; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">United States</font></p></td> <td width=2% style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td style="HEIGHT:0.2in; WIDTH:0.18%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:0.2in; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>445,000/6.6%</font></p></td> <td width=2% style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:0.2in; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>&nbsp; 523,000/10.1%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Asia</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td style="HEIGHT:15pt; WIDTH:0.18%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right> </p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>1,867,000/27.9%</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>2,514,000/48.3%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">S. America</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td style="HEIGHT:15pt; WIDTH:0.18%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>1,615,000/24.1%</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>&nbsp;&nbsp;&nbsp;&nbsp; 256,000/4.9%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Middle East</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td style="HEIGHT:15pt; WIDTH:0.18%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>314,000/4.7%</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>&nbsp;&nbsp; 214,000/4.1%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Other foreign</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:0.18%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&nbsp;&nbsp; &nbsp;&nbsp;18,000/ 0.3%</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>&nbsp;&nbsp;&nbsp;&nbsp; --%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total Sales</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#a7ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:0.18%; BACKGROUND:#a7ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#a7ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>6,693,000/100%</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#a7ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#a7ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#a7ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>5,201,000/100%</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>8</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">We recognize that our foreign sales could be subject to some special or unusual risks, which are not present in the ordinary course of business in the United States. Changes in economic factors, government regulations, terrorism, tariffs and import restrictions, disruptions in shipping and distribution channels and drop in demand for our products due to regional or national shut-downs from the COVID-19 pandemic, patients&#8217; fear or refusal to visit hospitals and healthcare provides due to the pandemic where our products are sold and used, the erosion of economic conditions in those countries, and many other factors all could impact sales within certain foreign countries. In addition, these factors could also impact the ability of the Company to collect foreign accounts receivable. Foreign countries have licensing requirements applicable to the sale of diagnostic products, which vary substantially from domestic requirements; depending upon the product and the foreign country, these may be more or less restrictive than requirements within the United States and may change without notice. Foreign diagnostic sales at Biomerica are made primarily through a network of approximately 100 independent distributors in approximately 65 countries.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The COVID-19 related factors mentioned above have also negatively impacted domestic sales of our non-Covid-19 products and may continue to negatively impact our domestic and international sales into the foreseeable future. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">INTELLECTUAL PROPERTY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">We regard the protection of our methodologies, designs, product formulations, manufacturing processes, diagnostic procedures, copyrights, service marks, trademarks and trade secrets as important to our future success. We rely on a combination of copyright, trademark, patent, service mark and trade secret laws and contractual restrictions to establish and protect our proprietary rights in products and services. We have entered into confidentiality and invention assignment agreements with our employees and contractors, and nondisclosure agreements with most of our fulfillment partners and strategic partners to limit access to and disclosure of proprietary information. We cannot be certain that these contractual arrangements or the other steps taken by us to protect our intellectual property will prevent misappropriation of our technology. We have licensed in the past, and expect that we may license in the future, certain of our proprietary rights, such as trademarks, patents or copyrighted material, to third parties. While we attempt to ensure that the quality of our product brands is maintained by such licensees, we cannot be certain that such licensees will not take actions that might hurt the value of our proprietary rights or reputation.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">LICENSE OF THIRD-PARTY INTELLECTUAL PROPERTY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On occasion, we in-licensed both exclusive and non-exclusive rights to intellectual property and patents owned by third parties. These license agreements typically require royalties and other payments. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company has a royalty agreement in which it has obtained rights to manufacture and market an ACTH test (used to detect chronic metabolic conditions). Royalty expense of approximately $15,000 and $19,000, respectively, is included in cost of sales for this agreement for the fiscal years ended May 31, 2020 and 2019. Sales of products manufactured under this agreement are non-material to total sales for the fiscal years ended May 31, 2020 and 2019, respectively. The Company may license other products or technology in the future as it deems necessary or opportunistic for conducting business.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In April 2020, we signed two license agreements with the Icahn School of Medicine at Mount Sinai, a New York not-for-profit education corporation, pertaining to certain technology that we have used to develop our ELISA COVID-19 serology test. This agreement requires a royalty payment on all sales of products that utilize the licensed technology. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In May, 2020, we signed an exclusive license agreement with</font> <font style="FONT-SIZE:10pt; COLOR:black">The Regents of the University of California, to license patents pertaining to a CRISPR-based technology that we hope to use to produce a rapid test for the COVID-19 virus, that could be used to test individuals to determine if they are currently infected with the COVID-19 virus. This agreement requires the payment of certain milestone payments and a royalty on all sales that utilize the licensed technology.&nbsp;&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Some of the products that we manufacture, sell or use may be covered by claims in issued patents held by other persons or entities, and as such, upon notice from such persons or entity we may be required to pay a license fee or may be required to cease all manufacture, sale or use of such products, which could negatively impact the Company. While we have not been notified of any such claims by third parties, we cannot guarantee that such claims will not be made in the future. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>9</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">BRANDS AND TRADEMARKS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">We occasionally register our tradenames with the Office of Patents and Trademarks. Of note, we registered the tradename &#8220;InFoods&#8221; on December 24, 2016. Our unregistered tradenames are "EZ Detect", "EZ-H.P." and "EZ-PSA". A trademark for "Aware" was issued and assigned in November 2001 and renewed in 2011. On January 11, 2020, the USPTO renewed the Company&#8217;s &#8220;FORTEL&#8221; trademark for another ten years. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The laws of some foreign countries do not protect our proprietary rights to the same extent as do the laws of the U.S. Effective copyright, trademark and trade secret protection may not be available in such jurisdictions. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">PATENTS AND INFOODS TECHNOLOGY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The Company has filed over 100 international and PCT patents, and has 22 provisional and non-provisional patents currently filed with the USPTO. Some of these patent applications pertain to COVID-19 and other products. However, the majority of our patents that are pending pertain to the <a name=_Hlk49356926>InFoods&reg; IBS </a>technology platform.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Our most important family of patent applications pertains to our </font><font style=FONT-SIZE:10pt>InFoods&reg; IBS technology platform, which is a revolutionary and disruptive new method of the symptoms of many different diseases. Our first planned product launch using this technology is the InFoods&reg; IBS product which diagnoses and treats Irritable Bowel Syndrome. Using a patient blood sample, a physician or lab can run our test to identify specific foods (e.g. pork, milk, shrimp, broccoli, eggs) that, if eliminated from the patient&#8217;s diet, can alleviate or reduce the individual's IBS symptoms, including, but not limited to, constipation, diarrhea, bloating, severe pain and indigestion. <font style=COLOR:black>We have filed many patent applications with the USPTO and with other such similar agencies in other countries outside of the United States pertaining to this </font>InFoods&reg; IBS<font style=COLOR:black> technology. These patent applications include claims that address the diagnosis and treatment of several disease states including IBS, functional dyspepsia, Crohn&#8217;s disease, ulcerative colitis, gastroesophageal reflux disease, migraine headaches, osteoarthritis, psoriasis and others. These applications include the use of this technology in both humans and animals.&nbsp; The first patents filed by us pertained to IBS. The International Search Authority (&#8220;ISA&#8221;) has deemed that for one of Biomerica&#8217;s key patent applications pertaining to IBS, all of the International Patent Application claims for its composition and methods to identify trigger foods for IBS are novel and non-obvious.&nbsp; Several of the patents pertaining to the</font> InFoods&reg; IBS <font style=COLOR:black>technology have been issued and many more are in active review and prosecution.&nbsp; </font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>In August 2018, the Korean Intellectual Property Office (&#8220;KIPO&#8221;) issued a Certificate of Patent (<font style=COLOR:black>#10-1887545) </font>covering our InFoods&reg; IBS product (entitled &#8220;COMPOSITIONS, DEVICES, AND METHODS OF IBS SENSIVITY TESTING&#8221;). This patent was the first for the InFoods&reg; patent portfolio, providing patent protection for InFoods&reg; IBS in Korea until November 13, 2035.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In June 2019, we received our first issued patent from the USPTO </font><font style=FONT-SIZE:10pt>(#15/526,240) <font style=COLOR:black>pertaining to our</font> InFoods&reg; IBS<font style=COLOR:black> product, with claims that covers the test kit that is used to determine patient food intolerances.&nbsp; </font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In May 2020, the Japanese Patent Office issued our first</font><font style=FONT-SIZE:10pt> InFoods&reg; IBS<font style=COLOR:black> patent in that country (JP,6681907,B) which covers the compositions, devices and methods of IBS sensitivity testing.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In August 2020, we received notice of allowance from the USPTO for our second patent for the </font><font style=FONT-SIZE:10pt>InFoods&reg; IBS<font style=COLOR:black> product (#16/385,322) that expands our claims to include the method for identifying and setting the antibody cut-off values for each individual food to determine if a person has an intolerance to that food.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">We believe the claims in these issued InFoods IBS patents, and claims in pending patents that protect the use of the </font><font style=FONT-SIZE:10pt>InFoods&reg; IBS <font style=COLOR:black>&nbsp;technology to diagnose and treat other diseases, provide us with broad protections from other companies making or selling competing products in this highly disruptive new field of medicine.&nbsp; </font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><a name=_Hlk48224651><font style="FONT-SIZE:10pt; COLOR:black">In addition to the use of our own patents, Biomerica has acquired from third parties the rights to manufacture and sell certain products that are protected by patents or intellectual property owned by these third parties. In some cases, royalties are paid on the sales of these products. Biomerica anticipates that it will license or purchase the rights to other products or technologies in the future.&nbsp;</font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>10</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;<b><font style="FONT-SIZE:10pt; COLOR:black">EMPLOYEES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">As of May 31, 2020 and 2019, the Company employed 45 and 39 employees, respectively, in the U.S. and Europe. Various employees listed in the production department also perform research and development duties as a routine function of their job. The Company occasionally employs temporary employees when needed. The following is a breakdown of employees by departments:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=70% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:70%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom><a name=_Hlk16605381 /><a name=_aciFooter9 /></td> <td width=15% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td width=15% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:70%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Administrative</font></p></td> <td width=15% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>5</font></p></td> <td width=15% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>4</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Research and Development</font></p></td> <td width=15% style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>9</font></p></td> <td width=15% style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>8</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Marketing &amp; Sales</font></p></td> <td width=15% style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>3</font></p></td> <td width=15% style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>4</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:70%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Production and Operations</font></p></td> <td width=15% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>28</font></p></td> <td width=15% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>23</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:70%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total</font></p></td> <td width=15% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>45</font></p></td> <td width=15% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>39</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In addition, Biomerica de Mexico employs 20 people at its Mexico facility. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">We also engage the services of many outside Ph.D. and M.D. and other types of industry expert consultants as well as medical institutions for technical support, regulatory advisors, marketing and public relations advisors, financial advisors, contract product development and manufacturing organization, and other advisors on a regular basis. We try to protect the Company with the use of confidentiality, intellectual property ownership and indemnifications agreements. However, we cannot guarantee that the use of such third parties will fully protect the Company from third-party claims or from theft of our intellectual property.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 1A.&nbsp;&nbsp;&nbsp;RISK FACTORS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The risks described below are not the only ones we face. Additional risks and uncertainties we are not presently aware of or that we currently believe </font><font style=FONT-SIZE:10pt>are immaterial may also impair our business operations. Our business could be harmed by any of these risks and uncertainties. The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. In assessing these risks, you should also refer to the other information contained or incorporated by reference into this annual report on Form&nbsp;10-K, including our consolidated financial statements and related notes.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'><a name=s9B1D8344AA2ED028FBF5BF856A071139 /><b><font style="FONT-SIZE:10pt; LINE-HEIGHT:120%">RISKS RELATED TO OUR BUSINESS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:11pt; COLOR:black">Our business could be adversely affected by the effects of widespread public health epidemics<i>.</i></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:#222222">We are susceptible to a widespread outbreak of an illness or other health issue, such as the recent COVID-19 Coronavirus outbreak first reported in Wuhan, Hubei Province, China in December 2019 and subsequently spreading throughout the world resulting in millions of confirmed cases worldwide and many deaths. The outbreak of the COVID-19 virus has caused the various governments, including the U.S., to implement quarantines, various restrictions on travel causing airlines to suspend international and certain domestic flights, shelter in place orders and other restrictions. Governments have also implemented work restrictions that prohibit many employees from going to work, and for businesses that are allowed to remain open, many employees are electing to remain at home to avoid spread of the disease. As a result of this COVID-19 virus outbreak and potential future pandemic outbreaks, the Company faces significant risks including, but not limited to: a) supply chain disruptions making it difficult for the Company to contract and receive materials needed for production of its products, and needed to ship finished products to our end customers, b) loss of contracts and customers from the financial strains or other disruptions they are experiencing as a result of the pandemic, c) financial risks pertaining to receivables due from customers that may fall into insolvency or otherwise be unable to pay their bills, d) government responses including orders that make it difficult to remain open for business, restrict imports of raw materials or exports of finished goods, refusal to allow the Company&#8217;s product to be licensed for sale in their countries, and other seen and unforeseen actions taken by government agencies, e) absenteeism or loss of employees at the Company, or at our partner&#8217;s companies, due to health reasons or government restrictions, that are needed to develop, validate, manufacture and perform other necessary functions for our operations, f) equipment failures, loss of utilities and other disruptions that could impact our operations or render them inoperable, g) litigation or government actions against the Company pertaining to existing products new products sold by the Company that are directed at limiting or treating the spread of the pandemic outbreak, h) a local or global recession or depression that could harm the international banking system, limit demand for all products including those made by the Company, &nbsp;i) a drop in demand for our products, that are all medical related, due to patients&#8217; reluctance or refusal to visit hospitals, labs, and doctors&#8217; offices where our products are used due to their fear of contracting a disease, and many other seen and unforeseen events and circumstances, all of which could negatively impact the Company.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; TEXT-ALIGN:center; MARGIN:6pt 0in 0pt' align=center><font style=FONT-SIZE:10pt>11</font></p> <div style="BACKGROUND:white; TEXT-ALIGN:center; MARGIN:6pt 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:6pt 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:6pt 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">If our COVID-19 tests are unable to gain acceptance in the market, proves to be ineffective or less effective than expected, and/or we do not receive regulatory approvals for our COVID-19 tests to be sold, our results of operation could be materially harmed. </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:6pt 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Although we believe that our COVID-19 tests represent promising tests to detect prior COVID-19 virus exposure, the tests may never gain significant acceptance in the marketplace and therefore may never generate substantial revenue or profits for us. We will need to establish a market for our COVID-19 antibody tests. Gaining acceptance in medical communities requires increasing awareness of our COVID-19 tests and their benefits. &nbsp;Also, there are a large number of companies around the world now making and selling COVID-19 tests that compete with our COVID-19 tests. Many of these competitor products are made in China and other parts of Asia where manufacturing costs are low. As such, we are seeing supply and price competition which could make it difficult for the Company to compete.&nbsp; Other risks pertaining to these products include:&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style="FONT-SIZE:10pt; COLOR:black">&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black">our ability to demonstrate the efficacy, speed and cost competitiveness of our COVID-19 tests;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style="FONT-SIZE:10pt; COLOR:black">&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black">whether healthcare providers and governmental agencies believe our COVID-19 tests are sufficiently safe, effective, and accurate; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style="FONT-SIZE:10pt; COLOR:black">&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black">our ability to transfer, further develop, integrate and use third-party licensed technology; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style="FONT-SIZE:10pt; COLOR:black">&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black">our ability to manufacture and scale commercial products; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style="FONT-SIZE:10pt; COLOR:black">&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black">our ability to source required raw materials in a cost effective and timely manner;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style="FONT-SIZE:10pt; COLOR:black">&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black">development of effective vaccines to the Covid-19 virus that reduce the need to do antibody testing;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style="FONT-SIZE:10pt; COLOR:black">&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black">mutations in the COVID-19 virus that render our tests ineffective; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style="FONT-SIZE:10pt; COLOR:black">&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black">receipt of regulatory approvals necessary prior to commercialization of our products; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt 0.25in; TEXT-INDENT:-0.25in'><font style="FONT-SIZE:10pt; COLOR:black">&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black">the FDA or other regulatory agencies retracting their prior approval for our products to be sold in their market or changing regulations for approval; and</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in; TEXT-INDENT:-0.25in'><font style="FONT-SIZE:10pt; COLOR:black">&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style="FONT-SIZE:10pt; COLOR:black">whether the medical community accepts our COVID-19 tests as a supplement to, alternative to, or complimentary to, current PCR or other tests for COVID-19 infection.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:1.5pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In addition, each country in which we wish to sell these tests has its own regulatory approval requirements.&nbsp; We will need to comply with the regulatory requirements of each country before we are permitted to sell in that country.&nbsp; There can be no assurance that governmental agencies, including the FDA, will provide clearance of our COVID-19 tests to be sold in their markets.&nbsp; Failure to achieve widespread&nbsp;market acceptance&nbsp;of our COVID-19 tests, or failure to achieve regulatory clearance of our COVID-19 tests, could materially harm our business, financial condition, and results of operations.&nbsp; Our COVID-19 tests are new tests that only generated revenue during the last two months of our fiscal year. It is uncertain how long we will be able to generate revenues from these tests, and what level of sales, if any, we will attain in the future. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:11pt>Our operating results may fluctuate adversely as a result of many factors that are outside our control, which may negatively impact our stock price. </font></b><b><font style=FONT-SIZE:11pt>Fluctuations in our operating results, for any reason, could cause our growth or operating results to fall below the expectations of investors and securities analysts.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We base the scope of our operations and related expenses on our estimates of future revenues. A significant portion of our operating expenses are fixed, and we may not be able to rapidly adjust our expenses if our revenues fall short of our expectations. Our revenue estimates for future periods are based, among other factors, on estimated end-user demand for our products. If end-user consumption is less than estimated, revenues from our distribution partners and other distribution channels would be expected to fall short of expectations, and because such a significant portion of our costs are fixed, could result in operating losses.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Factors that are beyond our control and that could affect our operating results in the future include:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>regulatory clearance;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt 0.25in; TEXT-INDENT:-0.25in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>changes in the level of competition, such as would occur if one of our competitors introduced a new, better performing or lower priced product to compete with one or more of our products;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>changes in the reimbursement systems or reimbursement amounts that end-users may rely upon in choosing to use our products;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>12</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt 0.25in; TEXT-INDENT:-0.25in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>changes in economic conditions in our domestic and international markets, such as economic downturns, decreased healthcare spending, reduced consumer demand, inflation and currency fluctuations; changes in government laws and regulations affecting our business; reluctance for consumers to visit healthcare providers;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>lower than anticipated market penetration of our new or more recently introduced products;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>significant quantities of our product or that of our competitors in our distributors&#8217; inventories or distribution channels;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>changes in distributor buying patterns;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>government mandated shelter-in-place or other lock-down orders;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>continued spread of the COVID-19 virus or mutations of the virus; and</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>changes in the healthcare market including consolidation in our customer base.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>To remain competitive, we must continue to develop, obtain and protect our proprietary technology rights; otherwise, we may lose market share or need to reduce prices as a result of competitors selling technologically superior products that compete with our products.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Our ability to compete successfully in the diagnostic market depends on continued development and introduction of new products, technology and the improvement of existing technology. If we cannot continue to improve upon or develop, obtain and protect our technology, our operating results could be adversely affected.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Our competitive position is heavily dependent on obtaining and protecting our own proprietary technology or obtaining licenses from others. Our ability to obtain patents and licenses, and their benefits, is uncertain.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>The Company is required to obtain government or regulatory certification in many countries and the European community to sell its products in those countries or regions.&nbsp; There is no assurance that the Company will be able to retain its certification in the future.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Significant government regulation exists in countries in which we conduct business. </font><font style=FONT-SIZE:10pt>A large part of the Company&#8217;s sales are to distributors in Europe, China and other countries, which require us to maintain certain certifications to sell our products.&nbsp; <font style=COLOR:black>Failure to comply with current governmental regulations and quality assurance guidelines could cause the loss of these certifications, which could materially adversely affect the results of the Company.&nbsp; Loss of certifications could lead to temporary manufacturing shutdowns, product recalls, product shortages or delays in product manufacturing and a decline in sales.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>The Company maintains a manufacturing plant in Mexico which presents risks to the Company including risks associated with doing business outside the United States.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The Company has a significant investment in its manufacturing facility in Mexico through its subsidiary, Biomerica de Mexico &nbsp;&nbsp;</font><font style="FONT-SIZE:10pt; COLOR:black">There are a number of risks associated with doing business in Mexico, including, exposure to local economic and political conditions, social unrest, including risks of terrorism or other hostilities, export and import restrictions, the potential for shortages of trained labor, and the possible effects of currency exchange rate fluctuations.<b><i> </i></b></font><font style=FONT-SIZE:10pt>These risks could lead to additional costs that we cannot foresee at this time and may materially adversely impact our business, results of operations and financial condition.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>We use hazardous materials in our research and production that may result in unexpected and substantial claims against us relating to handling, storage or disposal. </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We use hazardous materials in our research and production. The risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, the Company could be held liable for any harm or damages that result and any such liability could exceed the resources of the Company.&nbsp; The Company may incur substantial costs to comply with environmental regulations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>If any governmental authorities were to impose new environmental regulations requiring compliance in addition to that required by existing regulations, or alter their interpretation of the requirements of such existing regulations, such environmental and safety regulations could impair our research, development or production efforts by imposing additional, and possibly substantial, costs, restrictions or compliance procedures on our business. In addition, because of the nature of the penalties provided for in some of these environmental and safety regulations, we could be required to pay sizable fines, penalties or damages in the event of noncompliance with regulations and environmental laws. Any environmental or safety violation or remediation requirement could also partially or completely shut down our research and manufacturing facilities and operations, which would have a material adverse effect on our business. The risk of accidental contamination or injury from these hazardous materials cannot be completely eliminated and exposure of individuals to these materials could result in substantial fines, penalties or damages that may not be covered by insurance.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>13</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>In order to remain competitive, we must expend considerable resources to research new technologies and products and develop new markets, and there is no assurance our efforts to develop new technologies, products or markets will be successful or such technologies, products or markets will be commercially viable.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We devote a significant amount of financial and other resources to researching and developing new technologies, new products and new markets. The development, manufacture and sale of diagnostic products require a significant investment of resources. The development of new products and markets also requires a substantial investment of resources, such as new employees, offices and manufacturing facilities, consultants and clinical trials. No assurances can be given that our efforts to develop new technologies or products will be successful, that such technologies and products will be commercially viable, or our expansion into new markets will be profitable.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>There is also no guarantee that our new products, including our InFoods&reg; IBS products, will get approval and be well accepted into the marketplace.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Our operations will be adversely affected if our operating results do not correspondingly increase with our increased expenditures or if our technology, product and market development efforts are unsuccessful or delayed. Furthermore, our failure to successfully introduce new technologies or products and develop new markets could have a material adverse effect on our business and prospects.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>We rely on a limited number of key distributors that account for a substantial majority of our total revenue. The loss of any key distributor or an unsuccessful effort by us to directly distribute our products could lead to reduced sales.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">For the fiscal years ended May 31, 2020 and 2019, the Company had three and two distributors, respectively, which accounted for a total of 57.2% and 46.3% of our sales, respectively. Of this, for the fiscal years ended May 31, 2020 and 2019, one of the distributors mentioned above accounted for 25.7% and 36.3%, respectively, of net consolidated sales.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">At May 31, 2020 and 2019, the Company had three distributors and two distributors which accounted for a total of 80.08% and 68.1%, respectively, of gross accounts receivable. </font><font style=FONT-SIZE:10pt>The loss of these sales to these accounts could adversely impact the results of the Company. </font><font style="FONT-SIZE:10pt; COLOR:black">Of the 80.0% as of May 31, 2020, 43.9% was owed by a distributor in Ecuador. Total gross receivables for fiscal 2020 and 2019 were $1,836,852 and $1,527,762, respectively. Adverse changes in our relationships with these distributors and other partners, or adverse developments in their financial condition, performance or purchasing patterns, could adversely affect our business and consolidated financial statements.&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>We extend credit to customers outside the U.S. which can be difficult to collect.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We extend credit to many of our customers including those outside of the U.S. It is often difficult to obtain adequate credit information on these customers. Further, our ability to collect receivables from these customers through the court systems in those countries can be more difficult than here in the U.S.&nbsp; Our inability to collect on receivables from customers outside of the U.S. could negatively impact the Company. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>If we are not able to manage our growth strategy our operating results may be adversely affected.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Our business strategy contemplates further growth, which would likely result in expanding the scope of operating and financial systems and the geographical area of our operations, including further expansion outside the U.S., as new products and technologies are developed and commercialized or new geographical markets are entered. Because we have a small executive staff, acquisitions and other future growth may divert management&#8217;s attention from other aspects of our business, and place a strain on existing management and our operational, financial and management information systems. Furthermore, we may expand into markets in which we have less experience or incur higher costs. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>Intellectual property risks and third-party claims of infringement, misappropriation of proprietary rights or other claims against us could adversely affect our ability to market our products, require us to redesign our products or attempt to seek licenses from third parties, and materially adversely affect our operating results. In addition, the defense of such claims could result in significant costs and divert the attention of our management and other key employees.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>14</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Companies in or related to our industry often aggressively protect and pursue their intellectual property rights. There are often intellectual property risks associated with developing and producing new products and entering new markets, and we may not be able to obtain, at reasonable cost or upon commercially reasonable terms, if at all, licenses to intellectual property of others that is alleged to be part of such new or existing products. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We have hired and will continue to hire individuals or contractors who have experience in medical diagnostics and these individuals or contractors may have confidential trade secret or proprietary information of third parties. We cannot assure you that these individuals or contractors will not use this third-party information in connection with performing services for us or otherwise reveal this third-party information to us. Thus, we could be sued for misappropriation of proprietary information and trade secrets. Such claims are expensive to defend and could divert our attention and result in substantial damage awards and injunctions that could have a material adverse effect on our business, financial condition or results of operations. In addition, to the extent that individuals or contractors apply technical or scientific information independently developed by them to our projects, disputes may arise as to the proprietary rights to such data and may result in litigation.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The defense and prosecution of patent and trade secret claims are both costly and time consuming. We or our customers may be sued by other parties that claim that our products have infringed their patents or misappropriated their proprietary rights or that may seek to invalidate one or more of our patents. An adverse determination in any of these types of disputes could prevent us from manufacturing or selling some of our products, limit or restrict the type of work that employees involved with such products may perform for us, increase our costs and expose us to significant liability.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>As a general matter, our involvement in litigation or in any claims to determine proprietary rights, as may arise from time to time, could materially and adversely affect our business, financial condition and results of operations for reasons such as:</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:24pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>pending litigation may of itself cause our distributors or end-users to reduce or terminate purchases of our products;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>it may consume a substantial portion of our managerial and financial resources;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in; TEXT-INDENT:-0.25in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>its outcome would be uncertain and a court may find any third-party patent claims valid and infringed by our products (issuing a preliminary or permanent injunction) that would require us to procure costly licensing arrangements from third parties or withdraw or recall such products from the market, redesign such products offered for sale or under development or restrict employees from performing work in their areas of expertise;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in; TEXT-INDENT:-0.25in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>governmental agencies may commence investigations or criminal proceedings against our employees, former employees and us relating to claims of misappropriation or misuse of another party&#8217;s proprietary rights;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in; TEXT-INDENT:-0.25in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>an adverse outcome could subject us to significant liability in the form of past royalty payments, penalties, special and punitive damages, the opposing party&#8217;s attorneys' fees, and future royalty payments significantly affecting our future earnings; and</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in; TEXT-INDENT:-0.25in'>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style=FONT-SIZE:10pt>failure to obtain a necessary license (upon commercially reasonable terms, if at all) upon an adverse outcome could prevent us from selling our current products or other products we may develop.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>In addition to the foregoing, we may also be required to indemnify some customers, distributors and strategic partners under our agreements with such parties if a third party alleges or if a court finds that our products or activities have infringed upon, misappropriated or misused another person&#8217;s proprietary rights. Further, our products may contain technology provided to us by other parties such as contractors, suppliers or customers. We may have little or no ability to determine in advance whether such technology infringes the intellectual property rights of a third party. Our contractors, suppliers and licensors may not be required or financially able to indemnify us in the event that a claim of infringement is asserted against us, or they may be required to indemnify us only up to a maximum amount, above which we would be responsible for any further costs or damages.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Some of the products that we manufacture, sell or use may be covered by claims in issued patents held by other persons or entities, and as such, upon notice from such persons or entity, we may be required to pay a license fee or may be required to cease all manufacture, sale or use of such products, which could negatively impact our financial results or operations. We cannot guarantee that such claims will not be made in the future. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>We need to continue to raise additional funds to finance our future capital or operating needs, which could have adverse consequences on our operations and the interests of our stockholders.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We need to continue to raise funds through public or private debt or sale of equity to achieve our business strategy. When we raise funds or acquire other technologies or businesses through issuance of equity, this dilutes the interests of our stockholders. Moreover, the availability of additional capital, whether debt or equity from private capital sources (including banks) or the public capital markets, fluctuates as our financial condition and industry or market conditions in general change. There may be times when the private capital markets and the public debt or equity markets lack sufficient liquidity or when our securities cannot be sold at attractive prices, in which case we would not be able to access capital from these sources on favorable terms, if at all. We can give no assurance as to the terms or availability of additional capital.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>15</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Our inability to raise additional funds to finance our future capital or operating needs could force us to delay, reduce or eliminate our development programs or commercialization efforts.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Costs related to development projects and approvals are hard to estimate due to factors that are unknown to us at this time. These costs could be much higher than anticipated and current operations may not be able to cover these costs.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of studies and trials may not be predictive of future trial results.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Clinical trials are expensive, time consuming and difficult to design and implement. Regulatory agencies may analyze or interpret the results differently than we do. Even if the results of our clinical trials are favorable, the clinical trials for a number of our product candidates may take a significant amount of time to complete. Regulatory authorities, including state and local authorities, may suspend, delay or terminate our clinical trials at any time, require us to conduct additional clinical trials, require a particular clinical trial to continue for a longer duration than originally planned, or require a change to our development plans such that we conduct clinical trials for a product candidate in a different order.&nbsp; </font><font style=FONT-SIZE:10pt>There is no assurance that the results of the clinical trials will be positive.&nbsp; A negative clinical trial could affect our ability to obtain regulatory clearances and/or potential licensing partners.&nbsp; There is also no assurance that our clinical trials will not be delayed or will be completed. &nbsp;<font style=COLOR:black>Any of the foregoing could have a material adverse effect on our business, results of operations and financial condition.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>Our results of operations and financial conditions may be adversely affected by the financial soundness of our customers, distributors and suppliers.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>If our customers&#8217; or suppliers&#8217; operating and financial performance deteriorates, or if they are unable to make scheduled payments or obtain credit, our customers may not be able to pay, or may delay payment of, accounts receivable owed to us, and our suppliers may restrict credit or impose different payment terms or reduce or terminate production of products they supply to us, or may cease all operations. Any inability of customers to pay us for our products and services, or any demands by suppliers for different payment terms, or inability for such suppliers to continue operations may adversely affect our operating results and financial condition. Additionally, both state and federal government sponsored and private payers, as a result of budget deficits or reductions, may seek to reduce their healthcare expenditures by cutting or eliminating reimbursements for, or cutting purchase of our products. Any reduction in payments by such government sponsored or private payers may adversely affect our earnings and cash flow. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>We may not achieve market acceptance of our new products among healthcare providers and physicians, and this would have a negative effect on future sales.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">We believe our ability to introduce new products that gain acceptance among healthcare providers and physicians is an important part of our ability to grow our revenue in future periods. However, any new products we introduce may not gain market acceptance to the extent we anticipate or project. </font><font style=FONT-SIZE:10pt>The acceptance of which in the medical community is unpredictable at this time. In addition, the Company will need to spend considerable funds in order to introduce the products into the marketplace. Sales, if any, of these products in the future are uncertain.<font style=COLOR:black>&nbsp; In addition, </font></font><font style="FONT-SIZE:10pt; COLOR:black">our competitors may offer different products and product formats at suggested prices that are lower than for our products or are more accurate than our products. We can provide no assurances that the medical community will purchase our products or that they will not prefer to purchase a competitive product.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>The industry and market segments in which we operate are highly competitive, and intense competition with other providers of diagnostic products may reduce our sales and margins.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Our diagnostic tests compete with similar products made by our competitors. There are a large number of multinational and regional competitors making investments in competing technologies and products. We also face competition from our distributors as some have created, and others may decide to create, their own products to compete with ours. A number of our competitors have a potential competitive advantage because they have substantially greater financial, technical, research and other resources, and larger, more established marketing, sales, distribution and service organizations than we have. Moreover, some competitors offer broader product lines and have greater name recognition than we have. If our competitors&#8217; products are more effective than ours or take market share from our products through more effective marketing or competitive pricing, our operating results could be materially and adversely affected.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>16</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>In addition, there has been a trend toward industry consolidation in our markets over the last few years. We may not be able to compete successfully in an increasingly consolidated industry. We expect this trend toward industry consolidation may continue as companies attempt to strengthen or hold their market positions in an evolving industry and as companies are acquired or are unable to continue operations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>Our business and products are highly regulated by various governmental agencies. Our results of operations would be negatively affected by failures or delays in the receipt of regulatory approvals or clearances, the loss of previously received approvals or other changes to the existing laws and regulations that adversely impact our ability to manufacture and market our products.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The testing, manufacture and sale of our products are subject to regulation by numerous governmental authorities in the U.S., principally the FDA and corresponding state and foreign regulatory agencies. Our future performance depends on, among other matters, if, when and at what cost we will receive regulatory approval for new products, and if we can continue to comply with the many regulatory requirements that enable us to manufacture and sell medical related products and tests. Regulatory review can be a lengthy, expensive and uncertain process, making the timing and costs of clearances and approvals difficult to predict. Meeting all regulatory requirements, laws and mandates, and maintaining compliance with such in order to manufacture and sell medical products can be difficult and expensive. Our results of operations would be negatively affected by failures or delays in the receipt of regulatory approvals or clearances, the loss of previously received approvals or clearances, the placement of limits on the marketing and use of our products, and restrictions on our ability to manufacture our products. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>Changes in government policy could adversely affect our business and potential profitability.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Changes in government policy could have a significant impact on our business by increasing the cost of doing business, affecting our ability to sell our products and negatively impacting our profitability. Such changes could include tariffs or modifications to existing legislation, such as U.S. tax policy, or entirely new legislation, such as the Affordable Healthcare Act ("AHA") in the U.S. We cannot fully predict the many ways that healthcare reform might affect our business. It is unclear whether and to what extent, if at all, other anticipated developments, including changes due to new presidential administration priorities, or changes resulting from healthcare reform, such as a change in the number of people with health insurance, may impact us. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>We are subject to numerous government regulations in addition to FDA regulation, and compliance with laws, including changed or new laws, could increase our costs and adversely affect our operations.&nbsp; There is also the risk that our facilities could fail to get the proper licensing at our next inspection or renewal.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>In addition to FDA and other regulations referred to above, numerous laws relating to such matters as safe working conditions, manufacturing practices, data privacy, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances impact our business operations. If these laws or their interpretation change or new laws regulating any of our businesses are adopted, the costs of compliance with these laws could substantially increase our overall costs. Failure to comply with any laws, including laws regulating the manufacture and marketing of our products, could result in substantial costs and loss of sales or customers. Because of the number and extent of the laws and regulations affecting our industry, and the number of governmental agencies whose actions could affect our operations, it is impossible to reliably predict the full nature and impact of future legislation or regulatory developments relating to our industry and our products. To the extent the costs and procedures associated with meeting new or changing requirements are substantial, our business, results of operations and financial condition could be adversely affected.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>Our total revenue could be affected by third-party reimbursement policies and potential cost constraints.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The end-users of our products are primarily physicians, labs and other healthcare providers. In the U.S., healthcare providers such as hospitals and physicians who purchase diagnostic products generally rely on third-party payers, principally private health insurance plans, federal Medicare and state Medicaid, to reimburse all or part of the cost of the procedure. Use of our products would be adversely impacted if physicians and other healthcare providers do not receive adequate reimbursement for the cost of our products by their patients&#8217; third-party payers both in the U.S. and in foreign markets. Our total revenue could also be adversely affected by changes or trends in reimbursement policies of governmental or private healthcare payers. We believe that the overall escalating cost of medical products and services has led to, and will continue to lead to, increased pressures on the healthcare industry, both foreign and domestic, to reduce the cost of products and services. Given the efforts to control and reduce healthcare costs in recent years, currently available levels of reimbursement may not continue to be available in the future for our existing products or products under development. Third-party reimbursement and coverage may not be available or adequate in either the U.S. or foreign markets, current reimbursement amounts may be decreased in the future and future legislation, regulation or reimbursement policies of third-party payers may reduce the demand for our products or adversely impact our ability to sell our products on a profitable basis.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>17</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>Unexpected increases in, or inability to meet, demand for our products could require us to spend considerable resources to meet the demand or harm our reputation and customer relationships if we are unable to meet demand.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Our inability to meet customer demand for our products, whether as a result of manufacturing problems or supply shortfalls, could harm our customer relationships and impair our reputation within the industry. In addition, our product manufacturing of certain product lines is concentrated in our two manufacturing sites. Weather, natural disasters (including pandemics), fires, terrorism, political change, failure to follow specific internal protocols and procedures, equipment malfunction, environmental factors or damage to one or more of our facilities could adversely affect our ability to manufacture our products. This, in turn, could have a material adverse effect on our business.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>If we experience unexpected increases in the demand for our products, we may be required to expend additional capital resources to meet these demands. These capital resources could involve the cost of new machinery or even the cost of new manufacturing facilities. This would increase our capital costs, which could adversely affect our earnings and cash resources. If we are unable to develop or obtain necessary manufacturing capabilities in a timely manner, our total revenue could be adversely affected. Failure to cost-effectively increase production volumes, if required, or lower than anticipated yields or production problems, including those encountered as a result of changes that we may make in our manufacturing processes to meet increased demand or changes in applicable laws and regulations, could result in shipment delays as well as increased manufacturing costs, which could also have a material adverse effect on our business, operating results and financial condition.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Unexpected increases in demand for our products could also require us to obtain additional raw materials in order to manufacture products to meet the demand. Some raw materials require significant ordering lead time and we may not be able to timely access sufficient raw materials in the event of an unexpected increase in demand, particularly those obtained from a sole supplier or a limited group of suppliers.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:24pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>If one or more of our products is claimed to be defective, or does not meet the performance criteria we claim in our marketing materials we could be subject to claims of liability and harm to our reputation that could adversely affect our business.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>A claim of a defect in the design or manufacture of our products could have a material adverse effect on our reputation in the industry and subject us to claims of liability for injuries and otherwise. Further, a claim that one of our products is defective or does not actually meet the performance criteria we claim in our marketing materials, could have a substantial impact on our revenues and financial performance. Any substantial underinsured loss resulting from such a claim would have a material adverse effect on our operating results and financial conditions and the damage to our reputation or product lines in the industry could have a material adverse effect on our business.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>We are exposed to business risks which, if not covered by insurance, could have an adverse effect on our results of operations. We face potential product liability exposure, and, if claims brought against us are successful, we could incur substantial liabilities.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We face a number of business risks, including exposure to product liability claims, employment law claims, claims that the Company or its officers, directors or employees have engaged in illegal or wrongful acts, claims of violation of environmental laws and many other possible claims. Although we maintain insurance for a number of these risks, we may face claims for types of damages, or for amounts of damages, that are not covered by our insurance. For example, although we currently carry product liability insurance for liability losses, there is a risk that product liability or other claims may exceed the amount of our insurance coverage or may be excluded from coverage under the terms of our policy. Also, our existing insurance may not be renewed at the same cost and level of coverage as currently in effect, or may not be renewed at all. Further, we do not currently have insurance against many environmental risks we confront in our business. If we are held liable for a claim against which we are not insured or for damages exceeding the limits of our insurance coverage, whether arising out of product liability matters, cybersecurity matters, or from some other matter, that claim could have a material adverse effect on our results of operations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>18</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>We may rely on third parties to conduct or be part of our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to seek or obtain regulatory approval for or commercialize our product candidates.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We rely on third-party contract research organizations (&#8220;CROs&#8221;), Universities or/clinical sites (&#8220;Vendors&#8221;), to coordinate, monitor and conduct of our clinical trials and to manage data for our clinical programs. We, our Vendors, and our clinical sites are required to comply with current Good Clinical Practices(&#8220;GCPs&#8221;), regulations and guidelines issued by the FDA and by similar governmental authorities in other countries where we are conducting clinical trials. We have an ongoing obligation to monitor the activities conducted by our Vendors and at our clinical sites to confirm compliance with these requirements. In the future, if we, our Vendors or our clinical sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our marketing applications. If our Vendors do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>Failures in our information technology and storage systems could significantly disrupt our business or force us to expend excessive costs.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We utilize complex information technology systems&nbsp;to support our business and store information. We cannot be sure that our systems will meet our future business needs or that necessary upgrades will operate as designed, which could result in excessive costs or disruptions in portions of our business. In particular, any disruptions, delays or deficiencies caused by our enterprise resource planning system could adversely affect our ability to process orders, ship products, provide services and customer support, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. In addition, despite the implementation of security measures, information technology systems are vulnerable to damage from a variety of sources, including computer viruses, unauthorized access, telecommunications or network failures, malicious human acts, terrorism and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our systems, sustained or repeated system failures that interrupt our ability to generate and maintain data, could result in a material disruption in our operations. Furthermore, to the extent that any disruption or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could face a variety of negative consequences, including regulatory actions or litigation, fines or penalties, adverse publicity, increased cybersecurity protection costs, and lost revenue.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>There is a risk that our measures to protect our systems from cyber-attack are not sufficient to avoid attacks by new sources and methods.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>Our business could be negatively affected by the loss of or the inability to hire key personnel.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Our future success depends in part on our ability to retain our key technical, sales, marketing and executive personnel and our ability to identify and hire additional qualified personnel. Competition for these personnel is intense, both in the industry in which we operate and where our operations are located. Further, we expect to grow our operations, and our needs for additional management and other key personnel are expected to increase. If we are not able to retain existing key personnel, or timely identify and hire replacement or additional qualified personnel to meet expected growth, our business could be adversely impacted. In addition, the loss of any of our key personnel, particularly key research and development personnel, could harm our business and prospects and could impede the achievement of our research and development, operation or strategic objectives.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>We face risks relating to our international sales, including inherent economic, political and regulatory risks, which could impact our financial performance, cause interruptions in our current business operations and impede our growth strategy.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Our products are primarily sold internationally, with the majority of our international sales to our distributors in Asia, Europe and South America. We currently sell and market our products through distributor organizations and sales agents which creates foreign risks include, among others:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>19</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in; TEXT-INDENT:-0.25in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>compliance with multiple different registration requirements and new and changing registration requirements, our inability to benefit from registration for our products inasmuch as registrations may be controlled by a distributor, and the difficulty in transitioning our product registrations;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in; TEXT-INDENT:-0.25in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>compliance with complex foreign and U.S. laws and regulations that apply to our international operations, including U.S. laws such as import/export limitations, the Foreign Corrupt Practices Act, and local laws;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in; TEXT-INDENT:-0.25in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>tariffs or other barriers as we continue to expand into new countries and geographic regions, especially related to China as tariffs are changing constantly;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>exposure to currency exchange fluctuations against the U.S. dollar;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>longer payment cycles, generally lower average selling prices and greater difficulty in accounts receivable collection;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>lack of ability to enforce receivables collections contracts in foreign legal courts;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>reduced, or lack of, protection for, and enforcement of, intellectual property rights;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in; TEXT-INDENT:-0.25in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>political and economic instability in some of the regions where we currently sell our products or that we may expand into in the future;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>complex and potentially adverse tax consequences; and</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=FONT-SIZE:10pt>diversion to the U.S. of our products sold into international markets at lower prices.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Currently, most of our international sales are negotiated for and paid in U.S. dollars. Nonetheless, these sales are subject to currency risks, since changes in the values of foreign currencies relative to the value of the U.S. dollar can render our products comparatively more expensive. These exchange rate fluctuations could negatively impact international sales of our products, as could changes in the general economic conditions in those markets. In order to maintain a competitive price for our products internationally, we may have to continue to provide discounts or otherwise effectively reduce our prices, resulting in a lower margin on products sold internationally. Continued change in the values of the Euro, the Mexican peso and other foreign currencies could have a negative impact on our business, financial condition and results of operations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>In addition, we have certain supply agreements with foreign vendors whereby we share the foreign currency exchange fluctuation risk. We may, in the future, enter into similar arrangements.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>Sales of our common stock in the public market could lower the market price for our common stock and adversely impact the trading price of our securities.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Future sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the then prevailing market price of our common stock and could make it more difficult for us to raise funds in the future through a public offering of our securities.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On July 21, 2020, we filed with the SEC a new &#8220;Shelf&#8221; registration statement on Form S-3. The new registration statement registers our common shares to be issued in a maximum aggregate amount of $90,000,000.&nbsp; Shares of our common stock may be sold from time to time under this registration statement once it is declared effective.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The issuance of additional shares of our common stock, or issuances of additional securities, could dilute the ownership interest of our common stockholders and could depress the market price of shares of our common stock and impair our ability to raise capital through the sale of additional equity securities. We cannot predict the size of future issuances or the effect, if any, that they may have on the market price for our common stock.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We also have a number of stockholders who own large blocks of our common stock. If one or more of these stockholders were to sell large portions of their holdings in a relatively short time, for liquidity or other reasons, the prevailing market price of shares of our common stock could be negatively affected.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>The price of our stock may fluctuate unpredictably in response to factors unrelated to our operating performance.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The stock market periodically experiences significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These broad market fluctuations may cause the market price of our common stock to drop. In particular, the market price of our common stock has been very volatile and unpredictable and may vary substantially in the future in response to:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; announcements by us or our competitors concerning technological innovations;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; introductions of new products;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FDA, SEC, FINRA and foreign regulatory actions against the Company;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>20</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; developments or disputes relating to patents or proprietary rights;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; failure to meet the expectations of stock market analysts and investors;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in stock market analyst recommendations regarding our common stock;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in healthcare policy in the U.S. or other countries; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>&#8226;<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=FONT-SIZE:10pt>lawsuits or liability claims from shareholders or other parties; and</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; general stock market conditions and other factors unrelated to our operating performance.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'><font style="FONT-SIZE:10pt; LINE-HEIGHT:120%">A sale of a substantial number of shares of the common stock by the Company may cause the price of our common stock to decline.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Trading of our common stock is not significant, therefore sales of a larger volume of the stock could adversely affect the stock price.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">As of August 26, 2016, the Company's stock has been traded on the Nasdaq Capital Market. &nbsp;Trading of the Company's stock is limited and liquidation of the Company&#8217;s stock may be difficult as there is a limited market for the Company&#8217;s stock.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'><b><font style="FONT-SIZE:10pt; LINE-HEIGHT:120%">Our ability to use our net operating loss carry forwards in the future may be subject to limitation.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Although the Company has Federal income tax net operating loss carryforwards of approximately $9,213,000 and California state income tax net operating loss carryforwards of approximately $5,025,000, use of these loss carryforwards will depend on future income in relationship to expirations dates of these carryforwards.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'><b><font style="FONT-SIZE:10pt; LINE-HEIGHT:120%">We do not anticipate declaring any cash dividends on our common stock.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'>&nbsp;</p> <div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We have never declared or paid cash dividends on our common stock and do not plan to pay any cash dividends in the near future. Our current policy is to retain all </font><font style=FONT-SIZE:10pt>funds and any earnings for use in the operation and expansion of our business. <font style=COLOR:black>As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future. Further, we may in the future become subject to contractual restrictions on, or prohibitions against, the payment of dividends. Consequently, in the foreseeable future, gains will likely only be experienced from investments in our common stock if the price of our common stock increases. There is no guarantee that our common stock will appreciate in value or even maintain the price at which shares were purchased, and returns may not be realized on investments in our common stock.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'>&nbsp;</p></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 1B.&nbsp; UNRESOLVED STAFF COMMENTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">None.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 2.&nbsp; &nbsp;PROPERTIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in'><font style=FONT-SIZE:10pt>The Company leases its office facilities. At May 31, 2020, the Company had approximately 22,000 square feet of floor space at its corporate headquarters at 17571 Von Karman Avenue in Irvine, California, 92614 which it has been leasing since 2009. The lease for its headquarters expired on August 31, 2016. &nbsp;The Company had an option to extend the term of its lease for two additional sixty-month periods. On November 30, 2015, the Company exercised its option to extend its lease for an additional sixty-month period and entered into the First Amendment to Lease wherein it extended its lease until August 31, 2021. The initial base rent for the lease extension was $21,000 per month, increasing to $23,637 through August 31, 2021. The rent is currently $22,948 per month and will increase on September 1, 2020 to $23,637 per month.&nbsp; The security deposit of $22,080 remains the same.<font style=COLOR:black>&nbsp;</font> In November 2016, the Company&#8217;s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space with initial base rent of $2,926 per month. The Company has one 10-year option to renew at the end of the initial lease period. The rent is currently $3,239 per month. &nbsp;Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. In addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany subsidiary.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LEGAL PROCEEDINGS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><a name=_Hlk48148933 /><a name=_Hlk48056653><font style=FONT-SIZE:10pt>On July 2, 2020, we received a notice of investigation and subpoena to produce information and documents from the Division of Enforcement of the SEC. The subpoena seeks information and documents related to events and circumstances leading up to our March 17, 2020 announcement that we had commenced shipping samples of our COVID-19 IgG/IgM Rapid Test to countries outside of the United States, and had initiated the application process with the United States Food and Drug Administration under the COVID-19 Emergency Use Authorization for approval to market and sell the test in the United States. The subpoena also seeks information and documents about the identity of any persons who were aware of the substance of the March 17, 2020 announcement prior to that date, as well as certain corporate policies and documentation. We are cooperating and intend to continue cooperating fully with the SEC&#8217;s investigation. At this time, we are unable to predict the duration, scope or outcome of this investigation.</font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>21</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 4.&nbsp; &nbsp;&nbsp;&nbsp; MINE SAFETY DISCLOSURES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Not applicable.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">PART II</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On August 2, 2016, the Company&#8217;s common stock became listed and began trading on the Nasdaq Capital Market stock exchange where it trades under the symbol BMRA. &nbsp;Previous to that date, the Company&#8217;s stock traded on the OTC Bulletin Board.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; TEXT-ALIGN:justify;FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><a name=_aciFooter11 /><font style=FONT-SIZE:10pt>As of May 31, 2020, the number of holders of record of Biomerica's common stock was approximately 810, excluding stock held in street name. The number of record holders does not bear any relationship to the number of beneficial owners of the common stock as most of the Company&#8217;s common stock is held in street name at securities brokerage firms. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company has not paid any cash dividends on its common stock in the past and does not plan to pay any cash dividends on its common stock in the foreseeable future. The Company's Board of Directors (&#8220;Board&#8221;) intends, for the foreseeable future, to retain any earnings to finance the continued operation and expansion of the Company's business.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On June 30, 2017, the Company filed an S-3 Registration Statement with the SEC primarily for the purposes of raising capital to support is research, development and intellectual property projects. The registration statement became effective on July 20, 2017. A prospectus supplement to the Form S-3 Registration Statement was filed December 4, 2017 which stated that up to $7,000,000 of funds would be raised from time to time under the Form S-3 Registration Statement through an At Market Issuance Sales Agreement (&#8220;ATM&#8221;) with B. Riley, FBR, acting as the agent for these transactions. As of May 31, 2020, a total of approximately $6,997,935 in gross proceeds had been raised under this prospectus supplement. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On March 20, 2020, the Company filed a second prospectus supplement to the base prospectus dated July 20, 2017 for purposes of raising up to $12,500,000 from time to time pursuant to the terms of the ATM. </font><font style=FONT-SIZE:10pt>As of May 31, 2020, a total of $6,817,329 in gross proceeds had been raised under this prospectus supplement.&nbsp; No additional shares will be sold under this prospectus supplement.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On July 21, 2020, the Company filed with the SEC a new &#8220;Shelf&#8221; registration statement on Form S-3 to replace the registration statement that expired the day before. The new registration statement registers common shares to be issued in a maximum aggregate amount of $90,000,000.&nbsp; Our shares of common stock may be sold from time to time under this registration statement once it is declared effective.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">We did not purchase any of our shares of common stock or other securities during our fiscal year ended May 31, 2020. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The table below provides information relating to our equity compensation plans as of May 31, 2020:</font></p> <div align=center> <table width=800 bordercolor=transparent style="WIDTH:600pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15.75pt> <td width=25% nowrap style="HEIGHT:15.75pt; WIDTH:25.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=3% nowrap style="HEIGHT:15.75pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=22% nowrap style="HEIGHT:15.75pt; WIDTH:22.36%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=3% nowrap style="HEIGHT:15.75pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=22% nowrap style="HEIGHT:15.75pt; WIDTH:22.36%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=3% nowrap style="HEIGHT:15.75pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=20% style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:20.18%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" rowspan=5 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Securities Remaining</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Available for Future Issuance</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Under Compensation Plans</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">(Excluding those Reflected in</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">First Column)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=25% nowrap style="HEIGHT:15.75pt; WIDTH:25.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=3% nowrap style="HEIGHT:15.75pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=22% nowrap style="HEIGHT:15.75pt; WIDTH:22.36%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=3% nowrap style="HEIGHT:15.75pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=22% nowrap style="HEIGHT:15.75pt; WIDTH:22.36%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=3% nowrap style="HEIGHT:15.75pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=25% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:25.28%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" rowspan=3 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Securities</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Plan</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Category</font></p></td> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=22% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:22.36%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" rowspan=3 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Number of Securities to Be</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;Issued Upon Exercise of </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;Outstanding Options</font></p></td> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=22% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:22.36%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" rowspan=3 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Compensation Plans</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Weighted-Average Exercise</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Price of Outstanding Options</font></p></td> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=25% nowrap style="HEIGHT:15pt; WIDTH:25.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=22% nowrap style="HEIGHT:15pt; WIDTH:22.36%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=22% nowrap style="HEIGHT:15pt; WIDTH:22.36%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=20% style="HEIGHT:15pt; WIDTH:20.18%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=25% nowrap style="HEIGHT:15pt; WIDTH:25.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Equity compensation </font></p></td> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=22% nowrap style="HEIGHT:15pt; WIDTH:22.36%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=22% nowrap style="HEIGHT:15pt; WIDTH:22.36%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=20% style="HEIGHT:15pt; WIDTH:20.18%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=25% nowrap style="HEIGHT:15.75pt; WIDTH:25.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Plans approved</font></p></td> <td width=3% nowrap style="HEIGHT:15.75pt; WIDTH:3.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=22% nowrap style="HEIGHT:15.75pt; WIDTH:22.36%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>1,789,251</font></p></td> <td width=3% nowrap style="HEIGHT:15.75pt; WIDTH:3.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=22% nowrap style="HEIGHT:15.75pt; WIDTH:22.36%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>$2.75</font></p></td> <td width=3% nowrap style="HEIGHT:15.75pt; WIDTH:3.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.18%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>799,041</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=25% nowrap style="HEIGHT:15pt; WIDTH:25.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">by Securities holders </font></p></td> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=22% nowrap style="HEIGHT:15pt; WIDTH:22.36%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=22% nowrap style="HEIGHT:15pt; WIDTH:22.36%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=20% style="HEIGHT:15pt; WIDTH:20.18%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>There were no sales of unregistered equity securities during the year ended May 31, 2020 except as described in Note 5-Shareholders&#8217; Equity- of the Consolidated Financial Statements.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>22</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 6.&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;SELECTED FINANCIAL DATA</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Not required.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 7.&nbsp; &nbsp;&nbsp;&nbsp; MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">EXCEPT FOR HISTORICAL INFORMATION CONTAINED HEREIN, THE STATEMENTS IN THIS ANNUAL REPORT ON FORM 10-K MAY BE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934 AND SECTION 27A OF THE SECURITIES ACT OF 1933. FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES WHICH MAY CAUSE BIOMERICA'S RESULTS IN FUTURE PERIODS TO DIFFER MATERIALLY FROM FORECASTED RESULTS. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;<font style=TEXT-TRANSFORM:uppercase>Like other businesses, WE are susceptible to macroeconomic downturns in the United States or abroad, as were experienced recently, that may affect the general economic climate and OUR performance or OUR customers.&nbsp; Aside from general macroeconomic downturns, the additional material factors, RISKS AND UNCERTAINTIES that could affect future financial results include, but are not limited to: </font>THE CONTINUED DEMAND FOR THE COMPANY'S PRODUCTS; AVAILABILITY OF RAW MATERIALS; RESULTS OF RESEARCH AND DEVELOPMENT ACTIVITIES; THE ABILITY TO RETAIN KEY EMPLOYEES AND CUSTOMERS; THE ABILITY TO COLLECT RECEIVABLES FROM CUSTOMERS; THE CONTINUED ABILITY OF THE COMPANY TO ATTAIN AND MAINTAIN THE LICENSES AND APPROVALS REQUIRED,.<font style=TEXT-TRANSFORM:uppercase>Regional or global pandemics and the economic and social disruptions these cause; terrorist attacks and the impact of such events; existing and potential increase in trade tariffs, especially with China, diminished or no access to raw materials that directly enter into our manufacturing process; shipping labor disruption or other major degradation of the ability to ship out products to end users; inability to successfully control our margins which are affected by many factors including competition and product mix; protracted shutdown of the U.S. border due to an escalation of terrorist or counter terrorist activity; any changes in our business relationships with international distributors or the economic climate they operate in; any event that has a material adverse impact on our foreign manufacturing operations may adversely affect our operations as a whole; failure to manage the future expansion of our business could have a material adverse effect on our revenues and profitability; possible costs in complying with government regulations and the delays in receiving required regulatory approvals or the enactment of new adverse regulations or regulatory requirements; numerous competitors, some of which have substantially greater financial and other resources than we do; potential claims and litigation brought by patients or medical professionals alleging harm caused by the use of or exposure to our products; recalls of products; inability to obtain FDA clearance on products or excessive costs incurred in order to obtain such approvals; regulatory actions taken by government agencies such as the FDA, SEC, USDA and other regulators; quarterly variations in operating results caused by a number of factors, including business and industry conditions; and other factors beyond our control. All these factors make it difficult to predict operating results for any particular period.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>23</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">EXCEPT AS MAY BE REQUIRED BY APPLICABLE LAW, WE MAY NOT UPDATE OR REVISE OUR FORWARD-LOOKING STATEMENTS AND THE LACK OF SUCH UPDATE DOES NOT IMPLY THAT ACTUAL EVENTS ARE AS ORIGINALLY EXPRESSED BY SUCH FORWARD-LOOKING STATEMENTS. YOU SHOULD READ THE DISCLOSURES IN THIS REPORT AND OTHER REPORTS, WHICH WE FILE WITH THE SECURITIES AND EXCHANGE COMMISSION, INCLUDING THE RISK FACTORS CONTAINED THEREIN.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">Overview</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Biomerica, Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH), is</font><font style=FONT-SIZE:10pt> a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care </font><font style="FONT-SIZE:10pt; COLOR:black">(physicians' offices and over-the-counter through drugstores and online) </font><font style=FONT-SIZE:10pt>and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases</font><font style="FONT-SIZE:10pt; COLOR:black">. Our diagnostic test kits are used to analyze blood, urine or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The</font><font style=FONT-SIZE:10pt> Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in'><font style=FONT-SIZE:10pt>Our primary focus is the research and development of revolutionary, patented diagnostic-guided therapy products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. If these DGT products prove effective in their clinical trials, and are ultimately cleared for sale by the FDA, the revenues potential to the Company is significant.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in'><font style=FONT-SIZE:10pt>Due to the global COVID-19 pandemic, in March 2020 we began redirecting and focused a majority of our resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been exposed to COVID-19. These diagnostic tests use a patient&#8217;s blood sample to determine if the patient has certain antibodies to COVID-19 that were created as part of their body&#8217;s immune response to a COVID-19 infection. During the fiscal fourth quarter, we began marketing and selling outside of the U.S. a disposable rapid finger-prick blood test, which detects COVID-19 IgG/IgM antibodies within 10 minutes. </font><font style="FONT-SIZE:10pt; COLOR:black">This test is designed to be performed by trained professionals anywhere, e.g. airports, schools, work, pharmacies and doctors&#8217; offices. </font><font style=FONT-SIZE:10pt>Following fiscal 2020 year-end we submitted to the FDA an application under an EUA to sell in the U.S.</font><font style="FONT-SIZE:10pt; COLOR:black"> a lab-scale, high throughput ELISA COVID-19 antibody test kit that would be sold to labs and hospitals to perform COVID-19 antibody testing. The Company also anticipates selling this test kit outside of the U.S. under a CE Mark. Initial sales for this product are expected during the Company&#8217;s second quarter of fiscal 2021 upon EUA clearance. The Company manufactures this COVID-19 ELISA test on its automated equipment at the Company&#8217;s California facility that is also used to produce serology antibody tests for other diseases. These antibody tests are designed to detect if a person has been infected by COVID-19 and mounted an immune response even if the infection was asymptomatic. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">RESULTS OF OPERATIONS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Our consolidated net sales were $6,692,711 for fiscal 2020 compared to $5,200,682 for fiscal 2019. This represents an increase of $1,492,029, or 28.7%.&nbsp;<a name=_Hlk49411916>This increase in annual sales is primarily attributable to sales of COVID-19 tests during the last quarter of the fiscal year, which offset decreases in other product lines that were negatively impacted by the COVID-19 pandemic and related national and international mandates affecting consumers. </a>Our consolidated net sales were $2,725,000 for the fiscal fourth quarter 2020, compared to $1,165,860 for fiscal fourth quarter of 2019. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Consolidated cost of sales in fiscal 2020 as compared to fiscal 2019 increased from $3,908,668 to $4,910,935, or by $1,002,267. The percentage of cost of sales relative to sales decreased from 75.2% to 73.4%, due to various factors, primarily due to higher margins on the COVID-19 products. Our cost of goods sold for the fiscal fourth quarter 2020 were $1,991,378, or 73.0%, compared to $985,053, or 84.4%, for the fourth quarter of 2019.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Consolidated selling, general and administrative costs increased in fiscal 2020 as compared to fiscal 2019 from $2,025,706 to $2,274,415, or by $248,709, or 12.3%.&nbsp;The increase was due to increases in legal and consulting fees, personnel costs as the Company is expanding and strengthening its management team in sales and marketing, and an increase in administrative expenses due to a non-cash option expense of $156,750 in fiscal 2020 compared to $143,299 in the prior fiscal year. Our consolidated selling, general and administrative expenses were $559,872 for the fiscal fourth quarter 2020, compared to $536,816 for the fourth quarter of 2019.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>24</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Consolidated research and development expense was $1,910,209 in fiscal 2020 as compared to $1,679,098 in fiscal 2019, an increase of $231,111, or 13.8%, primarily as a result of increases in costs related to the research, development and validation of COVID-19 tests, and increased costs related to our clinical trials for our </font><font style=FONT-SIZE:10pt>InFoods&reg; IBS<font style=COLOR:black> product. &nbsp;See &#8220;Research and Development&#8221; for a more extensive description of the research being conducted. Our consolidated research and development expenses were $661,610 for the fourth quarter of 2020, compared to $408,810 for the fourth quarter of 2019. These costs increased in fiscal 2020 due to additional research on COVID-19 products.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Interest expense remained constant in fiscal 2020 at $9 as compared to $47 in fiscal 2019. Interest and dividend income for those same years increased from $44,014 to $71,193, respectively. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">LIQUIDITY AND CAPITAL RESOURCES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">As of May 31, 2020, the Company had cash and cash equivalents in the amount of $8,641,027 as compared to $686,785 of cash and cash equivalents as of May 31, 2019. &nbsp;As of May 31, 2020 and 2019, the Company had working capital of $13,289,670 and $3,230,535, respectively.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><i><font style="FONT-SIZE:10pt; COLOR:black">Operating Activities</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">During fiscal 2020, cash used in operating activities was $4,297,498 as compared to $2,244,039 in fiscal 2019. The factors that contributed to this were a loss of $2,339,054, an increase in accounts receivable of $309,090, an increase in inventories of $717,460, and an increase in prepaid expenses of $1,306,681, which was a result of prepayments for inventory purchase orders.&nbsp; These were offset by an increase in accrued compensation of $51,798, a non-cash stock option expense of $200,470 and depreciation and amortization of $129,172. &nbsp;During fiscal 2019, the Company had a net loss of $2,393,060 and an increase in accounts receivable of $670,126. &nbsp;These were offset by an increase in accounts payable and accrued expenses of $343,994, a non-cash stock option expense of $151,224 and depreciation and amortization of $162,905.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><i><font style="FONT-SIZE:10pt; COLOR:black">Investing Activities</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">During fiscal 2020, cash used in investing activities was $118,927 as compared to $171,111 in fiscal 2019. During fiscal 2020, the Company purchased $33,608 of property and equipment and had $85,319 in increased intangible assets related to patents. During fiscal 2019, the Company purchased $101,137 of property and equipment and $69,974 in increased intangible assets related to patents. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><i><font style="FONT-SIZE:10pt; COLOR:black">Financing Activities</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Cash provided by financing activities in fiscal 2020 was $12,373,977 as compared to $1,907,427 in fiscal 2019.&nbsp; In fiscal 2020 and 2019, the Company had proceeds from the exercise of stock options of $223,534 and $121,790, respectively. During fiscal 2020 and 2019, the Company received $10,232,857 and $1,776,575, respectively, in net proceeds from the sale of common stock through the S-3 Registration Statement, net of subscriptions receivable. The common stock issued in fiscal 2020 and fiscal 2019 was issued under the S-3 &#8220;shelf&#8221; Registration Statement base prospectus filed with the SEC on June 30, 2017 and declared effective by the SEC on July 20, 2017, and under the prospectus supplement and At Market Issuance Sales Agreement, filed with the SEC on December 4, 2017 and the prospectus supplement filed with the SEC on March 20, 2020. (See Shareholders&#8217; Equity and Subsequent Events in the notes to the consolidated financial statements for further details about SEC registrations).</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On February 24, 2020, Biomerica, Inc. (the &#8220;Company&#8221;) entered into and closed on a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with </font><font style=FONT-SIZE:10pt>Palm Global Small Cap Master Fund LP (&#8220;Palm&#8221;) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed to purchase from the Company, 571,429 shares of the Company&#8217;s Series A 5% Convertible Preferred Stock, $0.08 par value per share for a purchase price of approximately $2 million, or $3.50 per Series A Preferred Share. Under the terms of the Stock Purchase Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company&#8217;s common stock. On March 24, 2020, Palm converted 250,000 shares of Convertible Preferred Stock into 250,000 shares of unregistered common stock. The Company received approximately $1,917,586 in net proceeds from this sale.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The Company intends to use the net proceeds from this offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>25</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Subsequent Events</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><u><font style=FONT-SIZE:10pt></font></u>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 12pt'><font style="FONT-SIZE:10pt; COLOR:black">On June 16, 2020, the Company announced it had submitted to the U.S. FDA an EUA application for an ELISA lab-based serology blood test for the detection of antibodies that identify if a person has been infected with COVID-19.&nbsp; This is the third COVID-19 antibody test introduced by the Company. The other two, which are finger-prick rapid tests, are only being sold outside of the US. The Company also intends to obtain a CE Mark to allow the sale and marketing of this ELISA laboratory test outside of the US.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On July 20, 2020, the Company filed with the SEC an S-3 registration statement that among other things registered all of the common shares issued, or to be issued, to Palm upon conversion of the Convertible Preferred Stock into common shares. The Company anticipates this registration statement shall become effective promptly following the filing of this annual report on Form 10-K with the SEC. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 12pt'><font style="FONT-SIZE:10pt; COLOR:black">On July 20, 2020, the Company&#8217;s outstanding Securities and Exchange Commission (&#8220;SEC&#8221;) Form S-3 &#8220;Shelf&#8221; registration statement dated July 20, 2017 expired. This prior registration statement registered an indeterminant number of shares equating to a maximum aggregate offering amount of $45,000,000 of shares. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On July 20, 2020, the Company filed with the SEC a new Form S-3 &#8220;Shelf&#8221; registration statement to replace the registration statement that expired on that day. The new registration statement registers common shares to be issued in a maximum aggregate amount of $90,000,000. On July 27, 2020 the Company received notice from the SEC that they did not intend to review this new registration statement, and as such the Company expects this Form S-3 registration statement to be declared effective promptly following the filing of this Form 10-K. The Company filed for a larger maximum issuance amount in anticipation of the approaching completion of the Company&#8217;s clinical trials for its </font><font style=FONT-SIZE:10pt>InFoods&reg; IBS<font style=COLOR:black> product and the subsequent product launch that may require raising significant capital associated with this substantial opportunity to grow revenues and profits. Further, the Company&#8217;s current data shows that the InFoods technology platform has great promise in diagnosing and treating several other disease states outside of IBS. The pursuit of this expanded portfolio of disease states and other opportunities may also require significant capital in the future.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On August 7, 2020, the Company received notice of allowance from the USPTO of a key patent pertaining to the Company&#8217;s InFoods IBS Product. This is the second patent issued in the U.S. for the InFoods&reg; IBS technology, and contains broad issued claims that the Company believes create strong protection for the InFoods&reg; IBS product that is in clinical trials with several major medical institutions including Mayo Clinic, University of Texas Houston, Michigan Medicine University of Michigan, Houston Methodist and Beth Israel Deaconess Medical Center, a Harvard teaching hospital. The Company has also been issued patents for the InFoods&reg; IBS product in Japan and Korea, and has numerous InFoods&reg; IBS patents in review and prosecution in other countries. In addition, the Company has also filed several patents, both in the U.S. and internationally, for the InFoods&reg; IBS technology platform that include broad claims protecting the uses of the Infoods Technology to diagnose and treat other disease states outside of IBS. Several of these patents are currently in active prosecution and review. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On August 3, 2020, the Company hired Steven Sloan, whom the Board intends to appoint as Chief Financial Officer (&#8220;CFO&#8221;) on September 3, 2020, following the filing of this Form 10K.&nbsp; In approximately December 2019, Janet Moore, the Company&#8217;s current CFO, announced to the Board her desire to retire from the Company at some point in the future once a suitable replacement could be found and hired. As such, the Company conducted an exhaustive search for a new CFO, and having determined Mr. Sloan to be an excellent candidate, hired Mr. Sloan on August 3, 2020.&nbsp; At the Board meeting held on August 27, 2020, the Board officially appointed and approved Mr. Sloan to serve as the Company&#8217;s CFO effective September 3, 2020.&nbsp; Mr. Sloan&#8217;s background and experience includes 13 years at General Electric with roles in internal audit, corporate finance and manufacturing finance.&nbsp; Most recently, Mr. Sloan spent 10 years with medical device maker Medtronic.&nbsp; At Medtronic, Mr. Sloan worked in four divisions over the 10 years, and most recently served as a divisional finance director.&nbsp; The Board is excited to have Mr. Sloan join the company as an executive officer. Janet Moore will remain an employee of the Company during a transition period. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On August 27, 2020, at a Board meeting held on that day, the Board nominated, unanimously approved and elected Cathy Coste to join the Board of Directors as a member of the Board effective September 3, 2020. Ms. Coste was elected to serve as a Board member until the Company&#8217;s annual meeting in December 2020, at which time she will stand for re-election along with several other members of the Board. Ms. Coste is replacing Janet Moore, the Company&#8217;s current CFO and Board member who, as previously stated, has announced her retirement from the Company and the Board and will not be standing for re-election at the upcoming annual meeting in December 2020. Cathy Coste is in the process of retiring from Deloitte and Touche where she is currently a senior partner and is an industry executive leader in Deloitte&#8217;s life sciences group. During her career at Deloitte, Ms. Coste has been directly involved with over 30 life science corporations, the majority of which were large-cap and medium-cap public corporations. Ms. Coste also has extensive public company Board experience, often attending multiple Board and Board Committee meetings per month. Ms. Coste also has extensive experience in Sarbanes-Oxley compliance, corporate risk analysis and management, cyber risk assessment, fraud prevention, IT systems analysis and upgrades, internal controls and corporate governance. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 16.2pt 0pt 0in' align=center><font style=FONT-SIZE:10pt>26</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 16.2pt 0pt 0in' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 12pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>On August 27, 2020, at a Board meeting held on that day, Board Member, Allen Barbieri, agreed to change from independent outside director status to become an executive director. Further, Mr. Barbieri&#8217;s title was changed to Executive Vice- Chairman. As the Company&#8217;s many new products, projects and opportunities have expanded, the CEO and the other members of the Board felt it was necessary to have additional executive support with managing the strategic transactions, operations and affairs of the Company, and to manage communications between the Board and management. Mr. Barbieri agreed to take on this additional responsibility. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 12pt; TEXT-INDENT:0in'><font style=FONT-SIZE:10pt>On August 27, 2020, at a Board of Directors meeting held on that day, with the election of Ms. Coste as a member of the Board, and the designation of Mr. Barbieri as an executive Board member, the Board deemed it necessary to make certain changes to the Committees of the Board. As such, effective September 3, 2020, the following Board members will be serving in the following Board committees;&nbsp; 1) Audit Committee: Cathy Coste, Mark Sirgo and Jane Emerson, with Cathy Coste as the Chair of the Committee,&nbsp; 2) Compensation Committee: Mark Sirgo, Francis Cano and Jane Emerson, with Mark Sirgo as the Chair of the Committee,&nbsp; 3) Nominating and Corporate Governance Committee: Francis Cano, Cathy Coste and Jane Emerson, with Francis Cano as Chair of the Committee. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;<b><font style="FONT-SIZE:10pt; COLOR:black">OFF BALANCE SHEET ITEMS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">There were no off-balance sheet arrangements as of May 31, 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">CRITICAL ACCOUNTING POLICIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The discussion and analysis of our financial condition and results of operations are based on the consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. Note 2 of the Consolidated Financial Statements describe the significant accounting policies essential to the consolidated financial statements. The preparation of these consolidated financial statements requires estimates and assumptions that affect the reported amounts and disclosures.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In general, the critical accounting policies that may require judgments or estimates relate specifically to Revenues, Allowance for Doubtful Accounts, Inventory Reserves, Stock-Based Compensation, Income Taxes, Right-of-Use Asset and Lease Liability.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">We believe the following to be critical accounting policies as they require more significant judgments and estimates used in the preparation of our consolidated financial statements. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when transfer of control of goods has occurred and at which point title passes. An allowance is established, if necessary, for estimated returns as revenue is recognized. Services for some contract work are invoiced and recognized for work that has been performed as the project progresses.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">An allowance for doubtful accounts is established for estimated losses resulting from the inability of our customers to make required payments. The assessment of specific receivable balances and required reserves is performed by management and discussed with the audit committee. We have identified specific customers where collection is not probable and have established specific reserves, but to the extent collection is made, the allowance will be released. Additionally, if the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Reserves are provided for excess and obsolete inventory, which are estimated based on a comparison of the quantity and cost of inventory on hand to management's forecast of customer demand. Customer demand is dependent on many factors and requires us to use significant judgment in our forecasting process. We must also make assumptions regarding the rate at which new products will be accepted in the marketplace and at which customers will transition from older products to newer products. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of, even if in subsequent periods we forecast demand for the product.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>27</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>We measure stock-based compensation costs at fair value, including estimated forfeitures, and recognize the expense over the period that the recipient is required to provide service in exchange for the award, which generally is the vesting period. We use the Black-Scholes option pricing model to measure the fair value of our stock options. In determining the amount of expense to be recorded, we also estimate forfeiture rates for all awards based on historical experience to reflect the probability that employees will complete the required service period. Employee retention patterns could vary in the future and result in a change to our estimated forfeiture rate which would directly impact stock-based compensation expense.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">We follow authoritative guidance to evaluate whether a valuation allowance should be established against our deferred tax assets based on the consideration of all available evidence using a &#8220;more likely than not&#8221; standard.&nbsp; In making such judgments, significant weight is given to evidence that can be objectively verified.&nbsp;We assess our deferred tax assets annually under more likely than not scenarios in which they may be realized through future income.&nbsp;We have determined that although we believe our net deferred tax assets of $3,175,000 will be utilized at a future date, based on our recent losses and plans to continue our research and development, we have established a valuation allowance of $3,175,000, which fully covers the asset.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 13.55pt 0pt 0in'><u><font style=FONT-SIZE:10pt>Leases</font></u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 13.55pt 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in'><font style=FONT-SIZE:10pt>During the year ended May 31, 2020, the Company adopted ASC 842, Leases. As a result, the existing deferred rent liability was netted against the Right-of-Use Asset which was capitalized at that time.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in; TEXT-INDENT:0.5in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0in'><font style=FONT-SIZE:10pt>In February 2016, the Financial Accounting Standards Board issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&nbsp; Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&nbsp; Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&nbsp; Leases will be classified as financing or operating which will drive the expense recognition pattern.&nbsp; For lessees, the statement of operations presentation and expense recognition pattern for financing and operating leases is similar to the current model for capital and operating leases, respectively.&nbsp; The Company has elected to exclude short-term leases.&nbsp; The update also requires additional disclosures that will better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases.&nbsp; The Company adopted this guidance as of June 1, 2019, the required effective date, using the effective date transition method.&nbsp; As permitted under the effective date transition method, financial information and disclosure for periods prior to the date of initial application will not be updated. An adjustment to opening accumulated deficit was not required in conjunction with adoption. The adoption of this statement resulted in a right-of-use asset being recorded in the amount of $1,942,999 and a lease liability being recorded in the amount of $1,980,970. Both will be amortized over the life of the underlying leases. For additional information, see Note 8-Commitments and Contingencies. The Company has elected not to reassess whether expired or existing contracts contain leases, or reassess the classification of existing leases as of the adoption date. The Company leases office space and copy machines, all of which are operating leases.&nbsp; Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&nbsp; The leases do not include the options to purchase the leased property.&nbsp; The depreciable life of assets and leasehold improvements are limited by the expected lease term.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black"><b>RECENT ACCOUNTING PRONOUNCEMENTS</b></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">See Note 2 to our consolidated&nbsp;financial statements for a listing of adopted and soon to be adopted accounting pronouncements.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 7A.&nbsp;&nbsp; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Not required.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Exhibit 99.3, "Biomerica, Inc. and Subsidiaries Consolidated Financial Statements" is incorporated herein by this reference.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>28</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">None.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 9A.&nbsp;&nbsp; CONTROLS AND PROCEDURES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Attached as exhibits to this Form 10-K are certifications of our Chief Executive Officer (&#8220;CEO&#8221;) and Chief Financial Officer (&#8220;CFO&#8221;) that are required in accordance with Rule 13a-14 of the Exchange Act. This &#8220;Disclosure Controls and Procedures&#8221; section includes information concerning the controls and controls evaluation referred to in the certifications.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&nbsp;&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">EVALUATION OF DISCLOSURE CONTROLS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Our management evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act as of the end of the period covered by this report. &nbsp;Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. &nbsp;The disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives and the CEO and CFO have concluded that our disclosure controls and procedures are effective at the &#8220;reasonable assurance&#8221; level. Based on that evaluation the CEO and CFO concluded that information required to be disclosed in the reports that we file and submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms; and (2) accumulated and communicated to the Company&#8217;s management, including its CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">For the reasons discussed in "Management's Report on Internal Control over Financial Reporting" below, Company management, including the CEO and CFO concluded that, as of May 31, 2020, the Company's internal control over financial reporting was effective. Management has concluded that the consolidated financial statements included in this annual report present fairly, in all material respects, the Company's financial position, results of operations, and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">There have been no changes in our internal control over financial reporting identified in connection with the evaluation that occurred during the last fiscal year that have materially affected, or that are reasonably likely to affect, our internal control over financial reporting.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Company management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. The Company's internal control over financial reporting is designed to provide reasonable assurance to the Company's management and Board of Directors regarding the reliability of financial reporting and the preparation and fair presentation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">A Company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the consolidated financial statements.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The effectiveness of any system of internal control over financial reporting is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating and evaluating the controls and procedures. Because of these inherent limitations, internal control over financial reporting cannot provide absolute assurance regarding the reliability of financial reporting and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>29</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Company management, with the participation of the CEO and the CFO, evaluated the effectiveness of the Company's disclosure controls and procedures as defined in Rules 13(a)-15(e) and 15(d)-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of the end of the period covered by this report. In making this assessment, Management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in Internal Control - Integrated Framework (2013). Based on this assessment, management, with the participation of the CEO and CFO, believes that, as of May 31, 2020, the Company's internal control over financial reporting was effective based on those criteria.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Company management will continue to monitor and evaluate the effectiveness of its disclosure controls and procedures and its internal controls over financial reporting on an ongoing basis and are committed to taking further action and implementing improvements, as necessary and as funds allow.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Note: This 10-K does not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management's report in this 10-K.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 9B.&nbsp;&nbsp; OTHER INFORMATION.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">None.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">PART III</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 10.&nbsp;&nbsp;&nbsp; DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</font></b><font style="FONT-SIZE:10pt; COLOR:black">.&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">This information is incorporated by reference to the Company's proxy statement for its 2020 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 11.&nbsp;&nbsp; &nbsp;EXECUTIVE COMPENSATION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">This information is incorporated by reference to the Company's proxy statement for its 2020 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 12.&nbsp;&nbsp;&nbsp; SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">This information is incorporated by reference to the Company's proxy statement for its 2020 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 13.&nbsp;&nbsp; CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Other information regarding related transactions is incorporated by reference to the Company's proxy statement for its 2020 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ITEM 14.&nbsp;&nbsp; PRINCIPAL ACCOUNTANT FEES AND SERVICES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Please refer to the Company&#8217;s proxy statement for its 2020 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company&#8217;s fiscal year ended May 31, 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>30</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">PART IV</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <table width=800 bordercolor=transparent style=WIDTH:600pt cellpadding=0 cellspacing=0> <tr> <td width=100% style="WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>ITEM 15. EXHIBITS LIST AND FINANCIAL SCHEDULES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The following documents are filed as part of this Annual Report on Form&nbsp;10-K: </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 260pt 0pt 0in'><font style=FONT-SIZE:10pt>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1. <i>Consolidated Financial Statements</i></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reference is made to the Index to the consolidated financial statements as set forth on page&nbsp;FS-1 of this Annual Report on Form&nbsp;10-K. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2. <i>Consolidated Financial Statement Schedules</i></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All schedules have been omitted as the pertinent information is either not required, not applicable, or otherwise included in the financial statements and notes thereto. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3. <i>Exhibits&nbsp;</i></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See below.</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <table width=80% bordercolor=transparent style="WIDTH:80%; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Exhibit No.</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Description</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" /> </tr><tr style=HEIGHT:0.35in> <td width=10% style="HEIGHT:0.35in; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">3.1</font></p></td> <td width=89% style="HEIGHT:0.35in; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Certificate of Incorporation of Registrant filed with the Secretary of the State of Delaware on September 22, 1971 (incorporated by reference to Exhibit 3.1 filed with Amendment No. 1 to Registration Statement on Form S-1, Commission File No. 2-83308).</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:25.5pt> <td width=10% style="HEIGHT:25.5pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">3.2</font></p></td> <td width=89% style="HEIGHT:25.5pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Certificate of Amendment to Certificate of Incorporation of Registrant filed with the Secretary of the State of Delaware on February 6, 1978 (incorporated by reference to Exhibit 3.1 filed with Amendment No. 1 to Registration Statement on Form S-1, Commission File No. 2-83308).</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:25.5pt> <td width=10% style="HEIGHT:25.5pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">3.3</font></p></td> <td width=89% style="HEIGHT:25.5pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Certificate of Amendment to Certificate of Incorporation of Registrant filed with the Secretary of the State of Delaware on February 4, 1983 (incorporated by reference to Exhibit 3.1 filed with Amendment No. 1 to Registration Statement on Form S-1, Commission File No. 2-83308).</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:25.5pt> <td width=10% style="HEIGHT:25.5pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">3.4</font></p></td> <td width=89% style="HEIGHT:25.5pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Certificate of Amendment to Certificate of Incorporation of Registrant filed with the Secretary of the State of Delaware on January 19, 1987 (incorporated by reference to Exhibit 3.4 filed with Form 8 Amendment No. 1 to the Registrant's Annual Report on Form 10-K for the fiscal year ended May 31, 1987).</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:25.5pt> <td width=10% style="HEIGHT:25.5pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">3.5</font></p></td> <td width=89% style="HEIGHT:25.5pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Certificate of Amendment of Certificate of Incorporation of Registrant filed with the Secretary of the State of Delaware on November 4, 1987 (incorporated by reference to Exhibit 3.1 filed with Amendment No. 1 to Registration Statement on Form S-1, Commission File No. 2-83308).</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">3.6</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 filed with Amendment No. 1 to Registration Statement on Form S-1, Commission File No. 2-83308).</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:25.5pt> <td width=10% style="HEIGHT:25.5pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">3.7</font></p></td> <td width=89% style="HEIGHT:25.5pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Certificate of Amendment of Certificate of Incorporation of Registrant filed with the Secretary of the State of Delaware on December 20, 1994 (incorporated by reference to Exhibit 3.7 filed with Registrant's Annual Report on Form 10-KSB for the fiscal year ended May 31, 1995).</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:25.5pt> <td width=10% style="HEIGHT:25.5pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">3.8</font></p></td> <td width=89% style="HEIGHT:25.5pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black"><a href=http://www.sec.gov/Archives/edgar/data/73290/000102140800002832/0001021408-00-002832-0002.txt>First Amended and Restated Certificate of Incorporation of Biomerica, Inc. filed with the Secretary of State of Delaware on August 1, 2000 (incorporated by reference to Exhibit 3.8 filed with the Registrant's Annual Report on Form 10-KSB for the fiscal year ended May 31, 2000).</a></font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:25.5pt> <td width=10% style="HEIGHT:25.5pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">4.1</font></p></td> <td width=89% style="HEIGHT:25.5pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Specimen Stock Certificate of Common Stock of Registrant (incorporated by reference to Exhibit 4.1 filed with Registrant's Registration Statement on Form SB-2, Commission No. 333-87231 filed on September 16, 1999).</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>31</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <table width=80% bordercolor=transparent style="WIDTH:80%; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:25.5pt> <td width=10% style="HEIGHT:25.5pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">10.1</font></p></td> <td width=89% style="HEIGHT:25.5pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black"><a href=http://www.sec.gov/Archives/edgar/data/73290/000101968709003694/lease1.htm>Standard Industrial/Commercial Single-Tenant Lease for 17571 Von Karman Avenue, Irvine, CA 92614, incorporated by reference to Exhibit 10.1 of the Company's August 31, 2009 Form 10Q filed October 15, 2009.</a></font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:25.5pt> <td width=10% style="HEIGHT:25.5pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">10.4</font></p></td> <td width=89% style="HEIGHT:25.5pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">2010 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on February 2, 2012.</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:25.5pt> <td width=10% style="HEIGHT:25.5pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">10.5</font></p></td> <td width=89% style="HEIGHT:25.5pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">2014 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 22, 2015.</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; BACKGROUND:#80ffff">10.6</font></p></td> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; BACKGROUND:#80ffff">2017 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 10, 2018.</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; BACKGROUND:#80ffff">10.7</font></p></td> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; BACKGROUND:#80ffff">2020 Stock Incentive Plan as approved by the Board on December 11, 2019, and to be voted on by shareholders at the shareholder meeting to be held December 20, 2020.</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">23.1</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black"><a href=exhibit23_1.htm>Consent of Independent Registered Public Accounting Firm (PKF, LLP).</a></font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">31.1</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black"><a href=exhibit31_1.htm>Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">31.2</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black"><a href=exhibit31_2.htm>Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">32.1</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black"><a href=exhibit32_1.htm>Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">32.2</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black"><a href=exhibit32_2.htm>Certification of Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">99.3</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Biomerica, Inc. and Subsidiaries Consolidated Financial Statements</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">101.INS</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">XBRL Instance Document.</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">101.SCH</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">XBRL Taxonomy Extension Schema Document.</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">101.CAL</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">XBRL Taxonomy Extension Calculation Linkbase Document.</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">101.DEF</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">XBRL Taxonomy Extension Definition Linkbase Document.</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">101.LAB</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">XBRL Taxonomy Extension Label Linkbase Document.</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=10% style="HEIGHT:15.75pt; WIDTH:10.52%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <td width=89% style="HEIGHT:15.75pt; WIDTH:89.48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> </tr><tr style=HEIGHT:15pt> <td width=10% style="HEIGHT:15pt; WIDTH:10.52%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">101.PRE</font></p></td> <td width=89% style="HEIGHT:15pt; WIDTH:89.48%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">XBRL Taxonomy Extension Presentation Linkbase Document.</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The certifications attached as Exhibits 32.1 and 32.2 accompany this Annual Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant&#8217;s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>32</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">SIGNATURES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=51% style="HEIGHT:15pt; WIDTH:51.78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">BIOMERICA, INC.</font></b></p></td></tr> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=51% style="HEIGHT:15pt; WIDTH:51.78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Registrant</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=51% style="HEIGHT:15pt; WIDTH:51.78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=51% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:51.78%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">By /s/ Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=51% style="HEIGHT:15pt; WIDTH:51.78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Zackary S. Irani,</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=51% style="HEIGHT:15pt; WIDTH:51.78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Chief Executive Officer</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=51% style="HEIGHT:15pt; WIDTH:51.78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=48% nowrap style="HEIGHT:15pt; WIDTH:48.22%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=51% style="HEIGHT:15pt; WIDTH:51.78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Dated: August 31, 2020</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Signature and Capacity</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=45% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:45.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">/s/ Zackary S. Irani &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=20% style="HEIGHT:15pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">Date: 8/31/20</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Zackary S. Irani</font></p></td> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Director, Chief Executive Officer</font></p></td> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=45% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:45.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">/s/ Janet Moore &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=20% style="HEIGHT:15pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">Date: 8/31/20</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Janet Moore,</font></p></td> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Secretary, Director, Chief Financial Officer</font></p></td> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=45% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:45.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">/s/ Francis R. Cano, Ph.D. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=20% nowrap style="HEIGHT:15pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">Date: 8/31/20</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Francis R. Cano, Ph.D.</font></p></td> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Director</font></p></td> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=45% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:45.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">/s/ Allen Barbieri &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=20% style="HEIGHT:15pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">Date: 8/31/20</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Allen Barbieri</font></p></td> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Director, Audit Committee Member</font></p></td> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=45% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:45.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">/s/ Jane Emerson, M.D., Ph.D. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=20% nowrap style="HEIGHT:15pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">Date: 8/31/20</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Jane Emerson, M.D., Ph.D</font></p></td> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Director, Audit Committee Member</font></p></td> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=45% nowrap style="HEIGHT:15pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=20% nowrap style="HEIGHT:15pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=34% style="HEIGHT:15pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=45% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:45.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">/s/ Mark Sirgo,&nbsp; Pharm.D&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=20% nowrap style="HEIGHT:15pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">Date: 8/31/20</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Mark Sirgo, Pharm.D., Audit Committee Member</font></p></td> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=45% style="HEIGHT:15.75pt; WIDTH:45.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Director</font></p></td> <td width=20% style="HEIGHT:15.75pt; WIDTH:20.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=34% style="HEIGHT:15.75pt; WIDTH:34.64%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr></table></div></div><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"'><br clear=all style=PAGE-BREAK-BEFORE:none></font> <div style=page:WordSection2> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>33</font></p> <div style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">BIOMERICA, INC. &nbsp;AND SUBSIDIARIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black"><a name=TOC>TABLE OF CONTENTS</a></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=800 bordercolor=transparent style="WIDTH:600pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black"><a href=#Report>Report of Independent Registered Public Accounting Firm</a></font></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">FS-2</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">CONSOLIDATED FINANCIAL STATEMENTS</font></b></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black"><a href=#BS>Consolidated Balance Sheets as of May 31, 2020 and 2019</a></font></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">FS-3</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black"><a href=#IS>Consolidated Statements of Operations and Comprehensive Loss for the Years Ended May 31, 2020 and 2019</a></font></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">FS-4</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black"><a href=#SSE>Consolidated Statements of Shareholders' Equity for the Years Ended May 31, 2020 and 2019</a></font></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">FS-5</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black"><a href=#CFS>Consolidated Statements of Cash Flows for the Years Ended May 31, 2020 and 2019</a></font></p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td style="HEIGHT:15.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">FS-6</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" /> <td style="HEIGHT:15.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td nowrap style="HEIGHT:15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black"><a href=#Notes>Notes to Consolidated Financial Statements</a></font></p></td> <td nowrap style="HEIGHT:15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td nowrap style="HEIGHT:15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">FS-7 &#8211; FS-22</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:6pt 0in' align=center><b><font style='FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white'><a name=Report>REPORT</a> OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:6pt 0in' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:left; MARGIN:0in 0in 0pt' align=left><font style='FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white'>Board of Directors and Shareholders<br>Biomerica, Inc. and Subsidiaries</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:left; MARGIN:0in 0in 0pt' align=left><font style='FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white'>Irvine, California</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:left; MARGIN:0in 0in 0pt' align=left>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:6pt 0in'><u><font style='FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white'>Opinion on the Consolidated Financial Statements</font></u></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:6pt 0in'><font style='FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white'>We have audited the accompanying consolidated balance sheets of Biomerica, Inc. (a Delaware Corporation) and Subsidiaries (the &#8220;Company&#8221;) as of May 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, shareholders&#8217; equity, and cash flows for each of the two years in the period ended May 31, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of May 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended May 31, 2020, in conformity with accounting principles generally accepted in the United States of America.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:6pt 0in'><u><font style='FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white'>Basis for Opinion</font></u></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:6pt 0in'><font style='FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white'>These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits.&nbsp; We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:6pt 0in'><font style='FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white'>We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.&nbsp; The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.&nbsp; As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.&nbsp; Accordingly, we express no such opinion.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:6pt 0in'><font style='FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white'>Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.&nbsp; Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.&nbsp; Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.&nbsp; We believe that our audits provide a reasonable basis for our opinion.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>/s/PKF, LLP</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>We have served as the Company&#8217;s auditor since 2004.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>San Diego, California</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>August 31, 2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><a name=page_23><font style=FONT-SIZE:10pt>FS-2</font></a></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p></div> <div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b></b>&nbsp;</p> <div align=center> <table width=1000 bordercolor=transparent style="WIDTH:750pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:30pt> <td width=100% colspan=6 nowrap style="HEIGHT:30pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;<b>BIOMERICA, INC. AND SUBSIDIARIES</b></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black"><a name=BS>CONSOLIDATED BALANCE SHEETS</a></font></b><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=100% colspan=6 nowrap style="HEIGHT:15pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom><a name=RANGE!A4 /></td> <td width=14% colspan=2 style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2020</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=14% colspan=2 style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2019</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">ASSETS</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">CURRENT ASSETS:</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Cash and cash equivalents</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">8,641,027 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">686,785 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Accounts receivable, less allowance for doubtful accounts of $70,981 and $73,110, respectively</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,765,871 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,454,652 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Inventories, net</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2,850,836 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2,151,090 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Prepaid expenses and other</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,509,083 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">202,402 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total current assets</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">14,766,817 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">4,494,929 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">PROPERTY AND EQUIPMENT:</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Equipment</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,921,833 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,891,381 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Furniture, fixtures and leasehold improvements</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">225,189 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">222,033 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total property and equipment</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2,147,022 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2,113,414 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Accumulated depreciation</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(1,867,643)</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(1,762,344)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Net property and equipment</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">279,379 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">351,070 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">INTANGIBLE ASSETS, net of accumulated amortization&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">168,655 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">107,209 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">RIGHT OF USE ASSETS, net of accumulated amortization</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,711,510 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">INVESTMENTS</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">165,324 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">165,324 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">OTHER ASSETS</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">168,193 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">126,832 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">TOTAL ASSETS</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">17,259,878 </font></p></td> <td width=2% style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">5,245,364 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">LIABILITIES AND SHAREHOLDERS' EQUITY</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">CURRENT LIABILITIES:</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Accounts payable and accrued expenses</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">986,711 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,037,565 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Accrued compensation</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">278,627 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">226,829 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Lease liability, current portion</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">211,809 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total current liabilities</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,477,147 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,264,394 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;Lease liability, net of current portion</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,569,678 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total liabilities</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">3,046,825 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,264,394 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;COMMITMENTS AND CONTINGENCIES (NOTE 8)</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">SHAREHOLDERS' EQUITY:</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:0.7in> <td width=70% style="HEIGHT:0.7in; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Preferred stock, Series A 5%, convertible, <br>&nbsp;&nbsp;&nbsp; $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding <br>&nbsp;&nbsp;&nbsp; at May 31, 2020 and no shares authorized, issued and outstanding <br>&nbsp;&nbsp;&nbsp; at May 31, 2019</font></p></td> <td width=2% style="HEIGHT:0.7in; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:0.7in; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">25,714 </font></p></td> <td width=2% style="HEIGHT:0.7in; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:0.7in; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:0.7in; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td></tr> <tr style=HEIGHT:49.5pt> <td width=70% style="HEIGHT:49.5pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Preferred stock, undesignated, no par value, authorized 4,428,571 <br>&nbsp;&nbsp;&nbsp; and 5,000,000 shares, at May 31, 2020 and May 31, <br>&nbsp;&nbsp;&nbsp; 2019, respectively and none issued and outstanding at <br>&nbsp;&nbsp;&nbsp; May 31, 2020 and May 31, 2019</font></p></td> <td width=2% style="HEIGHT:49.5pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:49.5pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=2% style="HEIGHT:49.5pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:49.5pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:49.5pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td></tr> <tr style=HEIGHT:26.25pt> <td width=70% style="HEIGHT:26.25pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Common stock, $.08 par value; 25,000,000 shares authorized; 11,740,089 and 9,677,188 shares issued and outstanding at May 31, 2020 and 2019, respectively</font></p></td> <td width=2% style="HEIGHT:26.25pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:26.25pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">939,205 </font></p></td> <td width=2% style="HEIGHT:26.25pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:26.25pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:26.25pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">774,173 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Additional paid-in capital</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">35,213,707 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">22,830,006 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Accumulated other comprehensive loss</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(39,841)</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(36,531)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Accumulated deficit</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(21,925,732)</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(19,586,678)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total shareholders' equity</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">14,213,053 </font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">3,980,970 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY </font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">17,259,878 </font></p></td> <td width=2% style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">5,245,364 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=100% colspan=6 nowrap style="HEIGHT:15.75pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=100% colspan=6 nowrap style="HEIGHT:15pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">See accompanying notes to consolidated financial statements.</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-3</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p></div> <div> <div align=center> <table width=1000 bordercolor=transparent style="WIDTH:750pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:30pt> <td width=100% colspan=6 nowrap style="HEIGHT:30pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">BIOMERICA, INC. AND SUBSIDIARIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black"><a name=IS>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</a></font></b><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=100% colspan=6 nowrap style="HEIGHT:15pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:70%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">FOR THE YEARS ENDED MAY 31,</font></p></td> <td width=14% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=14% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Net sales</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">6,692,711 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp; </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">5,200,682 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Cost of sales</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;&nbsp;&nbsp; </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;(4,910,935)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;&nbsp;&nbsp; </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;&nbsp;&nbsp; </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(3,908,668)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">GROSS PROFIT</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,781,776 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,292,014 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">OPERATING EXPENSES:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Selling, general and administrative</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;&nbsp; </font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2,274,415&nbsp;&nbsp; </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2,025,706 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Research and development</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,910,209&nbsp;&nbsp; </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,679,098 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total operating expenses</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">4,184,624&nbsp;</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">3,704,804 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">LOSS FROM OPERATIONS</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,402,848)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,412,790)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">OTHER INCOME (EXPENSE):</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Interest expense</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;(9)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(47)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Interest and dividend income</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">71,193 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">44,014 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total other income</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">71,184 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">43,967 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">LOSS BEFORE INCOME TAXES</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,331,664)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,368,823)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">INCOME TAX EXPENSE</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(7,390)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(24,237)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">NET LOSS</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,339,054)</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,393,060)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">BASIC NET LOSS PER COMMON SHARE </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(0.23)</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(0.26)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">DILUTED NET LOSS PER COMMON SHARE</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(0.23)</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(0.26)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">WEIGHTED AVERAGE NUMBER OF COMMON AND COMMON EQUIVALENT SHARES</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Basic</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">10,166,296&nbsp;</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">9,212,557 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Diluted</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">10,166,296&nbsp;</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">9,212,557 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">NET LOSS</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,339,054)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,393,060)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">OTHER COMPREHENSIVE LOSS:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Foreign currency translation </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (3,310)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(10,395)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">COMPREHENSIVE LOSS</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,342,364)</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,403,455)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=100% colspan=6 nowrap style="HEIGHT:15.75pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=100% colspan=6 nowrap style="HEIGHT:15pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">See accompanying notes to consolidated financial statements.</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-4</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></div> <div> <div align=center> <table width=1000 bordercolor=transparent style="WIDTH:750pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:45pt> <td width=100% colspan=25 nowrap style="HEIGHT:45pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;<b>BIOMERICA, INC. AND SUBSIDIARIES</b></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black"><a name=SSE>CONSOLIDATED STATEMENTS OF SHAREHOLDERS</a>' EQUITY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">YEARS ENDED MAY 31, 2020 AND 2019</font></b></p></td></tr> <tr style=HEIGHT:15pt> <td width=100% colspan=25 nowrap style="HEIGHT:15pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=15% colspan=4 nowrap style="HEIGHT:15pt; WIDTH:15.62%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" rowspan=3 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Series A 5%</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Convertible</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Preferred Stock</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=8% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:8.38%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" rowspan=4 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Accumulated</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Other</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Comprehensive</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Loss</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=7% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:7.94%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" rowspan=3 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Additional</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Paid-in</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Capital</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=15% colspan=4 nowrap style="HEIGHT:15pt; WIDTH:15.76%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;Common Stock</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=7% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:7.82%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" rowspan=2 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Subscriptions</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Receivable</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=8% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:8.84%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" rowspan=2 valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Accumulated</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Deficit</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=8% colspan=2 nowrap style="HEIGHT:15pt; WIDTH:8.34%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6.04%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Shares</font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=7% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:7.82%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Amount</font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:5.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Shares&nbsp; </font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=7% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:7.82%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;Amount</font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=8% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:8.34%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Total</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Balances, May 31, 2018</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">8,888,011 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">711,040 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">20,843,550 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(9,062)</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(26,136)</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(17,193,618)</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">4,325,774 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Exercise of stock options</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">163,500 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">13,080 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">108,710 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">121,790 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Net proceeds from ATM</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">625,677 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">50,053 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,726,522 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,776,575 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Stock subscription <br>receivable</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp; --</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">9,062 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">9,062 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><a name=RANGE!A17></a>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Foreign currency <br>translation</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(10,395)</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(10,395)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Compensation expense in <br>connection with options <br>granted</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">151,224 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">151,224 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Net loss</font></p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.04%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5.92%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5.92%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.04%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5.92%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2.1%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.28%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.94%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,393,060)</font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.44%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,393,060)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5.92%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5.92%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5.92%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2.1%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.28%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.94%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.44%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Balances, May 31, 2019&nbsp;&nbsp; </font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">9,677,188 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">774,173 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">22,830,006 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(36,531)</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(19,586,678)</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">3,980,970 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Exercise of stock options</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">137,958 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">11,037 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">212,497 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">223,534 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Net proceeds from ATM</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,674,943 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">133,995 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">10,098,862 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">10,232,857 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Issuance of preferred <br>stock</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">571,429 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">45,714 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,871,872 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,917,586 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Foreign currency <br>translation</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(3,310)</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(3,310)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Conversion of preferred <br>to common stock</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">250,000 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">20,000 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(250,000)</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(20,000)</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Compensation expense in <br>connection with options <br>granted&nbsp;&nbsp; </font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">200,470 </font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">200,470 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Net loss</font></p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.04%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="HEIGHT:15pt; WIDTH:5.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2.1%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.28%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,339,054)</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="HEIGHT:15pt; WIDTH:6.44%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,339,054)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.04%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5.92%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5.92%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.04%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:5.92%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2.1%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.28%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.94%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.44%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Balances, May 31, 2020&nbsp;&nbsp;&nbsp;&nbsp; </font></p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6.04%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">11,740,089 </font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:5.92%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">939,205 </font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:5.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">321,429 </font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:5.92%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">25,714 </font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6.04%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">35,213,707 </font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=5% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:5.92%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2.1%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6.28%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(39,841)</font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6.94%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(21,925,732)</font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=6% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6.44%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">14,213,053 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=100% colspan=25 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:100%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=100% colspan=25 nowrap style="HEIGHT:15pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">See accompanying notes to consolidated financial statements.</font><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-5</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><a name=_aciHeader26><b></b></a>&nbsp;</p> <div align=center> <table width=1000 bordercolor=transparent style="WIDTH:750pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:30pt> <td width=100% colspan=6 nowrap style="HEIGHT:30pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">BIOMERICA, INC. AND SUBSIDIARIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black"><a name=CFS>CONSOLIDATED STATEMENTS OF CASH FLOWS</a></font></b></p></td></tr> <tr style=HEIGHT:15pt> <td width=100% colspan=6 nowrap style="HEIGHT:15pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">For the Years Ended May 31,</font></p></td> <td width=14% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=14% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">CASH FLOWS FROM OPERATING ACTIVITIES:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Net loss</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,339,054)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,393,060)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Adjustments to reconcile net loss to net cash used in operating activities:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Depreciation and amortization</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">129,172 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">162,905 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Change in provision for allowance for doubtful accounts</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,129)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">15,415 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Inventory reserve</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">17,714 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">6,300 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Stock option expense</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">200,470 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">151,224 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Reduction (increase) in deferred rent liability </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(37,971)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">6,615 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Decrease in deferred tax asset</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">10,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Amortization of right-of-use asset</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">269,460 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Changes in assets and liabilities: </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:20pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Accounts receivable</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(309,090)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(670,126)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:20pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Inventories</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(717,460)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">21,387 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:20pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Prepaid expenses and other</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(1,306,681)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">98,007 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:20pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Reduction in lease liability</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(199,483)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:20pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Other assets</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(41,361)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(13,677)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:20pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Accounts payable and accrued expenses</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(12,883)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">343,994 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:20pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Accrued compensation</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">51,798 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">16,977 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Net cash used in operating activities </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(4,297,498)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,244,039)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">CASH FLOWS FROM INVESTING ACTIVITIES:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Increase in intangibles</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(85,319)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(69,974)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Purchases of property and equipment</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(33,608)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(101,137)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Net cash used in investing activities</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(118,927)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(171,111)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">CASH FLOWS FROM FINANCING ACTIVITIES:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Common stock subscribed</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">9,062 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Proceeds from sale of convertible preferred stock, net</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,917,586 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Proceeds from sales of common stock, net</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">10,232,857 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,776,575 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Proceeds from exercise of stock options </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">223,534 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">121,790&nbsp;</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Net cash provided by financing activities</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">12,373,977 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,907,427&nbsp;</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Effect of exchange rate changes on cash&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(3,310)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(10,395)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Net increase (decrease) in cash and cash equivalents</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">7,954,242 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(518,118)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">CASH AND CASH EQUIVALENTS, beginning of year</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">686,785 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,204,903 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">CASH AND CASH EQUIVALENTS, end of year</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">8,641,027 </font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">686,785 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">SUPPLEMENTAL DISCLOSURE OF CASH-FLOW INFORMATION</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=70% nowrap style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Cash paid during the year for:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Interest </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">9 </font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">47 </font></p></td></tr> <tr style=HEIGHT:16.5pt> <td width=70% nowrap style="HEIGHT:16.5pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Income taxes</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">7,390 </font></p></td> <td width=2% nowrap style="HEIGHT:16.5pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">14,237 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Non-cash Investing and Financing Activities:</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /></tr> <tr style=HEIGHT:15.75pt> <td width=70% nowrap style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Establishment of Right-of-use asset per ASC 842</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,942,999 </font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td></tr> <tr style=HEIGHT:16.5pt> <td width=70% nowrap style="HEIGHT:16.5pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Establishment of Lease liability per ASC 842</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,980,970 </font></p></td> <td width=2% nowrap style="HEIGHT:16.5pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">--</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=100% colspan=6 nowrap style="HEIGHT:15.75pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=100% colspan=6 nowrap style="HEIGHT:15pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The accompanying notes are an integral part of these statements.</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-6</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">BIOMERICA, INC. AND SUBSIDIARIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black"><a name=Notes>NOTES</a> TO CONSOLIDATED FINANCIAL STATEMENTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">YEARS ENDED MAY 31, 2020 AND 2019</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">1. &nbsp;&nbsp;&nbsp;ORGANIZATION </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Biomerica Inc. and Subsidiaries (collectively the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, or &#8220;our&#8221;) develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care </font><font style="FONT-SIZE:10pt; COLOR:black">(physicians' offices and over-the-counter through drugstores and online)</font><font style=FONT-SIZE:10pt> and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. </font><font style="FONT-SIZE:10pt; COLOR:black">Our diagnostic test kits are used to analyze blood, urine or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The</font><font style=FONT-SIZE:10pt> Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in'><font style=FONT-SIZE:10pt>Our primary focus is the research and development of revolutionary, patented diagnostic guided therapy (&#8220;DGT&#8221;) products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. If these DGT products prove effective in their clinical trials, and are ultimately cleared for sale by the U.S. Food and Drug Administrations (&#8220;FDA&#8221;), the revenues potential to the Company is significant.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in'><font style=FONT-SIZE:10pt>Due to the global 2019 SARS-CoV-2 novel coronavirus (&#8220;COVID-19&#8221;) pandemic, in March 2020 we began redirecting and focused a majority of our resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been exposed to COVID-19. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">2. &nbsp;&nbsp;&nbsp;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">PRINCIPLES OF CONSOLIDATION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The enclosed consolidated financial statements for the years ended May 31, 2020 and 2019 include the accounts of Biomerica, Inc. ("Biomerica") as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ACCOUNTING ESTIMATES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; and inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, likelihood of lease extensions to occur, asset valuation, among other things; (and other items that may be necessary to estimate using current, historical and judgment based). Actual results could materially differ from those estimates. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">FAIR VALUE OF FINANCIAL INSTRUMENTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company's financial instruments consist of its cash and cash equivalents, accounts receivable,&nbsp;and accounts payable. The carrying amounts of the Company's financial instruments approximate their fair values.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">CONCENTRATION OF CREDIT RISK</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.&nbsp; As of May 31, 2020, the Company had approximately $8,595,241 of uninsured cash.</font> <font style="FONT-SIZE:10pt; COLOR:black">The Company does not believe it is exposed to any significant credit risks.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-7</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets.&nbsp; The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">For the years ended May 31, 2020 and 2019, the Company had three distributors and two distributors which accounted for a total of 57.2% and 46.3% of our net consolidated sales, respectively. Of this, for the years ended May 31, 2020 and 2019 one of the distributors mentioned above accounted for 25.7% and 36.3%, respectively, of net consolidated sales.&nbsp; At May 31, 2020 and 2019, the Company had three distributors and two distributors which accounted for a total of 80.0% and 68.1%, respectively, of gross accounts receivable. <a name=_Hlk48558057>Of the 80.0% as of May 31, 2020, 43.9% was owed by a distributor in Ecuador. Total gross receivables at May 31, 2020 and 2019 were $1,836,852 and $1,527,762, respectively.</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">For the year ended May 31, 2020, one vendor accounted for 59.3% of the purchases of raw materials. For the year ended May 31, 2019, two vendors accounted for a total of 23.8 % of the purchases of raw materials.</font><font style=FONT-SIZE:10pt>&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">GEOGRAPHIC CONCENTRATION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">As of May 31, 2020 and 2019, approximately $613,000 and $665,000 of Biomerica's gross inventory and approximately $31,000 and $39,000, of Biomerica's property and equipment, net of accumulated depreciation, was located in Mexicali, Mexico, respectively.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>CASH AND</font></b><font style=FONT-SIZE:10pt><b><font style=COLOR:black> CASH EQUIVALENTS</font></b></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ACCOUNTS RECEIVABLE</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company extends unsecured credit to its customers on a regular basis. &nbsp;International accounts are required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. &nbsp;Based on various criteria,&nbsp;initial credit levels for individual distributors are approved by designated officers and managers of the company. All increases in credit limits are also approved by designated upper level management. &nbsp;Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. &nbsp;Balances over ninety days old are usually reserved for unless collection is reasonably assured. &nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. &nbsp; Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">INVENTORIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Inventories approximate the following at May 31:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;<font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=210 style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=12% colspan=2 style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>2020</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=12% colspan=2 style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style=HEIGHT:16.6pt> <td width=210 style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Raw materials</font></p></td> <td width=2% style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; BACKGROUND:#80ffff">$</font></p></td> <td width=12% style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; BACKGROUND:#80ffff">1,635,000</font></p></td> <td width=2% style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&nbsp;&nbsp; </font></p></td> <td width=2% style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>$</font></p></td> <td width=12% style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,208,000</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=210 style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Work in progress</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>&nbsp;&nbsp; 988,000</font></p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>&nbsp;&nbsp; 771,000</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=210 style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Finished products </font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; BACKGROUND:#80ffff">&nbsp;&nbsp; 228,000</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>&nbsp;&nbsp; 172,000</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=210 style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:black 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; BORDER-LEFT:0px; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total </font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>$</font></p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:black 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style=FONT-SIZE:10pt>2,851,000</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>$</font></p></td> <td width=12% style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:black 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2,151,000</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of May 31, 2020 and 2019, inventory reserves were approximately $67,000 and $49,000, respectively.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-8</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">PROPERTY AND EQUIPMENT</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $105,299 and $101,216 for the years ended May 31, 2020 and 2019, respectively. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">INTANGIBLE ASSETS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#8220;ASC&#8221;), ASC 350 Intangibles &#8211; Goodwill and Other (&#8220;ASC 350&#8221;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to $23,873 and $61,689 for the years ended May 31, 2020 and 2019, respectively.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset's balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of May 31, 2020 or 2019.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">INVESTMENTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">From time-to-time, the Company makes investments in privately-held companies. &nbsp;The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee&#8217;s industry), a write-down to estimated fair value is recorded. Investments represent the Company&#8217;s investment in a Polish distributor which is primarily engaged in distributing medical products and devices. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value of the investment to be greater than the fair value. The Company owns approximately 6% of the investee and, accordingly, applies the cost method to account for the investment. &nbsp;Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">SHARE-BASED COMPENSATION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company follows the guidance of the accounting provisions of ASC 718<a name=_Hlk17621381>, </a>Share-based Compensation (&#8220;ASC 718&#8221;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#8217;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#8220;simplified method&#8221; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company has not paid dividends historically and does not expect to pay them in the foreseeable future.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-9</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In applying the Black-Scholes options-pricing model, assumptions used were as follows: &nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=191 nowrap style="HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td width=1% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.94%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=191 nowrap style="HEIGHT:15pt; WIDTH:143.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Dividend yield</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0%</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">0%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=191 nowrap style="HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Expected volatility</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;55.52-72.62%</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">57.90-60.41%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=191 nowrap style="HEIGHT:15pt; WIDTH:143.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Risk free interest rate</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;0.43-1.80%</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2.33-2.85%</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=191 nowrap style="HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Expected life</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">3.75-6.25 years</font></p></td> <td width=1% nowrap style="HEIGHT:15pt; WIDTH:1.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">3.75-6.25 years</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">REVENUE RECOGNITION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company has various contracts with customers.&nbsp; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of May 31, 2020 and does not believe that any additional discounts will be given through the end of the contract periods. </font><font style=FONT-SIZE:10pt>Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. <font style=COLOR:black>The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. &nbsp;Physicians&#8217; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. </font><a name=_Hlk49511094 /></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Disaggregation of revenue:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The following is a breakdown of revenues according to markets to which the products are sold:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:550pt; BORDER-COLLAPSE:collapse; BORDER-BOTTOM:0px; MARGIN-LEFT:-0.75pt; BORDER-LEFT:0px" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=499 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=220 colspan=5 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:165pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">Year Ended</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=499 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;&nbsp; </font></p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=103 colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2020</font></p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=103 colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2019</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=499 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Clinical Lab</font></p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=88 nowrap style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2,922,425 </font></p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=88 nowrap style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">4,043,993 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=499 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">OTC</font></p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=88 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,269,535 </font></p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=88 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">868,605 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=499 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Physicians&#8217; Office</font></p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=88 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2,194,991 </font></p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=88 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">170,871 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=499 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Contract Manufacturing</font></p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=88 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">305,760 </font></p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=88 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">117,213 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=499 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total</font></p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=88 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">6,692,711 </font></p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=15 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=88 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">5,200,682 </font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">See Note 7 for additional information regarding revenue concentrations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">SHIPPING AND HANDLING FEES </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company includes shipping and handling fees billed to customers in net sales. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">RESEARCH AND DEVELOPMENT</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Research and development costs are expensed as incurred. The Company expensed $1,910,209 and $1,679,098 of research and development costs during the years ended May 31, 2020 and 2019, respectively.</font></p><p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-10</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">INCOME TAXES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. At May 31, 2020 and 2019, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its deferred tax assets.&nbsp;&nbsp; During the fiscal year ended May 31, 2020, this valuation allowance was increased to approximately </font><font style="FONT-SIZE:9pt; COLOR:black">$</font><font style="FONT-SIZE:10pt; COLOR:black">3,175,000, which fully covers the net tax asset of $3,175,000</font><font style="FONT-SIZE:9pt; COLOR:black">.</font></p><p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p><p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company&#8217;s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. Upon adopting the revisions in ASC 740, the Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the &#8220;Interest expense&#8221; line and penalties related to liabilities for income taxes within the &#8220;Other expense&#8221; line of the consolidated statements of operations and comprehensive loss. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">ADVERTISING COSTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately <font style=BACKGROUND:white>$174</font> and $0 for the years ended May 31, 2020 and 2019, respectively. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">FOREIGN CURRENCY TRANSLATION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the years ended May 31, 2020 and 2019.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">RIGHT-OF-USE ASSETS AND LEASE LIABILITY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Incentive payments received from landlords are recorded as deferred lease incentives and are amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. When the terms of an operating lease provide for periods of free rent, rent concessions, and/or rent escalations, the Company establishes a deferred rent liability for the difference between the scheduled rent payment and the straight-line rent expense recognized. This deferred rent liability was amortized over the underlying lease term on a straight-line basis as a reduction of rent expense.<font style=COLOR:black>&nbsp;During the year ended May 31, 2020, the Company adopted ASC 842, Leases.&nbsp; As a result, the existing deferred rent liability was netted against the Right-of-Use Asset which was capitalized at that time.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&nbsp; Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&nbsp; Right-of-Use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&nbsp; Leases will be classified as financing or operating which will drive the expense recognition pattern.&nbsp; For lessees, the statement of operations presentation and expense recognition pattern for financing and operating leases is similar to the current model for capital and operating leases, respectively.&nbsp; The Company has elected to exclude short-term leases.&nbsp; The update also requires additional disclosures that will better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases.&nbsp; The Company adopted this guidance as of June 1, 2019, the required effective date, using the effective date transition method.&nbsp; As permitted under the effective date transition method, financial information and disclosure for periods prior to the date of initial application will not be updated. An adjustment to opening accumulated deficit was not required in conjunction with adoption. The adoption of this statement resulted in a right-of-use asset being recorded in the amount of $1,942,999 and a lease liability being recorded in the amount of $1,980,970. Both will be amortized over the life of the underlying leases. For additional information, see Note 8-Commitments and Contingencies. The Company has elected not to reassess whether expired or existing contracts contain leases, or reassess the classification of existing leases as of the adoption date. The Company leases office space and copy machines, all of which are operating leases.&nbsp; Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&nbsp; The leases do not include the options to purchase the leased property.&nbsp; The depreciable life of assets and leasehold improvements are limited by the expected lease term.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-11</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">NET LOSS PER SHARE</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2020 and 2019 were 1,789,251 and 1,476,209, respectively. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company also has outstanding 321,429 of Series A 5% Convertible Preferred Stock, which may be converted at any time to common stock.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>&nbsp;&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">SEGMENT REPORTING</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">ASC 280, Segment Reporting (&#8220;ASC 280&#8221;), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company&#8217;s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing and sales of diagnostic kits.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">REPORTING COMPREHENSIVE LOSS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders&#8217; equity. Accumulated other comprehensive loss consists solely of foreign currency translation adjustments. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">RECENT ACCOUNTING PRONOUNCEMENTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On February 15, 2018, the FASB issued ASU 2018-02, &#8220;Reclassification of Certain Tax Effects From Accumulated Comprehensive Income&#8221; (&#8220;ASU 2018-02&#8221;).&nbsp; ASU 2018-02 will give companies the option to reclassify stranded tax effects caused by the newly-enacted U.S. Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) from accumulated other comprehensive income (&#8220;ASCI&#8221;) to retained earnings.&nbsp; ASU 2018-02 was effective for all companies for the fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.&nbsp; Management is taking the provisions of this statement into account in the preparation of the consolidated financial statements for the year ended May 31, 2020.&nbsp; The adoption of this standard has not had a significant impact on the Company&#8217;s consolidated financial statements.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On June 20, 2018, the FASB issued ASU 2018-07,&nbsp;&#8220;Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&#8221; (&#8220;ASU 2018-07&#8221;). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for share-based payments to nonemployees (service providers, external legal counsel, and suppliers). ASU 2018-07 was effective </font><font style=FONT-SIZE:10pt>for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.&nbsp;During the year ended May 31, 2020, the Company adopted the provisions of this statement and is taking them into account in the preparation of the consolidated financial statements for the year ended May 31, 2020. The adoption of this standard has not had a significant impact on the Company&#8217;s consolidated financial statements.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0pt 0in'><font style="FONT-SIZE:10pt; COLOR:black">Other recent ASU's issued by the FASB and guidance issued by the Securities and Exchange Commission (&#8220;SEC&#8221;) did not, or are not believed by management to, have a material effect on the Company&#8217;s present or future consolidated financial statements. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">3. &nbsp;&nbsp;&nbsp;INTANGIBLE ASSETS, NET</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets, net of accumulated amortization, consist of the following at May 31:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;<a name=_aciHeader32 />&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=258 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:193.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=258 nowrap style="HEIGHT:15pt; WIDTH:193.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Licenses</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">551,397 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">510,600 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=258 nowrap style="HEIGHT:15pt; WIDTH:193.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Patents</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">113,382 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">68,860 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=258 nowrap style="HEIGHT:15pt; WIDTH:193.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-<br>licenses</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(487,989)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(471,530)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=258 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:193.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-<br>patents</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(8,135)</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(721)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=258 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:193.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets, net</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">168,655 </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">107,209 </font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-12</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Expected amortization of intangible assets for the years ending May 31:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=165 nowrap style="HEIGHT:15pt; WIDTH:123.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=16% nowrap style="HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=165 nowrap style="HEIGHT:15pt; WIDTH:123.85pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=16% nowrap style="HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">18,112 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=165 nowrap style="HEIGHT:15pt; WIDTH:123.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">2022</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=16% nowrap style="HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">8,503 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=165 nowrap style="HEIGHT:15pt; WIDTH:123.85pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">2023</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=16% nowrap style="HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">6,211 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=165 nowrap style="HEIGHT:15pt; WIDTH:123.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">2024</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=16% nowrap style="HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">6,136 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=165 nowrap style="HEIGHT:15pt; WIDTH:123.85pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">2025</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=16% nowrap style="HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">5,219 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=165 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:123.85pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Thereafter</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=16% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:16%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">124,474 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=165 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:123.85pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:20pt; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=16% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:16%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">168,655 </font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">4.&nbsp;&nbsp;&nbsp; ACCOUNTS PAYABLE AND ACCRUED EXPENSES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company&#8217;s accounts payable and accrued expense balances consist of the following at May 31:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=275 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:205.9pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=275 nowrap style="HEIGHT:15pt; WIDTH:205.9pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Accounts payable and accrued expenses</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">986,711 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">999,594 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=275 nowrap style="HEIGHT:15pt; WIDTH:205.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Deferred rent</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">-</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">37,971 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=275 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:205.9pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">986,711 </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,037,565 </font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>As of May 31, 2020 and 2019 the Company had two vendors and one vendor which accounted for 26.9% and 32.1%, respectively, of accounts payable.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">5. &nbsp;&nbsp;&nbsp;SHAREHOLDERS' EQUITY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On February 24, 2020, the Company filed with the Secretary of State of Delaware a certificate of designation to authorize for issuance 571,429 shares of Series A 5% Convertible Preferred Stock.&nbsp; On February 26, 2020, the Company filed with the Secretary of State of Delaware a certificate of correction, correcting certain language defects in the previously filed certificate of designation.&nbsp; Please see below a description of the Series A 5% Convertible Preferred Stock shares that were issued in February 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">STOCK OPTION AND RESTRICTED STOCK PLANS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In August 2010, the Company adopted a stock option and restricted stock plan (the "2010 Plan") which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company's unissued common stock may be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2010. &nbsp;The 2010 Plan expires in December 2020. Options granted under the 2010 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In December 2014, the Company adopted a stock option and restricted stock plan (the "2014 Plan") which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company's unissued common stock may be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2014. &nbsp;The 2014 Plan expires in December 2024. Options granted under the 2014 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-13</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In December 2017, the Company adopted a stock option and restricted stock plan (the &#8220;2017 Plan&#8221;) which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 900,000 shares of the Company&#8217;s unissued common stock may be granted to affiliates, employees or consultants of the Company.&nbsp; This plan was approved by shareholders in December 2017.&nbsp; The 2017 Plan expires in December 2027.&nbsp; Options granted under the 2017 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In February 2020, the Board approved the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which will be presented to the Company&#8217;s shareholders for final approval and adoption at the Company&#8217;s annual meeting to be held in December 2020. The 2020 Plan authorizes the issuance of an </font><font style="FONT-SIZE:10pt; COLOR:black">aggregate number of common stock options and/or restricted common shares to be issued in an amount not to exceed 900,000. &nbsp;The 2020 Plan authorizes the issuance of common stock options and restricted common shares to employees, directors and consultants of the Company. During fiscal 2020, certain common stock options were granted under this plan, the actual vesting of which is subject to the plan being approved and adopted by shareholders at our upcoming annual meeting of shareholders.&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Stock option expense during fiscal 2020 was $200,470. This included, by department, $17,892 for research and development, $156,750 in administrative, $2,933 in sales and marketing, $22,895 for production and $0 in Mexico. In fiscal 2019, stock option expense was $151,224. This included $3,714 in research and development, $143,299 in administrative, $4,163 in sales and marketing and $48 in Mexico.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Activity as to aggregate stock options outstanding is as follows: </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:39pt> <td width=234 nowrap style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">NUMBER OF STOCK OPTIONS</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=15% style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">EXERCISE PRICE&nbsp; RANGE PER SHARE</font></p></td> <td width=2% style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=12% colspan=2 style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">WEIGHTED AVERAGE EXERCISE PRICE</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=234 nowrap style="HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Options outstanding at May 31, 2018</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,138,625 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">$0.71-$3.90</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1.65 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=234 nowrap style="HEIGHT:15pt; WIDTH:175.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Options granted</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">558,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">$2.25-$3.62</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2.60 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=234 nowrap style="HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Options exercised</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(163,500)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">$0.71-$1.04</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">0.76 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=234 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Options canceled or expired</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(56,916)</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">$0.71-$3.62</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2.49 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=234 nowrap style="HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Options outstanding at May 31, 2019</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,476,209 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$3.90</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2.07 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=234 nowrap style="HEIGHT:15pt; WIDTH:175.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Options granted</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">517,500 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">$2.68-$8.18</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">4.47 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=234 nowrap style="HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Options exercised</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(137,958)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$3.90</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1.64 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=234 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Options canceled or expired</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(66,500)</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">$0.85-$8.18</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">3.43 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=234 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Options outstanding at May 31, 2020</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,789,251 </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$8.18</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2.75 </font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The weighted average fair value of options granted during 2020 and 2019 was $4.47 and $2.60, respectively. The aggregate intrinsic value of options exercised during 2020 and 2019 was approximately $589,000 and $364,000, respectively. The aggregate intrinsic value of options outstanding at May 31, 2020 and 2019 was approximately $6,923,000 and $808,000, respectively. The aggregate intrinsic value of options vested and exercisable at May 31, 2020 and 2019 was approximately $4,442,000 and $685,000, respectively.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Number of non-vested stock options included in table above is as follows:</font>&nbsp;&nbsp; </p> <div> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:82.5pt> <td width=224 nowrap style="HEIGHT:82.5pt; WIDTH:167.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=15% style="BORDER-TOP:0px; HEIGHT:82.5pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">NUMBER OF SHARES</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:82.5pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=15% colspan=2 style="BORDER-TOP:0px; HEIGHT:82.5pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">STOCK OPTIONS WEIGHTED AVERAGE AVERAGE GRANT DATE FAIR VALUE</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=224 nowrap style="HEIGHT:15pt; WIDTH:167.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2019</font></p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">769,584 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2.49 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=224 nowrap style="HEIGHT:15pt; WIDTH:167.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Granted</font></p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">517,500 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">4.47 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=224 nowrap style="HEIGHT:15pt; WIDTH:167.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Vested</font></p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(407,750)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2.25 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=224 nowrap style="HEIGHT:15pt; WIDTH:167.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Forfeited</font></p></td> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(56,750)</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">3.55 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=224 nowrap style="HEIGHT:15pt; WIDTH:167.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2020</font></p></td> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">822,584 </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=15% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">3.78 </font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-14</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">At May 31, 2020, total compensation cost related to non-vested stock option awards not yet recognized totaled approximately $663,000. The weighted-average period over which this amount is expected to be recognized is 3.67 years. The weighted average remaining contractual term of options that were exercisable at May 31, 2020 was 6.19 years.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The following summarizes information about all of the Company's stock options outstanding at May 31, 2020. These options are comprised of those granted under the 2010, 2014, 2017 and 2020 plans.</font></p></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:64.5pt> <td width=17% style="BORDER-TOP:0px; HEIGHT:64.5pt; BORDER-RIGHT:0px; WIDTH:17%; solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">RANGE OF EXERCISE PRICES</font></p></td> <td width=17% style="BORDER-TOP:0px; HEIGHT:64.5pt; BORDER-RIGHT:0px; WIDTH:17%;  PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;NUMBER OUTSTANDING <br>May 31, 2020</font></p></td> <td width=17% style="BORDER-TOP:0px; HEIGHT:64.5pt; BORDER-RIGHT:0px; WIDTH:17%;  PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE IN YEARS</font></p></td> <td width=16% style="BORDER-TOP:0px; HEIGHT:64.5pt; BORDER-RIGHT:0px; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">WEIGHTED AVERAGE EXERCISE PRICE</font></p></td> <td width=15% style="BORDER-TOP:0px; HEIGHT:64.5pt; BORDER-RIGHT:0px; WIDTH:15.78%;  PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;NUMBER EXERCISABLE AT MAY 31, 2020</font></p></td> <td width=16% style="BORDER-TOP:0px; HEIGHT:64.5pt; BORDER-RIGHT:0px; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;WEIGHTED AVERAGE EXERCISE PRICE</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=17% nowrap style="HEIGHT:15pt; WIDTH:17%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">$ 0.82-$1.04</font></p></td> <td width=17% nowrap style="HEIGHT:15pt; WIDTH:17%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">276,000</font></p></td> <td width=17% nowrap style="HEIGHT:15pt; WIDTH:17%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">4.44</font></p></td> <td width=16% nowrap style="HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">$0.84 </font></p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.78%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">276,000</font></p></td> <td width=16% nowrap style="HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">$0.84 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=17% nowrap style="HEIGHT:15pt; WIDTH:17%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">$ 1.20-$ 2.81</font></p></td> <td width=17% nowrap style="HEIGHT:15pt; WIDTH:17%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">1,072,500</font></p></td> <td width=17% nowrap style="HEIGHT:15pt; WIDTH:17%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">7.57</font></p></td> <td width=16% nowrap style="HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">$2.17 </font></p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">506,000</font></p></td> <td width=16% nowrap style="HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">$1.71 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=17% nowrap style="HEIGHT:15pt; WIDTH:17%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">$ 3.62-$ 8.18</font></p></td> <td width=17% nowrap style="HEIGHT:15pt; WIDTH:17%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">440,751</font></p></td> <td width=17% nowrap style="HEIGHT:15pt; WIDTH:17%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">7.62</font></p></td> <td width=16% nowrap style="HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">$5.38 </font></p></td> <td width=15% nowrap style="HEIGHT:15pt; WIDTH:15.78%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">184,667</font></p></td> <td width=16% nowrap style="HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">$3.87 </font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">COMMON STOCK ACTIVITY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>During the year ended May 31, 2020, options to purchase 137,958 shares of common stock were exercised at prices ranging from $0.82 to $3.90.&nbsp; Total net proceeds to the Company were $223,534.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>During the year ended May 31, 2019, options to purchase 163,500 shares of common stock were exercised at prices ranging from $0.71 to $1.04.&nbsp; <a name=_Hlk17185589>Total net proceeds to the Company were $121,790.</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On December 1, 2017, the Company entered into an At Market Issuance Sales Agreement (or &#8220;ATM Agreement&#8221;) with an agent, and filed a prospectus supplement with the SEC pursuant to which the Company could offer and sell from time to time up to an aggregate of $7,000,000 of shares of the Company&#8217;s common stock, par value $0.08 per share (the &#8220;Placement Shares&#8221;), through the agent. From December 1, 2017 to March 19, 2020, the Company sold common stock resulting in $6,997,935 of gross proceeds under this ATM Agreement, of which $3,771,048 were sold during the year ended May 31, 2020. </font><font style=FONT-SIZE:10pt>This At Market Issuance Agreement expired on July 20, 2020 upon the expiration of the Company&#8217;s S-3 registration statement base prospectus dated July 20, 2017. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:40.5pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 12pt'><font style="FONT-SIZE:10pt; COLOR:black">The Placement Shares sold and issued under the ATM Agreement have been registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to the Registration Statement on Form S-3 (File No. 333-219130) (the &#8220;Registration Statement&#8221;), which was originally filed with the SEC on June 30, 2017 and declared effective by the SEC on July 20, 2017, the base prospectus contained within the Registration Statement, and the prospectus supplement related to the sale of shares under the ATM Agreement was filed with the SEC on December 1, 2017.&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On March 20, 2020, the Company filed a new prospectus supplement to the S-3 registration statement base prospectus dated July 20, 2017 for purposes of raising up to $12,500,000 from time to time pursuant to the terms of the ATM Agreement. </font><a name=_Hlk47966232><font style=FONT-SIZE:10pt>This ATM Agreement expired on July 20, 2020 upon the expiration of the Company&#8217;s S-3 registration statement base prospectus dated July 20, 2017. Gross proceeds for the year ended May 31, 2020, were $6,817,330.</font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Please refer to &#8220;Subsequent Events&#8221; for a description of the Form S-3 filed with the Securities and Exchange Commission on July 20, 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Combined Placement Shares sold under the ATM during the twelve months ended May 31, 2020 under the two prospectus supplements dated December 1, 2017 and March 20, 2020 totaled 1,674,943 shares. Total net proceeds from the sale of Placement Shares under the two prospectus supplements during the twelve months ended May 31, 2020 were $10,232,857 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.&nbsp; These shares were sold at prices ranging from $2.33 to $9.08 per share. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-15</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Under an ATM Agreement, sales of the Placement Shares are deemed to be &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act.&nbsp; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&#8217;s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">During the year ended May 31, 2020, 250,000 shares of common stock were converted from Preferred Stock as described below in &#8220;Preferred Stock Activity&#8221;.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><a name=_Hlk49188299></a>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>During the year ended May 31, 2020, the Company sold 1,674,943 shares of its common stock at prices ranging from $2.33 to $9.08 under its S-3 Registration Statement which resulted in gross proceeds of $10,588,378 and net proceeds to the Company of $10,232,857 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>During the year ended May 31, 2019, the Company sold 625,677 shares of its common stock at prices ranging from $2.59 to $4.16 under its S-3 Registration Statement which resulted in gross proceeds of $1,847,662 and net proceeds to the Company of $1,776,575 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>PREFERRED STOCK ACTIVITY</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><u><font style=FONT-SIZE:10pt></font></u></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On February 24, 2020, the Company entered into and closed on a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with </font><font style=FONT-SIZE:10pt>Palm Global Small Cap Master Fund LP (&#8220;Palm&#8221;) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed to purchase from the Company, 571,429 shares of the Company&#8217;s Series A 5% Convertible Preferred Stock, $0.08 par value per share for a purchase price of approximately $2 million, or $3.50 per Series A Convertible Preferred Stock. Under the terms of the Stock Purchase Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company&#8217;s common stock, subject to certain adjustments. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Series A 5% Convertible Preferred Stock shares are convertible at the option of the holder at any time into an equal number of common stock shares (&#8220;Conversion Shares&#8221;). The conversion price may be adjusted for stock splits or other common stock issuances. The Company may require the conversion of all of the outstanding Series A 5% Convertible Preferred Stock shares if the closing sale price of the Company&#8217;s common stock equals or exceeds $9.00 for a period of five consecutive trading days with a minimum average trading volume of 35,000 shares per day over such period; provided, that, on such date, the Conversion Shares are registered for resale. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Series A 5% Convertible Preferred Stock shares accrue annual preferred dividends at a rate of $0.175 per Series A 5% Convertible Preferred Stock share. The shares of Series A 5% Convertible Preferred Stock are also entitled to receive participating dividends. The shares of Series A 5% Convertible Preferred Stock have no voting rights. Accruing dividends are payable only when, as, and if declared by the Board and the Company has no obligation to pay such accruing dividends. As such, since the dividend payment is conditional on events that are deemed unlikely at this time, a liability has not been recorded at year-end for these dividends. Dividends that have &nbsp;accumulated through May 31, 2020 total approximately $18,000.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The 5% dividend is a cumulative dividend, and is only payable if the Board elects to pay a dividend on the Company&#8217;s common shares, at which point the accrued cumulative dividend must be paid current. At the conversion of any preferred shares into common shares, all accrued, unpaid dividends on the converted preferred shares are canceled and forgiven by Palm. As part of the purchase, Palm was given the right to appoint a Board Observer to the Board. The preferred shares have many material preferential rights over common shareholders in the event of a filing for bankruptcy or dissolution of the Company. For further details on the rights of these preferred shares, please refer to the Company&#8217;s disclosures filed under an SEC 8-K on February 26, 2020. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On March 24, 2020, Palm converted 250,000 shares of Convertible Preferred Stock into 250,000 shares of unregistered common stock. On July 21, 2020, the Company filed with the SEC a registration statement on Form S-3 that among other things registered all of the common shares issued, or to be issued, to Palm upon conversion of the Convertible Preferred Stock into common shares. The Company anticipates the registration statement shall become effective promptly following the filing of this annual report on Form 10-K with the SEC. The Company incurred approximately $82,000 in issuance costs associated with this stock issuance.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">6. &nbsp;&nbsp;&nbsp;INCOME TAXES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Income tax expense from continuing operations for the years ended May 31, 2020 and 2019 consists of the following:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-16</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=291 nowrap style="HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;Years ended May 31,</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=291 nowrap style="HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Current:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=291 nowrap style="HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">U.S. Federal</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;-- </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;-- </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=291 nowrap style="HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Foreign Taxes Subsidiaries</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(6,590)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(13,437)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=291 nowrap style="HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">State and local</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(800)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(800)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=291 nowrap style="HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total current</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(7,390)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(14,237)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=291 nowrap style="HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Deferred:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=291 nowrap style="HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">U.S. Federal&nbsp;</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;-- </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(10,000)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=291 nowrap style="HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">State and local</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;-- </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;-- </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=291 nowrap style="HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total deferred</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;-- </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(10,000)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=291 nowrap style="HEIGHT:15.75pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Income tax expense</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(7,390)</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(24,237)</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Income tax expense from continuing operations differs from the amounts computed by applying the U.S. Federal income tax rate applicable for each year (21% for 2020 and 2019) to pretax income as a result of the following:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=336 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:3.5in; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Years ended May 31,</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=336 nowrap style="HEIGHT:15pt; WIDTH:3.5in; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Computed "expected" tax benefit </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">489,651 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:left; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">497,453 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=336 nowrap style="HEIGHT:15pt; WIDTH:3.5in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Increase (reduction) in income taxes resulting from:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=336 nowrap style="HEIGHT:15pt; WIDTH:3.5in; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Change in valuation allowance</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(716,000)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(910,000)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=336 nowrap style="HEIGHT:15pt; WIDTH:3.5in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">State income taxes, net of federal benefit</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">154,254 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">89,267 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=336 nowrap style="HEIGHT:15pt; WIDTH:3.5in; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Research and development tax credits</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">49,770 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">55,908 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=336 nowrap style="HEIGHT:15pt; WIDTH:3.5in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Permanent tax differences and other</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">21,525 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(256,572)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=336 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:3.5in; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Foreign taxes of subsidiaries</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(6,590)</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(13,437)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=336 nowrap style="HEIGHT:15.75pt; WIDTH:3.5in; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Income tax expense</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(7,390)</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:left; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(24,237)</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The tax effect of significant temporary differences&nbsp;is presented below:</font>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=402 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:301.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">As of May 31,</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=402 nowrap style="HEIGHT:15pt; WIDTH:301.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Deferred tax assets:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=402 nowrap style="HEIGHT:15pt; WIDTH:301.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Accounts receivable, principally due to allowance for doubtful accounts</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">17,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">18,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=402 nowrap style="HEIGHT:15pt; WIDTH:301.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Inventory valuation&nbsp;&nbsp;&nbsp; </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">16,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">12,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=402 nowrap style="HEIGHT:15pt; WIDTH:301.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Compensated absences</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">64,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">48,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=402 nowrap style="HEIGHT:15pt; WIDTH:301.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Net operating loss carryforwards&nbsp;&nbsp;&nbsp; </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2,286,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,735,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=402 nowrap style="HEIGHT:15pt; WIDTH:301.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Tax credit carryforwards</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">599,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">467,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=402 nowrap style="HEIGHT:15pt; WIDTH:301.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Deferred rent expense/Capitalized leases</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">17,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">9,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=402 nowrap style="HEIGHT:15pt; WIDTH:301.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Other</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">171,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">176,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=402 nowrap style="HEIGHT:15pt; WIDTH:301.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Accumulated depreciation and amortization</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">5,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(6,000)</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=402 nowrap style="HEIGHT:15pt; WIDTH:301.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total deferred tax assets&nbsp;&nbsp;&nbsp; </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">3,175,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2,459,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=402 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:301.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Less valuation allowance</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(3,175,000)</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">(2,459,000)</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=402 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:301.7pt; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Net deferred tax asset</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;-- </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;-- </font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company has provided a valuation allowance of approximately $3,175,000 and $2,459,000 as of May 31, 2020 and 2019, respectively. The net change in the valuation allowance for the years ended May 31, 2020 and 2019 was an increase of $716,000 and $900,000, respectively.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">At May 31, 2020, the Company has Federal income tax NOL carryforwards of approximately $9,213,000. &nbsp;At May 31, 2020, the Company has California state income tax net operating loss carryforwards of approximately $5,025,000.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-17</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">At May 31, 2020, the Company has Federal research and development tax credit carryforward of approximately $438,000. &nbsp;The Federal credits begin to expire in 2027. &nbsp;The Company also had similar credit carryforwards for state purposes of $160,000 at May 31, 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Pursuant to Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383, annual use of the Company's net operating loss ("NOL") and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections 382 and 383 of the IRC, the annual use of the Company's NOLs and credit carryforwards would be limited if there is a cumulative change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period. Management has not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">For the year ended May 31, 2020, the Company did an analysis of its ASC 740 position and has not identified any uncertain tax positions as defined under ASC 740. Should such position be identified in the future and should the Company owe interest and penalties as a result of this, these would be recognized as interest expense and other expense, respectively, in the consolidated financial statements. The Company is no longer subject to any significant U.S. federal tax examinations by tax authorities for years before fiscal year 2016.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;<b><font style="FONT-SIZE:10pt; COLOR:black">7. &nbsp;&nbsp;&nbsp;GEOGRAPHIC INFORMATION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;<font style="FONT-SIZE:10pt; COLOR:black">The Company operates as one segment. Geographic information regarding net sales is approximately as follows: </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=210 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Years ended May 31,</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% colspan=2 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=210 nowrap style="HEIGHT:15pt; WIDTH:157.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Net sales:</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=210 nowrap style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Europe</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2,434,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,694,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=210 nowrap style="HEIGHT:15pt; WIDTH:157.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">United States &nbsp;</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">445,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">523,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=210 nowrap style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Asia</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,867,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">2,514,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=210 nowrap style="HEIGHT:15pt; WIDTH:157.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">South America</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,615,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">256,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=210 nowrap style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Middle East</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">314,000 </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=10% nowrap style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">214,000 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=210 nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Other foreign</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">18,000 </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;-- </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=210 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.25in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total net sales</font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">6,693,000 </font></p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=10% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">5,201,000 </font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">8. &nbsp;&nbsp;&nbsp;COMMITMENTS AND CONTINGENCIES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">OPERATING LEASES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On June 18, 2009, the Company entered into an agreement to lease a building in Irvine, California. The lease commenced September 1, 2009 and ended August 31, 2016. </font><font style=FONT-SIZE:10pt>&nbsp;On November 30, 2015, the Company entered into the First Amendment to Lease wherein it exercised its option to extend its lease until August 31, 2021. The initial base rent for the lease extension was $21,000 per month, increasing to $23,637 through August 31, 2021. The monthly rent is currently $22,948. The security deposit of $22,080 remains the same.<font style=COLOR:black>&nbsp;</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>In November 2016, the Company&#8217;s subsidiary, Biomerica de Mexico, entered into a ten-year lease for approximately 8,104 square feet at a monthly rent of $2,926. The Company has one 10-year option to renew at the end of the initial lease period. The yearly rate is subject to an annual adjustment for inflation according to the United States Bureau of Labor Statistics Consumer Price Index for All Urban Consumers. The monthly rate is currently $3,239. &nbsp;Biomerica, Inc. is not a guarantor of such lease.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total gross rent expense in the U.S. for fiscal 2020 was $300,267 and 2019 was $268,550.&nbsp; Rent expense for the Mexico facility for fiscal 2020 and 2019 was $43,481 and $46,040, respectively. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0pt 0pt 0in'><font style=FONT-SIZE:10pt>For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company&#8217;s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included in the measurement of the right-of-use asset and related lease liability.&nbsp; Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss when they are incurred.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 13.55pt 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-18</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 13.55pt 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>Supplemental cash flow information related to leases for the year ended May 31, 2020:&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=487 nowrap style="HEIGHT:15pt; WIDTH:365.05pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Operating cash flows from operating leases&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">311,742 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=487 nowrap style="HEIGHT:15pt; WIDTH:365.05pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=487 nowrap style="HEIGHT:15pt; WIDTH:365.05pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Right-of-use assets obtained in exchange for <br>&nbsp;&nbsp;&nbsp;&nbsp;new operating lease liabilities</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">&nbsp;-- </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=487 nowrap style="HEIGHT:15pt; WIDTH:365.05pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Weighted average remaining lease term (in years)</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">6.27</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=487 nowrap style="HEIGHT:15pt; WIDTH:365.05pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Weighted average discount rate</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">6.5%</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The maturity of lease liabilities as of May 31, 2020 are as follows:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=198 nowrap style="HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Years ending May 31,</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=198 nowrap style="HEIGHT:15pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">211,808 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=198 nowrap style="HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">2022</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">236,391 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=198 nowrap style="HEIGHT:15pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">2023</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">262,810 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=198 nowrap style="HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">2024</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">291,329 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=198 nowrap style="HEIGHT:15pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">2025</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">322,098 </font></p></td></tr> <tr style=HEIGHT:15pt> <td width=198 nowrap style="HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Thereafter</font></p></td> <td width=2% nowrap style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">457,051 </font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=198 nowrap style="HEIGHT:15.75pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Total</font></p></td> <td width=2% nowrap style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=2% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td width=12% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt' align=right><font style="FONT-SIZE:10pt; COLOR:black">1,781,487 </font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">According to the terms of the lease in Irvine, the Company is also responsible for routine repairs of the building and for certain increases in property tax. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company also has various insignificant leases for office equipment.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">RETIREMENT SAVINGS PLAN</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Effective September 1, 1986, the Company established a 401(k) plan for the benefit of its employees. The plan permits eligible employees to contribute to the plan up to the maximum percentage of total annual compensation allowable under the limits of IRC Sections 415, 401(k) and 404. The Company, at the discretion of its Board of Directors, may make contributions to the plan in amounts determined by the Board each year. No contributions by the Company have been made since the plan's inception.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">LITIGATION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. While the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that exist. Therefore, it is possible the outcome of such legal proceedings, claims and litigation could have a material effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows. There were no legal proceedings pending as of May 31, 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On July 2, 2020, we received a notice of investigation and subpoena to produce information and documents from the Division of Enforcement of the SEC. The subpoena seeks information and documents related to events and circumstances leading up to our March 17, 2020 announcement that we had commenced shipping samples of our COVID-19 IgG/IgM Rapid Test to countries outside of the United States, and had initiated the application process with the United States Food and Drug Administration under the COVID-19 Emergency Use Authorization for approval to market and sell the test in the United States. The subpoena also seeks information and documents about the identity of any persons who were aware of the substance of the March 17, 2020 announcement prior to that date. We are cooperating and intends to continue cooperating fully with the SEC&#8217;s investigation. At this time, we are unable to predict the duration, scope or outcome of this investigation.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-19</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10pt; COLOR:black">CONTRACTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:10pt>Contracts and Licensing Agreements</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">The Company has one royalty agreement in which it has obtained rights to manufacture and market certain products for the life of the products. Royalty expense of approximately $15,000 and $19,000 is included in cost of sales for the agreement for each of the years ended May 31, 2020 and 2019, respectively. Sales of products manufactured under these agreements comprise approximately 1.8% and 2.9% of total sales for the years ended May 31, 2020 and 2019, respectively. The Company may license other products or technology in the future as it deems necessary for conducting business.&nbsp; The Company has other royalty agreements, however they are not considered material.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On May 25, 2016, the Company entered into an Exclusive Marketing License Agreement (&#8220; Telcon Agreement&#8221;) with Celtis Pharm Co., Ltd., who subsequently changed their name to Telcon Pharmaceutical Co., LTD (&#8220;Telcon&#8221;), a medical company in the South Korea. The Telcon Agreement grants to Telcon an exclusive license to market and sell Biomerica&#8217;s new InFoods&reg; IBS products (&#8220;IBS Products&#8221;) in South Korea. The term of the agreement is for a period of five years following Korean FDA clearance of the product and provides an additional two years for Telcon to attain such Korean FDA clearance. The sequential two-year and five-year terms do not begin until after Biomerica first receives final clearance for sale of the IBS Products in the United States from the FDA. Telcon, at its sole cost and expense, must use its commercially reasonable good faith efforts to obtain Korean FDA for the IBS Product to be sold in South Korea. The agreement may be cancelled if Biomerica has not obtained final USFDA clearance for sale of the IBS Products on or before December 31, 2019. Biomerica is also obligated to maintain a full quality assurance system for the IBS Products following the harmonized standards according to Annex IV of Directive 98/79/EC. We are working with Telcon management to extend the term of the Telcon Agreement. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The terms of the Telcon Agreement provide up to $1.25 million in exclusivity fees based on certain milestones including Biomerica&#8217;s starting clinical trials in the United States, receipt of US FDA clearance and Telcon&#8217;s first sales of IBS Products in Korea. If Biomerica commences FDA Trials and Telcon pays the initial $250,000 milestone-based exclusivity fees, and the Agreement is subsequently terminated by either party for lack of performance, then Biomerica shall issue to Telcon 83,333 shares of Biomerica common in consideration for the $250,000 of paid exclusivity fee. No exclusivity fees have yet been paid.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Additionally, the Telcon Agreement provides for&nbsp;a royalty of 15% paid to Biomerica on all sales in Korea of the IBS Product, and further sets the pricing of IBS Products sold to Telcon.&nbsp; In order to retain the exclusivity within South Korean, Telcon must meet certain annual minimum royalty payments to Biomerica following Telcon&#8217;s receipt of Korean FDA approval or clearance for the IBS Product to be sold in Korea, which in no case will be later than May 31, 2019.<b> </b>&nbsp;&nbsp;In September 2017, an agreement to extend this date was signed extending the date until April 30, 2020. We are working with Telcon management to extend the date for the completion of this obligation.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><a name=_Hlk48120529><font style="FONT-SIZE:10pt; COLOR:black">In October 2018, the Company entered into an agreement with a customer for the sale of its EZ Detect product in the United States. The term of the Agreement is for three years and is renewable for one-year terms upon written notice.&nbsp; The agreement defines the price and rebate to the customer. There were no sales under this agreement in fiscal 2020.</font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In December 2018, the Company entered into an agreement with a company for the purpose of procuring and assisting in transactions related to its EZ Detect product with China.&nbsp; The contract is for a period of twelve months and is cancellable by either party with forty-five days written notice.&nbsp; The contract specifies 2.5-6% success fees and milestone payments upon certain events transpiring. During fiscal 2019, the Company incurred $27,579 in expenses for this contract. There were no expenses incurred in fiscal 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In April 2019, the Company entered into a consulting agreement with the former, retired president of the Company. The agreement stipulates that he shall be available by consultation if needed for the period of April 8, 2019 through April 7, 2020.&nbsp; In return, the Company has agreed to allow his stock options in the Company to continue to vest and be exercisable until April 7, 2020. At that time, no options will vest and any vested, unexercised options must be exercised by July 2, 2020 at which time they will be forfeited. All options that were eligible to vest according to this agreement were vested and exercised.&nbsp; There were no fees incurred for this agreement for consultation services.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In May 2019, the Company entered into an agreement with MaxHealth Medical International Limited and MaxHealth China (&#8220;MaxHealth&#8221;) giving MaxHealth exclusive distribution rights to Biomerica&#8217;s EZ Detect Product in China.&nbsp; Among other things, the Agreement called for MaxHealth to deposit $100,000 upon execution of the agreement, and an additional $900,000 (for a total of $1,000,000 USD) upon clearance of Chinese customs of the initial order of $100,000. The $1,000,000 was to be used as a prepayment for the first $1,000,000 of purchase orders for the product. While the Company received the first deposit of $100,000, and shipped $100,000 of product to Maxhealth, the Company has not received the second deposit, and has not shipped any further product, which has placed MaxHealth in Default of the agreement.&nbsp; MaxHealth and the Company have been negotiating a possible remedy for the default. There is no assurance these negotiations will be successful or that the default will be rectified.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-20</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On April 1, 2020, the Company entered into two separate non-exclusive license agreements (the &#8220;Mount Sinai License Agreements&#8221;) with the Mount Sinai Icahn School of Medicine in New York (&#8220;Mount Sinai&#8221;) to license technology from Mount Sinai that the Company intends to use to scale up and manufacture a laboratory version serological test for SARS-CoV-2 coronavirus.&nbsp; This test uses the ELISA microplate format that can run on existing open system equipment found in most hospitals and clinical laboratories in the United States.&nbsp; The non-exclusive Mount Sinai License Agreements provide for royalty payments to Mount Sinai based on a percentage of gross sales of commercial products manufactured and sold by Biomerica that incorporate the Mount Sinai technology licensed under the Mount Sinai License Agreement. On June 20, 2020, the Company filed for EUA with the FDA based on this on this technology. The Company purchased materials in the amount of $5,100 during fiscal 2020 and subsequently to that another $2,850.&nbsp; No royalty fees have been paid yet on these agreements.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">On May 7, 2020, the Company entered into an exclusive license agreement (the &#8220;UC License Agreements&#8221;) with The Regents of the University of California (&#8220;UC&#8221;) to license all patent rights pertaining to certain licensed technology from UC. This technology is being developed at the University by one of the professors and his team utilizing CRISPR technology. This group is developing a viral detection test for SARS-CoV-2 coronavirus.&nbsp;If this technology development is successful, the Company will work with the University to transfer the technology to Biomerica where the CRISPR based product will need to be further developed, validated and cleared with regulatory agencies for commercial sale into the market.&nbsp; The exclusive UC License Agreements provide for an initial and annual license fee, and a royalty payment on all commercial revenues, to the UC Regents. The UC License Agreement also includes certain investment requirements and milestones the Company will need to meet for the launch of a commercial product based on the licensed technology. The Company paid an initial license fee of $5,000 with the execution of the agreement. An additional $5,000 is due in September 2020.&nbsp; No royalties have been paid yet on this agreement. A license maintenance fee of $10,000 is due annually. This is creditable against earned royalties due each year in the amount of five percent on net sales of licensed products.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><a name=_Hlk48645104><font style=FONT-SIZE:10pt>On May 18, 2020, the Company signed a non-exclusive distributor agreement with a company in Russia for the distribution of COVID-19 tests. The term of the agreement is for an initial two years, however, the agreement may be terminated for breach of contract. The agreement allows for quantity discounts based on certain milestones.</font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0pt 0in'><b><font style=FONT-SIZE:10pt>Clinical Trial Agreements</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In September 2017, the Company signed a Clinical Samples Agreement with the University of Southern California for the purpose of providing clinical samples for use by the Company in conducting future clinical trials for one of the products which the Company is developing.&nbsp; The initial budget was estimated to be $82,472. The work started in October 2017 with charges for work performed being invoiced and paid monthly.&nbsp; This study ended in February 2020. The Company incurred $2,200 in fiscal 2020 and $12,567 in expenses previously invoiced for a total of $14,767. In addition, $17,064 in fees has been accrued for unbilled charges as of May 31, 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In November 2017, the Company entered into a Clinical Trial Agreement with the University of Michigan to perform an InFoods 24 Endpoint Determination Study.&nbsp; The Company will be invoiced monthly for work performed the previous month. The maximum budget for the study is $181,015. The Company incurred $30,900 and $40,885 in expenses for this study during fiscal 2020 and 2019, respectively. This commitment is approximately 47% billed.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">In January 2018, the Company entered into a Clinical Trial Agreement with Beth Israel Deaconess Medical Center for the purposes of conducting an Antibody Guided Restriction Trial Using Biomerica InFoods 24G Test in patients with a previous diagnosis of Irritable Bowel Syndrome (&#8220;IBS&#8221;).&nbsp; The study began in the first quarter of fiscal 2019. The Company was invoiced monthly for work performed the previous month.&nbsp; The total cost of the study was initially estimated to be $142,000, however the study was expanded and total costs of the trial was approximately $305,000. The Company incurred $141,640 and $146,760 in expenses for this study during fiscal 2020 and 2019, respectively. This study was closed in February 2020 and no additional costs are expected.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On July 12, 2019, the Company entered into a Clinical Trial Agreement with a research management institution for the purpose of conducting a clinical trial of the Biomerica HP Stool Antigen test.&nbsp; The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month.&nbsp; The maximum budgeted costs was approximately $117,200.&nbsp; During fiscal 2020, $13,111 in charges were billed and the Company accrued $6,670 in charges as of May 31, 2020. This study is now closed so no further charges will be incurred.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On July 22, 2019, the Company entered into a Clinical Trial Agreement with a research institution, for the purpose of conducting a clinical trial of the Biomerica Infoods product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be approximately $107,000.&nbsp; The Company incurred $20,875 in charges during fiscal 2020. This commitment is approximately 19% billed. In addition, the Company accrued $2,650 in unbilled charges as of May 31, 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On September 25, 2019, the Company entered into a Clinical Trial Agreement with a medical practice for the purpose of conducting a clinical trial of the Biomerica Infoods IBS product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $136,000. During fiscal 2020, the Company was invoiced $45,250 in expenses. This commitment is approximately 33% billed. In addition, the Company accrued $5,975 in unbilled charges as of May 31, 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-21</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On September 25, 2019, the Company entered into a Clinical Trial Agreement with a research institution for the purpose of conducting a clinical trial of the Biomerica H. pylori product.&nbsp; The term of the agreement shall be until completion of the work outlined and the charges were invoiced monthly for work performed in the previous month.&nbsp; The maximum budgeted costs will be approximately $57,800. The Company was invoiced $41,845 in charges during the year ended May 31, 2020. At May 31, 2020, the commitment was approximately 72% billed and the study has been closed so no further charges will be incurred.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>In December 2019, the Company entered into a Clinical Trial Agreement with Houston Methodist Research Institute for the purpose of conducting a clinical trial of the Biomerica InFoods&reg; IBS product.&nbsp; The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month.&nbsp; The maximum budgeted costs will be approximately $133,000. During the year ended May 31, 2020, the Company was invoiced $4,000 in charges. This commitment is approximately 3% billed.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On May 28, 2020, the Company entered into a Clinical Trial Agreement with the Mayo Clinic Arizona for the purpose of participating in the ongoing end point clinical trial of the Biomerica Infoods IBS product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $135,515. &nbsp;At May 31, 2020, $17,390 had been invoiced to the Company. This commitment is approximately 13% billed.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On May 28, 2020, the Company entered into a Clinical Trial Agreement with the Mayo Clinic Jacksonville for the purpose of participating in the ongoing end point clinical trial of the Biomerica Infoods IBS product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $135,515. The Company has not received any billings as of May 31, 2020, however accrued $17,390 in charges as of that date.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>The addition of both Mayo Clinic sites and other major medical centers were brought into the Infoods&reg; IBS clinicals studies in order to accelerate patient enrollment.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0pt 0in'><b><font style="FONT-SIZE:10pt; COLOR:black">9.&nbsp;&nbsp;&nbsp; SUBSEQUENT EVENTS</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>Subsequent to May 31, 2020 and through August 31, 2020, 12,500 stock options were exercised at $1.20 per share.&nbsp; Net proceeds to the Company were approximately $14,900.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On June 15, 2020, the Board approved the grant of 52,000 stock options to certain employees.&nbsp; The options vest one-quarter on June 15, 2021 and then one-quarter per year thereafter.&nbsp; The options have an exercise price of $5.46 per share and have a ten-year life.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On July 13, 2020, the Board approved the grant of 76,000 stock options to certain employees and consultants.&nbsp; The options vest one-quarter on July 13, 2021 and then one-quarter per year thereafter.&nbsp; The options have an exercise price of $8.70 per share and have a ten-year life.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On July 13, 2020, the approved the grant of 7,500 stock options to a consultant.&nbsp; The options vest one-half on January 13, 2021 and one-half on July 13, 2021.&nbsp; The options have an exercise price of $8.70 per share and have a ten-year life.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On June 25, 2020, the Company entered into a Clinical Trial Agreement with the University of Texas Health Science Center for the purpose of conducting a clinical trial of the Biomerica Infoods product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $139,850.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On July 20, 2020, the Company filed with the SEC a new Form S-3 &#8220;Shelf&#8221; registration statement to replace the registration statement that expired on that day.&nbsp; The new registration statement registers common shares to be issued in a maximum aggregate of $90,000,000.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On August 27, 2020, the Board approved the grant of 33,000 stock options to an employee and a board member. The options vest one-quarter on August 27, 2021 and then one-quarter per year thereafter.&nbsp; The options have an exercise price of $7.47 per share and have a ten-year life.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>On August 27, 2020, the Board approved the grant of 2,500 stock options to a consultant. The options vest one-half on January 13, 2021 and 50% on July 13, 2021. The options have an exercise price of $7.47 per share and have a ten-year life.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p></div> <div style=page:WordSection3> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-BEFORE:none; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:10pt>FS-22</font></p></div></body>
<!-- EDGAR Validation Code: A5A714F8 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>2
<FILENAME>exhibit10_8.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<HTML>
<head><title>Exhibit 10.8</title> </head> <body lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-FAMILY:"Times New Roman","serif"'>EXHIBIT A</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-FAMILY:"Times New Roman","serif"'>BIOMERICA, INC.</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-FAMILY:"Times New Roman","serif"'>2020 STOCK INCENTIVE PLAN</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style='FONT-FAMILY:"Times New Roman","serif"'>ARTICLE 1. INTRODUCTION.</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; The Plan was adopted by the Board effective February 10, 2020, and submitted to shareholders for approval at the Biomerica Annual Shareholder meeting in December, 2020. The purpose of the Plan is to promote the long-term success of the Company and the creation of stockholder value by (a) encouraging Employees, Outside Directors and Consultants to focus on critical long-range objectives, (b) encouraging the attraction and retention of Employees, Outside Directors and Consultants with exceptional qualifications and (c) linking Employees, Outside Directors and Consultants directly to stockholder interests through increased stock ownership. The Plan seeks to achieve this purpose by providing for Awards in the form of Restricted Shares or Options (which may constitute incentive stock options or non-statutory stock options).</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>The Plan shall be governed by, and construed in accordance with, the laws of the State of California.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style='FONT-FAMILY:"Times New Roman","serif"'>ARTICLE 2. ADMINISTRATION</font></b><font style='FONT-FAMILY:"Times New Roman","serif"'>.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 2.1 COMMITTEE COMPOSITION. The Plan shall be administered by the Board of Directors of the Company, provided the Board may delegate administration of the Plan to a Committee consisting exclusively of two or more Outside Directors of the Company, who shall be appointed by the Board. In addition, the composition of the Committee shall satisfy:</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) Such requirements as the Securities and Exchange Commission may establish for administrators acting under plans intended to qualify for exemption under Rule 16b-3 (or its successor) under the Exchange Act; and</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) Such requirements as the Internal Revenue Service may establish for outside directors acting under plans intended to qualify for exemption under Section 162(m)(4)(C) of the Code.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 2.2 COMMITTEE RESPONSIBILITIES. The Board (or the Committee, if applicable) shall (a) review management's recommendation as to the Employees, Outside Directors and Consultants who are to receive Awards under the Plan, (b) determine the type, number, vesting requirements and other features and conditions of such Awards, (c) interpret the Plan and (d) make all other decisions relating to the operation of the Plan. The Board and Committee may adopt such rules or guidelines as it deems appropriate to implement the Plan. The Board's and Committee's determinations under the Plan shall be final and binding on all persons.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 2.3 COMMITTEE FOR NON-OFFICER GRANTS. The Board may also appoint a secondary committee of the Board, which shall be composed of one or more directors of the Company who need not satisfy the requirements of Section 2.1. Such secondary committee may administer the Plan with respect to Employees and Consultants who are not considered officers or directors of the Company under section 16 of the Exchange Act or covered employees under Section 162(m)(3) of the Code, may grant Awards under the Plan to such Employees and Consultants and may determine all features and conditions of such Awards. Within the limitations of this Section 2.3, any reference in the Plan to the Committee shall include such secondary committee.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style='FONT-FAMILY:"Times New Roman","serif"'>ARTICLE 3. SHARES AVAILABLE FOR GRANTS.</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 3.1 BASIC LIMITATION. Common Shares issued pursuant to the Plan may be authorized but unissued shares or treasury shares. The aggregate number of Options and Restricted Shares awarded under the Plan shall not exceed NINE HUNDRED THOUSAND (900,000). The limitations of this Section 3.1 and Section 3.2 shall be subject to adjustment pursuant to Article 9.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 3.2 ADDITIONAL SHARES. If Options are forfeited or terminate for any other reason before being exercised, then the corresponding Common Shares shall again become available for the grant of Options or Restricted Shares under the Plan. If Restricted Shares or Common Shares issued upon the exercise of Options are forfeited, then such Common Shares shall again become available for the grant of NSOs and Restricted Shares under the Plan. The aggregate number of Common Shares that may be issued under the Plan upon the exercise of ISOs shall not be increased when Restricted Shares or other Common Shares are forfeited.</font></p> <div style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style='FONT-FAMILY:"Times New Roman","serif"'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </font></b></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style='FONT-FAMILY:"Times New Roman","serif"'>ARTICLE 4.&nbsp;&nbsp;&nbsp;&nbsp; ELIGIBILITY.</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 4.1 NONSTATUTORY STOCK OPTIONS AND RESTRICTED SHARES. Only Employees, Outside Directors and Consultants shall be eligible for the grant of NSOs and Restricted Shares.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 4.2 INCENTIVE STOCK OPTIONS. Only Employees who are employees of the Company, a Parent or a Subsidiary shall be eligible for the grant of ISOs. In addition, an Employee who owns more than 10% of the total combined voting power of all classes of outstanding stock of the Company or any of its Parents or Subsidiaries shall not be eligible for the grant of an ISO unless the requirements set forth in section 422(c)(5) of the Code are satisfied.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style='FONT-FAMILY:"Times New Roman","serif"'>ARTICLE 5.&nbsp;&nbsp;&nbsp;&nbsp; OPTIONS</font></b><font style='FONT-FAMILY:"Times New Roman","serif"'>.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 5.1 STOCK OPTION AGREEMENT. Each grant of an Option under the Plan shall be evidenced by a Stock Option Agreement between the Optionee and the Company. Such Option shall be subject to all applicable terms of the Plan and may be subject to any other terms that are not inconsistent with the Plan. The provisions of the various Stock Option Agreements entered into under the Plan need not be identical. A Stock Option Agreement may provide that a new Option will be granted automatically to the Optionee when he or she exercises a prior Option and pays the Exercise Price in the form described in Section 6.2. </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 5.2 NUMBER OF SHARES. Each Stock Option Agreement shall specify the number of Common Shares subject to the Option and shall provide for the adjustment of such number in accordance with Article 9. The limitations set forth in the preceding sentence shall be subject to adjustment in accordance with Article 9.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 5.3 EXERCISE PRICE. Each Stock Option Agreement shall specify the Exercise Price; provided that the Exercise Price under an ISO shall in no event be less than 100% of the Fair Market Value of a Common Share on the date of grant and the Exercise Price under an NSO shall in no event be less than 85% of the Fair Market Value of a Common Share on the date of grant. In the case of an NSO, a Stock Option Agreement may specify an Exercise Price that varies in accordance with a predetermined formula while the NSO is outstanding.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 5.4 VESTING, EXERCISABILITY AND TERM. Unless otherwise approved by the Board of Directors and provided in the Stock Option Agreement, an Optionee's right to exercise the Option shall vest pro rata over a period of four (4) years, with 25% of the Option vesting on each of the first, second, third and fourth anniversaries of the date of grant. The Stock Option Agreement shall also specify the term or expiration of the Option; provided that the term of an ISO shall in no event exceed 10 years from the date of grant. A Stock Option Agreement may provide for accelerated exercisability in the event of the Optionee's death, disability or retirement or other events and may provide for expiration prior to the end of its term in the event of the termination of the Optionee's service.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 5.5 EFFECT OF CHANGE IN CONTROL. Notwithstanding Section 5.4 above, each Option shall automatically fully vest (e.g., become exercisable) as to all or part of the Common Shares subject to such Option in the event that a Change in Control (as defined in Section 14.4 below) occurs with respect to the Company, subject to the following limitations.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 5.6 MODIFICATION OR ASSUMPTION OF OPTIONS. Within the limitations of the Plan, the Board or the Committee may modify, extend or assume outstanding options or may accept the cancellation of outstanding options (whether granted by the Company or by another issuer) in return for the grant of new options for the same or a different number of shares and at the same or a different exercise price. The foregoing notwithstanding, no modification of an Option shall, without the consent of the Optionee, alter or impair his or her rights or obligations under such Option.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 5.7 BUYOUT PROVISIONS. The Committee may at any time (a) offer to buy out for a payment in cash or cash equivalents an Option previously granted or (b) authorize an Optionee to elect to cash out the vested portion of an Option previously granted, in either case at such time and based upon such terms and conditions as the Board or the Committee shall establish.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-FAMILY:"Times New Roman","serif"'>1</font></p> <div style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-FAMILY:"Times New Roman","serif"'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </font></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style='FONT-FAMILY:"Times New Roman","serif"'>ARTICLE 6.&nbsp;&nbsp;&nbsp;&nbsp; PAYMENT FOR OPTION SHARES.</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 6.1 GENERAL RULE. The entire Exercise Price of Common Shares issued upon exercise of Options shall be payable in cash or cash equivalents at the time when such Common Shares are purchased, except as follows:</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) In the case of an ISO granted under the Plan, payment shall be made only pursuant to the express provisions of the applicable Stock Option Agreement. The Stock Option Agreement may specify that payment may be made in any form(s) described in this Article 6.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) In the case of an NSO, the Committee may at any time accept payment in any form(s) described in this Article 6.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 6.2 EXERCISE/SALE. To the extent that this Section 6.2 is applicable, all or any part of the Exercise Price and any withholding taxes may be paid by delivering (on a form prescribed by the Company) an irrevocable direction to a securities broker approved by the Company to sell all or part of the Common Shares being purchased under the Plan and to deliver all or part of the sales proceeds to the Company.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 6.3 EXERCISE/PLEDGE. To the extent that this Section 6.3 is applicable, all or any part of the Exercise Price and any withholding taxes may be paid by delivering (on a form prescribed by the Company) an irrevocable direction to pledge all or part of the Common Shares being purchased under the Plan to a securities broker or lender approved by the Company, as security for a loan, and to deliver all or part of the loan proceeds necessary to cover the Exercise Price to the Company.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 6.4 PROMISSORY NOTE. To the extent that this Section 6.4 is applicable, all or any part of the Exercise Price and any withholding taxes may be paid by delivering (on a form prescribed by the Company) a full-recourse promissory note, which may include a security interest in the shares issued under the Option. However, the par value of the Common Shares being purchased under the Plan, if newly issued, shall be paid in cash or cash equivalents.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 6.5 OTHER FORMS OF PAYMENT. To the extent that this Section 6.5 is applicable, all or any part of the Exercise Price and any withholding taxes may be paid in any other form that is consistent with applicable laws, regulations and rules.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style='FONT-FAMILY:"Times New Roman","serif"'>ARTICLE 7.</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 7.1 ACCELERATED EXERCISABILITY. All NSOs granted to an Outside Director under this Article 7 shall become exercisable in full in the event of:</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) the termination of such Outside Director's service because of death, total and permanent disability or retirement at or after age 70; or</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) a Change in Control (as defined in Section 14.4 below) with respect to the Company, except as provided in the next following sentence.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 7.2 EXERCISE PRICE. The Exercise Price under all NSOs granted to an Outside Director under this Article 7 shall be equal to 100% of the Fair Market Value of a Common Share on the date of grant, payable in one of the forms described in Sections 6.1, 6.2, 6.3 and 6.4.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 7.3 TERM. Unless otherwise provided in the Stock Option Agreement, all NSOs granted to an Outside Director under this Article 7 shall terminate on the earliest of (a) the 10th anniversary of the date of grant, or (b) the date 12 months after the termination of such Outside Director's service as a Director. </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 7.4 AFFILIATES OF OUTSIDE DIRECTORS. The Committee may provide that the NSOs that otherwise would be granted to an Outside Director under this Article 7 shall instead be granted to an affiliate of such Outside Director. Such affiliate shall then be deemed to be an Outside Director for purposes of the Plan, including that the service-related vesting and termination provisions pertaining to the NSOs shall be applied with regard to the service of the Outside Director.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-FAMILY:"Times New Roman","serif"'>2</font></p> <div style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-FAMILY:"Times New Roman","serif"'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </font></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style='FONT-FAMILY:"Times New Roman","serif"'>ARTICLE 8.&nbsp;&nbsp;&nbsp;&nbsp; RESTRICTED SHARES.</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 8.1 RESTRICTED STOCK AGREEMENT. Each grant of Restricted Shares of Common Stock under the Plan shall be evidenced by a Restricted Stock Agreement between the recipient and the Company. Such Restricted Shares shall be subject to all applicable terms of the Plan and may be subject to any other terms that are not inconsistent with the Plan. The provisions of the various Restricted Stock Agreements entered into under the Plan need not be identical.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 8.2 PAYMENT FOR AWARDS. Subject to the following sentence, Restricted Shares may be sold or awarded under the Plan for such consideration as the Board or the Committee may determine, including (without limitation) cash, cash equivalents, full-recourse promissory notes, past services and future services. To the extent that an Award consists of newly issued Restricted Shares, the Award recipient shall furnish consideration with a value not less than the par value of such Restricted Shares in the form of cash, cash equivalents or past services rendered to the Company (or a Parent or Subsidiary), as the Committee may determine.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 8.3 VESTING CONDITIONS. Unless otherwise approved by the Board of Directors and provided in the Restricted Stock Agreement, the Restricted Shares shall vest pro rata over a period of four (4) years, with 25% of the Option vesting on each of the first, second, third and fourth anniversaries of the date of grant. A Restricted Stock Agreement may provide for accelerated vesting in the event of the Participant's death, disability or retirement or other events. All Restricted Shares shall become vested in the event that a Change in Control (as defined in Section 14.4) occurs with respect to the Company, except as provided in the next following sentence.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 8.4 VOTING AND DIVIDEND RIGHTS. The holders of Restricted Shares awarded under the Plan shall have the same voting, dividend and other rights as the Company's other stockholders.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style='FONT-FAMILY:"Times New Roman","serif"'>ARTICLE 9.&nbsp;&nbsp;&nbsp;&nbsp; PROTECTION AGAINST DILUTION.</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp; &nbsp;9.1 ADJUSTMENTS. In the event of a subdivision of the outstanding Common Shares, a declaration of a dividend payable in Common Shares, a declaration of a dividend payable in a form other than Common Shares in an amount that has a material effect on the price of Common Shares, a combination or consolidation of the outstanding Common Shares (by reclassification or otherwise) into a lesser number of Common Shares, a recapitalization, a spin-off or a similar occurrence, the Board of the Committee shall make such adjustments as it, in its sole discretion, deems appropriate in one or more of (a) the number of Options and Restricted Shares available for future Awards under Article 3, (b) the limitations set forth in Section 5.2, (c) the number of Common Shares covered by each outstanding Option or (d) the Exercise Price under each outstanding Option. Except as provided in this Article 9, a Participant shall have no rights by reason of any issue by the Company of stock of any class or securities convertible into stock of any class, any subdivision or consolidation of shares of stock of any class, the payment of any stock dividend or any other increase or decrease in the number of shares of stock of any class.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 9.2 DISSOLUTION OR LIQUIDATION. To the extent not previously exercised, Options shall terminate immediately prior to the dissolution or liquidation of the Company.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 9.3 REORGANIZATIONS. In the event that the Company is a party to a merger or other reorganization, outstanding Options and Restricted Shares shall be subject to the agreement of merger or reorganization. Such agreement may, but is not required to, provide for one or more of the following: (a) the continuation of the outstanding Awards by the Company, if the Company is a surviving corporation, (b) the assumption of the outstanding Awards by the surviving corporation or its parent or subsidiary, (c) the substitution by the surviving corporation or its parent or subsidiary of its own awards for the outstanding Awards, (d) full exercisability or vesting and accelerated expiration of the outstanding Awards or (e) settlement of the full value of the outstanding Awards</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>in cash or cash equivalents followed by cancellation of such Awards.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style='FONT-FAMILY:"Times New Roman","serif"'>ARTICLE 10.&nbsp;&nbsp;&nbsp; AWARDS UNDER OTHER PLANS.</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; The Company may grant awards under other plans or programs. Such awards may be settled in the form of Common Shares issued under this Plan. Such Common Shares shall be treated for all purposes under the Plan like Restricted Shares and shall, when issued, reduce the number of Common Shares available under Article 3.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-FAMILY:"Times New Roman","serif"'>3</font></p> <div style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-FAMILY:"Times New Roman","serif"'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </font></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style='FONT-FAMILY:"Times New Roman","serif"'>ARTICLE 11.&nbsp;&nbsp;&nbsp; LIMITATION ON RIGHTS</font></b><font style='FONT-FAMILY:"Times New Roman","serif"'>.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 11.1 RETENTION RIGHTS. Neither the Plan nor any Award granted under the Plan shall be deemed to give any individual a right to remain an Employee, Outside Director or Consultant. The Company and its Parents, Subsidiaries and Affiliates reserve the right to terminate the service of any Employee, Outside Director or Consultant at any time, with or without cause, subject to applicable laws, the Company's certificate of incorporation and by-laws and a written employment agreement (if any).</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 11.2 STOCKHOLDERS' RIGHTS. A Participant shall have no dividend rights, voting rights or other rights as a stockholder with respect to any Common Shares covered by his or her Award prior to the time when a stock certificate for such Common Shares is issued or, in the case of an Option, the time when he or she becomes entitled to receive such Common Shares by filing a notice of exercise and paying the Exercise Price. No adjustment shall be made for cash dividends or other rights for which the record date is prior to such time, except as expressly provided in the Plan.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 11.3 REGULATORY REQUIREMENTS. Any other provision of the Plan notwithstanding, the obligation of the Company to issue Common Shares under the Plan shall be subject to all applicable laws, rules and regulations and such approval by any regulatory body as may be required. The Company reserves the right to restrict, in whole or in part, the delivery of Common Shares pursuant to any Award prior to the satisfaction of all legal requirements relating to the issuance of such Common Shares, to their registration, qualification or listing or to an exemption from registration, qualification or listing.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style='FONT-FAMILY:"Times New Roman","serif"'>ARTICLE 12.&nbsp;&nbsp;&nbsp; WITHHOLDING TAXES.</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 12.1 GENERAL. To the extent required by applicable federal, state, local or foreign law, a Participant or his or her successor shall make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise in connection with the Plan. The Company shall not be required to issue any Common Shares or make any cash payment under the Plan until such obligations are satisfied.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style='FONT-FAMILY:"Times New Roman","serif"'>ARTICLE 13.&nbsp;&nbsp;&nbsp; FUTURE OF THE PLAN.</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 13.1 TERM OF THE PLAN. The Plan, as set forth herein, shall become effective upon approval of the Plan by the Company's stockholders (expected to be obtained on or about December 10, 2020). The Plan shall remain in effect until December 10, 2030, unless earlier terminated under Section 13.2, except that no ISOs shall be granted on or after the 10th anniversary of the later of (a) the date when the Board adopted the Plan or (b) the date when the Board adopted the most recent increase in the number of Common Shares available under Article 3 which was approved by the Company's stockholders.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13.2 AMENDMENT OR TERMINATION. The Board may, at any time and for any reason, amend or terminate the Plan. An amendment of the Plan shall be subject to the approval of the Company's stockholders only to the extent required by applicable laws, regulations or rules. No Awards shall be granted under the Plan after the termination thereof. The termination of the Plan, or any amendment thereof, shall not affect any Award previously granted under the Plan.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style='FONT-FAMILY:"Times New Roman","serif"'>ARTICLE 14. DEFINITIONS</font></b><font style='FONT-FAMILY:"Times New Roman","serif"'>.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.1 "AFFILIATE" means any entity other than a Subsidiary, if the Company and/or one or more Subsidiaries own not less than 50% of such entity. </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.2 "AWARD" means any award of an Option or a Restricted Share under the Plan.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.3 "BOARD" means the Company's Board of Directors, as constituted from time to time.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-FAMILY:"Times New Roman","serif"'>4</font></p> <div style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-FAMILY:"Times New Roman","serif"'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </font></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.4 "CHANGE IN CONTROL" shall mean:</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) the consummation of a merger or consolidation of the Company with or into another entity or any other corporate reorganization, if more than 50% of the combined voting power of the continuing or surviving entity's securities outstanding immediately after such merger, consolidation or other reorganization is owned by persons who were not stockholders of the Company immediately prior to such merger, consolidation or other reorganization;</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) the sale, transfer or other disposition of all or substantially all of the Company's assets;</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (c) a change in the identity of a majority of the members of the Company's Board of Directors that becomes effective on a single date (provided, however, that the appointments of new directors upon the deaths or resignations</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>of directors by the remaining directors then in office shall not constitute a change in identity with respect to such departed director); or </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (d) any transaction as a result of which any person is the "beneficial owner" (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing at least 50% of the total voting power represented by the Company's then outstanding voting securities. For purposes of this Subsection (d), the term "person" shall have the same meaning as when used in sections 13(d) and 14(d) of the Exchange Act but shall</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>exclude (i) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or of a Parent or Subsidiary and (ii) a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the common stock of the Company.&nbsp; A transaction shall not constitute a Change in Control if its sole purpose is to change the state of the Company's incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company's securities immediately before such transaction.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.5 "CODE" means the Internal Revenue Code of 1986, as amended.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.6 "COMMITTEE" means a committee of the Board, as described in Article 2.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.7 "COMMON SHARE" means one share of the common stock of the Company.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.8 "COMPANY" means Biomerica, Inc., a Delaware corporation.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.9 "CONSULTANT" means a consultant or adviser who provides bona fide services to the Company, a Parent, a Subsidiary or an Affiliate as an independent contractor. Service as a Consultant shall be considered employment for all purposes of the Plan, except as provided in Section 4.2.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.10 "EMPLOYEE" means an employee of the Company, a Parent, a Subsidiary or an Affiliate.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.11 "EXCHANGE ACT" means the Securities Exchange Act of 1934, as amended.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.12 "EXERCISE PRICE" means the amount for which one Common Share may be purchased upon exercise of such Option, as specified in the applicable Stock Option Agreement.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.13 "FAIR MARKET VALUE" means the market price of Common Shares, determined by the Board or the Committee in good faith on such basis as it deems appropriate. Whenever possible, the determination of Fair Market Value by the Committee shall be based on the prices reported in The Wall Street Journal. Such determination shall be conclusive and binding on all persons.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.14 "ISO" means an incentive stock option described in section 422(b) of the Code.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.15 "NSO" means a stock option not described in sections 422 of the Code.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.16 "OPTION" means an ISO or NSO granted under the Plan and entitling the holder to purchase Common Shares.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.17 "OPTIONEE" means an individual or estate who holds an Option.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-FAMILY:"Times New Roman","serif"'>5</font></p> <div style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-FAMILY:"Times New Roman","serif"'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </font></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.18 "OUTSIDE DIRECTOR" shall mean a member of the Board who is not an Employee. Service as an Outside Director shall be considered employment for all purposes of the Plan, except as provided in Section 4.2.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.19 "PARENT" means any corporation (other than the Company) in an unbroken chain of corporations ending with the Company, if each of the corporations other than the Company owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. A corporation that attains the status of a Parent on a date after the adoption of the Plan shall be considered a Parent commencing as</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>of such date.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.20 "PARTICIPANT" means an individual or estate who holds an Award.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.21 "PLAN: means this Biomerica, Inc. 2020 Stock Incentive Plan, as amended from time to time.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.22 "RESTRICTED SHARE" means a Common Share awarded under the Plan.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.23 "RESTRICTED STOCK AGREEMENT" means the agreement between the Company and the recipient of a Restricted Share that contains the terms, conditions and restrictions pertaining to such Restricted Share.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.24 "STOCK OPTION AGREEMENT" means the agreement between the Company and an Optionee that contains the terms, conditions and restrictions pertaining to his or her Option.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; 14.25 "SUBSIDIARY" means any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company, if each of the corporations other than the last corporation in the unbroken chain owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. A corporation that attains the status of a Subsidiary on a date after the adoption of the Plan shall be considered a Subsidiary commencing as of such date.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style='FONT-FAMILY:"Times New Roman","serif"'>ARTICLE 15.&nbsp;&nbsp;&nbsp; EXECUTION.</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp; To record the adoption of the Plan by the Board, the Company has caused its duly authorized officer to execute this document in the name of the Company.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BIOMERICA, INC.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; By<u>: /s/ Janet Moore</u></font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Name: Janet Moore</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Title: Secretary</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>Date approved by Board of Directors: February 7, 2020</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>Date Approved by Shareholders: _______________________________</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'><font style='FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman New"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 10pt; LINE-HEIGHT:115%' align=center>6</p></div></body>
<!-- EDGAR Validation Code: B5AE8FF9 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>exhibit23_1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<head> <title>Exhibit 23.1</title> </head> <body lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">EXHIBIT 23.1</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">CONSENT OF INDEPENDENT</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style="FONT-SIZE:10pt; COLOR:black">REGISTERED PUBLIC ACCOUNTING FIRM</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Biomerica, Inc. and Subsidiaries</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">Irvine, California</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10pt; COLOR:black">We hereby consent to the incorporation by reference in, the previously filed Registration Statements on Form S-8 (Nos. 333-33494, 333-179443, &nbsp;333-204410 and 333-224836) and Form S-3 (No. 333-239980) of Biomerica, Inc. and Subsidiaries, of our report dated August 31, 2020, relating to the consolidated financial statements as of May 31, 2020 and 2019 and for the years ended May 31, 2020 and 2019, which appears in this Form 10-K. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <table width=221 bordercolor=transparent style="WIDTH:166pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=221 style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:166pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt lang=DE>/s/ PKF, LLP</font></p></td></tr> <tr style=HEIGHT:9.4pt> <td style="HEIGHT:9.4pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt lang=DE>PKF, LLP</font></p></td></tr> <tr style=HEIGHT:9.9pt> <td style="HEIGHT:9.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:30pt> <td style="HEIGHT:30pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>San Diego, CA</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:10pt>August 31, 2020</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></div></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit31_1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<head> <title>Exhibit 31.1</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:'Times New Roman'; COLOR:#000000; MARGIN-TOP:0px"> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px>EXHIBIT 31.1</p> <p style=MARGIN:0px align=center><b>CERTIFICATION OF CHIEF EXECUTIVE OFFICER</b></p> <p style=MARGIN:0px align=center><b>PURSUANT TO</b></p> <p style=MARGIN:0px align=center><b>18 U.S.C. SECTION 1350,</b></p> <p style=MARGIN:0px align=center><b>AS ADOPTED PURSUANT TO</b></p> <p style=MARGIN:0px align=center><b>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px>I, Zackary S. Irani, certify that:</p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px align=justify>1. I have reviewed this Annual Report on Form 10-K of Biomerica, Inc.;</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of our internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or other persons performing the equivalent functions):</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px> <table width=221 bordercolor=transparent style="WIDTH:166pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr height=20 style=HEIGHT:15pt> <td width=221 height=20 style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:166pt; BORDER-BOTTOM:0.5pt solid; BORDER-LEFT:0px" valign=bottom><font lang=DE><font size=2>/s/ Zackary S. Irani</font></font></td></tr> <tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-LEFT-WIDTH:0px; HEIGHT:15pt; BORDER-RIGHT-WIDTH:0px; BORDER-BOTTOM-WIDTH:0px; BORDER-TOP-WIDTH:0px" valign=bottom><font lang=DE><font size=2>Zackary S. Irani</font></font></td></tr> <tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-LEFT-WIDTH:0px; HEIGHT:15pt; BORDER-RIGHT-WIDTH:0px; BORDER-BOTTOM-WIDTH:0px; BORDER-TOP-WIDTH:0px" valign=bottom><font size=2>Chief Executive Officer</font></td></tr> <tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-LEFT-WIDTH:0px; HEIGHT:15pt; BORDER-RIGHT-WIDTH:0px; BORDER-BOTTOM-WIDTH:0px; BORDER-TOP-WIDTH:0px" valign=bottom /> </tr><tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-LEFT-WIDTH:0px; HEIGHT:15pt; BORDER-RIGHT-WIDTH:0px; BORDER-BOTTOM-WIDTH:0px; BORDER-TOP-WIDTH:0px" valign=bottom><font size=2>Date: August 31, 2020</font></td></tr></table></p> <p style=MARGIN:0px></p> <p style=MARGIN:0px></p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit31_2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<head> <title>Exhibit 31.2</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:'Times New Roman'; COLOR:#000000; MARGIN-TOP:0px"> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px>EXHIBIT 31.2</p> <p style=MARGIN:0px align=center><b>CERTIFICATION OF CHIEF FINANCIAL OFFICER</b></p> <p style=MARGIN:0px align=center><b>PURSUANT TO</b></p> <p style=MARGIN:0px align=center><b>18 U.S.C. SECTION 1350,</b></p> <p style=MARGIN:0px align=center><b>AS ADOPTED PURSUANT TO</b></p> <p style=MARGIN:0px align=center><b>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px align=justify>I, Janet Moore, certify that:</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>1. I have reviewed this Annual Report on Form 10-K of Biomerica, Inc.;</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of our internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or other persons performing the equivalent functions):</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px>&nbsp;</p> <p style=MARGIN:0px> <table width=202 bordercolor=transparent style="WIDTH:152pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr height=20 style=HEIGHT:15pt> <td width=202 height=20 style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:152pt; BORDER-BOTTOM:0.5pt solid; BORDER-LEFT:0px" valign=bottom><font size=2>/s/ Janet Moore</font></td></tr> <tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-LEFT-WIDTH:0px; HEIGHT:15pt; BORDER-RIGHT-WIDTH:0px; BORDER-BOTTOM-WIDTH:0px; BORDER-TOP-WIDTH:0px" valign=bottom><font size=2>Janet Moore</font></td></tr> <tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-LEFT-WIDTH:0px; HEIGHT:15pt; BORDER-RIGHT-WIDTH:0px; BORDER-BOTTOM-WIDTH:0px; BORDER-TOP-WIDTH:0px" valign=bottom><font size=2>Chief Financial Officer</font></td></tr> <tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-LEFT-WIDTH:0px; HEIGHT:15pt; BORDER-RIGHT-WIDTH:0px; BORDER-BOTTOM-WIDTH:0px; BORDER-TOP-WIDTH:0px" valign=bottom /> </tr><tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-LEFT-WIDTH:0px; HEIGHT:15pt; BORDER-RIGHT-WIDTH:0px; BORDER-BOTTOM-WIDTH:0px; BORDER-TOP-WIDTH:0px" valign=bottom><font size=2>Date: August 31, 2020</font></td></tr></table></p> <p style=MARGIN:0px></p> <p style=MARGIN:0px></p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit32_1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<head> <title>Exhibit 32.1</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:'Times New Roman'; COLOR:#000000; MARGIN-TOP:0px"> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px>EXHIBIT 32.1</p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px align=center><b>CERTIFICATION OF CHIEF EXECUTIVE OFFICER</b></p> <p style=MARGIN:0px align=center><b>PURSUANT TO</b></p> <p style=MARGIN:0px align=center><b>18 U.S.C. SECTION 1350,</b></p> <p style=MARGIN:0px align=center><b>AS ADOPTED PURSUANT TO</b></p> <p style=MARGIN:0px align=center><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px align=justify>In connection with the Annual Report of Biomerica, Inc. (the "Company") on Form 10-K for the year ended May 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Zackary Irani, Chief Executive Officer of the Company, certify, to the best of my knowledge, Pursuant to Exchange Act Rule 15d-14(b) and 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002,</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>i. &nbsp;&nbsp;&nbsp;The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, and</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>ii. &nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p> <p style=MARGIN:0px align=justify><br>&nbsp;</p> <p style=MARGIN:0px> <table width=221 bordercolor=transparent style="WIDTH:166pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr height=20 style=HEIGHT:15pt> <td width=221 height=20 style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:166pt; BORDER-BOTTOM:0.5pt solid; BORDER-LEFT:0px" valign=bottom><font lang=DE><font size=2>/s/ Zackary S. Irani</font></font></td></tr> <tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-LEFT-WIDTH:0px; HEIGHT:15pt; BORDER-RIGHT-WIDTH:0px; BORDER-BOTTOM-WIDTH:0px; BORDER-TOP-WIDTH:0px" valign=bottom><font lang=DE><font size=2>Zackary S. Irani</font></font></td></tr> <tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-LEFT-WIDTH:0px; HEIGHT:15pt; BORDER-RIGHT-WIDTH:0px; BORDER-BOTTOM-WIDTH:0px; BORDER-TOP-WIDTH:0px" valign=bottom><font size=2>Chief Executive Officer</font></td></tr> <tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-LEFT-WIDTH:0px; HEIGHT:15pt; BORDER-RIGHT-WIDTH:0px; BORDER-BOTTOM-WIDTH:0px; BORDER-TOP-WIDTH:0px" valign=bottom /> </tr><tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-LEFT-WIDTH:0px; HEIGHT:15pt; BORDER-RIGHT-WIDTH:0px; BORDER-BOTTOM-WIDTH:0px; BORDER-TOP-WIDTH:0px" valign=bottom><font size=2>Date: August 31, 2020</font></td></tr></table></p>  <p style=MARGIN:0px><br><br></p> <p style=MARGIN:0px><br></p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>exhibit32_2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<head> <title>Exhibit 32.2</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:Times New Roman; COLOR:#000000; MARGIN-TOP:0px"> <p style=MARGIN:0px><br></p><p style=MARGIN:0px>EXHIBIT 32.2</p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px align=center><b>CERTIFICATION OF CHIEF FINANCIAL OFFICER</b></p> <p style=MARGIN:0px align=center><b>PURSUANT TO</b></p> <p style=MARGIN:0px align=center><b>18 U.S.C. SECTION 1350</b></p> <p style=MARGIN:0px align=center><b>AS ADOPTED PURSUANT TO</b></p> <p style=MARGIN:0px align=center><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p> <p style=MARGIN:0px align=center><br></p> <p style=MARGIN:0px align=justify>In connection with the Annual Report of Biomerica, Inc. (the "Company") on Form 10-K for the year ended May 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Janet Moore, Chief Financial Officer of the Company, certify, to the best of my knowledge, Pursuant to Exchange Act Rule 15d-14(b) and 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002,</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>i. &nbsp;&nbsp;&nbsp;The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, and</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify>ii. &nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px>&nbsp;</p> <p style=MARGIN:0px> <table width=202 bordercolor=transparent style="WIDTH:152pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr height=20 style=HEIGHT:15pt> <td width=202 height=20 style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:152pt; BORDER-BOTTOM:windowtext 0.5pt solid; BORDER-LEFT:0px"><font size=2>/s/ Janet Moore</font></td></tr> <tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; BORDER-BOTTOM:0px; BORDER-LEFT:0px"><font size=2>Janet Moore</font></td></tr> <tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; BORDER-BOTTOM:0px; BORDER-LEFT:0px"><font size=2>Chief Financial Officer</font></td></tr> <tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; BORDER-BOTTOM:0px; BORDER-LEFT:0px" /></tr> <tr height=20 style=HEIGHT:15pt> <td height=20 style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; BORDER-BOTTOM:0px; BORDER-LEFT:0px"><font size=2>Date: August 31, 2020</font></td></tr></table></p> <p style=MARGIN:0px>&nbsp;</p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>bmra-20200531.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Aug 31 13:38:24 EDT 2020 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:pf0="http://xbrl.sec.gov/country/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:bmra="http://www.biomerica.com/20200531" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:compsci="http://compsciresources.com" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="bmra-20200531.xsd"/>
  <context id="c0_From1Jun2019To31May2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c1_AsOf31Aug2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
    </entity>
    <period>
      <instant>2020-08-31</instant>
    </period>
  </context>
  <context id="c2_AsOf30Nov2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
    </entity>
    <period>
      <instant>2019-11-30</instant>
    </period>
  </context>
  <context id="c3_AsOf31May2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c4_AsOf31May2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c5_AsOf31May2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c6_AsOf31May2019_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c7_AsOf31May2020_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c8_AsOf31May2019_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c9_From1Jun2018To31May2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c10_AsOf31May2018_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-05-31</instant>
    </period>
  </context>
  <context id="c11_AsOf31May2018_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-05-31</instant>
    </period>
  </context>
  <context id="c12_AsOf31May2018_SubscriptionsReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:SubscriptionsReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-05-31</instant>
    </period>
  </context>
  <context id="c13_AsOf31May2018_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-05-31</instant>
    </period>
  </context>
  <context id="c14_AsOf31May2018_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-05-31</instant>
    </period>
  </context>
  <context id="c15_AsOf31May2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
    </entity>
    <period>
      <instant>2018-05-31</instant>
    </period>
  </context>
  <context id="c16_From1Jun2018To31May2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c17_From1Jun2018To31May2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c18_From1Jun2018To31May2019_SubscriptionsReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:SubscriptionsReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c19_From1Jun2018To31May2019_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c20_From1Jun2018To31May2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c21_AsOf31May2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c22_AsOf31May2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c23_AsOf31May2019_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c24_AsOf31May2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c25_From1Jun2019To31May2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c26_From1Jun2019To31May2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c27_From1Jun2019To31May2020_SeriesAPreferredStockMember_A5PercentConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c28_From1Jun2019To31May2020_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c29_From1Jun2019To31May2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c30_AsOf31May2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c31_AsOf31May2020_SeriesAPreferredStockMember_A5PercentConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c32_AsOf31May2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c33_AsOf31May2020_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c34_AsOf31May2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c35_From1Jun2019To31May2020_SalesRevenueNetMember_ThreeDistributorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">bmra:ThreeDistributorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c36_From1Jun2018To31May2019_SalesRevenueNetMember_TwoDistributorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">bmra:TwoDistributorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c37_From1Jun2019To31May2020_SalesRevenueNetMember_OneDistributorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">bmra:OneDistributorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c38_From1Jun2018To31May2019_SalesRevenueNetMember_OneDistributorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">bmra:OneDistributorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c39_From1Jun2019To31May2020_AccountsReceivableMember_ThreeDistributorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">bmra:ThreeDistributorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c40_From1Jun2018To31May2019_AccountsReceivableMember_TwoDistributorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">bmra:TwoDistributorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c41_From1Jun2019To31May2020_AccountsReceivableMember_DistributorsInEcuadorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">bmra:DistributorsInEcuadorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c42_From1Jun2019To31May2020_CostOfGoodsProductLineMember_SupplierConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c43_From1Jun2018To31May2019_CostOfGoodsProductLineMember_SupplierConcentrationRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c44_AsOf31May2020_MX">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:MX</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c45_AsOf31May2019_MX">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:MX</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c46_From1Jun2019To31May2020_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c47_From1Jun2019To31May2020_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c48_From1Jun2019To31May2020_DistributionRightsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c49_From1Jun2019To31May2020_PurchasedTechnologyRightsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmra:PurchasedTechnologyRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c50_From1Jun2019To31May2020_PatentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c51_AsOf31May2020_AccountingStandardsUpdate201602Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c52_AsOf31May2020_A5PercentConvertiblePreferredStockMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c53_From1Jun2018To31May2019_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c54_From1Jun2018To31May2019_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c55_From1Jun2019To31May2020_ClinicalLabMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ClinicalLabMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c56_From1Jun2018To31May2019_ClinicalLabMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ClinicalLabMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c57_From1Jun2019To31May2020_OTCMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:OTCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c58_From1Jun2018To31May2019_OTCMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:OTCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c59_From1Jun2019To31May2020_PhysiciansOfficeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:PhysiciansOfficeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c60_From1Jun2018To31May2019_PhysiciansOfficeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:PhysiciansOfficeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c61_From1Jun2019To31May2020_ContractManufacturingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ContractManufacturingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c62_From1Jun2018To31May2019_ContractManufacturingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ContractManufacturingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c63_From1Jun2019To31May2020_AccountsPayableMember_TwoVendorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">bmra:TwoVendorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c64_From1Jun2018To31May2019_AccountsPayableMember_OneVendorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">bmra:OneVendorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c65_AsOf26Feb2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-02-26</instant>
    </period>
  </context>
  <context id="c66_AsOf31Aug2010_EmployeeStockOptionMember_A2010PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2010PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-08-31</instant>
    </period>
  </context>
  <context id="c67_From31Aug2010To31Aug2010_EmployeeStockOptionMember_A2010PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2010PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-08-31</startDate>
      <endDate>2010-08-31</endDate>
    </period>
  </context>
  <context id="c68_AsOf31Dec2014_EmployeeStockOptionMember_A2014PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2014PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c69_From31Dec2014To31Dec2014_EmployeeStockOptionMember_A2014PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2014PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-12-31</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="c70_AsOf31Dec2017_EmployeeStockOptionMember_A2017PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2017PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c71_From31Dec2017To31Dec2017_EmployeeStockOptionMember_A2017PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2017PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-12-31</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="c72_AsOf29Feb2020_EmployeeStockOptionMember_A2020PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bmra:A2020PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-02-29</instant>
    </period>
  </context>
  <context id="c73_From1Jun2019To31May2020_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c74_From1Jun2019To31May2020_EmployeeStockOptionMember_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c75_From1Jun2019To31May2020_EmployeeStockOptionMember_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c76_From1Jun2019To31May2020_EmployeeStockOptionMember_SellingAndMarketingExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c77_From1Jun2019To31May2020_EmployeeStockOptionMember_CostOfSalesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c78_From1Jun2019To31May2020_MX_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:MX</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c79_From1Jun2018To31May2019_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c80_From1Jun2018To31May2019_EmployeeStockOptionMember_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c81_From1Jun2018To31May2019_EmployeeStockOptionMember_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c82_From1Jun2018To31May2019_EmployeeStockOptionMember_SellingAndMarketingExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c83_From1Jun2018To31May2019_MX_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:MX</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c84_AsOf31May2020_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c85_AsOf31May2019_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c86_From1Jun2019To31May2020_EmployeeStockOptionMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c87_From1Jun2018To31May2019_EmployeeStockOptionMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c88_From1Dec2017To1Dec2017_MaximumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-12-01</startDate>
      <endDate>2017-12-01</endDate>
    </period>
  </context>
  <context id="c89_AsOf1Dec2017_CommonStockMember_AtMarketIssuanceSalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-01</instant>
    </period>
  </context>
  <context id="c90_From1Dec2017To19Mar2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-12-01</startDate>
      <endDate>2020-03-19</endDate>
    </period>
  </context>
  <context id="c91_From1Jun2019To31May2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c92_From20Jul2017To20Jul2017_MaximumMember_CommonStockMember_RegistrationRightsAgreementMember_AtMarketIssuanceSalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:RegistrationRightsAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-20</startDate>
      <endDate>2017-07-20</endDate>
    </period>
  </context>
  <context id="c93_From1Jun2019To31May2020_CommonStockMember_RegistrationRightsAgreementMember_AtMarketIssuanceSalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:RegistrationRightsAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c94_AsOf31May2020_MinimumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c95_AsOf31May2020_MaximumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bmra:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c96_From1Jun2019To31May2020_PreferredStockMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c97_From1Jun2019To31May2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c98_AsOf31May2020_MinimumMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c99_AsOf31May2020_MaximumMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c100_From1Jun2018To31May2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c101_AsOf31May2019_MinimumMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c102_AsOf31May2019_MaximumMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c103_AsOf24Feb2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-02-24</instant>
    </period>
  </context>
  <context id="c104_From24Feb2020To24Feb2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-02-24</startDate>
      <endDate>2020-02-24</endDate>
    </period>
  </context>
  <context id="c105_AsOf24Feb2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-02-24</instant>
    </period>
  </context>
  <context id="c106_From1Jun2019To31May2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c107_From24Mar2020To24Mar2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-03-24</startDate>
      <endDate>2020-03-24</endDate>
    </period>
  </context>
  <context id="c108_From24Mar2020To24Mar2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bmra:A5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-03-24</startDate>
      <endDate>2020-03-24</endDate>
    </period>
  </context>
  <context id="c109_AsOf31May2018_ExercisePriceRangePerShare071390Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare071390Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-05-31</instant>
    </period>
  </context>
  <context id="c110_From1Jun2018To31May2019_ExercisePriceRangePerShare225362Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare225362Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c111_From1Jun2018To31May2019_ExercisePriceRangePerShare071104Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare071104Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c112_From1Jun2018To31May2019_ExercisePriceRangePerShare071362Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare071362Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c113_AsOf31May2019_ExercisePriceRangePerShare082390Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082390Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c114_From1Jun2019To31May2020_ExercisePriceRangePerShare268818Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare268818Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c115_From1Jun2019To31May2020_ExercisePriceRangePerShare082390Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082390Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c116_From1Jun2019To31May2020_ExercisePriceRangePerShare085818Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare085818Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c117_AsOf31May2020_ExercisePriceRangePerShare082818Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:ExercisePriceRangePerShare082818Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c118_From1Jun2019To31May2020_RangeOfExercisePrice082104Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice082104Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c119_AsOf31May2020_RangeOfExercisePrice082104Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice082104Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c120_From1Jun2019To31May2020_RangeOfExercisePrice120281Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice120281Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c121_AsOf31May2020_RangeOfExercisePrice120281Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice120281Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c122_From1Jun2019To31May2020_RangeOfExercisePrice362818Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice362818Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c123_AsOf31May2020_RangeOfExercisePrice362818Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bmra:RangeOfExercisePrice362818Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c124_AsOf31May2020_DomesticCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c125_AsOf31May2020_CaliforniaStateIncomeTaxMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bmra:CaliforniaStateIncomeTaxMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c126_AsOf31May2020_DomesticCountryMember_ResearchMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c127_AsOf31May2020_StateAndLocalJurisdictionMember_ResearchMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c128_From1Jun2019To31May2020_EuropeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c129_From1Jun2018To31May2019_EuropeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c130_From1Jun2019To31May2020_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c131_From1Jun2018To31May2019_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c132_From1Jun2019To31May2020_AsiaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c133_From1Jun2018To31May2019_AsiaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c134_From1Jun2019To31May2020_SouthAmericaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:SouthAmericaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c135_From1Jun2018To31May2019_SouthAmericaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:SouthAmericaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c136_From1Jun2019To31May2020_MiddleEastMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c137_From1Jun2018To31May2019_MiddleEastMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c138_From1Jun2019To31May2020_OtherForeignMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmra:OtherForeignMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c139_From1Jun2018To31May2019_OtherForeignMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmra:OtherForeignMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c140_From18Jun2009To18Jun2009_FirstAmendmentToLeaseMember_BuildingInIrvineCaliforniaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="bmra:LeaseAmendmentAxis">bmra:FirstAmendmentToLeaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">bmra:BuildingInIrvineCaliforniaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-06-18</startDate>
      <endDate>2009-06-18</endDate>
    </period>
  </context>
  <context id="c141_AsOf18Jun2009_FirstAmendmentToLeaseMember_BuildingInIrvineCaliforniaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="bmra:LeaseAmendmentAxis">bmra:FirstAmendmentToLeaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">bmra:BuildingInIrvineCaliforniaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-06-18</instant>
    </period>
  </context>
  <context id="c142_From30Nov2016To30Nov2016_MX_PropertyAvailableForOperatingLeaseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:MX</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertyAvailableForOperatingLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-11-30</startDate>
      <endDate>2016-11-30</endDate>
    </period>
  </context>
  <context id="c143_From1Jun2019To31May2020_MX">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:MX</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c144_From1Jun2018To31May2019_MX">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:MX</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c145_From1Jun2019To31May2020_RoyaltyAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c146_From1Jun2018To31May2019_RoyaltyAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c147_From1Jun2019To31May2020_SalesRevenueNetMember_RoyaltyAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c148_From1Jun2018To31May2019_SalesRevenueNetMember_RoyaltyAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c149_AsOf25May2016_TelconAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:TelconAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-05-25</instant>
    </period>
  </context>
  <context id="c150_From25May2016To25May2016_TelconAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:TelconAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-05-25</startDate>
      <endDate>2016-05-25</endDate>
    </period>
  </context>
  <context id="c151_From1Oct2018To31Oct2018_EZDetectProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bmra:EZDetectProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-10-01</startDate>
      <endDate>2018-10-31</endDate>
    </period>
  </context>
  <context id="c152_From1Dec2018To31Dec2018_EZDetectProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bmra:EZDetectProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-12-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c153_From1Dec2018To31Dec2018_MinimumMember_EZDetectProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bmra:EZDetectProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-12-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c154_From1Dec2018To31Dec2018_MaximumMember_EZDetectProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bmra:EZDetectProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-12-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c155_From1Jun2018To31May2019_EZDetectProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bmra:EZDetectProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c156_From1Jun2019To31May2020_EZDetectProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bmra:EZDetectProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c157_From1May2019To31May2019_EZDetectProductMember_MaxHealthMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bmra:EZDetectProductMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MaxHealthMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-05-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c158_AsOf31May2019_EZDetectProductMember_MaxHealthMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bmra:EZDetectProductMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MaxHealthMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c159_From1Jun2019To31May2020_MountSinaiLicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:MountSinaiLicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c160_From1Jun2020To31Aug2020_MountSinaiLicenseAgreementsMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:MountSinaiLicenseAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2020-08-31</endDate>
    </period>
  </context>
  <context id="c161_From7May2020To7May2020_UCLicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UCLicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-05-07</startDate>
      <endDate>2020-05-07</endDate>
    </period>
  </context>
  <context id="c162_From1Sep2020To30Sep2020_UCLicenseAgreementsMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UCLicenseAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-09-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c163_AsOf31May2020_UCLicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UCLicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c164_From18May2020To18May2020_NonexclusiveDistributorAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bmra:NonexclusiveDistributorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-05-18</startDate>
      <endDate>2020-05-18</endDate>
    </period>
  </context>
  <context id="c165_AsOf30Sep2017_UniversityOfSouthernCaliforniaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UniversityOfSouthernCaliforniaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="c166_From1Jun2019To31May2020_UniversityOfSouthernCaliforniaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UniversityOfSouthernCaliforniaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c167_From1Jun2019To31May2020_MaximumMember_UniversityOfSouthernCaliforniaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UniversityOfSouthernCaliforniaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c168_AsOf31May2020_UniversityOfSouthernCaliforniaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:UniversityOfSouthernCaliforniaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c169_AsOf30Nov2017_UniversityOFMichiganMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOFMichiganMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-11-30</instant>
    </period>
  </context>
  <context id="c170_From1Jun2019To31May2020_UniversityOFMichiganMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOFMichiganMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c171_From1Jun2018To31May2019_UniversityOFMichiganMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOFMichiganMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c172_AsOf31Jan2018_DeaconessMedicalCenterMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:DeaconessMedicalCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-01-31</instant>
    </period>
  </context>
  <context id="c173_AsOf31May2020_DeaconessMedicalCenterMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:DeaconessMedicalCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c174_From1Jun2019To31May2020_DeaconessMedicalCenterMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:DeaconessMedicalCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c175_From1Jun2018To31May2019_DeaconessMedicalCenterMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:DeaconessMedicalCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c176_AsOf12Jul2019_ResearchManagementInstitutionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:ResearchManagementInstitutionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-07-12</instant>
    </period>
  </context>
  <context id="c177_From1Jun2019To31May2020_ResearchManagementInstitutionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:ResearchManagementInstitutionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c178_AsOf31May2020_ResearchManagementInstitutionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:ResearchManagementInstitutionMember</xbrldi:explicitMember>
      </segment>
    </entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMasDJzLBFPhcZ39E819xIH5B6s9+QqmUnZaYcTPdiZJQG4iHDdujDjCMFWAPlk1IXbu5qod0zXC71jDSSWZ68hzrssnC2jdQRCZRntSimnRHL2VFQK46rtbC3o0LlaU0pyY=] CSR-->
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c179_AsOf22Jul2019_BiomericaInfoodsProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaInfoodsProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-07-22</instant>
    </period>
  </context>
  <context id="c180_From1Jun2019To31May2020_BiomericaInfoodsProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaInfoodsProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c181_AsOf31May2020_BiomericaInfoodsProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaInfoodsProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c182_AsOf25Sep2019_BiomericaInfoodsIBSProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaInfoodsIBSProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-25</instant>
    </period>
  </context>
  <context id="c183_From1Jun2019To31May2020_BiomericaInfoodsIBSProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaInfoodsIBSProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c184_AsOf31May2020_BiomericaInfoodsIBSProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaInfoodsIBSProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c185_AsOf25Sep2019_BiomericaHPyloriProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaHPyloriProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-25</instant>
    </period>
  </context>
  <context id="c186_From1Jun2019To31May2020_BiomericaHPyloriProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:BiomericaHPyloriProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c187_AsOf31Dec2019_HoustonMethodistResearchInstituteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:HoustonMethodistResearchInstituteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c188_From1Jun2019To31May2020_HoustonMethodistResearchInstituteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:HoustonMethodistResearchInstituteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c189_AsOf28May2020_MayoClinicArizonaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MayoClinicArizonaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-28</instant>
    </period>
  </context>
  <context id="c190_From1Jun2019To31May2020_MayoClinicArizonaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MayoClinicArizonaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c191_AsOf28May2020_MayoClinicJacksonvilleMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MayoClinicJacksonvilleMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-28</instant>
    </period>
  </context>
  <context id="c192_From1Jun2019To31May2020_MayoClinicJacksonvilleMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:MayoClinicJacksonvilleMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="c193_From1Jun2020To31Aug2020_EmployeeStockOptionMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2020-08-31</endDate>
    </period>
  </context>
  <context id="c194_From15Jun2020To15Jun2020_EmployeeStockOptionMember_EmployeesMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:EmployeesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-15</startDate>
      <endDate>2020-06-15</endDate>
    </period>
  </context>
  <context id="c195_From13Jul2020To13Jul2020_EmployeeStockOptionMember_EmployeesAndConsultantsMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:EmployeesAndConsultantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-13</startDate>
      <endDate>2020-07-13</endDate>
    </period>
  </context>
  <context id="c196_From13Jul2020To13Jul2020_EmployeeStockOptionMember_ConsultantMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:ConsultantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-13</startDate>
      <endDate>2020-07-13</endDate>
    </period>
  </context>
  <context id="c197_AsOf25Jun2020_UniversityOfTexasHealthScienceCenterMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:UniversityOfTexasHealthScienceCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-06-25</instant>
    </period>
  </context>
  <context id="c198_From20Jul2020To20Jul2020_MaximumMember_CommonStockMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-20</startDate>
      <endDate>2020-07-20</endDate>
    </period>
  </context>
  <context id="c199_From27Aug2020To27Aug2020_EmployeeStockOptionMember_EmployeeAndBoardMemberMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:EmployeeAndBoardMemberMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-27</startDate>
      <endDate>2020-08-27</endDate>
    </period>
  </context>
  <context id="c200_From27Aug2020To27Aug2020_EmployeeStockOptionMember_ConsultantMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:ConsultantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-27</startDate>
      <endDate>2020-08-27</endDate>
    </period>
  </context>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <dei:DocumentType contextRef="c0_From1Jun2019To31May2020">10-K</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="c0_From1Jun2019To31May2020">2020-05-31</dei:DocumentPeriodEndDate>
  <dei:EntityRegistrantName contextRef="c0_From1Jun2019To31May2020">BIOMERICA INC</dei:EntityRegistrantName>
  <dei:EntityWellKnownSeasonedIssuer contextRef="c0_From1Jun2019To31May2020">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers contextRef="c0_From1Jun2019To31May2020">Yes</dei:EntityVoluntaryFilers>
  <dei:EntityCurrentReportingStatus contextRef="c0_From1Jun2019To31May2020">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityInteractiveDataCurrent contextRef="c0_From1Jun2019To31May2020">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityFilerCategory contextRef="c0_From1Jun2019To31May2020">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntitySmallBusiness contextRef="c0_From1Jun2019To31May2020">true</dei:EntitySmallBusiness>
  <dei:EntityShellCompany contextRef="c0_From1Jun2019To31May2020">false</dei:EntityShellCompany>
  <dei:AmendmentFlag contextRef="c0_From1Jun2019To31May2020">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="c0_From1Jun2019To31May2020">--05-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="c0_From1Jun2019To31May2020">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="c0_From1Jun2019To31May2020">2020</dei:DocumentFiscalYearFocus>
  <dei:EntityCentralIndexKey contextRef="c0_From1Jun2019To31May2020">0000073290</dei:EntityCentralIndexKey>
  <dei:EntityEmergingGrowthCompany contextRef="c0_From1Jun2019To31May2020">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf31Aug2020" decimals="INF">11752589</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat unitRef="usd" contextRef="c2_AsOf30Nov2019" decimals="0">23397870</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">8641027</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">686785</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">1765871</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">1454652</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:InventoryNet unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">2850836</us-gaap:InventoryNet>
  <us-gaap:InventoryNet unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">2151090</us-gaap:InventoryNet>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">1509083</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">202402</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">14766817</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">4494929</us-gaap:AssetsCurrent>
  <bmra:EquipmentGross unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">1921833</bmra:EquipmentGross>
  <bmra:EquipmentGross unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">1891381</bmra:EquipmentGross>
  <bmra:FurnitureFixturesAndLeaseholdImprovementsGross unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">225189</bmra:FurnitureFixturesAndLeaseholdImprovementsGross>
  <bmra:FurnitureFixturesAndLeaseholdImprovementsGross unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">222033</bmra:FurnitureFixturesAndLeaseholdImprovementsGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">2147022</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">2113414</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">1867643</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">1762344</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">279379</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">351070</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">168655</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">107209</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">1711510</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c4_AsOf31May2019" xs:nil="true"/>
  <us-gaap:Investments unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">165324</us-gaap:Investments>
  <us-gaap:Investments unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">165324</us-gaap:Investments>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">168193</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">126832</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">17259878</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">5245364</us-gaap:Assets>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">986711</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">1037565</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">278627</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">226829</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">211809</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent unitRef="usd" contextRef="c4_AsOf31May2019" xs:nil="true"/>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">1477147</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">1264394</us-gaap:LiabilitiesCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">1569678</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent unitRef="usd" contextRef="c4_AsOf31May2019" xs:nil="true"/>
  <us-gaap:Liabilities unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">3046825</us-gaap:Liabilities>
  <us-gaap:Liabilities unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">1264394</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c3_AsOf31May2020" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c4_AsOf31May2019" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">25714</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c4_AsOf31May2019" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c5_AsOf31May2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">25714</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c6_AsOf31May2019_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c7_AsOf31May2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c8_AsOf31May2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">939205</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">774173</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">35213707</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">22830006</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">-39841</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">-36531</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">-21925732</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">-19586678</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">14213053</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">3980970</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">17259878</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">5245364</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">70981</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">73110</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c5_AsOf31May2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">0.08</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c6_AsOf31May2019_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c5_AsOf31May2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">571429</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c6_AsOf31May2019_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c5_AsOf31May2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">321429</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c6_AsOf31May2019_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" xs:nil="true"/>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c5_AsOf31May2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">321429</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c6_AsOf31May2019_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" xs:nil="true"/>
  <us-gaap:PreferredStockNoParValue unitRef="usdPershares" contextRef="c7_AsOf31May2020_PreferredStockMember" decimals="INF">0</us-gaap:PreferredStockNoParValue>
  <us-gaap:PreferredStockNoParValue unitRef="usdPershares" contextRef="c8_AsOf31May2019_PreferredStockMember" decimals="INF">0</us-gaap:PreferredStockNoParValue>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c7_AsOf31May2020_PreferredStockMember" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c8_AsOf31May2019_PreferredStockMember" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c7_AsOf31May2020_PreferredStockMember" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c8_AsOf31May2019_PreferredStockMember" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <bmra:PreferredStockUndesignatedShares unitRef="shares" contextRef="c7_AsOf31May2020_PreferredStockMember" decimals="INF">4428571</bmra:PreferredStockUndesignatedShares>
  <bmra:PreferredStockUndesignatedShares unitRef="shares" contextRef="c8_AsOf31May2019_PreferredStockMember" decimals="INF">5000000</bmra:PreferredStockUndesignatedShares>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c3_AsOf31May2020" decimals="INF">0.08</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c4_AsOf31May2019" decimals="INF">0.08</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c3_AsOf31May2020" decimals="INF">25000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c4_AsOf31May2019" decimals="INF">25000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c3_AsOf31May2020" decimals="INF">11740089</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c4_AsOf31May2019" decimals="INF">9677188</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c3_AsOf31May2020" decimals="INF">11740089</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c4_AsOf31May2019" decimals="INF">9677188</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:Revenues unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">6692711</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">5200682</us-gaap:Revenues>
  <us-gaap:CostOfRevenue unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">4910935</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">3908668</us-gaap:CostOfRevenue>
  <us-gaap:GrossProfit unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">1781776</us-gaap:GrossProfit>
  <us-gaap:GrossProfit unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">1292014</us-gaap:GrossProfit>
  <us-gaap:SellingGeneralAndAdministrativeExpense unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">2274415</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">2025706</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">1910209</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">1679098</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">4184624</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">3704804</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-2402848</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-2412790</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">9</us-gaap:InterestExpense>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">47</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterestAndDividend unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">71193</us-gaap:InvestmentIncomeInterestAndDividend>
  <us-gaap:InvestmentIncomeInterestAndDividend unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">44014</us-gaap:InvestmentIncomeInterestAndDividend>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">71184</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">43967</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-2331664</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-2368823</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">7390</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">24237</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-2339054</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-2393060</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasic unitRef="usdPershares" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-0.23</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic unitRef="usdPershares" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-0.26</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted unitRef="usdPershares" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-0.23</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted unitRef="usdPershares" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-0.26</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic unitRef="shares" contextRef="c0_From1Jun2019To31May2020" decimals="INF">10166296</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic unitRef="shares" contextRef="c9_From1Jun2018To31May2019" decimals="INF">9212557</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding unitRef="shares" contextRef="c0_From1Jun2019To31May2020" decimals="INF">10166296</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding unitRef="shares" contextRef="c9_From1Jun2018To31May2019" decimals="INF">9212557</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-3310</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-10395</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-2342364</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-2403455</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c10_AsOf31May2018_CommonStockMember" decimals="INF">8888011</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c10_AsOf31May2018_CommonStockMember" decimals="INF">711040</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c11_AsOf31May2018_AdditionalPaidInCapitalMember" decimals="INF">20843550</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c12_AsOf31May2018_SubscriptionsReceivableMember" decimals="INF">-9062</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c13_AsOf31May2018_AccumulatedOtherComprehensiveIncomeMember" decimals="INF">-26136</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c14_AsOf31May2018_RetainedEarningsMember" decimals="INF">-17193618</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c15_AsOf31May2018" decimals="INF">4325774</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c16_From1Jun2018To31May2019_CommonStockMember" decimals="INF">163500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c16_From1Jun2018To31May2019_CommonStockMember" decimals="INF">13080</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c17_From1Jun2018To31May2019_AdditionalPaidInCapitalMember" decimals="INF">108710</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">121790</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c16_From1Jun2018To31May2019_CommonStockMember" decimals="INF">625677</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c16_From1Jun2018To31May2019_CommonStockMember" decimals="INF">50053</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c17_From1Jun2018To31May2019_AdditionalPaidInCapitalMember" decimals="INF">1726522</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">1776575</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <bmra:AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable unitRef="usd" contextRef="c18_From1Jun2018To31May2019_SubscriptionsReceivableMember" decimals="INF">9062</bmra:AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable>
  <bmra:AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">9062</bmra:AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax unitRef="usd" contextRef="c19_From1Jun2018To31May2019_AccumulatedOtherComprehensiveIncomeMember" decimals="INF">-10395</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c17_From1Jun2018To31May2019_AdditionalPaidInCapitalMember" decimals="INF">151224</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">151224</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c20_From1Jun2018To31May2019_RetainedEarningsMember" decimals="INF">-2393060</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c21_AsOf31May2019_CommonStockMember" decimals="INF">9677188</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c21_AsOf31May2019_CommonStockMember" decimals="INF">774173</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c22_AsOf31May2019_AdditionalPaidInCapitalMember" decimals="INF">22830006</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c23_AsOf31May2019_AccumulatedOtherComprehensiveIncomeMember" decimals="INF">-36531</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c24_AsOf31May2019_RetainedEarningsMember" decimals="INF">-19586678</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c25_From1Jun2019To31May2020_CommonStockMember" decimals="INF">137958</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c25_From1Jun2019To31May2020_CommonStockMember" decimals="INF">11037</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c26_From1Jun2019To31May2020_AdditionalPaidInCapitalMember" decimals="INF">212497</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">223534</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c25_From1Jun2019To31May2020_CommonStockMember" decimals="INF">1674943</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c25_From1Jun2019To31May2020_CommonStockMember" decimals="INF">133995</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c26_From1Jun2019To31May2020_AdditionalPaidInCapitalMember" decimals="INF">10098862</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">10232857</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <bmra:StockIssuedDuringPeriodSharesPreferredStock unitRef="shares" contextRef="c27_From1Jun2019To31May2020_SeriesAPreferredStockMember_A5PercentConvertiblePreferredStockMember" decimals="INF">571429</bmra:StockIssuedDuringPeriodSharesPreferredStock>
  <bmra:StockIssuedDuringPeriodValuePreferredStock unitRef="usd" contextRef="c27_From1Jun2019To31May2020_SeriesAPreferredStockMember_A5PercentConvertiblePreferredStockMember" decimals="INF">45714</bmra:StockIssuedDuringPeriodValuePreferredStock>
  <bmra:StockIssuedDuringPeriodValuePreferredStock unitRef="usd" contextRef="c26_From1Jun2019To31May2020_AdditionalPaidInCapitalMember" decimals="INF">1871872</bmra:StockIssuedDuringPeriodValuePreferredStock>
  <bmra:StockIssuedDuringPeriodValuePreferredStock unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">1917586</bmra:StockIssuedDuringPeriodValuePreferredStock>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax unitRef="usd" contextRef="c28_From1Jun2019To31May2020_AccumulatedOtherComprehensiveIncomeMember" decimals="INF">-3310</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c25_From1Jun2019To31May2020_CommonStockMember" decimals="INF">250000</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockAmountConverted1 unitRef="usd" contextRef="c25_From1Jun2019To31May2020_CommonStockMember" decimals="INF">20000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c27_From1Jun2019To31May2020_SeriesAPreferredStockMember_A5PercentConvertiblePreferredStockMember" decimals="INF">-250000</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockAmountConverted1 unitRef="usd" contextRef="c27_From1Jun2019To31May2020_SeriesAPreferredStockMember_A5PercentConvertiblePreferredStockMember" decimals="INF">-20000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c26_From1Jun2019To31May2020_AdditionalPaidInCapitalMember" decimals="INF">200470</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">200470</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c29_From1Jun2019To31May2020_RetainedEarningsMember" decimals="INF">-2339054</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c30_AsOf31May2020_CommonStockMember" decimals="INF">11740089</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c30_AsOf31May2020_CommonStockMember" decimals="INF">939205</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c31_AsOf31May2020_SeriesAPreferredStockMember_A5PercentConvertiblePreferredStockMember" decimals="INF">321429</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c31_AsOf31May2020_SeriesAPreferredStockMember_A5PercentConvertiblePreferredStockMember" decimals="INF">25714</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c32_AsOf31May2020_AdditionalPaidInCapitalMember" decimals="INF">35213707</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c33_AsOf31May2020_AccumulatedOtherComprehensiveIncomeMember" decimals="INF">-39841</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c34_AsOf31May2020_RetainedEarningsMember" decimals="INF">-21925732</us-gaap:StockholdersEquity>
  <us-gaap:DepreciationAndAmortization unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">129172</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">162905</us-gaap:DepreciationAndAmortization>
  <us-gaap:ProvisionForDoubtfulAccounts unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-2129</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:ProvisionForDoubtfulAccounts unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">15415</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:InventoryLIFOReservePeriodCharge unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">17714</us-gaap:InventoryLIFOReservePeriodCharge>
  <us-gaap:InventoryLIFOReservePeriodCharge unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">6300</us-gaap:InventoryLIFOReservePeriodCharge>
  <us-gaap:StockOptionPlanExpense unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">200470</us-gaap:StockOptionPlanExpense>
  <us-gaap:StockOptionPlanExpense unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">151224</us-gaap:StockOptionPlanExpense>
  <bmra:IncreaseDecreaseInDeferredRentLiability unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-37971</bmra:IncreaseDecreaseInDeferredRentLiability>
  <bmra:IncreaseDecreaseInDeferredRentLiability unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">6615</bmra:IncreaseDecreaseInDeferredRentLiability>
  <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes unitRef="usd" contextRef="c0_From1Jun2019To31May2020" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-10000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
  <bmra:OperatingLeaseRightofUseAssetAmortization unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">269460</bmra:OperatingLeaseRightofUseAssetAmortization>
  <bmra:OperatingLeaseRightofUseAssetAmortization unitRef="usd" contextRef="c9_From1Jun2018To31May2019" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInAccountsReceivable unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">309090</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">670126</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInInventories unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">717460</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-21387</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">1306681</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-98007</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <bmra:IncreaseDecreaseInLeaseLiability unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-199483</bmra:IncreaseDecreaseInLeaseLiability>
  <bmra:IncreaseDecreaseInLeaseLiability unitRef="usd" contextRef="c9_From1Jun2018To31May2019" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">41361</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">13677</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-12883</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">343994</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">51798</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">16977</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-4297498</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-2244039</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquireIntangibleAssets unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">85319</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsToAcquireIntangibleAssets unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">69974</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">33608</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">101137</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-118927</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-171111</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <bmra:ProceedsFromCommonStockSubscribed unitRef="usd" contextRef="c0_From1Jun2019To31May2020" xs:nil="true"/>
  <bmra:ProceedsFromCommonStockSubscribed unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">9062</bmra:ProceedsFromCommonStockSubscribed>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">1917586</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock unitRef="usd" contextRef="c9_From1Jun2018To31May2019" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">10232857</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">1776575</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">223534</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">121790</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">12373977</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">1907427</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-3310</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-10395</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">7954242</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-518118</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c15_AsOf31May2018" decimals="INF">1204903</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:InterestPaidNet unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">9</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">47</us-gaap:InterestPaidNet>
  <us-gaap:IncomeTaxesPaid unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">7390</us-gaap:IncomeTaxesPaid>
  <us-gaap:IncomeTaxesPaid unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">14237</us-gaap:IncomeTaxesPaid>
  <bmra:EstablishmentOfRightOfUseAsset unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-1942999</bmra:EstablishmentOfRightOfUseAsset>
  <bmra:EstablishmentOfRightOfUseAsset unitRef="usd" contextRef="c9_From1Jun2018To31May2019" xs:nil="true"/>
  <bmra:EstablishmentOfLeaseLiability unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-1980970</bmra:EstablishmentOfLeaseLiability>
  <bmra:EstablishmentOfLeaseLiability unitRef="usd" contextRef="c9_From1Jun2018To31May2019" xs:nil="true"/>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1. &amp;#xa0;&amp;#xa0;&amp;#xa0;ORGANIZATION &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: justify; margin: 0in 0in 0pt;&quot;&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;Biomerica Inc. and Subsidiaries (collectively the &amp;#x201c;Company&amp;#x201d;, &amp;#x201c;we&amp;#x201d;, &amp;#x201c;us&amp;#x201d;, or &amp;#x201c;our&amp;#x201d;) develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care &lt;/font&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(physicians&apos; offices and over-the-counter through drugstores and online) &lt;/font&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. &lt;/font&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Our diagnostic test kits are used to analyze blood, urine or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The &lt;/font&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;Company&apos;s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Our primary focus is the research and development of revolutionary, patented diagnostic guided therapy (&amp;#x201c;DGT&amp;#x201d;) products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. If these DGT products prove effective in their clinical trials, and are ultimately cleared for sale by the U.S. Food and Drug Administrations (&amp;#x201c;FDA&amp;#x201d;), the revenues potential to the Company is significant.&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Due to the global 2019 SARS-CoV-2 novel coronavirus (&amp;#x201c;COVID-19&amp;#x201d;) pandemic, in March 2020 we began redirecting and focused a majority of our resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been exposed to COVID-19. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2. &amp;#xa0;&amp;#xa0;&amp;#xa0;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;PRINCIPLES OF CONSOLIDATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The enclosed consolidated financial statements for the years ended May 31, 2020 and 2019 include the accounts of Biomerica, Inc. (&quot;Biomerica&quot;) as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ACCOUNTING ESTIMATES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&amp;#x201c;GAAP&amp;#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; and inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, likelihood of lease extensions to occur, asset valuation, among other things; (and other items that may be necessary to estimate using current, historical and judgment based). Actual results could materially differ from those estimates. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company&apos;s financial instruments consist of its cash and cash equivalents, accounts receivable,&amp;#xa0;and accounts payable. The carrying amounts of the Company&apos;s financial instruments approximate their fair values.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;CONCENTRATION OF CREDIT RISK&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.&amp;#xa0; As of May 31, 2020, the Company had approximately $8,595,241 of uninsured cash.&lt;/font&gt; &lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company does not believe it is exposed to any significant credit risks.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets.&amp;#xa0; The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: justify; margin: 0in 0in 0pt;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;For the years ended May 31, 2020 and 2019, the Company had three distributors and two distributors which accounted for a total of 57.2% and 46.3% of our net consolidated sales, respectively. Of this, for the years ended May 31, 2020 and 2019 one of the distributors mentioned above accounted for 25.7% and 36.3%, respectively, of net consolidated sales.&amp;#xa0; At May 31, 2020 and 2019, the Company had three distributors and two distributors which accounted for a total of 80.0% and 68.1%, respectively, of gross accounts receivable. Of the 80.0% as of May 31, 2020, 43.9% was owed by a distributor in Ecuador. Total gross receivables at May 31, 2020 and 2019 were $1,836,852 and $1,527,762, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;For the year ended May 31, 2020, one vendor accounted for 59.3% of the purchases of raw materials. For the year ended May 31, 2019, two vendors accounted for a total of 23.8 % of the purchases of raw materials.&lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;GEOGRAPHIC CONCENTRATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;As of May 31, 2020 and 2019, approximately $613,000 and $665,000 of Biomerica&apos;s gross inventory and approximately $31,000 and $39,000, of Biomerica&apos;s property and equipment, net of accumulated depreciation, was located in Mexicali, Mexico, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: justify; margin: 0in 0in 0pt;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;CASH AND &lt;/font&gt;&lt;/strong&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;color: black;&quot;&gt;CASH EQUIVALENTS&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ACCOUNTS RECEIVABLE&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company extends unsecured credit to its customers on a regular basis. &amp;#xa0;International accounts are required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. &amp;#xa0;Based on various criteria,&amp;#xa0;initial credit levels for individual distributors are approved by designated officers and managers of the company. All increases in credit limits are also approved by designated upper level management. &amp;#xa0;Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. &amp;#xa0;Balances over ninety days old are usually reserved for unless collection is reasonably assured. &amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. &amp;#xa0; Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INVENTORIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; BACKGROUND:white; COLOR:black&quot;&gt;The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Inventories approximate the following at May 31:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:16.6pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Raw materials&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; BACKGROUND:aqua&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; BACKGROUND:aqua&quot;&gt;1,635,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,208,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Work in progress&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;&amp;#xa0; 988,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;&amp;#xa0; 771,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Finished products &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; BACKGROUND:aqua&quot;&gt;&amp;#xa0;&amp;#xa0; 228,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;&amp;#xa0; 172,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; BORDER-LEFT:0px; PADDING-RIGHT:0in&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;2,851,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,151,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of May 31, 2020 and 2019, inventory reserves were approximately $67,000 and $49,000, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;PROPERTY AND EQUIPMENT&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $105,299 and $101,216 for the years ended May 31, 2020 and 2019, respectively. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INTANGIBLE ASSETS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;), ASC 350 Intangibles &amp;#x2013; Goodwill and Other (&amp;#x201c;ASC 350&amp;#x201d;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to $23,873 and $61,689 for the years ended May 31, 2020 and 2019, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset&apos;s balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of May 31, 2020 or 2019.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INVESTMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;From time-to-time, the Company makes investments in privately-held companies. &amp;#xa0;The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee&amp;#x2019;s industry), a write-down to estimated fair value is recorded. Investments represent the Company&amp;#x2019;s investment in a Polish distributor which is primarily engaged in distributing medical products and devices. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value of the investment to be greater than the fair value. The Company owns approximately 6% of the investee and, accordingly, applies the cost method to account for the investment. &amp;#xa0;Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;SHARE-BASED COMPENSATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company follows the guidance of the accounting provisions of ASC 718&lt;a name=&quot;_Hlk17621381&quot;&gt;, &lt;/a&gt;Share-based Compensation (&amp;#x201c;ASC 718&amp;#x201d;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company&amp;#x2019;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &amp;#x201c;simplified method&amp;#x201d; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has not paid dividends historically and does not expect to pay them in the foreseeable future.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In applying the Black-Scholes options-pricing model, assumptions used were as follows: &amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.94%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:143.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0; 0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;55.52-72.62%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;57.90-60.41%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:143.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Risk free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;&amp;#xa0;0.43-1.80%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.33-2.85%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Expected life&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.75-6.25 years&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.75-6.25 years&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;REVENUE RECOGNITION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has various contracts with customers.&amp;#xa0; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of May 31, 2020 and does not believe that any additional discounts will be given through the end of the contract periods. &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. &lt;font style=&quot;COLOR:black&quot;&gt;The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. &amp;#xa0;Physicians&amp;#x2019; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. &lt;/font&gt;&lt;a name=&quot;_Hlk49511094&quot;&gt;&lt;/a&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Disaggregation of revenue:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The following is a breakdown of revenues according to markets to which the products are sold:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:550pt; BORDER-COLLAPSE:collapse; BORDER-BOTTOM:0px;  BORDER-LEFT:0px; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;5&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:165pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Year Ended&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Clinical Lab&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,922,425 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4,043,993 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;OTC&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,269,535 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;868,605 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Physicians&amp;#x2019; Office&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,194,991 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;170,871 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Contract Manufacturing&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;305,760 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;117,213 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6,692,711 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;5,200,682 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;See Note 7 for additional information regarding revenue concentrations.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;SHIPPING AND HANDLING FEES &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company includes shipping and handling fees billed to customers in net sales. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RESEARCH AND DEVELOPMENT&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Research and development costs are expensed as incurred. The Company expensed $1,910,209 and $1,679,098 of research and development costs during the years ended May 31, 2020 and 2019, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INCOME TAXES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company accounts for income taxes in accordance with ASC 740, Income Taxes (&amp;#x201c;ASC 740&amp;#x201d;). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. At May 31, 2020 and 2019, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its deferred tax assets.&amp;#xa0;&amp;#xa0; During the fiscal year ended May 31, 2020, this valuation allowance was increased to approximately &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:9pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3,175,000, which fully covers the net tax asset of $3,175,000&lt;/font&gt;&lt;font style=&quot;FONT-SIZE:9pt; COLOR:black&quot;&gt;.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company&amp;#x2019;s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. Upon adopting the revisions in ASC 740, the Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the &amp;#x201c;Interest expense&amp;#x201d; line and penalties related to liabilities for income taxes within the &amp;#x201c;Other expense&amp;#x201d; line of the consolidated statements of operations and comprehensive loss. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ADVERTISING COSTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately &lt;font style=&quot;BACKGROUND:white&quot;&gt;$174&lt;/font&gt; and $0 for the years ended May 31, 2020 and 2019, respectively. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;FOREIGN CURRENCY TRANSLATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the years ended May 31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RIGHT-OF-USE ASSETS AND LEASE LIABILITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Incentive payments received from landlords are recorded as deferred lease incentives and are amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. When the terms of an operating lease provide for periods of free rent, rent concessions, and/or rent escalations, the Company establishes a deferred rent liability for the difference between the scheduled rent payment and the straight-line rent expense recognized. This deferred rent liability was amortized over the underlying lease term on a straight-line basis as a reduction of rent expense.&lt;font style=&quot;COLOR:black&quot;&gt;&amp;#xa0;During the year ended May 31, 2020, the Company adopted ASC 842, Leases.&amp;#xa0; As a result, the existing deferred rent liability was netted against the Right-of-Use Asset which was capitalized at that time.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;In February 2016, the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&amp;#xa0; Right-of-use assets represent the Company&amp;#x2019;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&amp;#xa0; Right-of-Use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&amp;#xa0; Leases will be classified as financing or operating which will drive the expense recognition pattern.&amp;#xa0; For lessees, the statement of operations presentation and expense recognition pattern for financing and operating leases is similar to the current model for capital and operating leases, respectively.&amp;#xa0; The Company has elected to exclude short-term leases.&amp;#xa0; The update also requires additional disclosures that will better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases.&amp;#xa0; The Company adopted this guidance as of June 1, 2019, the required effective date, using the effective date transition method.&amp;#xa0; As permitted under the effective date transition method, financial information and disclosure for periods prior to the date of initial application will not be updated. An adjustment to opening accumulated deficit was not required in conjunction with adoption. The adoption of this statement resulted in a right-of-use asset being recorded in the amount of $1,942,999 and a lease liability being recorded in the amount of $1,980,970. Both will be amortized over the life of the underlying leases. For additional information, see Note 8-Commitments and Contingencies. The Company has elected not to reassess whether expired or existing contracts contain leases, or reassess the classification of existing leases as of the adoption date. The Company leases office space and copy machines, all of which are operating leases.&amp;#xa0; Most leases include the option to renew and the exercise of the renewal options is at the Company&amp;#x2019;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&amp;#xa0; The leases do not include the options to purchase the leased property.&amp;#xa0; The depreciable life of assets and leasehold improvements are limited by the expected lease term.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NET LOSS PER SHARE&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2020 and 2019 were 1,789,251 and 1,476,209, respectively. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company also has outstanding 321,429 of Series A 5% Convertible Preferred Stock, which may be converted at any time to common stock.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;SEGMENT REPORTING&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ASC 280, Segment Reporting (&amp;#x201c;ASC 280&amp;#x201d;), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company&amp;#x2019;s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing and sales of diagnostic kits.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;REPORTING COMPREHENSIVE LOSS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders&amp;#x2019; equity. Accumulated other comprehensive loss consists solely of foreign currency translation adjustments. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RECENT ACCOUNTING PRONOUNCEMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On February 15, 2018, the FASB issued ASU 2018-02, &amp;#x201c;Reclassification of Certain Tax Effects From Accumulated Comprehensive Income&amp;#x201d; (&amp;#x201c;ASU 2018-02&amp;#x201d;).&amp;#xa0; ASU 2018-02 will give companies the option to reclassify stranded tax effects caused by the newly-enacted U.S. Tax Cuts and Jobs Act (&amp;#x201c;TCJA&amp;#x201d;) from accumulated other comprehensive income (&amp;#x201c;ASCI&amp;#x201d;) to retained earnings.&amp;#xa0; ASU 2018-02 was effective for all companies for the fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.&amp;#xa0; Management is taking the provisions of this statement into account in the preparation of the consolidated financial statements for the year ended May 31, 2020.&amp;#xa0; The adoption of this standard has not had a significant impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On June 20, 2018, the FASB issued ASU 2018-07,&amp;#xa0;&amp;#x201c;Compensation&amp;#x2014;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&amp;#x201d; (&amp;#x201c;ASU 2018-07&amp;#x201d;). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for share-based payments to nonemployees (service providers, external legal counsel, and suppliers). ASU 2018-07 was effective &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.&amp;#xa0;During the year ended May 31, 2020, the Company adopted the provisions of this statement and is taking them into account in the preparation of the consolidated financial statements for the year ended May 31, 2020. The adoption of this standard has not had a significant impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0pt 0in&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Other recent ASU&apos;s issued by the FASB and guidance issued by the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) did not, or are not believed by management to, have a material effect on the Company&amp;#x2019;s present or future consolidated financial statements. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;PRINCIPLES OF CONSOLIDATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The enclosed consolidated financial statements for the years ended May 31, 2020 and 2019 include the accounts of Biomerica, Inc. (&quot;Biomerica&quot;) as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:UseOfEstimates contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ACCOUNTING ESTIMATES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&amp;#x201c;GAAP&amp;#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; and inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, likelihood of lease extensions to occur, asset valuation, among other things; (and other items that may be necessary to estimate using current, historical and judgment based). Actual results could materially differ from those estimates.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company&apos;s financial instruments consist of its cash and cash equivalents, accounts receivable,&amp;#xa0;and accounts payable. The carrying amounts of the Company&apos;s financial instruments approximate their fair values.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;CONCENTRATION OF CREDIT RISK&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.&amp;#xa0; As of May 31, 2020, the Company had approximately $8,595,241 of uninsured cash.&lt;/font&gt; &lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company does not believe it is exposed to any significant credit risks.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets.&amp;#xa0; The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: justify; margin: 0in 0in 0pt;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;For the years ended May 31, 2020 and 2019, the Company had three distributors and two distributors which accounted for a total of 57.2% and 46.3% of our net consolidated sales, respectively. Of this, for the years ended May 31, 2020 and 2019 one of the distributors mentioned above accounted for 25.7% and 36.3%, respectively, of net consolidated sales.&amp;#xa0; At May 31, 2020 and 2019, the Company had three distributors and two distributors which accounted for a total of 80.0% and 68.1%, respectively, of gross accounts receivable. Of the 80.0% as of May 31, 2020, 43.9% was owed by a distributor in Ecuador. Total gross receivables at May 31, 2020 and 2019 were $1,836,852 and $1,527,762, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;For the year ended May 31, 2020, one vendor accounted for 59.3% of the purchases of raw materials. For the year ended May 31, 2019, two vendors accounted for a total of 23.8 % of the purchases of raw materials.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:CashUninsuredAmount unitRef="usd" contextRef="c3_AsOf31May2020" decimals="0">8595241</us-gaap:CashUninsuredAmount>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c35_From1Jun2019To31May2020_SalesRevenueNetMember_ThreeDistributorsMember" decimals="3">0.572</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c36_From1Jun2018To31May2019_SalesRevenueNetMember_TwoDistributorsMember" decimals="3">0.463</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c37_From1Jun2019To31May2020_SalesRevenueNetMember_OneDistributorsMember" decimals="3">0.257</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c38_From1Jun2018To31May2019_SalesRevenueNetMember_OneDistributorsMember" decimals="3">0.363</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c39_From1Jun2019To31May2020_AccountsReceivableMember_ThreeDistributorsMember" decimals="3">0.800</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c40_From1Jun2018To31May2019_AccountsReceivableMember_TwoDistributorsMember" decimals="3">0.681</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c41_From1Jun2019To31May2020_AccountsReceivableMember_DistributorsInEcuadorMember" decimals="3">0.439</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:OtherReceivablesGrossCurrent unitRef="usd" contextRef="c3_AsOf31May2020" decimals="0">1836852</us-gaap:OtherReceivablesGrossCurrent>
  <us-gaap:OtherReceivablesGrossCurrent unitRef="usd" contextRef="c4_AsOf31May2019" decimals="0">1527762</us-gaap:OtherReceivablesGrossCurrent>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c42_From1Jun2019To31May2020_CostOfGoodsProductLineMember_SupplierConcentrationRiskMember" decimals="3">0.593</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c43_From1Jun2018To31May2019_CostOfGoodsProductLineMember_SupplierConcentrationRiskMember" decimals="3">0.238</us-gaap:ConcentrationRiskPercentage1>
  <bmra:ConcentrationRiskGeographicPolicyPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;GEOGRAPHIC CONCENTRATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;As of May 31, 2020 and 2019, approximately $613,000 and $665,000 of Biomerica&apos;s gross inventory and approximately $31,000 and $39,000, of Biomerica&apos;s property and equipment, net of accumulated depreciation, was located in Mexicali, Mexico, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</bmra:ConcentrationRiskGeographicPolicyPolicyTextBlock>
  <us-gaap:InventoryGross unitRef="usd" contextRef="c44_AsOf31May2020_MX" decimals="0">613000</us-gaap:InventoryGross>
  <us-gaap:InventoryGross unitRef="usd" contextRef="c45_AsOf31May2019_MX" decimals="0">665000</us-gaap:InventoryGross>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c44_AsOf31May2020_MX" decimals="0">31000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c45_AsOf31May2019_MX" decimals="0">39000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: justify; margin: 0in 0in 0pt;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;CASH AND &lt;/font&gt;&lt;/strong&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;&lt;strong&gt;&lt;font style=&quot;color: black;&quot;&gt;CASH EQUIVALENTS&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ACCOUNTS RECEIVABLE&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company extends unsecured credit to its customers on a regular basis. &amp;#xa0;International accounts are required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. &amp;#xa0;Based on various criteria,&amp;#xa0;initial credit levels for individual distributors are approved by designated officers and managers of the company. All increases in credit limits are also approved by designated upper level management. &amp;#xa0;Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. &amp;#xa0;Balances over ninety days old are usually reserved for unless collection is reasonably assured. &amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. &amp;#xa0; Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
  <us-gaap:ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable contextRef="c0_From1Jun2019To31May2020">P90D</us-gaap:ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable>
  <us-gaap:InventoryPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INVENTORIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; BACKGROUND:white; COLOR:black&quot;&gt;The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Inventories approximate the following at May 31:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:16.6pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Raw materials&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; BACKGROUND:aqua&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; BACKGROUND:aqua&quot;&gt;1,635,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,208,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Work in progress&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;&amp;#xa0; 988,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;&amp;#xa0; 771,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Finished products &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; BACKGROUND:aqua&quot;&gt;&amp;#xa0;&amp;#xa0; 228,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;&amp;#xa0; 172,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; BORDER-LEFT:0px; PADDING-RIGHT:0in&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;2,851,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,151,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of May 31, 2020 and 2019, inventory reserves were approximately $67,000 and $49,000, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:InventoryValuationReserves unitRef="usd" contextRef="c3_AsOf31May2020" decimals="0">67000</us-gaap:InventoryValuationReserves>
  <us-gaap:InventoryValuationReserves unitRef="usd" contextRef="c4_AsOf31May2019" decimals="0">49000</us-gaap:InventoryValuationReserves>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;PROPERTY AND EQUIPMENT&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $105,299 and $101,216 for the years ended May 31, 2020 and 2019, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c46_From1Jun2019To31May2020_MinimumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c47_From1Jun2019To31May2020_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:DepreciationDepletionAndAmortization unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="0">105299</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="0">101216</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INTANGIBLE ASSETS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;), ASC 350 Intangibles &amp;#x2013; Goodwill and Other (&amp;#x201c;ASC 350&amp;#x201d;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to $23,873 and $61,689 for the years ended May 31, 2020 and 2019, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset&apos;s balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of May 31, 2020 or 2019.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c48_From1Jun2019To31May2020_DistributionRightsMember">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c49_From1Jun2019To31May2020_PurchasedTechnologyRightsMember">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c50_From1Jun2019To31May2020_PatentsMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:AmortizationOfIntangibleAssets unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="0">23873</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="0">61689</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:InvestmentPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INVESTMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;From time-to-time, the Company makes investments in privately-held companies. &amp;#xa0;The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee&amp;#x2019;s industry), a write-down to estimated fair value is recorded. Investments represent the Company&amp;#x2019;s investment in a Polish distributor which is primarily engaged in distributing medical products and devices. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value of the investment to be greater than the fair value. The Company owns approximately 6% of the investee and, accordingly, applies the cost method to account for the investment. &amp;#xa0;Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c3_AsOf31May2020" decimals="2">0.06</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;SHARE-BASED COMPENSATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company follows the guidance of the accounting provisions of ASC 718&lt;a name=&quot;_Hlk17621381&quot;&gt;, &lt;/a&gt;Share-based Compensation (&amp;#x201c;ASC 718&amp;#x201d;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company&amp;#x2019;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &amp;#x201c;simplified method&amp;#x201d; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has not paid dividends historically and does not expect to pay them in the foreseeable future.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In applying the Black-Scholes options-pricing model, assumptions used were as follows: &amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.94%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:143.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0; 0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;55.52-72.62%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;57.90-60.41%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:143.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Risk free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;&amp;#xa0;0.43-1.80%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.33-2.85%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Expected life&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.75-6.25 years&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.75-6.25 years&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;REVENUE RECOGNITION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has various contracts with customers.&amp;#xa0; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of May 31, 2020 and does not believe that any additional discounts will be given through the end of the contract periods. &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. &lt;font style=&quot;COLOR:black&quot;&gt;The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. &amp;#xa0;Physicians&amp;#x2019; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. &lt;/font&gt;&lt;a name=&quot;_Hlk49511094&quot;&gt;&lt;/a&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Disaggregation of revenue:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The following is a breakdown of revenues according to markets to which the products are sold:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:550pt; BORDER-COLLAPSE:collapse; BORDER-BOTTOM:0px;  BORDER-LEFT:0px; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;5&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:165pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Year Ended&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Clinical Lab&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,922,425 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4,043,993 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;OTC&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,269,535 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;868,605 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Physicians&amp;#x2019; Office&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,194,991 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;170,871 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Contract Manufacturing&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;305,760 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;117,213 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6,692,711 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;5,200,682 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;See Note 7 for additional information regarding revenue concentrations.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:CostOfSalesPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;SHIPPING AND HANDLING FEES &lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company includes shipping and handling fees billed to customers in net sales.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RESEARCH AND DEVELOPMENT&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Research and development costs are expensed as incurred. The Company expensed $1,910,209 and $1,679,098 of research and development costs during the years ended May 31, 2020 and 2019, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;INCOME TAXES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company accounts for income taxes in accordance with ASC 740, Income Taxes (&amp;#x201c;ASC 740&amp;#x201d;). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. At May 31, 2020 and 2019, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its deferred tax assets.&amp;#xa0;&amp;#xa0; During the fiscal year ended May 31, 2020, this valuation allowance was increased to approximately &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:9pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3,175,000, which fully covers the net tax asset of $3,175,000&lt;/font&gt;&lt;font style=&quot;FONT-SIZE:9pt; COLOR:black&quot;&gt;.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company&amp;#x2019;s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. Upon adopting the revisions in ASC 740, the Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the &amp;#x201c;Interest expense&amp;#x201d; line and penalties related to liabilities for income taxes within the &amp;#x201c;Other expense&amp;#x201d; line of the consolidated statements of operations and comprehensive loss.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ADVERTISING COSTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately &lt;font style=&quot;BACKGROUND:white&quot;&gt;$174&lt;/font&gt; and $0 for the years ended May 31, 2020 and 2019, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
  <us-gaap:AdvertisingExpense unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="0">174</us-gaap:AdvertisingExpense>
  <us-gaap:AdvertisingExpense unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="0">0</us-gaap:AdvertisingExpense>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;FOREIGN CURRENCY TRANSLATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the years ended May 31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RIGHT-OF-USE ASSETS AND LEASE LIABILITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Incentive payments received from landlords are recorded as deferred lease incentives and are amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. When the terms of an operating lease provide for periods of free rent, rent concessions, and/or rent escalations, the Company establishes a deferred rent liability for the difference between the scheduled rent payment and the straight-line rent expense recognized. This deferred rent liability was amortized over the underlying lease term on a straight-line basis as a reduction of rent expense.&lt;font style=&quot;COLOR:black&quot;&gt;&amp;#xa0;During the year ended May 31, 2020, the Company adopted ASC 842, Leases.&amp;#xa0; As a result, the existing deferred rent liability was netted against the Right-of-Use Asset which was capitalized at that time.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;In February 2016, the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&amp;#xa0; Right-of-use assets represent the Company&amp;#x2019;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&amp;#xa0; Right-of-Use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&amp;#xa0; Leases will be classified as financing or operating which will drive the expense recognition pattern.&amp;#xa0; For lessees, the statement of operations presentation and expense recognition pattern for financing and operating leases is similar to the current model for capital and operating leases, respectively.&amp;#xa0; The Company has elected to exclude short-term leases.&amp;#xa0; The update also requires additional disclosures that will better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases.&amp;#xa0; The Company adopted this guidance as of June 1, 2019, the required effective date, using the effective date transition method.&amp;#xa0; As permitted under the effective date transition method, financial information and disclosure for periods prior to the date of initial application will not be updated. An adjustment to opening accumulated deficit was not required in conjunction with adoption. The adoption of this statement resulted in a right-of-use asset being recorded in the amount of $1,942,999 and a lease liability being recorded in the amount of $1,980,970. Both will be amortized over the life of the underlying leases. For additional information, see Note 8-Commitments and Contingencies. The Company has elected not to reassess whether expired or existing contracts contain leases, or reassess the classification of existing leases as of the adoption date. The Company leases office space and copy machines, all of which are operating leases.&amp;#xa0; Most leases include the option to renew and the exercise of the renewal options is at the Company&amp;#x2019;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&amp;#xa0; The leases do not include the options to purchase the leased property.&amp;#xa0; The depreciable life of assets and leasehold improvements are limited by the expected lease term.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c51_AsOf31May2020_AccountingStandardsUpdate201602Member" decimals="0">1942999</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseLiability unitRef="usd" contextRef="c51_AsOf31May2020_AccountingStandardsUpdate201602Member" decimals="0">1980970</us-gaap:OperatingLeaseLiability>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NET LOSS PER SHARE&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2020 and 2019 were 1,789,251 and 1,476,209, respectively. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company also has outstanding 321,429 of Series A 5% Convertible Preferred Stock, which may be converted at any time to common stock.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c0_From1Jun2019To31May2020" decimals="INF">1789251</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c9_From1Jun2018To31May2019" decimals="INF">1476209</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion unitRef="shares" contextRef="c52_AsOf31May2020_A5PercentConvertiblePreferredStockMember_CommonStockMember" decimals="INF">321429</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;SEGMENT REPORTING&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;ASC 280, Segment Reporting (&amp;#x201c;ASC 280&amp;#x201d;), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company&amp;#x2019;s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing and sales of diagnostic kits.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;REPORTING COMPREHENSIVE LOSS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders&amp;#x2019; equity. Accumulated other comprehensive loss consists solely of foreign currency translation adjustments.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RECENT ACCOUNTING PRONOUNCEMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On February 15, 2018, the FASB issued ASU 2018-02, &amp;#x201c;Reclassification of Certain Tax Effects From Accumulated Comprehensive Income&amp;#x201d; (&amp;#x201c;ASU 2018-02&amp;#x201d;).&amp;#xa0; ASU 2018-02 will give companies the option to reclassify stranded tax effects caused by the newly-enacted U.S. Tax Cuts and Jobs Act (&amp;#x201c;TCJA&amp;#x201d;) from accumulated other comprehensive income (&amp;#x201c;ASCI&amp;#x201d;) to retained earnings.&amp;#xa0; ASU 2018-02 was effective for all companies for the fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.&amp;#xa0; Management is taking the provisions of this statement into account in the preparation of the consolidated financial statements for the year ended May 31, 2020.&amp;#xa0; The adoption of this standard has not had a significant impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On June 20, 2018, the FASB issued ASU 2018-07,&amp;#xa0;&amp;#x201c;Compensation&amp;#x2014;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&amp;#x201d; (&amp;#x201c;ASU 2018-07&amp;#x201d;). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for share-based payments to nonemployees (service providers, external legal counsel, and suppliers). ASU 2018-07 was effective &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.&amp;#xa0;During the year ended May 31, 2020, the Company adopted the provisions of this statement and is taking them into account in the preparation of the consolidated financial statements for the year ended May 31, 2020. The adoption of this standard has not had a significant impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0pt 0in&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Other recent ASU&apos;s issued by the FASB and guidance issued by the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) did not, or are not believed by management to, have a material effect on the Company&amp;#x2019;s present or future consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:16.6pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Raw materials&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; BACKGROUND:aqua&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; BACKGROUND:aqua&quot;&gt;1,635,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,208,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Work in progress&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;&amp;#xa0; 988,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;&amp;#xa0; 771,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Finished products &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; BACKGROUND:aqua&quot;&gt;&amp;#xa0;&amp;#xa0; 228,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;&amp;#xa0; 172,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; BORDER-LEFT:0px; PADDING-RIGHT:0in&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;2,851,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,151,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:InventoryRawMaterialsNetOfReserves unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">1635000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryRawMaterialsNetOfReserves unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">1208000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">988000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">771000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">228000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">172000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.94%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:143.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0; 0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;55.52-72.62%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;57.90-60.41%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:143.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Risk free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;&amp;#xa0;0.43-1.80%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.33-2.85%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Expected life&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.75-6.25 years&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:1.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.75-6.25 years&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c0_From1Jun2019To31May2020" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c9_From1Jun2018To31May2019" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c46_From1Jun2019To31May2020_MinimumMember" decimals="4">0.5552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c47_From1Jun2019To31May2020_MaximumMember" decimals="4">0.7262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c53_From1Jun2018To31May2019_MinimumMember" decimals="4">0.5790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c54_From1Jun2018To31May2019_MaximumMember" decimals="4">0.6041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c46_From1Jun2019To31May2020_MinimumMember" decimals="4">0.0043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c47_From1Jun2019To31May2020_MaximumMember" decimals="4">0.0180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c53_From1Jun2018To31May2019_MinimumMember" decimals="4">0.0233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c54_From1Jun2018To31May2019_MaximumMember" decimals="4">0.0285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c46_From1Jun2019To31May2020_MinimumMember">P3Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c47_From1Jun2019To31May2020_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c53_From1Jun2018To31May2019_MinimumMember">P3Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c54_From1Jun2018To31May2019_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;table width=&quot;733&quot; style=&quot;BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:550pt; BORDER-COLLAPSE:collapse; BORDER-BOTTOM:0px;  BORDER-LEFT:0px; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;5&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:165pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Year Ended&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;May 31, 2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Clinical Lab&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,922,425 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4,043,993 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;OTC&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,269,535 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;868,605 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Physicians&amp;#x2019; Office&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,194,991 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;170,871 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Contract Manufacturing&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;305,760 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;117,213 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6,692,711 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;5,200,682 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c55_From1Jun2019To31May2020_ClinicalLabMember" decimals="INF">2922425</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c56_From1Jun2018To31May2019_ClinicalLabMember" decimals="INF">4043993</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c57_From1Jun2019To31May2020_OTCMember" decimals="INF">1269535</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c58_From1Jun2018To31May2019_OTCMember" decimals="INF">868605</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c59_From1Jun2019To31May2020_PhysiciansOfficeMember" decimals="INF">2194991</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c60_From1Jun2018To31May2019_PhysiciansOfficeMember" decimals="INF">170871</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c61_From1Jun2019To31May2020_ContractManufacturingMember" decimals="INF">305760</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c62_From1Jun2018To31May2019_ContractManufacturingMember" decimals="INF">117213</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">6692711</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">5200682</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3. &amp;#xa0;&amp;#xa0;&amp;#xa0;INTANGIBLE ASSETS, NET&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Intangible assets, net of accumulated amortization, consist of the following at May 31:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:193.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:193.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Licenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;551,397 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;510,600 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:193.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Patents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;113,382 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;68,860 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:193.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Less accumulated amortization-&lt;br/&gt;licenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(487,989)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(471,530)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:193.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Less accumulated amortization-&lt;br/&gt;patents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(8,135)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(721)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:193.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Intangible assets, net&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;168,655 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;107,209 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Expected amortization of intangible assets for the years ending May 31:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:123.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:123.85pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;18,112 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:123.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2022&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;8,503 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:123.85pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2023&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6,211 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:123.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2024&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6,136 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:123.85pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2025&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;5,219 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:123.85pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:16%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;124,474 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:123.85pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:20pt; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:16%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;168,655 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:193.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:193.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Licenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;551,397 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;510,600 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:193.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Patents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;113,382 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;68,860 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:193.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Less accumulated amortization-&lt;br/&gt;licenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(487,989)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(471,530)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:193.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Less accumulated amortization-&lt;br/&gt;patents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(8,135)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(721)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:193.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Intangible assets, net&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;168,655 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;107,209 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:FiniteLivedLicenseAgreementsGross unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">551397</us-gaap:FiniteLivedLicenseAgreementsGross>
  <us-gaap:FiniteLivedLicenseAgreementsGross unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">510600</us-gaap:FiniteLivedLicenseAgreementsGross>
  <us-gaap:FiniteLivedPatentsGross unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">113382</us-gaap:FiniteLivedPatentsGross>
  <us-gaap:FiniteLivedPatentsGross unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">68860</us-gaap:FiniteLivedPatentsGross>
  <bmra:FiniteLivedLicenseAccumulatedAmortization unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">487989</bmra:FiniteLivedLicenseAccumulatedAmortization>
  <bmra:FiniteLivedLicenseAccumulatedAmortization unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">471530</bmra:FiniteLivedLicenseAccumulatedAmortization>
  <bmra:FiniteLivedPatentsAccumulatedAmortization unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">8135</bmra:FiniteLivedPatentsAccumulatedAmortization>
  <bmra:FiniteLivedPatentsAccumulatedAmortization unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">721</bmra:FiniteLivedPatentsAccumulatedAmortization>
  <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:123.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:123.85pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;18,112 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:123.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2022&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;8,503 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:123.85pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2023&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6,211 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:123.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2024&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6,136 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:123.85pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2025&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;5,219 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:123.85pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:16%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;124,474 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:123.85pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:20pt; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:16%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;168,655 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">18112</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">8503</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">6211</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">6136</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">5219</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">124474</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsNet unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">168655</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4.&amp;#xa0;&amp;#xa0;&amp;#xa0; ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company&amp;#x2019;s accounts payable and accrued expense balances consist of the following at May 31:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:205.9pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:205.9pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Accounts payable and accrued expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;986,711 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;999,594 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:205.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Deferred rent&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;-&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;37,971 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:205.9pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;986,711 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,037,565 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;As of May 31, 2020 and 2019 the Company had two vendors and one vendor which accounted for 26.9% and 32.1%, respectively, of accounts payable.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c63_From1Jun2019To31May2020_AccountsPayableMember_TwoVendorsMember" decimals="3">0.269</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c64_From1Jun2018To31May2019_AccountsPayableMember_OneVendorMember" decimals="3">0.321</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:205.9pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:205.9pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Accounts payable and accrued expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;986,711 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;999,594 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:205.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Deferred rent&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;-&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;37,971 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:205.9pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;986,711 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,037,565 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">986711</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">999594</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
  <us-gaap:DeferredRentCreditCurrent unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">37971</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;5. &amp;#xa0;&amp;#xa0;&amp;#xa0;SHAREHOLDERS&apos; EQUITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On February 24, 2020, the Company filed with the Secretary of State of Delaware a certificate of designation to authorize for issuance 571,429 shares of Series A 5% Convertible Preferred Stock.&amp;#xa0; On February 26, 2020, the Company filed with the Secretary of State of Delaware a certificate of correction, correcting certain language defects in the previously filed certificate of designation.&amp;#xa0; Please see below a description of the Series A 5% Convertible Preferred Stock shares that were issued in February 2020.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;STOCK OPTION AND RESTRICTED STOCK PLANS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In August 2010, the Company adopted a stock option and restricted stock plan (the &quot;2010 Plan&quot;) which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company&apos;s unissued common stock may be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2010. &amp;#xa0;The 2010 Plan expires in December 2020. Options granted under the 2010 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In December 2014, the Company adopted a stock option and restricted stock plan (the &quot;2014 Plan&quot;) which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company&apos;s unissued common stock may be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2014. &amp;#xa0;The 2014 Plan expires in December 2024. Options granted under the 2014 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In December 2017, the Company adopted a stock option and restricted stock plan (the &amp;#x201c;2017 Plan&amp;#x201d;) which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 900,000 shares of the Company&amp;#x2019;s unissued common stock may be granted to affiliates, employees or consultants of the Company.&amp;#xa0; This plan was approved by shareholders in December 2017.&amp;#xa0; The 2017 Plan expires in December 2027.&amp;#xa0; Options granted under the 2017 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: justify; margin: 0in 0in 0pt;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;In February 2020, the Board approved the 2020 Stock Incentive Plan (the &amp;#x201c;2020 Plan&amp;#x201d;), which will be presented to the Company&amp;#x2019;s shareholders for final approval and adoption at the Company&amp;#x2019;s annual meeting to be held in December 2020. The 2020 Plan authorizes the issuance of an &lt;/font&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;aggregate number of common stock options and/or restricted common shares to be issued in an amount not to exceed 900,000. &amp;#xa0;The 2020 Plan authorizes the issuance of common stock options and restricted common shares to employees, directors and consultants of the Company. During fiscal 2020, certain common stock options were granted under this plan, the actual vesting of which is subject to the plan being approved and adopted by shareholders at our upcoming annual meeting of shareholders.&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Stock option expense during fiscal 2020 was $200,470. This included, by department, $17,892 for research and development, $156,750 in administrative, $2,933 in sales and marketing, $22,895 for production and $0 in Mexico. In fiscal 2019, stock option expense was $151,224. This included $3,714 in research and development, $143,299 in administrative, $4,163 in sales and marketing and $48 in Mexico.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Activity as to aggregate stock options outstanding is as follows: &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:39pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NUMBER OF STOCK OPTIONS&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;EXERCISE PRICE&amp;#xa0; RANGE PER SHARE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;WEIGHTED AVERAGE EXERCISE PRICE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options outstanding at May 31, 2018&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,138,625 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.71-$3.90&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1.65 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:175.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;558,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$2.25-$3.62&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.60 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(163,500)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.71-$1.04&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;0.76 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options canceled or expired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(56,916)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.71-$3.62&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.49 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options outstanding at May 31, 2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,476,209 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$3.90&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.07 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:175.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;517,500 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$2.68-$8.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4.47 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(137,958)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$3.90&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1.64 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options canceled or expired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(66,500)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.85-$8.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.43 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options outstanding at May 31, 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,789,251 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$8.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.75 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The weighted average fair value of options granted during 2020 and 2019 was $4.47 and $2.60, respectively. The aggregate intrinsic value of options exercised during 2020 and 2019 was approximately $589,000 and $364,000, respectively. The aggregate intrinsic value of options outstanding at May 31, 2020 and 2019 was approximately $6,923,000 and $808,000, respectively. The aggregate intrinsic value of options vested and exercisable at May 31, 2020 and 2019 was approximately $4,442,000 and $685,000, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Number of non-vested stock options included in table above is as follows:&lt;/font&gt;&amp;#xa0;&amp;#xa0; &lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:82.5pt&quot;&gt; &lt;td style=&quot;HEIGHT:82.5pt; WIDTH:167.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:82.5pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NUMBER OF SHARES&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:82.5pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:82.5pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;STOCK OPTIONS WEIGHTED AVERAGE AVERAGE GRANT DATE FAIR VALUE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:167.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Non-vested shares at May 31, 2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;769,584 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.49 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:167.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;517,500 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4.47 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:167.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Vested&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(407,750)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.25 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:167.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Forfeited&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(56,750)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.55 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:167.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Non-vested shares at May 31, 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;822,584 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.78 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;At May 31, 2020, total compensation cost related to non-vested stock option awards not yet recognized totaled approximately $663,000. The weighted-average period over which this amount is expected to be recognized is 3.67 years. The weighted average remaining contractual term of options that were exercisable at May 31, 2020 was 6.19 years.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The following summarizes information about all of the Company&apos;s stock options outstanding at May 31, 2020. These options are comprised of those granted under the 2010, 2014, 2017 and 2020 plans.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table style=&quot;width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;&quot; width=&quot;733&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
&lt;tr style=&quot;height: 64.5pt;&quot;&gt;
&lt;td style=&quot;border-top: 0px; height: 64.5pt; border-right: 0px; width: 17%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;RANGE OF EXERCISE PRICES&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 64.5pt; border-right: 0px; width: 17%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;NUMBER OUTSTANDING May 31, 2020&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 64.5pt; border-right: 0px; width: 17%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE IN YEARS&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 64.5pt; border-right: 0px; width: 16%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;WEIGHTED AVERAGE EXERCISE PRICE&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 64.5pt; border-right: 0px; width: 15.78%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;NUMBER EXERCISABLE AT MAY 31, 2020&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 64.5pt; border-right: 0px; width: 16%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;WEIGHTED AVERAGE EXERCISE PRICE&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$ 0.82-$1.04&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;276,000&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;4.44&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$0.84 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 15.78%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;276,000&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$0.84 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 17%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$ 1.20-$ 2.81&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 17%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;1,072,500&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 17%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;7.57&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 16%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$2.17 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 15.78%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;506,000&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 16%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$1.71 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$ 3.62-$ 8.18&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;440,751&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;7.62&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$5.38 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 15.78%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;184,667&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$3.87 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;COMMON STOCK ACTIVITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;During the year ended May 31, 2020, options to purchase 137,958 shares of common stock were exercised at prices ranging from $0.82 to $3.90.&amp;#xa0; Total net proceeds to the Company were $223,534.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;During the year ended May 31, 2019, options to purchase 163,500 shares of common stock were exercised at prices ranging from $0.71 to $1.04.&amp;#xa0; &lt;a name=&quot;_Hlk17185589&quot;&gt;Total net proceeds to the Company were $121,790.&lt;/a&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On December 1, 2017, the Company entered into an At Market Issuance Sales Agreement (or &amp;#x201c;ATM Agreement&amp;#x201d;) with an agent, and filed a prospectus supplement with the SEC pursuant to which the Company could offer and sell from time to time up to an aggregate of $7,000,000 of shares of the Company&amp;#x2019;s common stock, par value $0.08 per share (the &amp;#x201c;Placement Shares&amp;#x201d;), through the agent. From December 1, 2017 to March 19, 2020, the Company sold common stock resulting in $6,997,935 of gross proceeds under this ATM Agreement, of which $3,771,048 were sold during the year ended May 31, 2020. &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;This At Market Issuance Agreement expired on July 20, 2020 upon the expiration of the Company&amp;#x2019;s S-3 registration statement base prospectus dated July 20, 2017. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 12pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Placement Shares sold and issued under the ATM Agreement have been registered under the Securities Act of 1933, as amended (the &amp;#x201c;Securities Act&amp;#x201d;), pursuant to the Registration Statement on Form S-3 (File No. 333-219130) (the &amp;#x201c;Registration Statement&amp;#x201d;), which was originally filed with the SEC on June 30, 2017 and declared effective by the SEC on July 20, 2017, the base prospectus contained within the Registration Statement, and the prospectus supplement related to the sale of shares under the ATM Agreement was filed with the SEC on December 1, 2017.&amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On March 20, 2020, the Company filed a new prospectus supplement to the S-3 registration statement base prospectus dated July 20, 2017 for purposes of raising up to $12,500,000 from time to time pursuant to the terms of the ATM Agreement. &lt;/font&gt;&lt;a name=&quot;_Hlk47966232&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;This ATM Agreement expired on July 20, 2020 upon the expiration of the Company&amp;#x2019;s S-3 registration statement base prospectus dated July 20, 2017. Gross proceeds for the year ended May 31, 2020, were $6,817,330.&lt;/font&gt;&lt;/a&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Please refer to &amp;#x201c;Subsequent Events&amp;#x201d; for a description of the Form S-3 filed with the Securities and Exchange Commission on July 20, 2020.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Combined Placement Shares sold under the ATM during the twelve months ended May 31, 2020 under the two prospectus supplements dated December 1, 2017 and March 20, 2020 totaled 1,674,943 shares. Total net proceeds from the sale of Placement Shares under the two prospectus supplements during the twelve months ended May 31, 2020 were $10,232,857 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.&amp;#xa0; These shares were sold at prices ranging from $2.33 to $9.08 per share. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Under an ATM Agreement, sales of the Placement Shares are deemed to be &amp;#x201c;at the market offering&amp;#x201d; as defined in Rule 415 promulgated under the Securities Act.&amp;#xa0; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&amp;#x2019;s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;During the year ended May 31, 2020, 250,000 shares of common stock were converted from Preferred Stock as described below in &amp;#x201c;Preferred Stock Activity&amp;#x201d;.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;During the year ended May 31, 2020, the Company sold 1,674,943 shares of its common stock at prices ranging from $2.33 to $9.08 under its S-3 Registration Statement which resulted in gross proceeds of $10,588,378 and net proceeds to the Company of $10,232,857 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;During the year ended May 31, 2019, the Company sold 625,677 shares of its common stock at prices ranging from $2.59 to $4.16 under its S-3 Registration Statement which resulted in gross proceeds of $1,847,662 and net proceeds to the Company of $1,776,575 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;PREFERRED STOCK ACTIVITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On February 24, 2020, the Company entered into and closed on a Stock Purchase Agreement (the &amp;#x201c;Stock Purchase Agreement&amp;#x201d;) with &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Palm Global Small Cap Master Fund LP (&amp;#x201c;Palm&amp;#x201d;) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed to purchase from the Company, 571,429 shares of the Company&amp;#x2019;s Series A 5% Convertible Preferred Stock, $0.08 par value per share for a purchase price of approximately $2 million, or $3.50 per Series A Convertible Preferred Stock. Under the terms of the Stock Purchase Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company&amp;#x2019;s common stock, subject to certain adjustments. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Series A 5% Convertible Preferred Stock shares are convertible at the option of the holder at any time into an equal number of common stock shares (&amp;#x201c;Conversion Shares&amp;#x201d;). The conversion price may be adjusted for stock splits or other common stock issuances. The Company may require the conversion of all of the outstanding Series A 5% Convertible Preferred Stock shares if the closing sale price of the Company&amp;#x2019;s common stock equals or exceeds $9.00 for a period of five consecutive trading days with a minimum average trading volume of 35,000 shares per day over such period; provided, that, on such date, the Conversion Shares are registered for resale. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: justify; margin: 0in 0in 0pt;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;The Series A 5% Convertible Preferred Stock shares accrue annual preferred dividends at a rate of $0.175 per Series A 5% Convertible Preferred Stock share. The shares of Series A 5% Convertible Preferred Stock are also entitled to receive participating dividends. The shares of Series A 5% Convertible Preferred Stock have no voting rights. Accruing dividends are payable only when, as, and if declared by the Board and the Company has no obligation to pay such accruing dividends. As such, since the dividend payment is conditional on events that are deemed unlikely at this time, a liability has not been recorded at year-end for these dividends. Dividends that have &amp;#xa0;accumulated through May 31, 2020 total approximately $18,000.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;The 5% dividend is a cumulative dividend, and is only payable if the Board elects to pay a dividend on the Company&amp;#x2019;s common shares, at which point the accrued cumulative dividend must be paid current. At the conversion of any preferred shares into common shares, all accrued, unpaid dividends on the converted preferred shares are canceled and forgiven by Palm. As part of the purchase, Palm was given the right to appoint a Board Observer to the Board. The preferred shares have many material preferential rights over common shareholders in the event of a filing for bankruptcy or dissolution of the Company. For further details on the rights of these preferred shares, please refer to the Company&amp;#x2019;s disclosures filed under an SEC 8-K on February 26, 2020. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On March 24, 2020, Palm converted 250,000 shares of Convertible Preferred Stock into 250,000 shares of unregistered common stock. On July 21, 2020, the Company filed with the SEC a registration statement on Form S-3 that among other things registered all of the common shares issued, or to be issued, to Palm upon conversion of the Convertible Preferred Stock into common shares. The Company anticipates the registration statement shall become effective promptly following the filing of this annual report on Form 10-K with the SEC. The Company incurred approximately $82,000 in issuance costs associated with this stock issuance.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c65_AsOf26Feb2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">571429</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized unitRef="shares" contextRef="c66_AsOf31Aug2010_EmployeeStockOptionMember_A2010PlanMember" decimals="INF">850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent unitRef="pure" contextRef="c67_From31Aug2010To31Aug2010_EmployeeStockOptionMember_A2010PlanMember" decimals="2">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c67_From31Aug2010To31Aug2010_EmployeeStockOptionMember_A2010PlanMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized unitRef="shares" contextRef="c68_AsOf31Dec2014_EmployeeStockOptionMember_A2014PlanMember" decimals="INF">850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent unitRef="pure" contextRef="c69_From31Dec2014To31Dec2014_EmployeeStockOptionMember_A2014PlanMember" decimals="2">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c69_From31Dec2014To31Dec2014_EmployeeStockOptionMember_A2014PlanMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized unitRef="shares" contextRef="c70_AsOf31Dec2017_EmployeeStockOptionMember_A2017PlanMember" decimals="INF">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent unitRef="pure" contextRef="c71_From31Dec2017To31Dec2017_EmployeeStockOptionMember_A2017PlanMember" decimals="2">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c71_From31Dec2017To31Dec2017_EmployeeStockOptionMember_A2017PlanMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized unitRef="shares" contextRef="c72_AsOf29Feb2020_EmployeeStockOptionMember_A2020PlanMember" decimals="INF">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c73_From1Jun2019To31May2020_EmployeeStockOptionMember" decimals="0">200470</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c74_From1Jun2019To31May2020_EmployeeStockOptionMember_ResearchAndDevelopmentExpenseMember" decimals="0">17892</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c75_From1Jun2019To31May2020_EmployeeStockOptionMember_GeneralAndAdministrativeExpenseMember" decimals="0">156750</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c76_From1Jun2019To31May2020_EmployeeStockOptionMember_SellingAndMarketingExpenseMember" decimals="0">2933</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c77_From1Jun2019To31May2020_EmployeeStockOptionMember_CostOfSalesMember" decimals="0">22895</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c78_From1Jun2019To31May2020_MX_EmployeeStockOptionMember" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c79_From1Jun2018To31May2019_EmployeeStockOptionMember" decimals="0">151224</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c80_From1Jun2018To31May2019_EmployeeStockOptionMember_ResearchAndDevelopmentExpenseMember" decimals="0">3714</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c81_From1Jun2018To31May2019_EmployeeStockOptionMember_GeneralAndAdministrativeExpenseMember" decimals="0">143299</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c82_From1Jun2018To31May2019_EmployeeStockOptionMember_SellingAndMarketingExpenseMember" decimals="0">4163</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c83_From1Jun2018To31May2019_MX_EmployeeStockOptionMember" decimals="0">48</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c73_From1Jun2019To31May2020_EmployeeStockOptionMember" decimals="2">4.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c79_From1Jun2018To31May2019_EmployeeStockOptionMember" decimals="2">2.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue unitRef="usd" contextRef="c73_From1Jun2019To31May2020_EmployeeStockOptionMember" decimals="0">589000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue unitRef="usd" contextRef="c79_From1Jun2018To31May2019_EmployeeStockOptionMember" decimals="0">364000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c84_AsOf31May2020_EmployeeStockOptionMember" decimals="0">6923000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c85_AsOf31May2019_EmployeeStockOptionMember" decimals="0">808000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 unitRef="usd" contextRef="c84_AsOf31May2020_EmployeeStockOptionMember" decimals="0">4442000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 unitRef="usd" contextRef="c85_AsOf31May2019_EmployeeStockOptionMember" decimals="0">685000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions unitRef="usd" contextRef="c84_AsOf31May2020_EmployeeStockOptionMember" decimals="0">663000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c73_From1Jun2019To31May2020_EmployeeStockOptionMember">P3Y244D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c73_From1Jun2019To31May2020_EmployeeStockOptionMember">P6Y69D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c86_From1Jun2019To31May2020_EmployeeStockOptionMember_CommonStockMember" decimals="INF">137958</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit unitRef="usdPershares" contextRef="c86_From1Jun2019To31May2020_EmployeeStockOptionMember_CommonStockMember" decimals="2">0.82</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit unitRef="usdPershares" contextRef="c86_From1Jun2019To31May2020_EmployeeStockOptionMember_CommonStockMember" decimals="2">3.90</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c86_From1Jun2019To31May2020_EmployeeStockOptionMember_CommonStockMember" decimals="0">223534</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c87_From1Jun2018To31May2019_EmployeeStockOptionMember_CommonStockMember" decimals="INF">163500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit unitRef="usdPershares" contextRef="c9_From1Jun2018To31May2019" decimals="2">0.71</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit unitRef="usdPershares" contextRef="c87_From1Jun2018To31May2019_EmployeeStockOptionMember_CommonStockMember" decimals="2">1.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c87_From1Jun2018To31May2019_EmployeeStockOptionMember_CommonStockMember" decimals="0">121790</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c88_From1Dec2017To1Dec2017_MaximumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="0">7000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c89_AsOf1Dec2017_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="2">0.08</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c90_From1Dec2017To19Mar2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="0">6997935</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c91_From1Jun2019To31May2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="0">3771048</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c92_From20Jul2017To20Jul2017_MaximumMember_CommonStockMember_RegistrationRightsAgreementMember_AtMarketIssuanceSalesAgreementMember" decimals="0">12500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c93_From1Jun2019To31May2020_CommonStockMember_RegistrationRightsAgreementMember_AtMarketIssuanceSalesAgreementMember" decimals="0">6817330</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction unitRef="shares" contextRef="c91_From1Jun2019To31May2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="INF">1674943</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c91_From1Jun2019To31May2020_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="0">10232857</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c94_AsOf31May2020_MinimumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="2">2.33</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c95_AsOf31May2020_MaximumMember_CommonStockMember_AtMarketIssuanceSalesAgreementMember" decimals="2">9.08</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c96_From1Jun2019To31May2020_PreferredStockMember_CommonStockMember" decimals="INF">250000</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction unitRef="shares" contextRef="c97_From1Jun2019To31May2020_CommonStockMember" decimals="INF">1674943</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c98_AsOf31May2020_MinimumMember_CommonStockMember" decimals="2">2.33</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c99_AsOf31May2020_MaximumMember_CommonStockMember" decimals="2">9.08</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c97_From1Jun2019To31May2020_CommonStockMember" decimals="0">10588378</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c97_From1Jun2019To31May2020_CommonStockMember" decimals="0">10232857</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction unitRef="shares" contextRef="c100_From1Jun2018To31May2019_CommonStockMember" decimals="INF">625677</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c101_AsOf31May2019_MinimumMember_CommonStockMember" decimals="2">2.59</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c102_AsOf31May2019_MaximumMember_CommonStockMember" decimals="2">4.16</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c100_From1Jun2018To31May2019_CommonStockMember" decimals="0">1847662</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c100_From1Jun2018To31May2019_CommonStockMember" decimals="0">1776575</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c103_AsOf24Feb2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">571429</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c103_AsOf24Feb2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="2">0.08</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:ConversionOfStockAmountIssued1 unitRef="usd" contextRef="c104_From24Feb2020To24Feb2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember" decimals="-6">2000000</us-gaap:ConversionOfStockAmountIssued1>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c105_AsOf24Feb2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember" decimals="2">3.50</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ConversionOfStockDescription contextRef="c104_From24Feb2020To24Feb2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember">The Company may require the conversion of all of the outstanding Series A 5% Convertible Preferred Stock shares if the closing sale price of the Company&amp;#x2019;s common stock equals or exceeds $9.00 for a period of five consecutive trading days with a minimum average trading volume of 35,000 shares per day over such period; provided, that, on such date, the Conversion Shares are registered for resale</us-gaap:ConversionOfStockDescription>
  <us-gaap:PreferredStockDividendsPerShareDeclared unitRef="usdPershares" contextRef="c106_From1Jun2019To31May2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="3">0.175</us-gaap:PreferredStockDividendsPerShareDeclared>
  <us-gaap:DividendsPreferredStock unitRef="usd" contextRef="c106_From1Jun2019To31May2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="0">18000</us-gaap:DividendsPreferredStock>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c107_From24Mar2020To24Mar2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember" decimals="INF">250000</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockSharesIssued1 unitRef="shares" contextRef="c108_From24Mar2020To24Mar2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember" decimals="INF">250000</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:PaymentsOfStockIssuanceCosts unitRef="usd" contextRef="c108_From24Mar2020To24Mar2020_A5PercentConvertiblePreferredStockMember_SeriesAPreferredStockMember_CommonStockMember" decimals="0">82000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:39pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NUMBER OF STOCK OPTIONS&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;EXERCISE PRICE&amp;#xa0; RANGE PER SHARE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;WEIGHTED AVERAGE EXERCISE PRICE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options outstanding at May 31, 2018&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,138,625 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.71-$3.90&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1.65 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:175.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;558,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$2.25-$3.62&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.60 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(163,500)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.71-$1.04&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;0.76 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options canceled or expired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(56,916)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.71-$3.62&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.49 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options outstanding at May 31, 2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,476,209 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$3.90&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.07 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:175.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;517,500 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$2.68-$8.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4.47 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(137,958)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$3.90&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1.64 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options canceled or expired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(66,500)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.85-$8.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.43 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Options outstanding at May 31, 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,789,251 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$0.82-$8.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.75 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c109_AsOf31May2018_ExercisePriceRangePerShare071390Member" decimals="INF">1138625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c109_AsOf31May2018_ExercisePriceRangePerShare071390Member" decimals="INF">1.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c110_From1Jun2018To31May2019_ExercisePriceRangePerShare225362Member" decimals="INF">558000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c110_From1Jun2018To31May2019_ExercisePriceRangePerShare225362Member" decimals="INF">2.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c111_From1Jun2018To31May2019_ExercisePriceRangePerShare071104Member" decimals="INF">163500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c111_From1Jun2018To31May2019_ExercisePriceRangePerShare071104Member" decimals="INF">0.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod unitRef="shares" contextRef="c112_From1Jun2018To31May2019_ExercisePriceRangePerShare071362Member" decimals="INF">56916</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c112_From1Jun2018To31May2019_ExercisePriceRangePerShare071362Member" decimals="INF">2.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c113_AsOf31May2019_ExercisePriceRangePerShare082390Member" decimals="INF">1476209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c113_AsOf31May2019_ExercisePriceRangePerShare082390Member" decimals="INF">2.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c114_From1Jun2019To31May2020_ExercisePriceRangePerShare268818Member" decimals="INF">517500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c114_From1Jun2019To31May2020_ExercisePriceRangePerShare268818Member" decimals="INF">4.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c115_From1Jun2019To31May2020_ExercisePriceRangePerShare082390Member" decimals="INF">137958</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c115_From1Jun2019To31May2020_ExercisePriceRangePerShare082390Member" decimals="INF">1.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod unitRef="shares" contextRef="c116_From1Jun2019To31May2020_ExercisePriceRangePerShare085818Member" decimals="INF">66500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c116_From1Jun2019To31May2020_ExercisePriceRangePerShare085818Member" decimals="INF">3.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c117_AsOf31May2020_ExercisePriceRangePerShare082818Member" decimals="INF">1789251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c117_AsOf31May2020_ExercisePriceRangePerShare082818Member" decimals="INF">2.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:82.5pt&quot;&gt; &lt;td style=&quot;HEIGHT:82.5pt; WIDTH:167.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:82.5pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;NUMBER OF SHARES&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:82.5pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:82.5pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;STOCK OPTIONS WEIGHTED AVERAGE AVERAGE GRANT DATE FAIR VALUE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:167.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Non-vested shares at May 31, 2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;769,584 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.49 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:167.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;517,500 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;4.47 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:167.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Vested&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(407,750)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2.25 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:167.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Forfeited&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(56,750)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.55 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:167.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Non-vested shares at May 31, 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;822,584 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;3.78 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares unitRef="shares" contextRef="c4_AsOf31May2019" decimals="INF">769584</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c4_AsOf31May2019" decimals="INF">2.49</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c0_From1Jun2019To31May2020" decimals="INF">517500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c0_From1Jun2019To31May2020" decimals="INF">4.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares unitRef="shares" contextRef="c0_From1Jun2019To31May2020" decimals="INF">407750</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c0_From1Jun2019To31May2020" decimals="INF">2.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares unitRef="shares" contextRef="c0_From1Jun2019To31May2020" decimals="INF">56750</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c0_From1Jun2019To31May2020" decimals="INF">3.55</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares unitRef="shares" contextRef="c3_AsOf31May2020" decimals="INF">822584</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c3_AsOf31May2020" decimals="INF">3.78</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;table style=&quot;width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;&quot; width=&quot;733&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
&lt;tr style=&quot;height: 64.5pt;&quot;&gt;
&lt;td style=&quot;border-top: 0px; height: 64.5pt; border-right: 0px; width: 17%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;RANGE OF EXERCISE PRICES&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 64.5pt; border-right: 0px; width: 17%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;NUMBER OUTSTANDING May 31, 2020&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 64.5pt; border-right: 0px; width: 17%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE IN YEARS&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 64.5pt; border-right: 0px; width: 16%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;WEIGHTED AVERAGE EXERCISE PRICE&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 64.5pt; border-right: 0px; width: 15.78%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;NUMBER EXERCISABLE AT MAY 31, 2020&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 64.5pt; border-right: 0px; width: 16%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;WEIGHTED AVERAGE EXERCISE PRICE&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$ 0.82-$1.04&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;276,000&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;4.44&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$0.84 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 15.78%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;276,000&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$0.84 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 17%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$ 1.20-$ 2.81&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 17%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;1,072,500&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 17%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;7.57&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 16%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$2.17 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 15.78%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;506,000&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 16%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$1.71 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$ 3.62-$ 8.18&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;440,751&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;7.62&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$5.38 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 15.78%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;184,667&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$3.87 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit unitRef="usdPershares" contextRef="c118_From1Jun2019To31May2020_RangeOfExercisePrice082104Member" decimals="INF">0.82</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit unitRef="usdPershares" contextRef="c118_From1Jun2019To31May2020_RangeOfExercisePrice082104Member" decimals="INF">1.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c119_AsOf31May2020_RangeOfExercisePrice082104Member" decimals="INF">276000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c118_From1Jun2019To31May2020_RangeOfExercisePrice082104Member">P4Y160D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c119_AsOf31May2020_RangeOfExercisePrice082104Member" decimals="INF">0.84</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c119_AsOf31May2020_RangeOfExercisePrice082104Member" decimals="INF">276000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 unitRef="usdPershares" contextRef="c119_AsOf31May2020_RangeOfExercisePrice082104Member" decimals="INF">0.84</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit unitRef="usdPershares" contextRef="c120_From1Jun2019To31May2020_RangeOfExercisePrice120281Member" decimals="INF">1.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit unitRef="usdPershares" contextRef="c120_From1Jun2019To31May2020_RangeOfExercisePrice120281Member" decimals="INF">2.81</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c121_AsOf31May2020_RangeOfExercisePrice120281Member" decimals="INF">1072500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c120_From1Jun2019To31May2020_RangeOfExercisePrice120281Member">P7Y208D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c121_AsOf31May2020_RangeOfExercisePrice120281Member" decimals="INF">2.17</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c121_AsOf31May2020_RangeOfExercisePrice120281Member" decimals="INF">506000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 unitRef="usdPershares" contextRef="c121_AsOf31May2020_RangeOfExercisePrice120281Member" decimals="INF">1.71</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit unitRef="usdPershares" contextRef="c122_From1Jun2019To31May2020_RangeOfExercisePrice362818Member" decimals="INF">3.62</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit unitRef="usdPershares" contextRef="c122_From1Jun2019To31May2020_RangeOfExercisePrice362818Member" decimals="INF">8.18</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c123_AsOf31May2020_RangeOfExercisePrice362818Member" decimals="INF">440751</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c122_From1Jun2019To31May2020_RangeOfExercisePrice362818Member">P7Y226D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c123_AsOf31May2020_RangeOfExercisePrice362818Member" decimals="INF">5.38</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions unitRef="shares" contextRef="c123_AsOf31May2020_RangeOfExercisePrice362818Member" decimals="INF">184667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 unitRef="usdPershares" contextRef="c123_AsOf31May2020_RangeOfExercisePrice362818Member" decimals="INF">3.87</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6. &amp;#xa0;&amp;#xa0;&amp;#xa0;INCOME TAXES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Income tax expense from continuing operations for the years ended May 31, 2020 and 2019 consists of the following:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;Years ended May 31,&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Current:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;U.S. Federal&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Foreign Taxes Subsidiaries&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(6,590)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(13,437)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;State and local&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(800)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(800)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total current&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(7,390)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(14,237)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Deferred:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;U.S. Federal&amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(10,000)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;State and local&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total deferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(10,000)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Income tax expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(7,390)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(24,237)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Income tax expense from continuing operations differs from the amounts computed by applying the U.S. Federal income tax rate applicable for each year (21% for 2020 and 2019) to pretax income as a result of the following:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table style=&quot;width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;&quot; width=&quot;733&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 3.5in; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Years ended May 31,&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 3.5in; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Computed &quot;expected&quot; tax benefit &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;489,651 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;497,453 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 3.5in; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Increase (reduction) in income taxes resulting from:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 3.5in; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(716,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(910,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 3.5in; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;State income taxes, net of federal benefit&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;154,254 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;89,267 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 3.5in; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Research and development tax credits&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;49,770 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;55,908 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 3.5in; white-space: nowrap; padding: 0in 0in 0in 0pt;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Permanent tax differences and other&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;21,525 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(256,572)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 3.5in; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 0in 0in 0pt;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Foreign taxes of subsidiaries&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(6,590)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(13,437)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15.75pt;&quot;&gt;
&lt;td style=&quot;height: 15.75pt; width: 3.5in; white-space: nowrap; padding: 0in 0in 0in 0pt;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Income tax expense&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15.75pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(7,390)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15.75pt; width: 2%; white-space: nowrap; border: 0px; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(24,237)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The tax effect of significant temporary differences&amp;#xa0;is presented below:&lt;/font&gt;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;table style=&quot;width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;&quot; width=&quot;733&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 301.7pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;As of May 31,&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Deferred tax assets:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Accounts receivable, principally due to allowance for doubtful accounts&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;17,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;18,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Inventory valuation&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;16,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;12,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Compensated absences&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;64,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;48,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Net operating loss carryforwards&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2,286,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;1,735,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Tax credit carryforwards&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;599,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;467,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Deferred rent expense/Capitalized leases&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;17,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;9,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Other&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;171,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;176,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;5,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 0pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(6,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Total deferred tax assets&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;3,175,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2,459,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 301.7pt; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Less valuation allowance&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(3,175,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(2,459,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15.75pt;&quot;&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 301.7pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Net deferred tax asset&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has provided a valuation allowance of approximately $3,175,000 and $2,459,000 as of May 31, 2020 and 2019, respectively. The net change in the valuation allowance for the years ended May 31, 2020 and 2019 was an increase of $716,000 and $900,000, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;At May 31, 2020, the Company has Federal income tax NOL carryforwards of approximately $9,213,000. &amp;#xa0;At May 31, 2020, the Company has California state income tax net operating loss carryforwards of approximately $5,025,000.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;At May 31, 2020, the Company has Federal research and development tax credit carryforward of approximately $438,000. &amp;#xa0;The Federal credits begin to expire in 2027. &amp;#xa0;The Company also had similar credit carryforwards for state purposes of $160,000 at May 31, 2020.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Pursuant to Internal Revenue Code (&amp;#x201c;IRC&amp;#x201d;) Sections 382 and 383, annual use of the Company&apos;s net operating loss (&quot;NOL&quot;) and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections 382 and 383 of the IRC, the annual use of the Company&apos;s NOLs and credit carryforwards would be limited if there is a cumulative change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period. Management has not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;For the year ended May 31, 2020, the Company did an analysis of its ASC 740 position and has not identified any uncertain tax positions as defined under ASC 740. Should such position be identified in the future and should the Company owe interest and penalties as a result of this, these would be recognized as interest expense and other expense, respectively, in the consolidated financial statements. The Company is no longer subject to any significant U.S. federal tax examinations by tax authorities for years before fiscal year 2016.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c0_From1Jun2019To31May2020" decimals="2">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c9_From1Jun2018To31May2019" decimals="2">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="0">716000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="0">900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:OperatingLossCarryforwards unitRef="usd" contextRef="c124_AsOf31May2020_DomesticCountryMember" decimals="0">9213000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards unitRef="usd" contextRef="c125_AsOf31May2020_CaliforniaStateIncomeTaxMember" decimals="0">5025000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:TaxCreditCarryforwardAmount unitRef="usd" contextRef="c126_AsOf31May2020_DomesticCountryMember_ResearchMember" decimals="0">438000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount unitRef="usd" contextRef="c127_AsOf31May2020_StateAndLocalJurisdictionMember_ResearchMember" decimals="0">160000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;Years ended May 31,&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Current:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;U.S. Federal&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Foreign Taxes Subsidiaries&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(6,590)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(13,437)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;State and local&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(800)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(800)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total current&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(7,390)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(14,237)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Deferred:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;U.S. Federal&amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(10,000)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;State and local&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total deferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(10,000)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Income tax expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(7,390)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;(24,237)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:CurrentFederalTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2019To31May2020" xs:nil="true"/>
  <us-gaap:CurrentFederalTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2018To31May2019" xs:nil="true"/>
  <us-gaap:CurrentForeignTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-6590</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentForeignTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-13437</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-800</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-800</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-7390</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-14237</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2019To31May2020" xs:nil="true"/>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-10000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2019To31May2020" xs:nil="true"/>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2018To31May2019" xs:nil="true"/>
  <us-gaap:DeferredIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jun2019To31May2020" xs:nil="true"/>
  <us-gaap:DeferredIncomeTaxExpenseBenefit unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-10000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;table style=&quot;width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;&quot; width=&quot;733&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 3.5in; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Years ended May 31,&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 3.5in; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Computed &quot;expected&quot; tax benefit &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;489,651 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;497,453 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 3.5in; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Increase (reduction) in income taxes resulting from:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 3.5in; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(716,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(910,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 3.5in; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;State income taxes, net of federal benefit&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;154,254 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;89,267 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 3.5in; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Research and development tax credits&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;49,770 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;55,908 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 3.5in; white-space: nowrap; padding: 0in 0in 0in 0pt;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Permanent tax differences and other&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;21,525 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(256,572)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 3.5in; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 0in 0in 0pt;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Foreign taxes of subsidiaries&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(6,590)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(13,437)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15.75pt;&quot;&gt;
&lt;td style=&quot;height: 15.75pt; width: 3.5in; white-space: nowrap; padding: 0in 0in 0in 0pt;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Income tax expense&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15.75pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(7,390)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15.75pt; width: 2%; white-space: nowrap; border: 0px; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(24,237)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">489651</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">497453</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-716000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-910000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">154254</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">89267</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">49770</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">55908</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">21525</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-256572</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">-6590</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential unitRef="usd" contextRef="c9_From1Jun2018To31May2019" decimals="INF">-13437</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;table style=&quot;width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;&quot; width=&quot;733&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 301.7pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;As of May 31,&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Deferred tax assets:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Accounts receivable, principally due to allowance for doubtful accounts&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;17,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;18,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Inventory valuation&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;16,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;12,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Compensated absences&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;64,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;48,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Net operating loss carryforwards&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2,286,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;1,735,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Tax credit carryforwards&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;599,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;467,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Deferred rent expense/Capitalized leases&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;17,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;9,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Other&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;171,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;176,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;5,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 0pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(6,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Total deferred tax assets&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;3,175,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;2,459,000 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 301.7pt; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Less valuation allowance&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(3,175,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;(2,459,000)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15.75pt;&quot;&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 301.7pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Net deferred tax asset&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">17000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">18000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
  <us-gaap:DeferredTaxAssetsInventory unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">16000</us-gaap:DeferredTaxAssetsInventory>
  <us-gaap:DeferredTaxAssetsInventory unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">12000</us-gaap:DeferredTaxAssetsInventory>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">64000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">48000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">2286000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">1735000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">599000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">467000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">17000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">9000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
  <us-gaap:DeferredTaxAssetsOther unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">171000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">176000</us-gaap:DeferredTaxAssetsOther>
  <bmra:DeferredTaxAssetsAccumulatedDepreciationAndAmortization unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">5000</bmra:DeferredTaxAssetsAccumulatedDepreciationAndAmortization>
  <bmra:DeferredTaxAssetsAccumulatedDepreciationAndAmortization unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">-6000</bmra:DeferredTaxAssetsAccumulatedDepreciationAndAmortization>
  <us-gaap:DeferredTaxAssetsGross unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">3175000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">2459000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">3175000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c4_AsOf31May2019" decimals="INF">2459000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c3_AsOf31May2020" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c4_AsOf31May2019" xs:nil="true"/>
  <bmra:GeographicInformationDisclosureTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&amp;#xa0;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;7. &amp;#xa0;&amp;#xa0;&amp;#xa0;GEOGRAPHIC INFORMATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&amp;#xa0;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company operates as one segment. Geographic information regarding net sales is approximately as follows: &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Years ended May 31,&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Net sales:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Europe&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,434,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,694,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;United States &amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;445,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;523,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Asia&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,867,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,514,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;South America&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,615,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;256,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Middle East&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;314,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;214,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Other foreign&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;18,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.25in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total net sales&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6,693,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;5,201,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;/div&gt;</bmra:GeographicInformationDisclosureTextBlock>
  <us-gaap:NumberOfOperatingSegments unitRef="pure" contextRef="c0_From1Jun2019To31May2020" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Years ended May 31,&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Net sales:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Europe&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,434,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,694,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;United States &amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;445,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;523,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Asia&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,867,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2,514,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;South America&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,615,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;256,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Middle East&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;314,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;214,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Other foreign&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;18,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.25in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total net sales&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;6,693,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;5,201,000 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
  <us-gaap:Revenues unitRef="usd" contextRef="c128_From1Jun2019To31May2020_EuropeMember" decimals="INF">2434000</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c129_From1Jun2018To31May2019_EuropeMember" decimals="INF">1694000</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c130_From1Jun2019To31May2020_US" decimals="INF">445000</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c131_From1Jun2018To31May2019_US" decimals="INF">523000</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c132_From1Jun2019To31May2020_AsiaMember" decimals="INF">1867000</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c133_From1Jun2018To31May2019_AsiaMember" decimals="INF">2514000</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c134_From1Jun2019To31May2020_SouthAmericaMember" decimals="INF">1615000</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c135_From1Jun2018To31May2019_SouthAmericaMember" decimals="INF">256000</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c136_From1Jun2019To31May2020_MiddleEastMember" decimals="INF">314000</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c137_From1Jun2018To31May2019_MiddleEastMember" decimals="INF">214000</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c138_From1Jun2019To31May2020_OtherForeignMember" decimals="INF">18000</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c139_From1Jun2018To31May2019_OtherForeignMember" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;8. &amp;#xa0;&amp;#xa0;&amp;#xa0;COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;OPERATING LEASES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On June 18, 2009, the Company entered into an agreement to lease a building in Irvine, California. The lease commenced September 1, 2009 and ended August 31, 2016. &lt;/font&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;&amp;#xa0;On November 30, 2015, the Company entered into the First Amendment to Lease wherein it exercised its option to extend its lease until August 31, 2021. The initial base rent for the lease extension was $21,000 per month, increasing to $23,637 through August 31, 2021. The monthly rent is currently $22,948. The security deposit of $22,080 remains the same.&lt;font style=&quot;COLOR:black&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;In November 2016, the Company&amp;#x2019;s subsidiary, Biomerica de Mexico, entered into a ten-year lease for approximately 8,104 square feet at a monthly rent of $2,926. The Company has one 10-year option to renew at the end of the initial lease period. The yearly rate is subject to an annual adjustment for inflation according to the United States Bureau of Labor Statistics Consumer Price Index for All Urban Consumers. The monthly rate is currently $3,239. &amp;#xa0;Biomerica, Inc. is not a guarantor of such lease.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total gross rent expense in the U.S. for fiscal 2020 was $300,267 and 2019 was $268,550.&amp;#xa0; Rent expense for the Mexico facility for fiscal 2020 and 2019 was $43,481 and $46,040, respectively. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: justify; margin: 0in 0pt 0pt 0in;&quot;&gt;&lt;font style=&quot;font-size: 10pt;&quot;&gt;For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company&amp;#x2019;s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included in the measurement of the right-of-use asset and related lease liability.&amp;#xa0; Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss when they are incurred.&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Courier New&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;&quot;&gt;Supplemental cash flow information related to leases for the year ended May 31, 2020:&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table style=&quot;width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;&quot; width=&quot;733&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 365.05pt; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Operating cash flows from operating leases&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;311,742 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 365.05pt; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 365.05pt; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Right-of-use assets obtained in exchange for &lt;br/&gt;&amp;#xa0;&amp;#xa0; new operating lease liabilities&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 365.05pt; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Weighted average remaining lease term (in years)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;6.27&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 365.05pt; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Weighted average discount rate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;6.5%&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The maturity of lease liabilities as of May 31, 2020 are as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Years ending May 31,&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;211,808 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2022&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;236,391 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2023&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;262,810 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2024&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;291,329 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2025&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;322,098 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;457,051 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,781,487 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;According to the terms of the lease in Irvine, the Company is also responsible for routine repairs of the building and for certain increases in property tax. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company also has various insignificant leases for office equipment.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;RETIREMENT SAVINGS PLAN&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Effective September 1, 1986, the Company established a 401(k) plan for the benefit of its employees. The plan permits eligible employees to contribute to the plan up to the maximum percentage of total annual compensation allowable under the limits of IRC Sections 415, 401(k) and 404. The Company, at the discretion of its Board of Directors, may make contributions to the plan in amounts determined by the Board each year. No contributions by the Company have been made since the plan&apos;s inception.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;LITIGATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. While the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that exist. Therefore, it is possible the outcome of such legal proceedings, claims and litigation could have a material effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on the Company&apos;s consolidated financial position, results of operations or cash flows. There were no legal proceedings pending as of May 31, 2020.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On July 2, 2020, we received a notice of investigation and subpoena to produce information and documents from the Division of Enforcement of the SEC. The subpoena seeks information and documents related to events and circumstances leading up to our March 17, 2020 announcement that we had commenced shipping samples of our COVID-19 IgG/IgM Rapid Test to countries outside of the United States, and had initiated the application process with the United States Food and Drug Administration under the COVID-19 Emergency Use Authorization for approval to market and sell the test in the United States. The subpoena also seeks information and documents about the identity of any persons who were aware of the substance of the March 17, 2020 announcement prior to that date. We are cooperating and intends to continue cooperating fully with the SEC&amp;#x2019;s investigation. At this time, we are unable to predict the duration, scope or outcome of this investigation.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;CONTRACTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Contracts and Licensing Agreements&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;The Company has one royalty agreement in which it has obtained rights to manufacture and market certain products for the life of the products. Royalty expense of approximately $15,000 and $19,000 is included in cost of sales for the agreement for each of the years ended May 31, 2020 and 2019, respectively. Sales of products manufactured under these agreements comprise approximately 1.8% and 2.9% of total sales for the years ended May 31, 2020 and 2019, respectively. The Company may license other products or technology in the future as it deems necessary for conducting business.&amp;#xa0; The Company has other royalty agreements, however they are not considered material.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On May 25, 2016, the Company entered into an Exclusive Marketing License Agreement (&amp;#x201c; Telcon Agreement&amp;#x201d;) with Celtis Pharm Co., Ltd., who subsequently changed their name to Telcon Pharmaceutical Co., LTD (&amp;#x201c;Telcon&amp;#x201d;), a medical company in the South Korea. The Telcon Agreement grants to Telcon an exclusive license to market and sell Biomerica&amp;#x2019;s new InFoods&amp;#xae; IBS products (&amp;#x201c;IBS Products&amp;#x201d;) in South Korea. The term of the agreement is for a period of five years following Korean FDA clearance of the product and provides an additional two years for Telcon to attain such Korean FDA clearance. The sequential two-year and five-year terms do not begin until after Biomerica first receives final clearance for sale of the IBS Products in the United States from the FDA. Telcon, at its sole cost and expense, must use its commercially reasonable good faith efforts to obtain Korean FDA for the IBS Product to be sold in South Korea. The agreement may be cancelled if Biomerica has not obtained final USFDA clearance for sale of the IBS Products on or before December 31, 2019. Biomerica is also obligated to maintain a full quality assurance system for the IBS Products following the harmonized standards according to Annex IV of Directive 98/79/EC. We are working with Telcon management to extend the term of the Telcon Agreement. &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;The terms of the Telcon Agreement provide up to $1.25 million in exclusivity fees based on certain milestones including Biomerica&amp;#x2019;s starting clinical trials in the United States, receipt of US FDA clearance and Telcon&amp;#x2019;s first sales of IBS Products in Korea. If Biomerica commences FDA Trials and Telcon pays the initial $250,000 milestone-based exclusivity fees, and the Agreement is subsequently terminated by either party for lack of performance, then Biomerica shall issue to Telcon 83,333 shares of Biomerica common in consideration for the $250,000 of paid exclusivity fee. No exclusivity fees have yet been paid.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Additionally, the Telcon Agreement provides for&amp;#xa0;a royalty of 15% paid to Biomerica on all sales in Korea of the IBS Product, and further sets the pricing of IBS Products sold to Telcon.&amp;#xa0; In order to retain the exclusivity within South Korean, Telcon must meet certain annual minimum royalty payments to Biomerica following Telcon&amp;#x2019;s receipt of Korean FDA approval or clearance for the IBS Product to be sold in Korea, which in no case will be later than May 31, 2019.&lt;b&gt; &lt;/b&gt;&amp;#xa0;&amp;#xa0;In September 2017, an agreement to extend this date was signed extending the date until April 30, 2020. We are working with Telcon management to extend the date for the completion of this obligation.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;a name=&quot;_Hlk48120529&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In October 2018, the Company entered into an agreement with a customer for the sale of its EZ Detect product in the United States. The term of the Agreement is for three years and is renewable for one-year terms upon written notice.&amp;#xa0; The agreement defines the price and rebate to the customer. There were no sales under this agreement in fiscal 2020.&lt;/font&gt;&lt;/a&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In December 2018, the Company entered into an agreement with a company for the purpose of procuring and assisting in transactions related to its EZ Detect product with China.&amp;#xa0; The contract is for a period of twelve months and is cancellable by either party with forty-five days written notice.&amp;#xa0; The contract specifies 2.5-6% success fees and milestone payments upon certain events transpiring. During fiscal 2019, the Company incurred $27,579 in expenses for this contract. There were no expenses incurred in fiscal 2020.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In April 2019, the Company entered into a consulting agreement with the former, retired president of the Company. The agreement stipulates that he shall be available by consultation if needed for the period of April 8, 2019 through April 7, 2020.&amp;#xa0; In return, the Company has agreed to allow his stock options in the Company to continue to vest and be exercisable until April 7, 2020. At that time, no options will vest and any vested, unexercised options must be exercised by July 2, 2020 at which time they will be forfeited. All options that were eligible to vest according to this agreement were vested and exercised.&amp;#xa0; There were no fees incurred for this agreement for consultation services.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In May 2019, the Company entered into an agreement with MaxHealth Medical International Limited and MaxHealth China (&amp;#x201c;MaxHealth&amp;#x201d;) giving MaxHealth exclusive distribution rights to Biomerica&amp;#x2019;s EZ Detect Product in China.&amp;#xa0; Among other things, the Agreement called for MaxHealth to deposit $100,000 upon execution of the agreement, and an additional $900,000 (for a total of $1,000,000 USD) upon clearance of Chinese customs of the initial order of $100,000. The $1,000,000 was to be used as a prepayment for the first $1,000,000 of purchase orders for the product. While the Company received the first deposit of $100,000, and shipped $100,000 of product to Maxhealth, the Company has not received the second deposit, and has not shipped any further product, which has placed MaxHealth in Default of the agreement.&amp;#xa0; MaxHealth and the Company have been negotiating a possible remedy for the default. There is no assurance these negotiations will be successful or that the default will be rectified.&amp;#xa0; &lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On April 1, 2020, the Company entered into two separate non-exclusive license agreements (the &amp;#x201c;Mount Sinai License Agreements&amp;#x201d;) with the Mount Sinai Icahn School of Medicine in New York (&amp;#x201c;Mount Sinai&amp;#x201d;) to license technology from Mount Sinai that the Company intends to use to scale up and manufacture a laboratory version serological test for SARS-CoV-2 coronavirus.&amp;#xa0; This test uses the ELISA microplate format that can run on existing open system equipment found in most hospitals and clinical laboratories in the United States.&amp;#xa0; The non-exclusive Mount Sinai License Agreements provide for royalty payments to Mount Sinai based on a percentage of gross sales of commercial products manufactured and sold by Biomerica that incorporate the Mount Sinai technology licensed under the Mount Sinai License Agreement. On June 20, 2020, the Company filed for EUA with the FDA based on this on this technology. The Company purchased materials in the amount of $5,100 during fiscal 2020 and subsequently to that another $2,850.&amp;#xa0; No royalty fees have been paid yet on these agreements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;On May 7, 2020, the Company entered into an exclusive license agreement (the &amp;#x201c;UC License Agreements&amp;#x201d;) with The Regents of the University of California (&amp;#x201c;UC&amp;#x201d;) to license all patent rights pertaining to certain licensed technology from UC. This technology is being developed at the University by one of the professors and his team utilizing CRISPR technology. This group is developing a viral detection test for SARS-CoV-2 coronavirus.&amp;#xa0;If this technology development is successful, the Company will work with the University to transfer the technology to Biomerica where the CRISPR based product will need to be further developed, validated and cleared with regulatory agencies for commercial sale into the market.&amp;#xa0; The exclusive UC License Agreements provide for an initial and annual license fee, and a royalty payment on all commercial revenues, to the UC Regents. The UC License Agreement also includes certain investment requirements and milestones the Company will need to meet for the launch of a commercial product based on the licensed technology. The Company paid an initial license fee of $5,000 with the execution of the agreement. An additional $5,000 is due in September 2020.&amp;#xa0; No royalties have been paid yet on this agreement. A license maintenance fee of $10,000 is due annually. This is creditable against earned royalties due each year in the amount of five percent on net sales of licensed products.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;a name=&quot;_Hlk48645104&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On May 18, 2020, the Company signed a non-exclusive distributor agreement with a company in Russia for the distribution of COVID-19 tests. The term of the agreement is for an initial two years, however, the agreement may be terminated for breach of contract. The agreement allows for quantity discounts based on certain milestones.&lt;/font&gt;&lt;/a&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0pt 0in&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Clinical Trial Agreements&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In September 2017, the Company signed a Clinical Samples Agreement with the University of Southern California for the purpose of providing clinical samples for use by the Company in conducting future clinical trials for one of the products which the Company is developing.&amp;#xa0; The initial budget was estimated to be $82,472. The work started in October 2017 with charges for work performed being invoiced and paid monthly.&amp;#xa0; This study ended in February 2020. The Company incurred $2,200 in fiscal 2020 and $12,567 in expenses previously invoiced for a total of $14,767. In addition, $17,064 in fees has been accrued for unbilled charges as of May 31, 2020.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In November 2017, the Company entered into a Clinical Trial Agreement with the University of Michigan to perform an InFoods 24 Endpoint Determination Study.&amp;#xa0; The Company will be invoiced monthly for work performed the previous month. The maximum budget for the study is $181,015. The Company incurred $30,900 and $40,885 in expenses for this study during fiscal 2020 and 2019, respectively. This commitment is approximately 47% billed.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;In January 2018, the Company entered into a Clinical Trial Agreement with Beth Israel Deaconess Medical Center for the purposes of conducting an Antibody Guided Restriction Trial Using Biomerica InFoods 24G Test in patients with a previous diagnosis of Irritable Bowel Syndrome (&amp;#x201c;IBS&amp;#x201d;).&amp;#xa0; The study began in the first quarter of fiscal 2019. The Company was invoiced monthly for work performed the previous month.&amp;#xa0; The total cost of the study was initially estimated to be $142,000, however the study was expanded and total costs of the trial was approximately $305,000. The Company incurred $141,640 and $146,760 in expenses for this study during fiscal 2020 and 2019, respectively. This study was closed in February 2020 and no additional costs are expected.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On July 12, 2019, the Company entered into a Clinical Trial Agreement with a research management institution for the purpose of conducting a clinical trial of the Biomerica HP Stool Antigen test.&amp;#xa0; The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month.&amp;#xa0; The maximum budgeted costs was approximately $117,200.&amp;#xa0; During fiscal 2020, $13,111 in charges were billed and the Company accrued $6,670 in charges as of May 31, 2020. This study is now closed so no further charges will be incurred.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On July 22, 2019, the Company entered into a Clinical Trial Agreement with a research institution, for the purpose of conducting a clinical trial of the Biomerica Infoods product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be approximately $107,000.&amp;#xa0; The Company incurred $20,875 in charges during fiscal 2020. This commitment is approximately 19% billed. In addition, the Company accrued $2,650 in unbilled charges as of May 31, 2020.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On September 25, 2019, the Company entered into a Clinical Trial Agreement with a medical practice for the purpose of conducting a clinical trial of the Biomerica Infoods IBS product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $136,000. During fiscal 2020, the Company was invoiced $45,250 in expenses. This commitment is approximately 33% billed. In addition, the Company accrued $5,975 in unbilled charges as of May 31, 2020.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On September 25, 2019, the Company entered into a Clinical Trial Agreement with a research institution for the purpose of conducting a clinical trial of the Biomerica H. pylori product.&amp;#xa0; The term of the agreement shall be until completion of the work outlined and the charges were invoiced monthly for work performed in the previous month.&amp;#xa0; The maximum budgeted costs will be approximately $57,800. The Company was invoiced $41,845 in charges during the year ended May 31, 2020. At May 31, 2020, the commitment was approximately 72% billed and the study has been closed so no further charges will be incurred.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;In December 2019, the Company entered into a Clinical Trial Agreement with Houston Methodist Research Institute for the purpose of conducting a clinical trial of the Biomerica InFoods&amp;#xae; IBS product.&amp;#xa0; The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month.&amp;#xa0; The maximum budgeted costs will be approximately $133,000. During the year ended May 31, 2020, the Company was invoiced $4,000 in charges. This commitment is approximately 3% billed.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On May 28, 2020, the Company entered into a Clinical Trial Agreement with the Mayo Clinic Arizona for the purpose of participating in the ongoing end point clinical trial of the Biomerica Infoods IBS product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $135,515. &amp;#xa0;At May 31, 2020, $17,390 had been invoiced to the Company. This commitment is approximately 13% billed.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On May 28, 2020, the Company entered into a Clinical Trial Agreement with the Mayo Clinic Jacksonville for the purpose of participating in the ongoing end point clinical trial of the Biomerica Infoods IBS product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $135,515. The Company has not received any billings as of May 31, 2020, however accrued $17,390 in charges as of that date.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;The addition of both Mayo Clinic sites and other major medical centers were brought into the Infoods&amp;#xae; IBS clinicals studies in order to accelerate patient enrollment.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:LeaseExpirationDate1 contextRef="c140_From18Jun2009To18Jun2009_FirstAmendmentToLeaseMember_BuildingInIrvineCaliforniaMember">2021-08-31</us-gaap:LeaseExpirationDate1>
  <us-gaap:OperatingLeasesRentExpenseMinimumRentals unitRef="usd" contextRef="c140_From18Jun2009To18Jun2009_FirstAmendmentToLeaseMember_BuildingInIrvineCaliforniaMember" decimals="0">21000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
  <bmra:RentalExpenseIncreaseDuringPeriod unitRef="usd" contextRef="c140_From18Jun2009To18Jun2009_FirstAmendmentToLeaseMember_BuildingInIrvineCaliforniaMember" decimals="0">23637</bmra:RentalExpenseIncreaseDuringPeriod>
  <us-gaap:LeaseAndRentalExpense unitRef="usd" contextRef="c140_From18Jun2009To18Jun2009_FirstAmendmentToLeaseMember_BuildingInIrvineCaliforniaMember" decimals="0">22948</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseDepositLiability unitRef="usd" contextRef="c141_AsOf18Jun2009_FirstAmendmentToLeaseMember_BuildingInIrvineCaliforniaMember" decimals="0">22080</us-gaap:LeaseDepositLiability>
  <us-gaap:OperatingLeasesRentExpenseMinimumRentals unitRef="usd" contextRef="c142_From30Nov2016To30Nov2016_MX_PropertyAvailableForOperatingLeaseMember" decimals="0">2926</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
  <bmra:LeaseExpirationPeriod contextRef="c142_From30Nov2016To30Nov2016_MX_PropertyAvailableForOperatingLeaseMember">P10Y</bmra:LeaseExpirationPeriod>
  <us-gaap:LeaseAndRentalExpense unitRef="usd" contextRef="c142_From30Nov2016To30Nov2016_MX_PropertyAvailableForOperatingLeaseMember" decimals="0">3239</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense unitRef="usd" contextRef="c130_From1Jun2019To31May2020_US" decimals="0">300267</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense unitRef="usd" contextRef="c131_From1Jun2018To31May2019_US" decimals="0">268550</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense unitRef="usd" contextRef="c143_From1Jun2019To31May2020_MX" decimals="0">43481</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense unitRef="usd" contextRef="c144_From1Jun2018To31May2019_MX" decimals="0">46040</us-gaap:LeaseAndRentalExpense>
  <us-gaap:RoyaltyExpense unitRef="usd" contextRef="c145_From1Jun2019To31May2020_RoyaltyAgreementsMember" decimals="0">15000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense unitRef="usd" contextRef="c146_From1Jun2018To31May2019_RoyaltyAgreementsMember" decimals="0">19000</us-gaap:RoyaltyExpense>
  <bmra:RoyaltyExpensePercentageOfSales unitRef="pure" contextRef="c147_From1Jun2019To31May2020_SalesRevenueNetMember_RoyaltyAgreementsMember" decimals="3">0.018</bmra:RoyaltyExpensePercentageOfSales>
  <bmra:RoyaltyExpensePercentageOfSales unitRef="pure" contextRef="c148_From1Jun2018To31May2019_SalesRevenueNetMember_RoyaltyAgreementsMember" decimals="3">0.029</bmra:RoyaltyExpensePercentageOfSales>
  <us-gaap:AccruedFeesAndOtherRevenueReceivable unitRef="usd" contextRef="c149_AsOf25May2016_TelconAgreementMember" decimals="-4">1250000</us-gaap:AccruedFeesAndOtherRevenueReceivable>
  <us-gaap:StockIssuedDuringPeriodSharesOther unitRef="shares" contextRef="c150_From25May2016To25May2016_TelconAgreementMember" decimals="INF">83333</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:ProceedsFromFeesReceived unitRef="usd" contextRef="c150_From25May2016To25May2016_TelconAgreementMember" decimals="0">250000</us-gaap:ProceedsFromFeesReceived>
  <bmra:RoyaltyPercentage unitRef="pure" contextRef="c150_From25May2016To25May2016_TelconAgreementMember" decimals="2">0.15</bmra:RoyaltyPercentage>
  <bmra:ContractTerm contextRef="c151_From1Oct2018To31Oct2018_EZDetectProductMember">P3Y</bmra:ContractTerm>
  <bmra:ContractTerm contextRef="c152_From1Dec2018To31Dec2018_EZDetectProductMember">P12M</bmra:ContractTerm>
  <bmra:SuccessFeesPercentage unitRef="pure" contextRef="c153_From1Dec2018To31Dec2018_MinimumMember_EZDetectProductMember" decimals="3">0.025</bmra:SuccessFeesPercentage>
  <bmra:SuccessFeesPercentage unitRef="pure" contextRef="c154_From1Dec2018To31Dec2018_MaximumMember_EZDetectProductMember" decimals="2">0.06</bmra:SuccessFeesPercentage>
  <us-gaap:OtherNonoperatingExpense unitRef="usd" contextRef="c155_From1Jun2018To31May2019_EZDetectProductMember" decimals="0">27579</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense unitRef="usd" contextRef="c156_From1Jun2019To31May2020_EZDetectProductMember" decimals="0">0</us-gaap:OtherNonoperatingExpense>
  <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty unitRef="usd" contextRef="c157_From1May2019To31May2019_EZDetectProductMember_MaxHealthMember" decimals="0">100000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
  <us-gaap:RelatedPartyTransactionDueFromToRelatedParty unitRef="usd" contextRef="c158_AsOf31May2019_EZDetectProductMember_MaxHealthMember" decimals="0">900000</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" contextRef="c157_From1May2019To31May2019_EZDetectProductMember_MaxHealthMember" decimals="0">1000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c157_From1May2019To31May2019_EZDetectProductMember_MaxHealthMember">The $1,000,000 was to be used as a prepayment for the first $1,000,000 of purchase orders for the product. While the Company received the first deposit of $100,000, and shipped $100,000 of product to Maxhealth, the Company has not received the second deposit, and has not shipped any further product, which has placed MaxHealth in Default of the agreement</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
  <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty unitRef="usd" contextRef="c159_From1Jun2019To31May2020_MountSinaiLicenseAgreementsMember" decimals="0">5100</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
  <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty unitRef="usd" contextRef="c160_From1Jun2020To31Aug2020_MountSinaiLicenseAgreementsMember_SubsequentEventMember" decimals="0">2850</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
  <us-gaap:PaymentsForFees unitRef="usd" contextRef="c161_From7May2020To7May2020_UCLicenseAgreementsMember" decimals="0">5000</us-gaap:PaymentsForFees>
  <us-gaap:PaymentsForFees unitRef="usd" contextRef="c162_From1Sep2020To30Sep2020_UCLicenseAgreementsMember_SubsequentEventMember" decimals="0">5000</us-gaap:PaymentsForFees>
  <bmra:LicenseMaintenanceFee unitRef="usd" contextRef="c163_AsOf31May2020_UCLicenseAgreementsMember" decimals="0">10000</bmra:LicenseMaintenanceFee>
  <bmra:ContractTerm contextRef="c164_From18May2020To18May2020_NonexclusiveDistributorAgreementMember">P2Y</bmra:ContractTerm>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c165_AsOf30Sep2017_UniversityOfSouthernCaliforniaMember" decimals="0">82472</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c166_From1Jun2019To31May2020_UniversityOfSouthernCaliforniaMember" decimals="0">2200</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c166_From1Jun2019To31May2020_UniversityOfSouthernCaliforniaMember" decimals="0">12567</us-gaap:OtherResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c167_From1Jun2019To31May2020_MaximumMember_UniversityOfSouthernCaliforniaMember" decimals="0">14767</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AccruedFeesAndOtherRevenueReceivable unitRef="usd" contextRef="c168_AsOf31May2020_UniversityOfSouthernCaliforniaMember" decimals="0">17064</us-gaap:AccruedFeesAndOtherRevenueReceivable>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c169_AsOf30Nov2017_UniversityOFMichiganMember" decimals="0">181015</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c170_From1Jun2019To31May2020_UniversityOFMichiganMember" decimals="0">30900</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c171_From1Jun2018To31May2019_UniversityOFMichiganMember" decimals="0">40885</us-gaap:ResearchAndDevelopmentExpense>
  <bmra:BilledCommitmentPercentage unitRef="pure" contextRef="c170_From1Jun2019To31May2020_UniversityOFMichiganMember" decimals="2">0.47</bmra:BilledCommitmentPercentage>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c172_AsOf31Jan2018_DeaconessMedicalCenterMember" decimals="0">142000</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c173_AsOf31May2020_DeaconessMedicalCenterMember" decimals="0">305000</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c174_From1Jun2019To31May2020_DeaconessMedicalCenterMember" decimals="0">141640</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c175_From1Jun2018To31May2019_DeaconessMedicalCenterMember" decimals="0">146760</us-gaap:ResearchAndDevelopmentExpense>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c176_AsOf12Jul2019_ResearchManagementInstitutionMember" decimals="0">117200</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c177_From1Jun2019To31May2020_ResearchManagementInstitutionMember" decimals="0">13111</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:OtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c178_AsOf31May2020_ResearchManagementInstitutionMember" decimals="0">6670</us-gaap:OtherAccruedLiabilitiesCurrent>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c179_AsOf22Jul2019_BiomericaInfoodsProductMember" decimals="0">107000</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c180_From1Jun2019To31May2020_BiomericaInfoodsProductMember" decimals="0">20875</us-gaap:ResearchAndDevelopmentExpense>
  <bmra:BilledCommitmentPercentage unitRef="pure" contextRef="c180_From1Jun2019To31May2020_BiomericaInfoodsProductMember" decimals="2">0.19</bmra:BilledCommitmentPercentage>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c181_AsOf31May2020_BiomericaInfoodsProductMember" decimals="0">2650</us-gaap:AccruedLiabilitiesCurrent>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c182_AsOf25Sep2019_BiomericaInfoodsIBSProductMember" decimals="0">136000</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c183_From1Jun2019To31May2020_BiomericaInfoodsIBSProductMember" decimals="0">45250</us-gaap:ResearchAndDevelopmentExpense>
  <bmra:BilledCommitmentPercentage unitRef="pure" contextRef="c183_From1Jun2019To31May2020_BiomericaInfoodsIBSProductMember" decimals="2">0.33</bmra:BilledCommitmentPercentage>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c184_AsOf31May2020_BiomericaInfoodsIBSProductMember" decimals="0">5975</us-gaap:AccruedLiabilitiesCurrent>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c185_AsOf25Sep2019_BiomericaHPyloriProductMember" decimals="0">57800</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c186_From1Jun2019To31May2020_BiomericaHPyloriProductMember" decimals="0">41845</us-gaap:ResearchAndDevelopmentExpense>
  <bmra:BilledCommitmentPercentage unitRef="pure" contextRef="c186_From1Jun2019To31May2020_BiomericaHPyloriProductMember" decimals="2">0.72</bmra:BilledCommitmentPercentage>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c187_AsOf31Dec2019_HoustonMethodistResearchInstituteMember" decimals="0">133000</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c188_From1Jun2019To31May2020_HoustonMethodistResearchInstituteMember" decimals="0">4000</us-gaap:ResearchAndDevelopmentExpense>
  <bmra:BilledCommitmentPercentage unitRef="pure" contextRef="c188_From1Jun2019To31May2020_HoustonMethodistResearchInstituteMember" decimals="2">0.03</bmra:BilledCommitmentPercentage>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c189_AsOf28May2020_MayoClinicArizonaMember" decimals="0">135515</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c190_From1Jun2019To31May2020_MayoClinicArizonaMember" decimals="0">17390</us-gaap:ResearchAndDevelopmentExpense>
  <bmra:BilledCommitmentPercentage unitRef="pure" contextRef="c190_From1Jun2019To31May2020_MayoClinicArizonaMember" decimals="2">0.13</bmra:BilledCommitmentPercentage>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c191_AsOf28May2020_MayoClinicJacksonvilleMember" decimals="0">135515</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c192_From1Jun2019To31May2020_MayoClinicJacksonvilleMember" decimals="0">17390</us-gaap:ResearchAndDevelopmentExpense>
  <bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;table style=&quot;width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;&quot; width=&quot;733&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 365.05pt; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Operating cash flows from operating leases&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;311,742 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 365.05pt; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 365.05pt; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Right-of-use assets obtained in exchange for &lt;br/&gt;&amp;#xa0;&amp;#xa0; new operating lease liabilities&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;&amp;#xa0;-- &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 365.05pt; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Weighted average remaining lease term (in years)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;6.27&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 15pt;&quot;&gt;
&lt;td style=&quot;height: 15pt; width: 365.05pt; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;Weighted average discount rate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;
&lt;/td&gt;
&lt;td style=&quot;height: 15pt; width: 12%; background: #80ffff; white-space: nowrap; padding: 0in;&quot; valign=&quot;bottom&quot;&gt;
&lt;p style=&quot;font-size: 12pt; font-family: &apos;Times New Roman&apos;,&apos;serif&apos;; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;font-size: 10pt; color: black;&quot;&gt;6.5%&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock>
  <us-gaap:OperatingLeasePayments unitRef="usd" contextRef="c0_From1Jun2019To31May2020" decimals="INF">311742</us-gaap:OperatingLeasePayments>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability unitRef="usd" contextRef="c0_From1Jun2019To31May2020" xs:nil="true"/>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3_AsOf31May2020">P6Y98D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent unitRef="pure" contextRef="c3_AsOf31May2020" decimals="3">0.065</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;table width=&quot;733&quot; style=&quot;WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Years ending May 31,&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;211,808 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2022&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;236,391 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2023&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;262,810 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2024&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;291,329 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;2025&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;322,098 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;457,051 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&amp;#xa0;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style=&quot;BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;1,781,487 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">211808</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">236391</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">262810</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">291329</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">322098</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">457051</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue unitRef="usd" contextRef="c3_AsOf31May2020" decimals="INF">1781487</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:SubsequentEventsTextBlock contextRef="c0_From1Jun2019To31May2020">&lt;div style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12pt; &quot;&gt;
&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0pt 0in&quot;&gt;&lt;b&gt;&lt;font style=&quot;FONT-SIZE:10pt; COLOR:black&quot;&gt;9.&amp;#xa0;&amp;#xa0;&amp;#xa0; SUBSEQUENT EVENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;Subsequent to May 31, 2020 and through August 31, 2020, 12,500 stock options were exercised at $1.20 per share.&amp;#xa0; Net proceeds to the Company were approximately $14,900.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On June 15, 2020, the Board approved the grant of 52,000 stock options to certain employees.&amp;#xa0; The options vest one-quarter on June 15, 2021 and then one-quarter per year thereafter.&amp;#xa0; The options have an exercise price of $5.46 per share and have a ten-year life.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On July 13, 2020, the Board approved the grant of 76,000 stock options to certain employees and consultants.&amp;#xa0; The options vest one-quarter on July 13, 2021 and then one-quarter per year thereafter.&amp;#xa0; The options have an exercise price of $8.70 per share and have a ten-year life.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On July 13, 2020, the approved the grant of 7,500 stock options to a consultant.&amp;#xa0; The options vest one-half on January 13, 2021 and one-half on July 13, 2021.&amp;#xa0; The options have an exercise price of $8.70 per share and have a ten-year life.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On June 25, 2020, the Company entered into a Clinical Trial Agreement with the University of Texas Health Science Center for the purpose of conducting a clinical trial of the Biomerica Infoods product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $139,850.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On July 20, 2020, the Company filed with the SEC a new Form S-3 &amp;#x201c;Shelf&amp;#x201d; registration statement to replace the registration statement that expired on that day.&amp;#xa0; The new registration statement registers common shares to be issued in a maximum aggregate of $90,000,000.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On August 27, 2020, the Board approved the grant of 33,000 stock options to an employee and a board member. The options vest one-quarter on August 27, 2021 and then one-quarter per year thereafter.&amp;#xa0; The options have an exercise price of $7.47 per share and have a ten-year life.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt&quot;&gt;&lt;font style=&quot;FONT-SIZE:10pt&quot;&gt;On August 27, 2020, the Board approved the grant of 2,500 stock options to a consultant. The options vest one-half on January 13, 2021 and 50% on July 13, 2021. The options have an exercise price of $7.47 per share and have a ten-year life.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c193_From1Jun2020To31Aug2020_EmployeeStockOptionMember_SubsequentEventMember" decimals="INF">12500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c193_From1Jun2020To31Aug2020_EmployeeStockOptionMember_SubsequentEventMember" decimals="2">1.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c193_From1Jun2020To31Aug2020_EmployeeStockOptionMember_SubsequentEventMember" decimals="0">14900</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c194_From15Jun2020To15Jun2020_EmployeeStockOptionMember_EmployeesMember_SubsequentEventMember" decimals="INF">52000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c194_From15Jun2020To15Jun2020_EmployeeStockOptionMember_EmployeesMember_SubsequentEventMember" decimals="2">5.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c195_From13Jul2020To13Jul2020_EmployeeStockOptionMember_EmployeesAndConsultantsMember_SubsequentEventMember" decimals="INF">76000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c195_From13Jul2020To13Jul2020_EmployeeStockOptionMember_EmployeesAndConsultantsMember_SubsequentEventMember" decimals="2">8.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c196_From13Jul2020To13Jul2020_EmployeeStockOptionMember_ConsultantMember_SubsequentEventMember" decimals="INF">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c196_From13Jul2020To13Jul2020_EmployeeStockOptionMember_ConsultantMember_SubsequentEventMember" decimals="2">8.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <bmra:ClinicalTrialAgreementMaximumBudgetedCosts unitRef="usd" contextRef="c197_AsOf25Jun2020_UniversityOfTexasHealthScienceCenterMember_SubsequentEventMember" decimals="0">139850</bmra:ClinicalTrialAgreementMaximumBudgetedCosts>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c198_From20Jul2020To20Jul2020_MaximumMember_CommonStockMember_SubsequentEventMember" decimals="0">90000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c199_From27Aug2020To27Aug2020_EmployeeStockOptionMember_EmployeeAndBoardMemberMember_SubsequentEventMember" decimals="INF">33000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c199_From27Aug2020To27Aug2020_EmployeeStockOptionMember_EmployeeAndBoardMemberMember_SubsequentEventMember" decimals="2">7.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c200_From27Aug2020To27Aug2020_EmployeeStockOptionMember_ConsultantMember_SubsequentEventMember" decimals="INF">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c200_From27Aug2020To27Aug2020_EmployeeStockOptionMember_ConsultantMember_SubsequentEventMember" decimals="2">7.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c194_From15Jun2020To15Jun2020_EmployeeStockOptionMember_EmployeesMember_SubsequentEventMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c195_From13Jul2020To13Jul2020_EmployeeStockOptionMember_EmployeesAndConsultantsMember_SubsequentEventMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c196_From13Jul2020To13Jul2020_EmployeeStockOptionMember_ConsultantMember_SubsequentEventMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c199_From27Aug2020To27Aug2020_EmployeeStockOptionMember_EmployeeAndBoardMemberMember_SubsequentEventMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c200_From27Aug2020To27Aug2020_EmployeeStockOptionMember_ConsultantMember_SubsequentEventMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>bmra-20200531.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Aug 31 13:38:24 EDT 2020 -->
<xs:schema xmlns:bmra="http://www.biomerica.com/20200531" elementFormDefault="qualified" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" targetNamespace="http://www.biomerica.com/20200531" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20200531_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20200531_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20200531_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20200531_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet" id="bmra_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals" id="bmra_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement" id="bmra_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatementAlt0" id="bmra_r_ConsolidatedIncomeStatementAlt0">
        <link:definition>003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ShareholdersEquityType2or3" id="bmra_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS` EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow" id="bmra_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ORGANIZATION" id="bmra_r_ORGANIZATION">
        <link:definition>006 - Disclosure - ORGANIZATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" id="bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNET" id="bmra_r_INTANGIBLEASSETSNET">
        <link:definition>008 - Disclosure - INTANGIBLE ASSETS, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES" id="bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSES">
        <link:definition>009 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITY" id="bmra_r_SHAREHOLDERSEQUITY">
        <link:definition>010 - Disclosure - SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/INCOMETAXES" id="bmra_r_INCOMETAXES">
        <link:definition>011 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATION" id="bmra_r_GEOGRAPHICINFORMATION">
        <link:definition>012 - Disclosure - GEOGRAPHIC INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES" id="bmra_r_COMMITMENTSANDCONTINGENCIES">
        <link:definition>013 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTS" id="bmra_r_SUBSEQUENTEVENTS">
        <link:definition>014 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/AccountingPoliciesByPolicy" id="bmra_r_AccountingPoliciesByPolicy">
        <link:definition>015 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" id="bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNETTables" id="bmra_r_INTANGIBLEASSETSNETTables">
        <link:definition>017 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables" id="bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables">
        <link:definition>018 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables" id="bmra_r_SHAREHOLDERSEQUITYTables">
        <link:definition>019 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/INCOMETAXESTables" id="bmra_r_INCOMETAXESTables">
        <link:definition>020 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables" id="bmra_r_GEOGRAPHICINFORMATIONTables">
        <link:definition>021 - Disclosure - GEOGRAPHIC INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables" id="bmra_r_COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>022 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" id="bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/InventoriesTable" id="bmra_r_InventoriesTable">
        <link:definition>024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SharebasedcompensationassumptionsTable" id="bmra_r_SharebasedcompensationassumptionsTable">
        <link:definition>025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable" id="bmra_r_RevenuefromcontractswithcustomersTable">
        <link:definition>026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/IntangibleassetsnetTable" id="bmra_r_IntangibleassetsnetTable">
        <link:definition>027 - Disclosure - INTANGIBLE ASSETS, NET (Details) - Intangible assets, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable" id="bmra_r_ExpectedamortizationofintangibleassetsTable">
        <link:definition>028 - Disclosure - INTANGIBLE ASSETS, NET (Details) - Expected amortization of intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails" id="bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails">
        <link:definition>029 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable" id="bmra_r_AccountspayableandaccruedexpensebalancesTable">
        <link:definition>030 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense balances</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails" id="bmra_r_SHAREHOLDERSEQUITYDetails">
        <link:definition>031 - Disclosure - SHAREHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/OutstandingStockOptionsActivityTable" id="bmra_r_OutstandingStockOptionsActivityTable">
        <link:definition>032 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMasDJzLBFPhcZ39E819xIH5B6s9+QqmUnZaYcTPdiZJQG4iHDdujDjCMFWAPlk1IXbu5qod0zXC71jDSSWZ68hzrssnC2jdQRCYM8GZK7drI7lUNsyDwUsTcqUitjCVF6j4=] CSR-->
      <link:roleType roleURI="http://www.biomerica.com/role/NonvestedStockOptionsActivityTable" id="bmra_r_NonvestedStockOptionsActivityTable">
        <link:definition>033 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Non-vested Stock Options Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/StockOptionsSummaryTable" id="bmra_r_StockOptionsSummaryTable">
        <link:definition>034 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Stock Options Summary</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/INCOMETAXESDetails" id="bmra_r_INCOMETAXESDetails">
        <link:definition>035 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/IncometaxexpenseTable" id="bmra_r_IncometaxexpenseTable">
        <link:definition>036 - Disclosure - INCOME TAXES (Details) - Income tax expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/IncomeTaxRateReconciliationTable" id="bmra_r_IncomeTaxRateReconciliationTable">
        <link:definition>037 - Disclosure - INCOME TAXES (Details) - Income Tax Rate Reconciliation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/DeferredTaxTable" id="bmra_r_DeferredTaxTable">
        <link:definition>038 - Disclosure - INCOME TAXES (Details) - Deferred Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails" id="bmra_r_GEOGRAPHICINFORMATIONDetails">
        <link:definition>039 - Disclosure - GEOGRAPHIC INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable" id="bmra_r_GeographicinformationregardingnetsalesTable">
        <link:definition>040 - Disclosure - GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetails" id="bmra_r_COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable" id="bmra_r_SupplementalcashflowinformationrelatedtoleasesTable">
        <link:definition>042 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - Supplemental cash flow information related to leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable" id="bmra_r_ThematurityofleaseliabilitiesTable">
        <link:definition>043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - The maturity of lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails" id="bmra_r_SUBSEQUENTEVENTSDetails">
        <link:definition>044 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <xs:element name="InventoriesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_InventoriesAbstract"/>
  <xs:element name="ShareBasedCompensationAssumptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ShareBasedCompensationAssumptionsAbstract"/>
  <xs:element name="RevenueFromContractsWithCustomersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RevenueFromContractsWithCustomersAbstract"/>
  <xs:element name="IntangibleAssetsNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_IntangibleAssetsNetAbstract"/>
  <xs:element name="ExpectedAmortizationOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract"/>
  <xs:element name="AccountsPayableAndAccruedExpenseBalancesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract"/>
  <xs:element name="OutstandingStockOptionsActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OutstandingStockOptionsActivityAbstract"/>
  <xs:element name="NonVestedStockOptionsActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_NonVestedStockOptionsActivityAbstract"/>
  <xs:element name="StockOptionsSummaryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_StockOptionsSummaryAbstract"/>
  <xs:element name="IncomeTaxExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncomeTaxExpenseAbstract"/>
  <xs:element name="IncomeTaxRateReconciliationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncomeTaxRateReconciliationAbstract"/>
  <xs:element name="DeferredTaxAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_DeferredTaxAbstract"/>
  <xs:element name="GeographicInformationDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GeographicInformationDisclosureAbstract"/>
  <xs:element name="GeographicInformationRegardingNetSalesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GeographicInformationRegardingNetSalesAbstract"/>
  <xs:element name="SupplementalCashFlowInformationRelatedToLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
  <xs:element name="TheMaturityOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TheMaturityOfLeaseLiabilitiesAbstract"/>
  <xs:element name="SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract"/>
  <xs:element name="SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0"/>
  <xs:element name="SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00"/>
  <xs:element name="SupplementalDisclosureOfCashFlowInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SupplementalDisclosureOfCashFlowInformationAbstract"/>
  <xs:element name="CashPaidDuringTheYearForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_CashPaidDuringTheYearForAbstract"/>
  <xs:element name="TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract"/>
  <xs:element name="IncreaseReductionInIncomeTaxesResultingFromAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_DeferredTaxAssetsAbstract"/>
  <xs:element name="NetSalesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_NetSalesAbstract"/>
  <xs:element name="EquipmentGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_EquipmentGross"/>
  <xs:element name="FurnitureFixturesAndLeaseholdImprovementsGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_FurnitureFixturesAndLeaseholdImprovementsGross"/>
  <xs:element name="PreferredStockUndesignatedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="bmra_PreferredStockUndesignatedShares"/>
  <xs:element name="AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable"/>
  <xs:element name="StockIssuedDuringPeriodValuePreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_StockIssuedDuringPeriodValuePreferredStock"/>
  <xs:element name="StockIssuedDuringPeriodSharesPreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_StockIssuedDuringPeriodSharesPreferredStock"/>
  <xs:element name="IncreaseDecreaseInDeferredRentLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncreaseDecreaseInDeferredRentLiability"/>
  <xs:element name="OperatingLeaseRightofUseAssetAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_OperatingLeaseRightofUseAssetAmortization"/>
  <xs:element name="IncreaseDecreaseInLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncreaseDecreaseInLeaseLiability"/>
  <xs:element name="ProceedsFromCommonStockSubscribed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_ProceedsFromCommonStockSubscribed"/>
  <xs:element name="EstablishmentOfRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_EstablishmentOfRightOfUseAsset"/>
  <xs:element name="EstablishmentOfLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_EstablishmentOfLeaseLiability"/>
  <xs:element name="GeographicInformationDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GeographicInformationDisclosureTextBlock"/>
  <xs:element name="ConcentrationRiskGeographicPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock"/>
  <xs:element name="ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
  <xs:element name="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable"/>
  <xs:element name="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems"/>
  <xs:element name="FiniteLivedLicenseAccumulatedAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_FiniteLivedLicenseAccumulatedAmortization"/>
  <xs:element name="FiniteLivedPatentsAccumulatedAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_FiniteLivedPatentsAccumulatedAmortization"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems"/>
  <xs:element name="DeferredTaxAssetsAccumulatedDepreciationAndAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization"/>
  <xs:element name="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
  <xs:element name="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
  <xs:element name="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
  <xs:element name="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
  <xs:element name="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable"/>
  <xs:element name="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SHAREHOLDERSEQUITYDetailsTable"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SHAREHOLDERSEQUITYDetailsLineItems"/>
  <xs:element name="INCOMETAXESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_INCOMETAXESDetailsTable"/>
  <xs:element name="INCOMETAXESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_INCOMETAXESDetailsLineItems"/>
  <xs:element name="PropertySubjectToOrAvailableForOperatingLease_Domain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
  <xs:element name="LeaseAmendmentDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_LeaseAmendmentDomain"/>
  <xs:element name="COMMITMENTSANDCONTINGENCIESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable"/>
  <xs:element name="COMMITMENTSANDCONTINGENCIESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems"/>
  <xs:element name="RentalExpenseIncreaseDuringPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_RentalExpenseIncreaseDuringPeriod"/>
  <xs:element name="LeaseExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_LeaseExpirationPeriod"/>
  <xs:element name="RoyaltyExpensePercentageOfSales" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RoyaltyExpensePercentageOfSales"/>
  <xs:element name="RoyaltyPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RoyaltyPercentage"/>
  <xs:element name="ContractTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ContractTerm"/>
  <xs:element name="SuccessFeesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SuccessFeesPercentage"/>
  <xs:element name="LicenseMaintenanceFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_LicenseMaintenanceFee"/>
  <xs:element name="ClinicalTrialAgreementMaximumBudgetedCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_ClinicalTrialAgreementMaximumBudgetedCosts"/>
  <xs:element name="BilledCommitmentPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_BilledCommitmentPercentage"/>
  <xs:element name="SUBSEQUENTEVENTSDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SUBSEQUENTEVENTSDetailsTable"/>
  <xs:element name="SUBSEQUENTEVENTSDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SUBSEQUENTEVENTSDetailsLineItems"/>
  <xs:element name="LeaseAmendmentAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="bmra_LeaseAmendmentAxis"/>
  <xs:element name="A2010PlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_A2010PlanMember"/>
  <xs:element name="A2014PlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_A2014PlanMember"/>
  <xs:element name="A2017PlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_A2017PlanMember"/>
  <xs:element name="A2020PlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_A2020PlanMember"/>
  <xs:element name="A5PercentConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_A5PercentConvertiblePreferredStockMember"/>
  <xs:element name="AtMarketIssuanceSalesAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_AtMarketIssuanceSalesAgreementMember"/>
  <xs:element name="BiomericaHPyloriProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_BiomericaHPyloriProductMember"/>
  <xs:element name="BiomericaInfoodsIBSProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_BiomericaInfoodsIBSProductMember"/>
  <xs:element name="BiomericaInfoodsProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_BiomericaInfoodsProductMember"/>
  <xs:element name="BuildingInIrvineCaliforniaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_BuildingInIrvineCaliforniaMember"/>
  <xs:element name="CaliforniaStateIncomeTaxMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_CaliforniaStateIncomeTaxMember"/>
  <xs:element name="ClinicalLabMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ClinicalLabMember"/>
  <xs:element name="ConsultantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ConsultantMember"/>
  <xs:element name="ContractManufacturingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ContractManufacturingMember"/>
  <xs:element name="DeaconessMedicalCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_DeaconessMedicalCenterMember"/>
  <xs:element name="DistributorsInEcuadorMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_DistributorsInEcuadorMember"/>
  <xs:element name="EZDetectProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_EZDetectProductMember"/>
  <xs:element name="EmployeeAndBoardMemberMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_EmployeeAndBoardMemberMember"/>
  <xs:element name="EmployeesAndConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_EmployeesAndConsultantsMember"/>
  <xs:element name="EmployeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_EmployeesMember"/>
  <xs:element name="ExercisePriceRangePerShare071104Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare071104Member"/>
  <xs:element name="ExercisePriceRangePerShare071362Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare071362Member"/>
  <xs:element name="ExercisePriceRangePerShare071390Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare071390Member"/>
  <xs:element name="ExercisePriceRangePerShare082390Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare082390Member"/>
  <xs:element name="ExercisePriceRangePerShare082818Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare082818Member"/>
  <xs:element name="ExercisePriceRangePerShare085818Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare085818Member"/>
  <xs:element name="ExercisePriceRangePerShare225362Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare225362Member"/>
  <xs:element name="ExercisePriceRangePerShare268818Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ExercisePriceRangePerShare268818Member"/>
  <xs:element name="FirstAmendmentToLeaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_FirstAmendmentToLeaseMember"/>
  <xs:element name="HoustonMethodistResearchInstituteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_HoustonMethodistResearchInstituteMember"/>
  <xs:element name="MaxHealthMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_MaxHealthMember"/>
  <xs:element name="MayoClinicArizonaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_MayoClinicArizonaMember"/>
  <xs:element name="MayoClinicJacksonvilleMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_MayoClinicJacksonvilleMember"/>
  <xs:element name="MountSinaiLicenseAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_MountSinaiLicenseAgreementsMember"/>
  <xs:element name="NonexclusiveDistributorAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_NonexclusiveDistributorAgreementMember"/>
  <xs:element name="OTCMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OTCMember"/>
  <xs:element name="OneDistributorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OneDistributorsMember"/>
  <xs:element name="OneVendorMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OneVendorMember"/>
  <xs:element name="OtherForeignMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OtherForeignMember"/>
  <xs:element name="PhysiciansOfficeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PhysiciansOfficeMember"/>
  <xs:element name="PurchasedTechnologyRightsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PurchasedTechnologyRightsMember"/>
  <xs:element name="RangeOfExercisePrice082104Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RangeOfExercisePrice082104Member"/>
  <xs:element name="RangeOfExercisePrice120281Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RangeOfExercisePrice120281Member"/>
  <xs:element name="RangeOfExercisePrice362818Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RangeOfExercisePrice362818Member"/>
  <xs:element name="RegistrationRightsAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RegistrationRightsAgreementMember"/>
  <xs:element name="ResearchManagementInstitutionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ResearchManagementInstitutionMember"/>
  <xs:element name="SubscriptionsReceivableMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SubscriptionsReceivableMember"/>
  <xs:element name="TelconAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TelconAgreementMember"/>
  <xs:element name="ThreeDistributorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ThreeDistributorsMember"/>
  <xs:element name="TwoDistributorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TwoDistributorsMember"/>
  <xs:element name="TwoVendorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TwoVendorsMember"/>
  <xs:element name="UCLicenseAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UCLicenseAgreementsMember"/>
  <xs:element name="UniversityOFMichiganMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UniversityOFMichiganMember"/>
  <xs:element name="UniversityOfSouthernCaliforniaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UniversityOfSouthernCaliforniaMember"/>
  <xs:element name="UniversityOfTexasHealthScienceCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UniversityOfTexasHealthScienceCenterMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>bmra-20200531_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Aug 31 13:38:24 EDT 2020 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ConsolidatedBalanceSheet" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ConsolidatedIncomeStatement" roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ConsolidatedCashFlow" roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_InventoriesTable" roleURI="http://www.biomerica.com/role/InventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_IntangibleassetsnetTable" roleURI="http://www.biomerica.com/role/IntangibleassetsnetTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ExpectedamortizationofintangibleassetsTable" roleURI="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_AccountspayableandaccruedexpensebalancesTable" roleURI="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_IncometaxexpenseTable" roleURI="http://www.biomerica.com/role/IncometaxexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_DeferredTaxTable" roleURI="http://www.biomerica.com/role/DeferredTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ThematurityofleaseliabilitiesTable" roleURI="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:label="bmra_EquipmentGross" xlink:href="bmra-20200531.xsd#bmra_EquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="bmra_EquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_FurnitureFixturesAndLeaseholdImprovementsGross" xlink:href="bmra-20200531.xsd#bmra_FurnitureFixturesAndLeaseholdImprovementsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="bmra_FurnitureFixturesAndLeaseholdImprovementsGross" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Investments" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_StockOptionPlanExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInDeferredRentLiability" xlink:href="bmra-20200531.xsd#bmra_IncreaseDecreaseInDeferredRentLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bmra_IncreaseDecreaseInDeferredRentLiability" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_OperatingLeaseRightofUseAssetAmortization" xlink:href="bmra-20200531.xsd#bmra_OperatingLeaseRightofUseAssetAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bmra_OperatingLeaseRightofUseAssetAmortization" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20200531.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bmra_IncreaseDecreaseInLeaseLiability" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMasDJzLBFPhcZ39E819xIH5B6s9+QqmUnZaYcTPdiZJQG4iHDdujDjCMFWAPlk1IXbu5qod0zXC71jDSSWZ68hzrssnC2jdQRCYHEHAGl3Z22YrQErSGIeb7] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="bmra_ProceedsFromCommonStockSubscribed" xlink:href="bmra-20200531.xsd#bmra_ProceedsFromCommonStockSubscribed"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="bmra_ProceedsFromCommonStockSubscribed" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/InventoriesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IntangibleassetsnetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedLicenseAgreementsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedPatentsGross" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:href="bmra-20200531.xsd#bmra_FiniteLivedLicenseAccumulatedAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="bmra_FiniteLivedLicenseAccumulatedAmortization" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:href="bmra-20200531.xsd#bmra_FiniteLivedPatentsAccumulatedAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="bmra_FiniteLivedPatentsAccumulatedAmortization" order="4" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IncometaxexpenseTable">
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DeferredTaxTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:href="bmra-20200531.xsd#bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>bmra-20200531_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Aug 31 13:38:24 EDT 2020 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ConsolidatedBalanceSheet" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ConsolidatedIncomeStatement" roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ShareholdersEquityType2or3" roleURI="http://www.biomerica.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ConsolidatedCashFlow" roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ORGANIZATION" roleURI="http://www.biomerica.com/role/ORGANIZATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_INTANGIBLEASSETSNET" roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNET"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSES" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SHAREHOLDERSEQUITY" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_INCOMETAXES" roleURI="http://www.biomerica.com/role/INCOMETAXES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_GEOGRAPHICINFORMATION" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIES" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SUBSEQUENTEVENTS" roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_AccountingPoliciesByPolicy" roleURI="http://www.biomerica.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_INTANGIBLEASSETSNETTables" roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNETTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SHAREHOLDERSEQUITYTables" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_INCOMETAXESTables" roleURI="http://www.biomerica.com/role/INCOMETAXESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_GEOGRAPHICINFORMATIONTables" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_InventoriesTable" roleURI="http://www.biomerica.com/role/InventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SharebasedcompensationassumptionsTable" roleURI="http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_RevenuefromcontractswithcustomersTable" roleURI="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_IntangibleassetsnetTable" roleURI="http://www.biomerica.com/role/IntangibleassetsnetTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ExpectedamortizationofintangibleassetsTable" roleURI="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_AccountspayableandaccruedexpensebalancesTable" roleURI="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_OutstandingStockOptionsActivityTable" roleURI="http://www.biomerica.com/role/OutstandingStockOptionsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_NonvestedStockOptionsActivityTable" roleURI="http://www.biomerica.com/role/NonvestedStockOptionsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_StockOptionsSummaryTable" roleURI="http://www.biomerica.com/role/StockOptionsSummaryTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_IncometaxexpenseTable" roleURI="http://www.biomerica.com/role/IncometaxexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_IncomeTaxRateReconciliationTable" roleURI="http://www.biomerica.com/role/IncomeTaxRateReconciliationTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_DeferredTaxTable" roleURI="http://www.biomerica.com/role/DeferredTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_GeographicinformationregardingnetsalesTable" roleURI="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ThematurityofleaseliabilitiesTable" roleURI="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SHAREHOLDERSEQUITYDetails" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_INCOMETAXESDetails" roleURI="http://www.biomerica.com/role/INCOMETAXESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_GEOGRAPHICINFORMATIONDetails" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SUBSEQUENTEVENTSDetails" roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#DocumentAndEntityInformation" roleURI="http://www.biomerica.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20200531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="bmra_A5PercentConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_PreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_EquipmentGross" xlink:href="bmra-20200531.xsd#bmra_EquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="bmra_EquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_FurnitureFixturesAndLeaseholdImprovementsGross" xlink:href="bmra-20200531.xsd#bmra_FurnitureFixturesAndLeaseholdImprovementsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="bmra_FurnitureFixturesAndLeaseholdImprovementsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Investments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20200531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="bmra_A5PercentConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_PreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNoParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockNoParValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PreferredStockUndesignatedShares" xlink:href="bmra-20200531.xsd#bmra_PreferredStockUndesignatedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bmra_PreferredStockUndesignatedShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_SubscriptionsReceivableMember" xlink:href="bmra-20200531.xsd#bmra_SubscriptionsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="bmra_SubscriptionsReceivableMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20200531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="bmra_A5PercentConvertiblePreferredStockMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_StockIssuedDuringPeriodValuePreferredStock" xlink:href="bmra-20200531.xsd#bmra_StockIssuedDuringPeriodValuePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bmra_StockIssuedDuringPeriodValuePreferredStock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_StockIssuedDuringPeriodSharesPreferredStock" xlink:href="bmra-20200531.xsd#bmra_StockIssuedDuringPeriodSharesPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bmra_StockIssuedDuringPeriodSharesPreferredStock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable" xlink:href="bmra-20200531.xsd#bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInDeferredRentLiability" xlink:href="bmra-20200531.xsd#bmra_IncreaseDecreaseInDeferredRentLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bmra_IncreaseDecreaseInDeferredRentLiability" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OperatingLeaseRightofUseAssetAmortization" xlink:href="bmra-20200531.xsd#bmra_OperatingLeaseRightofUseAssetAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bmra_OperatingLeaseRightofUseAssetAmortization" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20200531.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bmra_IncreaseDecreaseInLeaseLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ProceedsFromCommonStockSubscribed" xlink:href="bmra-20200531.xsd#bmra_ProceedsFromCommonStockSubscribed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bmra_ProceedsFromCommonStockSubscribed" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_CashPaidDuringTheYearForAbstract" xlink:href="bmra-20200531.xsd#bmra_CashPaidDuringTheYearForAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="bmra_CashPaidDuringTheYearForAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_CashPaidDuringTheYearForAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_CashPaidDuringTheYearForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_EstablishmentOfRightOfUseAsset" xlink:href="bmra-20200531.xsd#bmra_EstablishmentOfRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="bmra_EstablishmentOfRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_EstablishmentOfLeaseLiability" xlink:href="bmra-20200531.xsd#bmra_EstablishmentOfLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="bmra_EstablishmentOfLeaseLiability" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ORGANIZATION">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INTANGIBLEASSETSNET">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITY">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXES">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATION">
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureAbstract" xlink:href="bmra-20200531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureTextBlock" xlink:href="bmra-20200531.xsd#bmra_GeographicInformationDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GeographicInformationDisclosureAbstract" xlink:to="bmra_GeographicInformationDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:href="bmra-20200531.xsd#bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INTANGIBLEASSETSNETTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables">
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureAbstract" xlink:href="bmra-20200531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GeographicInformationDisclosureAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:href="bmra-20200531.xsd#bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/InventoriesTable">
    <loc xlink:type="locator" xlink:label="bmra_InventoriesAbstract" xlink:href="bmra-20200531.xsd#bmra_InventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SharebasedcompensationassumptionsTable">
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:href="bmra-20200531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:href="bmra-20200531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ClinicalLabMember" xlink:href="bmra-20200531.xsd#bmra_ClinicalLabMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_ClinicalLabMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OTCMember" xlink:href="bmra-20200531.xsd#bmra_OTCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_OTCMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PhysiciansOfficeMember" xlink:href="bmra-20200531.xsd#bmra_PhysiciansOfficeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_PhysiciansOfficeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ContractManufacturingMember" xlink:href="bmra-20200531.xsd#bmra_ContractManufacturingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_ContractManufacturingMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IntangibleassetsnetTable">
    <loc xlink:type="locator" xlink:label="bmra_IntangibleAssetsNetAbstract" xlink:href="bmra-20200531.xsd#bmra_IntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedLicenseAgreementsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedPatentsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:href="bmra-20200531.xsd#bmra_FiniteLivedLicenseAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="bmra_FiniteLivedLicenseAccumulatedAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:href="bmra-20200531.xsd#bmra_FiniteLivedPatentsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="bmra_FiniteLivedPatentsAccumulatedAmortization" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:href="bmra-20200531.xsd#bmra_ExpectedAmortizationOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable">
    <loc xlink:type="locator" xlink:label="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:href="bmra-20200531.xsd#bmra_AccountsPayableAndAccruedExpenseBalancesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/OutstandingStockOptionsActivityTable">
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:href="bmra-20200531.xsd#bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:href="bmra-20200531.xsd#bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare071390Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare071390Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare071390Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare225362Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare225362Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare225362Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare071104Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare071104Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare071104Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare071362Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare071362Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare071362Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082390Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare082390Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare082390Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare268818Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare268818Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare268818Member" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare085818Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare085818Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare085818Member" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082818Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare082818Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_ExercisePriceRangePerShare082818Member" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/NonvestedStockOptionsActivityTable">
    <loc xlink:type="locator" xlink:label="bmra_NonVestedStockOptionsActivityAbstract" xlink:href="bmra-20200531.xsd#bmra_NonVestedStockOptionsActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/StockOptionsSummaryTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice082104Member" xlink:href="bmra-20200531.xsd#bmra_RangeOfExercisePrice082104Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_RangeOfExercisePrice082104Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice120281Member" xlink:href="bmra-20200531.xsd#bmra_RangeOfExercisePrice120281Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_RangeOfExercisePrice120281Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice362818Member" xlink:href="bmra-20200531.xsd#bmra_RangeOfExercisePrice362818Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bmra_RangeOfExercisePrice362818Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IncometaxexpenseTable">
    <loc xlink:type="locator" xlink:label="bmra_IncomeTaxExpenseAbstract" xlink:href="bmra-20200531.xsd#bmra_IncomeTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxExpenseAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMasDJzLBFPhcZ39E819xIH5B6s9+QqmUnZaYcTPdiZJQG4iHDdujDjCMFWAPlk1IXbu5qod0zXC71jDSSWZ68hzrssnC2jdQRCatDMBx9R1Y/J3WMP2YFMQyVKikJF0rGZY=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IncomeTaxRateReconciliationTable">
    <loc xlink:type="locator" xlink:label="bmra_IncomeTaxRateReconciliationAbstract" xlink:href="bmra-20200531.xsd#bmra_IncomeTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:href="bmra-20200531.xsd#bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxRateReconciliationAbstract" xlink:to="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DeferredTaxTable">
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAbstract" xlink:href="bmra-20200531.xsd#bmra_DeferredTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsAbstract" xlink:href="bmra-20200531.xsd#bmra_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="bmra_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:href="bmra-20200531.xsd#bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable">
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:href="bmra-20200531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:href="bmra-20200531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_AsiaMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_AsiaMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SouthAmericaMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SouthAmericaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SouthAmericaMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MiddleEastMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MiddleEastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_MiddleEastMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OtherForeignMember" xlink:href="bmra-20200531.xsd#bmra_OtherForeignMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="bmra_OtherForeignMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="bmra-20200531.xsd#bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:href="bmra-20200531.xsd#bmra_TheMaturityOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:href="bmra-20200531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_RangeAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DistributionRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DistributionRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DistributionRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PurchasedTechnologyRightsMember" xlink:href="bmra-20200531.xsd#bmra_PurchasedTechnologyRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bmra_PurchasedTechnologyRightsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ThreeDistributorsMember" xlink:href="bmra-20200531.xsd#bmra_ThreeDistributorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="bmra_ThreeDistributorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_TwoDistributorsMember" xlink:href="bmra-20200531.xsd#bmra_TwoDistributorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="bmra_TwoDistributorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OneDistributorsMember" xlink:href="bmra-20200531.xsd#bmra_OneDistributorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="bmra_OneDistributorsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_DistributorsInEcuadorMember" xlink:href="bmra-20200531.xsd#bmra_DistributorsInEcuadorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="bmra_DistributorsInEcuadorMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MX"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MX" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsProductLineMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_CostOfGoodsProductLineMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20200531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="bmra_A5PercentConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashUninsuredAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CashUninsuredAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OtherReceivablesGrossCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AdvertisingExpense" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails">
    <loc xlink:type="locator" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:href="bmra-20200531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:to="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_TwoVendorsMember" xlink:href="bmra-20200531.xsd#bmra_TwoVendorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="bmra_TwoVendorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OneVendorMember" xlink:href="bmra-20200531.xsd#bmra_OneVendorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="bmra_OneVendorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails">
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_SHAREHOLDERSEQUITYDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:href="bmra-20200531.xsd#bmra_SHAREHOLDERSEQUITYDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="srt_RangeAxis" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A2010PlanMember" xlink:href="bmra-20200531.xsd#bmra_A2010PlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bmra_A2010PlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A2014PlanMember" xlink:href="bmra-20200531.xsd#bmra_A2014PlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bmra_A2014PlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A2017PlanMember" xlink:href="bmra-20200531.xsd#bmra_A2017PlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bmra_A2017PlanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A2020PlanMember" xlink:href="bmra-20200531.xsd#bmra_A2020PlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bmra_A2020PlanMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MX"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MX" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_AtMarketIssuanceSalesAgreementMember" xlink:href="bmra-20200531.xsd#bmra_AtMarketIssuanceSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bmra_AtMarketIssuanceSalesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RegistrationRightsAgreementMember" xlink:href="bmra-20200531.xsd#bmra_RegistrationRightsAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_RegistrationRightsAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20200531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="bmra_A5PercentConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_PreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ConversionOfStockDescription" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_DividendsPreferredStock" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="29" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXESDetails">
    <loc xlink:type="locator" xlink:label="bmra_INCOMETAXESDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_INCOMETAXESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_INCOMETAXESDetailsTable" xlink:href="bmra-20200531.xsd#bmra_INCOMETAXESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="bmra_INCOMETAXESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_INCOMETAXESDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_INCOMETAXESDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_CaliforniaStateIncomeTaxMember" xlink:href="bmra-20200531.xsd#bmra_CaliforniaStateIncomeTaxMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="bmra_CaliforniaStateIncomeTaxMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails">
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureAbstract" xlink:href="bmra-20200531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GeographicInformationDisclosureAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetails">
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:href="bmra-20200531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:href="bmra-20200531.xsd#bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_0" xlink:href="bmra-20200531.xsd#bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_LeaseAmendmentAxis" xlink:href="bmra-20200531.xsd#bmra_LeaseAmendmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="bmra_LeaseAmendmentAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_LeaseAmendmentDomain" xlink:href="bmra-20200531.xsd#bmra_LeaseAmendmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="bmra_LeaseAmendmentAxis" xlink:to="bmra_LeaseAmendmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_LeaseAmendmentDomain_0" xlink:href="bmra-20200531.xsd#bmra_LeaseAmendmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="bmra_LeaseAmendmentAxis" xlink:to="bmra_LeaseAmendmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="srt_RangeAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_BuildingInIrvineCaliforniaMember" xlink:href="bmra-20200531.xsd#bmra_BuildingInIrvineCaliforniaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:to="bmra_BuildingInIrvineCaliforniaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyAvailableForOperatingLeaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_FirstAmendmentToLeaseMember" xlink:href="bmra-20200531.xsd#bmra_FirstAmendmentToLeaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_LeaseAmendmentDomain" xlink:to="bmra_FirstAmendmentToLeaseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_EZDetectProductMember" xlink:href="bmra-20200531.xsd#bmra_EZDetectProductMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bmra_EZDetectProductMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_NonexclusiveDistributorAgreementMember" xlink:href="bmra-20200531.xsd#bmra_NonexclusiveDistributorAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bmra_NonexclusiveDistributorAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MX"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MX" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_MaxHealthMember" xlink:href="bmra-20200531.xsd#bmra_MaxHealthMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_MaxHealthMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOFMichiganMember" xlink:href="bmra-20200531.xsd#bmra_UniversityOFMichiganMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_UniversityOFMichiganMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_DeaconessMedicalCenterMember" xlink:href="bmra-20200531.xsd#bmra_DeaconessMedicalCenterMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_DeaconessMedicalCenterMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ResearchManagementInstitutionMember" xlink:href="bmra-20200531.xsd#bmra_ResearchManagementInstitutionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_ResearchManagementInstitutionMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_BiomericaInfoodsProductMember" xlink:href="bmra-20200531.xsd#bmra_BiomericaInfoodsProductMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_BiomericaInfoodsProductMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_BiomericaInfoodsIBSProductMember" xlink:href="bmra-20200531.xsd#bmra_BiomericaInfoodsIBSProductMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_BiomericaInfoodsIBSProductMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_BiomericaHPyloriProductMember" xlink:href="bmra-20200531.xsd#bmra_BiomericaHPyloriProductMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_BiomericaHPyloriProductMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_HoustonMethodistResearchInstituteMember" xlink:href="bmra-20200531.xsd#bmra_HoustonMethodistResearchInstituteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_HoustonMethodistResearchInstituteMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_MayoClinicArizonaMember" xlink:href="bmra-20200531.xsd#bmra_MayoClinicArizonaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_MayoClinicArizonaMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_MayoClinicJacksonvilleMember" xlink:href="bmra-20200531.xsd#bmra_MayoClinicJacksonvilleMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_MayoClinicJacksonvilleMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RoyaltyAgreementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_TelconAgreementMember" xlink:href="bmra-20200531.xsd#bmra_TelconAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_TelconAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_MountSinaiLicenseAgreementsMember" xlink:href="bmra-20200531.xsd#bmra_MountSinaiLicenseAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_MountSinaiLicenseAgreementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_UCLicenseAgreementsMember" xlink:href="bmra-20200531.xsd#bmra_UCLicenseAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_UCLicenseAgreementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOfSouthernCaliforniaMember" xlink:href="bmra-20200531.xsd#bmra_UniversityOfSouthernCaliforniaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_UniversityOfSouthernCaliforniaMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RentalExpenseIncreaseDuringPeriod" xlink:href="bmra-20200531.xsd#bmra_RentalExpenseIncreaseDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_RentalExpenseIncreaseDuringPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseDepositLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseDepositLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_LeaseDepositLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_LeaseExpirationPeriod" xlink:href="bmra-20200531.xsd#bmra_LeaseExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_LeaseExpirationPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RoyaltyExpensePercentageOfSales" xlink:href="bmra-20200531.xsd#bmra_RoyaltyExpensePercentageOfSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_RoyaltyExpensePercentageOfSales" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedFeesAndOtherRevenueReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedFeesAndOtherRevenueReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_AccruedFeesAndOtherRevenueReceivable" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromFeesReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromFeesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromFeesReceived" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RoyaltyPercentage" xlink:href="bmra-20200531.xsd#bmra_RoyaltyPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_RoyaltyPercentage" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ContractTerm" xlink:href="bmra-20200531.xsd#bmra_ContractTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_ContractTerm" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_SuccessFeesPercentage" xlink:href="bmra-20200531.xsd#bmra_SuccessFeesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_SuccessFeesPercentage" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_PaymentsForFees" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_LicenseMaintenanceFee" xlink:href="bmra-20200531.xsd#bmra_LicenseMaintenanceFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_LicenseMaintenanceFee" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:href="bmra-20200531.xsd#bmra_ClinicalTrialAgreementMaximumBudgetedCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_BilledCommitmentPercentage" xlink:href="bmra-20200531.xsd#bmra_BilledCommitmentPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_BilledCommitmentPercentage" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="27" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails">
    <loc xlink:type="locator" xlink:label="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_SUBSEQUENTEVENTSDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:href="bmra-20200531.xsd#bmra_SUBSEQUENTEVENTSDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="bmra_SUBSEQUENTEVENTSDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_EmployeesMember" xlink:href="bmra-20200531.xsd#bmra_EmployeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_EmployeesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_EmployeesAndConsultantsMember" xlink:href="bmra-20200531.xsd#bmra_EmployeesAndConsultantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_EmployeesAndConsultantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ConsultantMember" xlink:href="bmra-20200531.xsd#bmra_ConsultantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_ConsultantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOfTexasHealthScienceCenterMember" xlink:href="bmra-20200531.xsd#bmra_UniversityOfTexasHealthScienceCenterMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_UniversityOfTexasHealthScienceCenterMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_EmployeeAndBoardMemberMember" xlink:href="bmra-20200531.xsd#bmra_EmployeeAndBoardMemberMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_EmployeeAndBoardMemberMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:href="bmra-20200531.xsd#bmra_ClinicalTrialAgreementMaximumBudgetedCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="18" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>bmra-20200531_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Aug 31 13:38:24 EDT 2020 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">CASH AND CASH EQUIVALENTS, beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">CASH AND CASH EQUIVALENTS, end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, less allowance for doubtful accounts of $70,981 and $73,110, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Allowance for doubtful accounts (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_EquipmentGross" xlink:href="bmra-20200531.xsd#bmra_EquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_EquipmentGross_lbl" xml:lang="en-US">Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EquipmentGross" xlink:to="bmra_EquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_FurnitureFixturesAndLeaseholdImprovementsGross" xlink:href="bmra-20200531.xsd#bmra_FurnitureFixturesAndLeaseholdImprovementsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_FurnitureFixturesAndLeaseholdImprovementsGross_lbl" xml:lang="en-US">Furniture, fixtures and leasehold improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FurnitureFixturesAndLeaseholdImprovementsGross" xlink:to="bmra_FurnitureFixturesAndLeaseholdImprovementsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Net property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">INTANGIBLE ASSETS, net of accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">RIGHT OF USE ASSETS, net of accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl" xml:lang="en-US">INVESTMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">OTHER ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (NOTE 8)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, Series A 5%, convertible, $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding at May 31, 2020 and no shares authorized, issued and outstanding at May 31, 2019 and Preferred stock, undesignated, no par value, authorized 4,428,571 and 5,000,000 shares, at May 31, 2020 and May 31, 2019, respectively and none issued and outstanding at May 31, 2020 and May 31, 2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_lbl" xml:lang="en-US">Equity Interest Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par Value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNoParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US">Preferred Stock, No Par Value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PreferredStockUndesignatedShares" xlink:href="bmra-20200531.xsd#bmra_PreferredStockUndesignatedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PreferredStockUndesignatedShares_lbl" xml:lang="en-US">Preferred Stock, undesignated shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PreferredStockUndesignatedShares" xlink:to="bmra_PreferredStockUndesignatedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.08 par value; 25,000,000 shares authorized; 11,740,089 and 9,677,188 shares issued and outstanding at May 31, 2020 and 2019, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders&apos; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">GROSS PROFIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xml:lang="en-US">Interest and dividend income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">LOSS BEFORE INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">INCOME TAX EXPENSE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">BASIC NET LOSS PER COMMON SHARE (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">DILUTED NET LOSS PER COMMON SHARE (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">COMPREHENSIVE LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Options exercised, number of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Net proceeds from ATM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Net proceeds from ATM (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable" xlink:href="bmra-20200531.xsd#bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable_lbl" xml:lang="en-US">Stock subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable" xlink:to="bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Compensation expense in connection with options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_StockIssuedDuringPeriodValuePreferredStock" xlink:href="bmra-20200531.xsd#bmra_StockIssuedDuringPeriodValuePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_StockIssuedDuringPeriodValuePreferredStock_lbl" xml:lang="en-US">Issuance of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_StockIssuedDuringPeriodValuePreferredStock" xlink:to="bmra_StockIssuedDuringPeriodValuePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_StockIssuedDuringPeriodSharesPreferredStock" xlink:href="bmra-20200531.xsd#bmra_StockIssuedDuringPeriodSharesPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_StockIssuedDuringPeriodSharesPreferredStock_lbl" xml:lang="en-US">Issuance of preferred stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_StockIssuedDuringPeriodSharesPreferredStock" xlink:to="bmra_StockIssuedDuringPeriodSharesPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion of preferred to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of preferred to common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Converted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Change in provision for allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge_lbl" xml:lang="en-US">Inventory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Stock option expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInDeferredRentLiability" xlink:href="bmra-20200531.xsd#bmra_IncreaseDecreaseInDeferredRentLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncreaseDecreaseInDeferredRentLiability_lbl" xml:lang="en-US">Reduction (increase) in deferred rent liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseDecreaseInDeferredRentLiability" xlink:to="bmra_IncreaseDecreaseInDeferredRentLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US">Decrease in deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OperatingLeaseRightofUseAssetAmortization" xlink:href="bmra-20200531.xsd#bmra_OperatingLeaseRightofUseAssetAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OperatingLeaseRightofUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OperatingLeaseRightofUseAssetAmortization" xlink:to="bmra_OperatingLeaseRightofUseAssetAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20200531.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncreaseDecreaseInLeaseLiability_lbl" xml:lang="en-US">Reduction in lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseDecreaseInLeaseLiability" xlink:to="bmra_IncreaseDecreaseInLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Increase in intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ProceedsFromCommonStockSubscribed" xlink:href="bmra-20200531.xsd#bmra_ProceedsFromCommonStockSubscribed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ProceedsFromCommonStockSubscribed_lbl" xml:lang="en-US">Common stock subscribed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ProceedsFromCommonStockSubscribed" xlink:to="bmra_ProceedsFromCommonStockSubscribed_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from sale of convertible preferred stock, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sales of common stock, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_EstablishmentOfRightOfUseAsset" xlink:href="bmra-20200531.xsd#bmra_EstablishmentOfRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bmra_EstablishmentOfRightOfUseAsset_lbl" xml:lang="en-US">Establishment of Right-of-use asset per ASC 842</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EstablishmentOfRightOfUseAsset" xlink:to="bmra_EstablishmentOfRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_EstablishmentOfLeaseLiability" xlink:href="bmra-20200531.xsd#bmra_EstablishmentOfLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bmra_EstablishmentOfLeaseLiability_lbl" xml:lang="en-US">Establishment of Lease liability per ASC 842</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EstablishmentOfLeaseLiability" xlink:to="bmra_EstablishmentOfLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_InventoriesAbstract" xlink:href="bmra-20200531.xsd#bmra_InventoriesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_InventoriesAbstract_lbl" xml:lang="en-US">Inventories [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_InventoriesAbstract" xlink:to="bmra_InventoriesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished products</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ShareBasedCompensationAssumptionsAbstract" xlink:href="bmra-20200531.xsd#bmra_ShareBasedCompensationAssumptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ShareBasedCompensationAssumptionsAbstract_lbl" xml:lang="en-US">Share based compensation assumptions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ShareBasedCompensationAssumptionsAbstract" xlink:to="bmra_ShareBasedCompensationAssumptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RevenueFromContractsWithCustomersAbstract" xlink:href="bmra-20200531.xsd#bmra_RevenueFromContractsWithCustomersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RevenueFromContractsWithCustomersAbstract_lbl" xml:lang="en-US">Revenue from contracts with customers [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RevenueFromContractsWithCustomersAbstract" xlink:to="bmra_RevenueFromContractsWithCustomersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue From Customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IntangibleAssetsNetAbstract" xlink:href="bmra-20200531.xsd#bmra_IntangibleAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Intangible assets, net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IntangibleAssetsNetAbstract" xlink:to="bmra_IntangibleAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedLicenseAgreementsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross_lbl" xml:lang="en-US">Licenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xml:lang="en-US">Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:href="bmra-20200531.xsd#bmra_FiniteLivedLicenseAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl" xml:lang="en-US">Less accumulated amortization- licenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:to="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:href="bmra-20200531.xsd#bmra_FiniteLivedPatentsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl" xml:lang="en-US">Less accumulated amortization- patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:to="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:href="bmra-20200531.xsd#bmra_ExpectedAmortizationOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Expected amortization of intangible assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="bmra_ExpectedAmortizationOfIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:href="bmra-20200531.xsd#bmra_AccountsPayableAndAccruedExpenseBalancesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract_lbl" xml:lang="en-US">Accounts payable and accrued expense balances [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="bmra_AccountsPayableAndAccruedExpenseBalancesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OutstandingStockOptionsActivityAbstract" xlink:href="bmra-20200531.xsd#bmra_OutstandingStockOptionsActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OutstandingStockOptionsActivityAbstract_lbl" xml:lang="en-US">Outstanding Stock Options Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OutstandingStockOptionsActivityAbstract" xlink:to="bmra_OutstandingStockOptionsActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, number of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Options outstanding, number of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options outstanding, weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Options outstanding, weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted, number of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Granted, number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options granted, weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercised, weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Options canceled or expired, number of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options canceled or expired, weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_NonVestedStockOptionsActivityAbstract" xlink:href="bmra-20200531.xsd#bmra_NonVestedStockOptionsActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_NonVestedStockOptionsActivityAbstract_lbl" xml:lang="en-US">Non-vested Stock Options Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_NonVestedStockOptionsActivityAbstract" xlink:to="bmra_NonVestedStockOptionsActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Non-vested shares, number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Non-vested shares, number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Non-vested shares, weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Non-vested shares, weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted, weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Vested, number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested, weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Forfeited, number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited, weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_StockOptionsSummaryAbstract" xlink:href="bmra-20200531.xsd#bmra_StockOptionsSummaryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_StockOptionsSummaryAbstract_lbl" xml:lang="en-US">Stock Options Summary [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_StockOptionsSummaryAbstract" xlink:to="bmra_StockOptionsSummaryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of Exercise Price, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of Exercise Price, Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options Outstanding, Number (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options Outstanding, Weighted Average Remaining Contractual Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Options Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Options Exercisable, Number (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Options Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncomeTaxExpenseAbstract" xlink:href="bmra-20200531.xsd#bmra_IncomeTaxExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncomeTaxExpenseAbstract_lbl" xml:lang="en-US">Income tax expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncomeTaxExpenseAbstract" xlink:to="bmra_IncomeTaxExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign Taxes Subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State and local</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State and local</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncomeTaxRateReconciliationAbstract" xlink:href="bmra-20200531.xsd#bmra_IncomeTaxRateReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncomeTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Income Tax Rate Reconciliation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncomeTaxRateReconciliationAbstract" xlink:to="bmra_IncomeTaxRateReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Computed &quot;expected&quot; tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Permanent tax differences and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign taxes of subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAbstract" xlink:href="bmra-20200531.xsd#bmra_DeferredTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DeferredTaxAbstract_lbl" xml:lang="en-US">Deferred Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAbstract" xlink:to="bmra_DeferredTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Accounts receivable, principally due to allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US">Inventory valuation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xml:lang="en-US">Compensated absences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Tax credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xml:lang="en-US">Deferred rent expense/Capitalized leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:href="bmra-20200531.xsd#bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US">Accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:to="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureAbstract" xlink:href="bmra-20200531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GeographicInformationDisclosureAbstract_lbl" xml:lang="en-US">Geographic Information Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureAbstract" xlink:to="bmra_GeographicInformationDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationRegardingNetSalesAbstract" xlink:href="bmra-20200531.xsd#bmra_GeographicInformationRegardingNetSalesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GeographicInformationRegardingNetSalesAbstract_lbl" xml:lang="en-US">Geographic information regarding net sales [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationRegardingNetSalesAbstract" xlink:to="bmra_GeographicInformationRegardingNetSalesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="bmra-20200531.xsd#bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract_lbl" xml:lang="en-US">Supplemental cash flow information related to leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:href="bmra-20200531.xsd#bmra_TheMaturityOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TheMaturityOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">The maturity of lease liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="bmra_TheMaturityOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract" xlink:href="bmra-20200531.xsd#bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US">See accompanying notes to consolidated financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSE):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF COMMON AND COMMON EQUIVALENT SHARES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">OTHER COMPREHENSIVE LOSS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0" xlink:href="bmra-20200531.xsd#bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0_lbl" xml:lang="en-US">See accompanying notes to consolidated financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00" xlink:href="bmra-20200531.xsd#bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00_lbl" xml:lang="en-US">See accompanying notes to consolidated financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:href="bmra-20200531.xsd#bmra_SupplementalDisclosureOfCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_SupplementalDisclosureOfCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH-FLOW INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:to="bmra_SupplementalDisclosureOfCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_CashPaidDuringTheYearForAbstract" xlink:href="bmra-20200531.xsd#bmra_CashPaidDuringTheYearForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_CashPaidDuringTheYearForAbstract_lbl" xml:lang="en-US">Cash paid during the year for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CashPaidDuringTheYearForAbstract" xlink:to="bmra_CashPaidDuringTheYearForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash Investing and Financing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract" xlink:href="bmra-20200531.xsd#bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract_lbl" xml:lang="en-US">The accompanying notes are an integral part of these statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract" xlink:to="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20200531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_A5PercentConvertiblePreferredStockMember_lbl" xml:lang="en-US">5% Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A5PercentConvertiblePreferredStockMember" xlink:to="bmra_A5PercentConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SubscriptionsReceivableMember" xlink:href="bmra-20200531.xsd#bmra_SubscriptionsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_SubscriptionsReceivableMember_lbl" xml:lang="en-US">Subscriptions Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SubscriptionsReceivableMember" xlink:to="bmra_SubscriptionsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Current:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Deferred:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:href="bmra-20200531.xsd#bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl" xml:lang="en-US">Increase (reduction) in income taxes resulting from:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DeferredTaxAssetsAbstract" xlink:href="bmra-20200531.xsd#bmra_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="bmra_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureTextBlock" xlink:href="bmra-20200531.xsd#bmra_GeographicInformationDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_GeographicInformationDisclosureTextBlock_lbl" xml:lang="en-US">Geographic Information Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureTextBlock" xlink:to="bmra_GeographicInformationDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_NetSalesAbstract" xlink:href="bmra-20200531.xsd#bmra_NetSalesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_NetSalesAbstract_lbl" xml:lang="en-US">Net sales:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_NetSalesAbstract" xlink:to="bmra_NetSalesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:href="bmra-20200531.xsd#bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl" xml:lang="en-US">Schedule Of Cash Flow Supplemental Disclosures Related To Lease [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ClinicalLabMember" xlink:href="bmra-20200531.xsd#bmra_ClinicalLabMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ClinicalLabMember_lbl" xml:lang="en-US">Clinical Lab [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalLabMember" xlink:to="bmra_ClinicalLabMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OTCMember" xlink:href="bmra-20200531.xsd#bmra_OTCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_OTCMember_lbl" xml:lang="en-US">OTC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OTCMember" xlink:to="bmra_OTCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PhysiciansOfficeMember" xlink:href="bmra-20200531.xsd#bmra_PhysiciansOfficeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_PhysiciansOfficeMember_lbl" xml:lang="en-US">Physicians Office [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PhysiciansOfficeMember" xlink:to="bmra_PhysiciansOfficeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ContractManufacturingMember" xlink:href="bmra-20200531.xsd#bmra_ContractManufacturingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ContractManufacturingMember_lbl" xml:lang="en-US">Contract Manufacturing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ContractManufacturingMember" xlink:to="bmra_ContractManufacturingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare071390Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare071390Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare071390Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $0.71 - $3.90 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare071390Member" xlink:to="bmra_ExercisePriceRangePerShare071390Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare225362Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare225362Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare225362Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $2.25 - $3.62 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare225362Member" xlink:to="bmra_ExercisePriceRangePerShare225362Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare071104Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare071104Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare071104Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $0.71 - $1.04 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare071104Member" xlink:to="bmra_ExercisePriceRangePerShare071104Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare071362Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare071362Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare071362Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $0.71 - $3.62 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare071362Member" xlink:to="bmra_ExercisePriceRangePerShare071362Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082390Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare082390Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare082390Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $0.82 - $3.90 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082390Member" xlink:to="bmra_ExercisePriceRangePerShare082390Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare268818Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare268818Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare268818Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $2.68 - $8.18 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare268818Member" xlink:to="bmra_ExercisePriceRangePerShare268818Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare085818Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare085818Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare085818Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $0.85 - $8.18 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare085818Member" xlink:to="bmra_ExercisePriceRangePerShare085818Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ExercisePriceRangePerShare082818Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare082818Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ExercisePriceRangePerShare082818Member_lbl" xml:lang="en-US">Exercise Price Range Per Share $0.82 - $8.18 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082818Member" xlink:to="bmra_ExercisePriceRangePerShare082818Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice082104Member" xlink:href="bmra-20200531.xsd#bmra_RangeOfExercisePrice082104Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RangeOfExercisePrice082104Member_lbl" xml:lang="en-US">Range Of Exercise Price $0.82 - $1.04 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice082104Member" xlink:to="bmra_RangeOfExercisePrice082104Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice120281Member" xlink:href="bmra-20200531.xsd#bmra_RangeOfExercisePrice120281Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RangeOfExercisePrice120281Member_lbl" xml:lang="en-US">Range Of Exercise Price $1.20 - $2.81 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice120281Member" xlink:to="bmra_RangeOfExercisePrice120281Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RangeOfExercisePrice362818Member" xlink:href="bmra-20200531.xsd#bmra_RangeOfExercisePrice362818Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RangeOfExercisePrice362818Member_lbl" xml:lang="en-US">Range Of Exercise Price $3.62 - $8.18 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice362818Member" xlink:to="bmra_RangeOfExercisePrice362818Member_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US">Europe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_AsiaMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_AsiaMember_lbl" xml:lang="en-US">Asia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SouthAmericaMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SouthAmericaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SouthAmericaMember_lbl" xml:lang="en-US">South America [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SouthAmericaMember" xlink:to="srt_SouthAmericaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MiddleEastMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MiddleEastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MiddleEastMember_lbl" xml:lang="en-US">Middle East [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MiddleEastMember" xlink:to="us-gaap_MiddleEastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OtherForeignMember" xlink:href="bmra-20200531.xsd#bmra_OtherForeignMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_OtherForeignMember_lbl" xml:lang="en-US">Other Foreign [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OtherForeignMember" xlink:to="bmra_OtherForeignMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Accounting Standards Update [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_LeaseAmendmentAxis" xlink:href="bmra-20200531.xsd#bmra_LeaseAmendmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_LeaseAmendmentAxis_lbl" xml:lang="en-US">Lease Amendment [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LeaseAmendmentAxis" xlink:to="bmra_LeaseAmendmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US">Other Commitments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashUninsuredAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl" xml:lang="en-US">Other Receivables, Gross, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesGrossCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US">Inventory, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_lbl" xml:lang="en-US">Threshold Period Past Due for Write-off of Trade Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:to="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Inventory Valuation Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US">Conversion of Stock, Amount Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockDescription_lbl" xml:lang="en-US">Conversion of Stock, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xml:lang="en-US">Preferred Stock, Dividends Per Share, Declared (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Dividends, Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of Stock, Shares Issued (in Shares)</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMasDJzLBFPhcZ39E819xIH5B6s9+QqmUnZaYcTPdiZJQG4iHDdujDjCMFWAPlk1IXbu5qod0zXC71jDSSWZ68hzrssnC2jdQRCa5q9eJtkv9QaJcd41nHwUHMWfp/65+2O4=] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xml:lang="en-US">Operating Leases, Rent Expense, Minimum Rentals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RentalExpenseIncreaseDuringPeriod" xlink:href="bmra-20200531.xsd#bmra_RentalExpenseIncreaseDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RentalExpenseIncreaseDuringPeriod_lbl" xml:lang="en-US">Rental Expense, Increase During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RentalExpenseIncreaseDuringPeriod" xlink:to="bmra_RentalExpenseIncreaseDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseDepositLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseDepositLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseDepositLiability_lbl" xml:lang="en-US">Lease Deposit Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseDepositLiability" xlink:to="us-gaap_LeaseDepositLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_LeaseExpirationPeriod" xlink:href="bmra-20200531.xsd#bmra_LeaseExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_LeaseExpirationPeriod_lbl" xml:lang="en-US">Lease Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LeaseExpirationPeriod" xlink:to="bmra_LeaseExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RoyaltyExpensePercentageOfSales" xlink:href="bmra-20200531.xsd#bmra_RoyaltyExpensePercentageOfSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RoyaltyExpensePercentageOfSales_lbl" xml:lang="en-US">Royalty Expense Percentage Of Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyExpensePercentageOfSales" xlink:to="bmra_RoyaltyExpensePercentageOfSales_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedFeesAndOtherRevenueReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedFeesAndOtherRevenueReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedFeesAndOtherRevenueReceivable_lbl" xml:lang="en-US">Accrued Fees and Other Revenue Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedFeesAndOtherRevenueReceivable" xlink:to="us-gaap_AccruedFeesAndOtherRevenueReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Other (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromFeesReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromFeesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl" xml:lang="en-US">Proceeds from Fees Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RoyaltyPercentage" xlink:href="bmra-20200531.xsd#bmra_RoyaltyPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyPercentage" xlink:to="bmra_RoyaltyPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ContractTerm" xlink:href="bmra-20200531.xsd#bmra_ContractTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ContractTerm_lbl" xml:lang="en-US">Contract Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ContractTerm" xlink:to="bmra_ContractTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SuccessFeesPercentage" xlink:href="bmra-20200531.xsd#bmra_SuccessFeesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_SuccessFeesPercentage_lbl" xml:lang="en-US">Success Fees Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SuccessFeesPercentage" xlink:to="bmra_SuccessFeesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xml:lang="en-US">Related Party Transaction, Description of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_LicenseMaintenanceFee" xlink:href="bmra-20200531.xsd#bmra_LicenseMaintenanceFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_LicenseMaintenanceFee_lbl" xml:lang="en-US">License Maintenance Fee, Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LicenseMaintenanceFee" xlink:to="bmra_LicenseMaintenanceFee_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:href="bmra-20200531.xsd#bmra_ClinicalTrialAgreementMaximumBudgetedCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl" xml:lang="en-US">Clinical Trial Agreement Maximum Budgeted Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:to="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_BilledCommitmentPercentage" xlink:href="bmra-20200531.xsd#bmra_BilledCommitmentPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_BilledCommitmentPercentage_lbl" xml:lang="en-US">Billed Commitment, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BilledCommitmentPercentage" xlink:to="bmra_BilledCommitmentPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:href="bmra-20200531.xsd#bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl" xml:lang="en-US">Concentration Risk Geographic Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:to="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ThreeDistributorsMember" xlink:href="bmra-20200531.xsd#bmra_ThreeDistributorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ThreeDistributorsMember_lbl" xml:lang="en-US">Three Distributors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ThreeDistributorsMember" xlink:to="bmra_ThreeDistributorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TwoDistributorsMember" xlink:href="bmra-20200531.xsd#bmra_TwoDistributorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TwoDistributorsMember_lbl" xml:lang="en-US">Two Distributors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TwoDistributorsMember" xlink:to="bmra_TwoDistributorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OneDistributorsMember" xlink:href="bmra-20200531.xsd#bmra_OneDistributorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_OneDistributorsMember_lbl" xml:lang="en-US">One Distributors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OneDistributorsMember" xlink:to="bmra_OneDistributorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DistributorsInEcuadorMember" xlink:href="bmra-20200531.xsd#bmra_DistributorsInEcuadorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_DistributorsInEcuadorMember_lbl" xml:lang="en-US">Distributors in Ecuador [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DistributorsInEcuadorMember" xlink:to="bmra_DistributorsInEcuadorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsProductLineMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsProductLineMember_lbl" xml:lang="en-US">Cost of Goods and Service, Product and Service Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsProductLineMember" xlink:to="us-gaap_CostOfGoodsProductLineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MX"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_MX_lbl" xml:lang="en-US">MEXICO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MX" xlink:to="country_MX_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DistributionRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DistributionRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DistributionRightsMember_lbl" xml:lang="en-US">Distribution Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DistributionRightsMember" xlink:to="us-gaap_DistributionRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PurchasedTechnologyRightsMember" xlink:href="bmra-20200531.xsd#bmra_PurchasedTechnologyRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_PurchasedTechnologyRightsMember_lbl" xml:lang="en-US">Purchased Technology Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PurchasedTechnologyRightsMember" xlink:to="bmra_PurchasedTechnologyRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US">Accounts Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TwoVendorsMember" xlink:href="bmra-20200531.xsd#bmra_TwoVendorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TwoVendorsMember_lbl" xml:lang="en-US">Two Vendors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TwoVendorsMember" xlink:to="bmra_TwoVendorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OneVendorMember" xlink:href="bmra-20200531.xsd#bmra_OneVendorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_OneVendorMember_lbl" xml:lang="en-US">One Vendor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OneVendorMember" xlink:to="bmra_OneVendorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_A2010PlanMember" xlink:href="bmra-20200531.xsd#bmra_A2010PlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_A2010PlanMember_lbl" xml:lang="en-US">2010 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2010PlanMember" xlink:to="bmra_A2010PlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_A2014PlanMember" xlink:href="bmra-20200531.xsd#bmra_A2014PlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_A2014PlanMember_lbl" xml:lang="en-US">2014 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2014PlanMember" xlink:to="bmra_A2014PlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_A2017PlanMember" xlink:href="bmra-20200531.xsd#bmra_A2017PlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_A2017PlanMember_lbl" xml:lang="en-US">2017 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2017PlanMember" xlink:to="bmra_A2017PlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_A2020PlanMember" xlink:href="bmra-20200531.xsd#bmra_A2020PlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_A2020PlanMember_lbl" xml:lang="en-US">2020 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2020PlanMember" xlink:to="bmra_A2020PlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US">Selling and Marketing Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_AtMarketIssuanceSalesAgreementMember" xlink:href="bmra-20200531.xsd#bmra_AtMarketIssuanceSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_AtMarketIssuanceSalesAgreementMember_lbl" xml:lang="en-US">At Market Issuance Sales Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_AtMarketIssuanceSalesAgreementMember" xlink:to="bmra_AtMarketIssuanceSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RegistrationRightsAgreementMember" xlink:href="bmra-20200531.xsd#bmra_RegistrationRightsAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RegistrationRightsAgreementMember_lbl" xml:lang="en-US">Registration Rights Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RegistrationRightsAgreementMember" xlink:to="bmra_RegistrationRightsAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_CaliforniaStateIncomeTaxMember" xlink:href="bmra-20200531.xsd#bmra_CaliforniaStateIncomeTaxMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_CaliforniaStateIncomeTaxMember_lbl" xml:lang="en-US">California State Income Tax [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CaliforniaStateIncomeTaxMember" xlink:to="bmra_CaliforniaStateIncomeTaxMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_FirstAmendmentToLeaseMember" xlink:href="bmra-20200531.xsd#bmra_FirstAmendmentToLeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_FirstAmendmentToLeaseMember_lbl" xml:lang="en-US">First Amendment To Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FirstAmendmentToLeaseMember" xlink:to="bmra_FirstAmendmentToLeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_BuildingInIrvineCaliforniaMember" xlink:href="bmra-20200531.xsd#bmra_BuildingInIrvineCaliforniaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_BuildingInIrvineCaliforniaMember_lbl" xml:lang="en-US">Building In Irvine California [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BuildingInIrvineCaliforniaMember" xlink:to="bmra_BuildingInIrvineCaliforniaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyAvailableForOperatingLeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl" xml:lang="en-US">Property Available for Operating Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyAgreementsMember_lbl" xml:lang="en-US">Royalty Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementsMember" xlink:to="us-gaap_RoyaltyAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TelconAgreementMember" xlink:href="bmra-20200531.xsd#bmra_TelconAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TelconAgreementMember_lbl" xml:lang="en-US">Telcon Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TelconAgreementMember" xlink:to="bmra_TelconAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_EZDetectProductMember" xlink:href="bmra-20200531.xsd#bmra_EZDetectProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_EZDetectProductMember_lbl" xml:lang="en-US">EZ Detect Product [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EZDetectProductMember" xlink:to="bmra_EZDetectProductMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_MaxHealthMember" xlink:href="bmra-20200531.xsd#bmra_MaxHealthMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_MaxHealthMember_lbl" xml:lang="en-US">MaxHealth [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MaxHealthMember" xlink:to="bmra_MaxHealthMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_MountSinaiLicenseAgreementsMember" xlink:href="bmra-20200531.xsd#bmra_MountSinaiLicenseAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_MountSinaiLicenseAgreementsMember_lbl" xml:lang="en-US">Mount Sinai License Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MountSinaiLicenseAgreementsMember" xlink:to="bmra_MountSinaiLicenseAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UCLicenseAgreementsMember" xlink:href="bmra-20200531.xsd#bmra_UCLicenseAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UCLicenseAgreementsMember_lbl" xml:lang="en-US">UC License Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UCLicenseAgreementsMember" xlink:to="bmra_UCLicenseAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_NonexclusiveDistributorAgreementMember" xlink:href="bmra-20200531.xsd#bmra_NonexclusiveDistributorAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_NonexclusiveDistributorAgreementMember_lbl" xml:lang="en-US">Non-exclusive Distributor Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_NonexclusiveDistributorAgreementMember" xlink:to="bmra_NonexclusiveDistributorAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOfSouthernCaliforniaMember" xlink:href="bmra-20200531.xsd#bmra_UniversityOfSouthernCaliforniaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UniversityOfSouthernCaliforniaMember_lbl" xml:lang="en-US">University Of Southern California [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOfSouthernCaliforniaMember" xlink:to="bmra_UniversityOfSouthernCaliforniaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOFMichiganMember" xlink:href="bmra-20200531.xsd#bmra_UniversityOFMichiganMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UniversityOFMichiganMember_lbl" xml:lang="en-US">University OF Michigan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOFMichiganMember" xlink:to="bmra_UniversityOFMichiganMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_DeaconessMedicalCenterMember" xlink:href="bmra-20200531.xsd#bmra_DeaconessMedicalCenterMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_DeaconessMedicalCenterMember_lbl" xml:lang="en-US">Deaconess Medical Center [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeaconessMedicalCenterMember" xlink:to="bmra_DeaconessMedicalCenterMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ResearchManagementInstitutionMember" xlink:href="bmra-20200531.xsd#bmra_ResearchManagementInstitutionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ResearchManagementInstitutionMember_lbl" xml:lang="en-US">Research Management Institution [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ResearchManagementInstitutionMember" xlink:to="bmra_ResearchManagementInstitutionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_BiomericaInfoodsProductMember" xlink:href="bmra-20200531.xsd#bmra_BiomericaInfoodsProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_BiomericaInfoodsProductMember_lbl" xml:lang="en-US">Biomerica Infoods Product [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BiomericaInfoodsProductMember" xlink:to="bmra_BiomericaInfoodsProductMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_BiomericaInfoodsIBSProductMember" xlink:href="bmra-20200531.xsd#bmra_BiomericaInfoodsIBSProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_BiomericaInfoodsIBSProductMember_lbl" xml:lang="en-US">Biomerica Infoods IBS Product [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BiomericaInfoodsIBSProductMember" xlink:to="bmra_BiomericaInfoodsIBSProductMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_BiomericaHPyloriProductMember" xlink:href="bmra-20200531.xsd#bmra_BiomericaHPyloriProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_BiomericaHPyloriProductMember_lbl" xml:lang="en-US">Biomerica H. Pylori Product [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BiomericaHPyloriProductMember" xlink:to="bmra_BiomericaHPyloriProductMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_HoustonMethodistResearchInstituteMember" xlink:href="bmra-20200531.xsd#bmra_HoustonMethodistResearchInstituteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_HoustonMethodistResearchInstituteMember_lbl" xml:lang="en-US">Houston Methodist Research Institute [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_HoustonMethodistResearchInstituteMember" xlink:to="bmra_HoustonMethodistResearchInstituteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_MayoClinicArizonaMember" xlink:href="bmra-20200531.xsd#bmra_MayoClinicArizonaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_MayoClinicArizonaMember_lbl" xml:lang="en-US">Mayo Clinic Arizona [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MayoClinicArizonaMember" xlink:to="bmra_MayoClinicArizonaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_MayoClinicJacksonvilleMember" xlink:href="bmra-20200531.xsd#bmra_MayoClinicJacksonvilleMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_MayoClinicJacksonvilleMember_lbl" xml:lang="en-US">Mayo Clinic Jacksonville [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MayoClinicJacksonvilleMember" xlink:to="bmra_MayoClinicJacksonvilleMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_EmployeesMember" xlink:href="bmra-20200531.xsd#bmra_EmployeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EmployeesMember" xlink:to="bmra_EmployeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_EmployeesAndConsultantsMember" xlink:href="bmra-20200531.xsd#bmra_EmployeesAndConsultantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_EmployeesAndConsultantsMember_lbl" xml:lang="en-US">Employees and Consultants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EmployeesAndConsultantsMember" xlink:to="bmra_EmployeesAndConsultantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ConsultantMember" xlink:href="bmra-20200531.xsd#bmra_ConsultantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ConsultantMember" xlink:to="bmra_ConsultantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UniversityOfTexasHealthScienceCenterMember" xlink:href="bmra-20200531.xsd#bmra_UniversityOfTexasHealthScienceCenterMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UniversityOfTexasHealthScienceCenterMember_lbl" xml:lang="en-US">University Of Texas Health Science Center [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOfTexasHealthScienceCenterMember" xlink:to="bmra_UniversityOfTexasHealthScienceCenterMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_EmployeeAndBoardMemberMember" xlink:href="bmra-20200531.xsd#bmra_EmployeeAndBoardMemberMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_EmployeeAndBoardMemberMember_lbl" xml:lang="en-US">Employee and Board Member [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EmployeeAndBoardMemberMember" xlink:to="bmra_EmployeeAndBoardMemberMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_lbl" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:href="bmra-20200531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:href="bmra-20200531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:href="bmra-20200531.xsd#bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) - Outstanding Stock Options Activity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:href="bmra-20200531.xsd#bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:href="bmra-20200531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable_lbl" xml:lang="en-US">GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:href="bmra-20200531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems_lbl" xml:lang="en-US">GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Accounting Standards Update [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:href="bmra-20200531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:href="bmra-20200531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:to="bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:href="bmra-20200531.xsd#bmra_SHAREHOLDERSEQUITYDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsTable_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_SHAREHOLDERSEQUITYDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsLineItems_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_INCOMETAXESDetailsTable" xlink:href="bmra-20200531.xsd#bmra_INCOMETAXESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_INCOMETAXESDetailsTable_lbl" xml:lang="en-US">INCOME TAXES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_INCOMETAXESDetailsTable" xlink:to="bmra_INCOMETAXESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_INCOMETAXESDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_INCOMETAXESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_INCOMETAXESDetailsLineItems_lbl" xml:lang="en-US">INCOME TAXES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_INCOMETAXESDetailsLineItems" xlink:to="bmra_INCOMETAXESDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:href="bmra-20200531.xsd#bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_lbl" xml:lang="en-US">PropertySubjectToOrAvailableForOperatingLease_ [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:to="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_LeaseAmendmentDomain" xlink:href="bmra-20200531.xsd#bmra_LeaseAmendmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_LeaseAmendmentDomain_lbl" xml:lang="en-US">LeaseAmendment [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LeaseAmendmentDomain" xlink:to="bmra_LeaseAmendmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US">Other Commitments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:href="bmra-20200531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="bmra_COMMITMENTSANDCONTINGENCIESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:href="bmra-20200531.xsd#bmra_SUBSEQUENTEVENTSDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUBSEQUENTEVENTSDetailsTable_lbl" xml:lang="en-US">SUBSEQUENT EVENTS (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUBSEQUENTEVENTSDetailsTable" xlink:to="bmra_SUBSEQUENTEVENTSDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_SUBSEQUENTEVENTSDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SUBSEQUENTEVENTSDetailsLineItems_lbl" xml:lang="en-US">SUBSEQUENT EVENTS (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="bmra_SUBSEQUENTEVENTSDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable_lbl0" xml:lang="en-US">Amount of stock subscription receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable" xlink:to="bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_BilledCommitmentPercentage_lbl0" xml:lang="en-US">Percentage of the commitment billed during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BilledCommitmentPercentage" xlink:to="bmra_BilledCommitmentPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl0" xml:lang="en-US">The maximum budgeted costs related to clinical trial agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:to="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for the description of risks that arise due to concentrations of operating facilities, revenues, assets, customers, vendors or the like in a certain geographic area, either domestic or foreign. The description may address risks inherent in the geographic area, and, at a minimum, informs users of the general nature of the risk, but excludes &quot;Information about Geographic Areas&quot; that may be disclosed elsewhere.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:to="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_ContractTerm_lbl0" xml:lang="en-US">Period of the contract in which it expires.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ContractTerm" xlink:to="bmra_ContractTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accumulated depreciation and amortization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:to="bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_EquipmentGross_lbl0" xml:lang="en-US">Gross amount, as of the balance sheet date, of long-lived, depreciable equipment used in the production process to produce goods and services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EquipmentGross" xlink:to="bmra_EquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_EstablishmentOfLeaseLiability_lbl0" xml:lang="en-US">The increase (decrease) during the reporting period in Establishment Of Lease Liability Per ASC 842</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EstablishmentOfLeaseLiability" xlink:to="bmra_EstablishmentOfLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_EstablishmentOfRightOfUseAsset_lbl0" xml:lang="en-US">The increase (decrease) during the reporting period in Establishment Of Right Of Use Asset Per ASC 842</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EstablishmentOfRightOfUseAsset" xlink:to="bmra_EstablishmentOfRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl0" xml:lang="en-US">Accumulated amount of amortization of licenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:to="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl0" xml:lang="en-US">Accumulated amount of amortization of patents.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:to="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_FurnitureFixturesAndLeaseholdImprovementsGross_lbl0" xml:lang="en-US">Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases and of additions or improvements to assets held under a lease arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FurnitureFixturesAndLeaseholdImprovementsGross" xlink:to="bmra_FurnitureFixturesAndLeaseholdImprovementsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_GeographicInformationDisclosureTextBlock_lbl0" xml:lang="en-US">The entire disclosure for reporting segments according to the geographic areas.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureTextBlock" xlink:to="bmra_GeographicInformationDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_IncreaseDecreaseInDeferredRentLiability_lbl0" xml:lang="en-US">The increase (decrease) during the period in the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseDecreaseInDeferredRentLiability" xlink:to="bmra_IncreaseDecreaseInDeferredRentLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_IncreaseDecreaseInLeaseLiability_lbl0" xml:lang="en-US">The increase (decrease) during the reporting period in LeaseLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseDecreaseInLeaseLiability" xlink:to="bmra_IncreaseDecreaseInLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_LeaseExpirationPeriod_lbl0" xml:lang="en-US">Represents the number of years in which the lease expires.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LeaseExpirationPeriod" xlink:to="bmra_LeaseExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_LicenseMaintenanceFee_lbl0" xml:lang="en-US">Amount of license maintenance fee payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LicenseMaintenanceFee" xlink:to="bmra_LicenseMaintenanceFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_OperatingLeaseRightofUseAssetAmortization_lbl0" xml:lang="en-US">Amortization of Right of Use Asset for Operating Lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OperatingLeaseRightofUseAssetAmortization" xlink:to="bmra_OperatingLeaseRightofUseAssetAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_PreferredStockUndesignatedShares_lbl0" xml:lang="en-US">Number of preferred shares undesignated during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PreferredStockUndesignatedShares" xlink:to="bmra_PreferredStockUndesignatedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_ProceedsFromCommonStockSubscribed_lbl0" xml:lang="en-US">The cash inflow from the common stock subscription.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ProceedsFromCommonStockSubscribed" xlink:to="bmra_ProceedsFromCommonStockSubscribed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_RentalExpenseIncreaseDuringPeriod_lbl0" xml:lang="en-US">Amount of rental expense increase during the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RentalExpenseIncreaseDuringPeriod" xlink:to="bmra_RentalExpenseIncreaseDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_RoyaltyExpensePercentageOfSales_lbl0" xml:lang="en-US">Royalty expenses expressed as a percentage of sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyExpensePercentageOfSales" xlink:to="bmra_RoyaltyExpensePercentageOfSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_RoyaltyPercentage_lbl0" xml:lang="en-US">Percentage of royalty to be received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyPercentage" xlink:to="bmra_RoyaltyPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of supplemental cash flow information related to lease for the periods.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_StockIssuedDuringPeriodSharesPreferredStock_lbl0" xml:lang="en-US">Number of preferred stock issued during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_StockIssuedDuringPeriodSharesPreferredStock" xlink:to="bmra_StockIssuedDuringPeriodSharesPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_StockIssuedDuringPeriodValuePreferredStock_lbl0" xml:lang="en-US">Equity impact of the value of preferred stock issued during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_StockIssuedDuringPeriodValuePreferredStock" xlink:to="bmra_StockIssuedDuringPeriodValuePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_SuccessFeesPercentage_lbl0" xml:lang="en-US">Percentage of success related to the contract.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SuccessFeesPercentage" xlink:to="bmra_SuccessFeesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UniversityOFMichiganMember_lbl0" xml:lang="en-US">UniversityOFMichiganMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOFMichiganMember" xlink:to="bmra_UniversityOFMichiganMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_CashPaidDuringTheYearForAbstract_lbl0" xml:lang="en-US">CashPaidDuringTheYearForAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CashPaidDuringTheYearForAbstract" xlink:to="bmra_CashPaidDuringTheYearForAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare268818Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare268818Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare268818Member" xlink:to="bmra_ExercisePriceRangePerShare268818Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ContractTerm_lbl1" xml:lang="en-US">ContractTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ContractTerm" xlink:to="bmra_ContractTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_FirstAmendmentToLeaseMember_lbl0" xml:lang="en-US">FirstAmendmentToLeaseMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FirstAmendmentToLeaseMember" xlink:to="bmra_FirstAmendmentToLeaseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">DeferredTaxAssetsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeferredTaxAssetsAbstract" xlink:to="bmra_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OtherForeignMember_lbl0" xml:lang="en-US">OtherForeignMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OtherForeignMember" xlink:to="bmra_OtherForeignMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ConsultantMember_lbl0" xml:lang="en-US">ConsultantMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ConsultantMember" xlink:to="bmra_ConsultantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_LicenseMaintenanceFee_lbl1" xml:lang="en-US">LicenseMaintenanceFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LicenseMaintenanceFee" xlink:to="bmra_LicenseMaintenanceFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_EmployeesAndConsultantsMember_lbl0" xml:lang="en-US">EmployeesAndConsultantsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EmployeesAndConsultantsMember" xlink:to="bmra_EmployeesAndConsultantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_EZDetectProductMember_lbl0" xml:lang="en-US">EZDetectProductMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EZDetectProductMember" xlink:to="bmra_EZDetectProductMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RangeOfExercisePrice082104Member_lbl0" xml:lang="en-US">RangeOfExercisePrice082104Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice082104Member" xlink:to="bmra_RangeOfExercisePrice082104Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UCLicenseAgreementsMember_lbl0" xml:lang="en-US">UCLicenseAgreementsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UCLicenseAgreementsMember" xlink:to="bmra_UCLicenseAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_BiomericaInfoodsIBSProductMember_lbl0" xml:lang="en-US">BiomericaInfoodsIBSProductMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BiomericaInfoodsIBSProductMember" xlink:to="bmra_BiomericaInfoodsIBSProductMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RoyaltyExpensePercentageOfSales_lbl1" xml:lang="en-US">RoyaltyExpensePercentageOfSales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyExpensePercentageOfSales" xlink:to="bmra_RoyaltyExpensePercentageOfSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ContractManufacturingMember_lbl0" xml:lang="en-US">ContractManufacturingMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ContractManufacturingMember" xlink:to="bmra_ContractManufacturingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SupplementalDisclosureOfCashFlowInformationAbstract_lbl0" xml:lang="en-US">SupplementalDisclosureOfCashFlowInformationAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:to="bmra_SupplementalDisclosureOfCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PurchasedTechnologyRightsMember_lbl0" xml:lang="en-US">PurchasedTechnologyRightsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PurchasedTechnologyRightsMember" xlink:to="bmra_PurchasedTechnologyRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_EmployeeAndBoardMemberMember_lbl0" xml:lang="en-US">EmployeeAndBoardMemberMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EmployeeAndBoardMemberMember" xlink:to="bmra_EmployeeAndBoardMemberMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OneDistributorsMember_lbl0" xml:lang="en-US">OneDistributorsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OneDistributorsMember" xlink:to="bmra_OneDistributorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl1" xml:lang="en-US">FiniteLivedPatentsAccumulatedAmortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedPatentsAccumulatedAmortization" xlink:to="bmra_FiniteLivedPatentsAccumulatedAmortization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SubscriptionsReceivableMember_lbl0" xml:lang="en-US">SubscriptionsReceivableMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SubscriptionsReceivableMember" xlink:to="bmra_SubscriptionsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_A2020PlanMember_lbl0" xml:lang="en-US">A2020PlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2020PlanMember" xlink:to="bmra_A2020PlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_A2014PlanMember_lbl0" xml:lang="en-US">A2014PlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2014PlanMember" xlink:to="bmra_A2014PlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_A5PercentConvertiblePreferredStockMember_lbl0" xml:lang="en-US">A5PercentConvertiblePreferredStockMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A5PercentConvertiblePreferredStockMember" xlink:to="bmra_A5PercentConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_EstablishmentOfLeaseLiability_lbl1" xml:lang="en-US">EstablishmentOfLeaseLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EstablishmentOfLeaseLiability" xlink:to="bmra_EstablishmentOfLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0_lbl0" xml:lang="en-US">SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ThreeDistributorsMember_lbl0" xml:lang="en-US">ThreeDistributorsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ThreeDistributorsMember" xlink:to="bmra_ThreeDistributorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_LeaseAmendmentAxis_lbl0" xml:lang="en-US">LeaseAmendmentAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LeaseAmendmentAxis" xlink:to="bmra_LeaseAmendmentAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_AtMarketIssuanceSalesAgreementMember_lbl0" xml:lang="en-US">AtMarketIssuanceSalesAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_AtMarketIssuanceSalesAgreementMember" xlink:to="bmra_AtMarketIssuanceSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GeographicInformationDisclosureTextBlock_lbl1" xml:lang="en-US">GeographicInformationDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureTextBlock" xlink:to="bmra_GeographicInformationDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare071390Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare071390Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare071390Member" xlink:to="bmra_ExercisePriceRangePerShare071390Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_NonexclusiveDistributorAgreementMember_lbl0" xml:lang="en-US">NonexclusiveDistributorAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_NonexclusiveDistributorAgreementMember" xlink:to="bmra_NonexclusiveDistributorAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare071362Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare071362Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare071362Member" xlink:to="bmra_ExercisePriceRangePerShare071362Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare082390Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare082390Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082390Member" xlink:to="bmra_ExercisePriceRangePerShare082390Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PhysiciansOfficeMember_lbl0" xml:lang="en-US">PhysiciansOfficeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PhysiciansOfficeMember" xlink:to="bmra_PhysiciansOfficeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_EstablishmentOfRightOfUseAsset_lbl1" xml:lang="en-US">EstablishmentOfRightOfUseAsset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EstablishmentOfRightOfUseAsset" xlink:to="bmra_EstablishmentOfRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_MayoClinicArizonaMember_lbl0" xml:lang="en-US">MayoClinicArizonaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MayoClinicArizonaMember" xlink:to="bmra_MayoClinicArizonaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00_lbl0" xml:lang="en-US">SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract00_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RoyaltyPercentage_lbl1" xml:lang="en-US">RoyaltyPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RoyaltyPercentage" xlink:to="bmra_RoyaltyPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TwoVendorsMember_lbl0" xml:lang="en-US">TwoVendorsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TwoVendorsMember" xlink:to="bmra_TwoVendorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_BiomericaHPyloriProductMember_lbl0" xml:lang="en-US">BiomericaHPyloriProductMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BiomericaHPyloriProductMember" xlink:to="bmra_BiomericaHPyloriProductMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_StockIssuedDuringPeriodSharesPreferredStock_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesPreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_StockIssuedDuringPeriodSharesPreferredStock" xlink:to="bmra_StockIssuedDuringPeriodSharesPreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ClinicalLabMember_lbl0" xml:lang="en-US">ClinicalLabMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalLabMember" xlink:to="bmra_ClinicalLabMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OneVendorMember_lbl0" xml:lang="en-US">OneVendorMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OneVendorMember" xlink:to="bmra_OneVendorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_A2017PlanMember_lbl0" xml:lang="en-US">A2017PlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2017PlanMember" xlink:to="bmra_A2017PlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare082818Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare082818Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare082818Member" xlink:to="bmra_ExercisePriceRangePerShare082818Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TelconAgreementMember_lbl0" xml:lang="en-US">TelconAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TelconAgreementMember" xlink:to="bmra_TelconAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_CaliforniaStateIncomeTaxMember_lbl0" xml:lang="en-US">CaliforniaStateIncomeTaxMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CaliforniaStateIncomeTaxMember" xlink:to="bmra_CaliforniaStateIncomeTaxMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare085818Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare085818Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare085818Member" xlink:to="bmra_ExercisePriceRangePerShare085818Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare225362Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare225362Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare225362Member" xlink:to="bmra_ExercisePriceRangePerShare225362Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_A2010PlanMember_lbl0" xml:lang="en-US">A2010PlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_A2010PlanMember" xlink:to="bmra_A2010PlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OTCMember_lbl0" xml:lang="en-US">OTCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OTCMember" xlink:to="bmra_OTCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ResearchManagementInstitutionMember_lbl0" xml:lang="en-US">ResearchManagementInstitutionMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ResearchManagementInstitutionMember" xlink:to="bmra_ResearchManagementInstitutionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_BiomericaInfoodsProductMember_lbl0" xml:lang="en-US">BiomericaInfoodsProductMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BiomericaInfoodsProductMember" xlink:to="bmra_BiomericaInfoodsProductMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl1" xml:lang="en-US">ConcentrationRiskGeographicPolicyPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:to="bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UniversityOfTexasHealthScienceCenterMember_lbl0" xml:lang="en-US">UniversityOfTexasHealthScienceCenterMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOfTexasHealthScienceCenterMember" xlink:to="bmra_UniversityOfTexasHealthScienceCenterMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl0" xml:lang="en-US">IncreaseReductionInIncomeTaxesResultingFromAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ExercisePriceRangePerShare071104Member_lbl0" xml:lang="en-US">ExercisePriceRangePerShare071104Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ExercisePriceRangePerShare071104Member" xlink:to="bmra_ExercisePriceRangePerShare071104Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RangeOfExercisePrice120281Member_lbl0" xml:lang="en-US">RangeOfExercisePrice120281Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice120281Member" xlink:to="bmra_RangeOfExercisePrice120281Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SuccessFeesPercentage_lbl1" xml:lang="en-US">SuccessFeesPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SuccessFeesPercentage" xlink:to="bmra_SuccessFeesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_LeaseExpirationPeriod_lbl1" xml:lang="en-US">LeaseExpirationPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LeaseExpirationPeriod" xlink:to="bmra_LeaseExpirationPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DistributorsInEcuadorMember_lbl0" xml:lang="en-US">DistributorsInEcuadorMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DistributorsInEcuadorMember" xlink:to="bmra_DistributorsInEcuadorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_BilledCommitmentPercentage_lbl1" xml:lang="en-US">BilledCommitmentPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BilledCommitmentPercentage" xlink:to="bmra_BilledCommitmentPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl1" xml:lang="en-US">ClinicalTrialAgreementMaximumBudgetedCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalTrialAgreementMaximumBudgetedCosts" xlink:to="bmra_ClinicalTrialAgreementMaximumBudgetedCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RegistrationRightsAgreementMember_lbl0" xml:lang="en-US">RegistrationRightsAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RegistrationRightsAgreementMember" xlink:to="bmra_RegistrationRightsAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract_lbl0" xml:lang="en-US">SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract" xlink:to="bmra_SeeAccompanyingNotesToConsolidatedFinancialStatementsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_EmployeesMember_lbl0" xml:lang="en-US">EmployeesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_EmployeesMember" xlink:to="bmra_EmployeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RentalExpenseIncreaseDuringPeriod_lbl1" xml:lang="en-US">RentalExpenseIncreaseDuringPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RentalExpenseIncreaseDuringPeriod" xlink:to="bmra_RentalExpenseIncreaseDuringPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_MountSinaiLicenseAgreementsMember_lbl0" xml:lang="en-US">MountSinaiLicenseAgreementsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MountSinaiLicenseAgreementsMember" xlink:to="bmra_MountSinaiLicenseAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RangeOfExercisePrice362818Member_lbl0" xml:lang="en-US">RangeOfExercisePrice362818Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RangeOfExercisePrice362818Member" xlink:to="bmra_RangeOfExercisePrice362818Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_DeaconessMedicalCenterMember_lbl0" xml:lang="en-US">DeaconessMedicalCenterMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_DeaconessMedicalCenterMember" xlink:to="bmra_DeaconessMedicalCenterMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl1" xml:lang="en-US">FiniteLivedLicenseAccumulatedAmortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_FiniteLivedLicenseAccumulatedAmortization" xlink:to="bmra_FiniteLivedLicenseAccumulatedAmortization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_HoustonMethodistResearchInstituteMember_lbl0" xml:lang="en-US">HoustonMethodistResearchInstituteMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_HoustonMethodistResearchInstituteMember" xlink:to="bmra_HoustonMethodistResearchInstituteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_MayoClinicJacksonvilleMember_lbl0" xml:lang="en-US">MayoClinicJacksonvilleMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MayoClinicJacksonvilleMember" xlink:to="bmra_MayoClinicJacksonvilleMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract_lbl0" xml:lang="en-US">TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract" xlink:to="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_MaxHealthMember_lbl0" xml:lang="en-US">MaxHealthMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MaxHealthMember" xlink:to="bmra_MaxHealthMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UniversityOfSouthernCaliforniaMember_lbl0" xml:lang="en-US">UniversityOfSouthernCaliforniaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UniversityOfSouthernCaliforniaMember" xlink:to="bmra_UniversityOfSouthernCaliforniaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_BuildingInIrvineCaliforniaMember_lbl0" xml:lang="en-US">BuildingInIrvineCaliforniaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BuildingInIrvineCaliforniaMember" xlink:to="bmra_BuildingInIrvineCaliforniaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_NetSalesAbstract_lbl0" xml:lang="en-US">NetSalesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_NetSalesAbstract" xlink:to="bmra_NetSalesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TwoDistributorsMember_lbl0" xml:lang="en-US">TwoDistributorsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TwoDistributorsMember" xlink:to="bmra_TwoDistributorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl0" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl0" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DistributionRightsMember_lbl0" xml:lang="en-US">Distribution Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DistributionRightsMember" xlink:to="us-gaap_DistributionRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsProductLineMember_lbl0" xml:lang="en-US">Cost of Goods and Service, Product and Service Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsProductLineMember" xlink:to="us-gaap_CostOfGoodsProductLineMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl0" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl0" xml:lang="en-US">Royalty Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl0" xml:lang="en-US">Selling and Marketing Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl0" xml:lang="en-US">Cash, Uninsured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl0" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl0" xml:lang="en-US">Europe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MiddleEastMember_lbl0" xml:lang="en-US">Middle East [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MiddleEastMember" xlink:to="us-gaap_MiddleEastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl1" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl0" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_lbl0" xml:lang="en-US">Preferred Stock, Dividends Per Share, Declared</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SouthAmericaMember_lbl0" xml:lang="en-US">South America [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SouthAmericaMember" xlink:to="srt_SouthAmericaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl0" xml:lang="en-US">Lease Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockDescription_lbl0" xml:lang="en-US">Conversion of Stock, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl0" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl0" xml:lang="en-US">Property Available for Operating Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl0" xml:lang="en-US">Advertising Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl0" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl0" xml:lang="en-US">Accounts Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl0" xml:lang="en-US">Other Receivables, Gross, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesGrossCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl3" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_lbl0" xml:lang="en-US">Threshold Period Past Due for Write-off of Trade Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:to="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl0" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl0" xml:lang="en-US">Proceeds from Fees Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl0" xml:lang="en-US">Dividends, Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Description of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AsiaMember_lbl0" xml:lang="en-US">Asia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl0" xml:lang="en-US">Operating Leases, Rent Expense, Minimum Rentals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_MX_lbl0" xml:lang="en-US">MEXICO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MX" xlink:to="country_MX_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl0" xml:lang="en-US">Inventory Valuation Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl0" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedFeesAndOtherRevenueReceivable_lbl0" xml:lang="en-US">Accrued Fees and Other Revenue Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedFeesAndOtherRevenueReceivable" xlink:to="us-gaap_AccruedFeesAndOtherRevenueReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl0" xml:lang="en-US">Inventory, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyAgreementsMember_lbl0" xml:lang="en-US">Royalty Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementsMember" xlink:to="us-gaap_RoyaltyAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl0" xml:lang="en-US">Other Nonoperating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl0" xml:lang="en-US">Cost of Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Amount Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseDepositLiability_lbl0" xml:lang="en-US">Lease Deposit Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseDepositLiability" xlink:to="us-gaap_LeaseDepositLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl0" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl0" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl0" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>bmra-20200531_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Aug 31 13:38:24 EDT 2020 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ConsolidatedBalanceSheet" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ConsolidatedIncomeStatement" roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ShareholdersEquityType2or3" roleURI="http://www.biomerica.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ConsolidatedCashFlow" roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ORGANIZATION" roleURI="http://www.biomerica.com/role/ORGANIZATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_INTANGIBLEASSETSNET" roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNET"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSES" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SHAREHOLDERSEQUITY" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_INCOMETAXES" roleURI="http://www.biomerica.com/role/INCOMETAXES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_GEOGRAPHICINFORMATION" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIES" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SUBSEQUENTEVENTS" roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_AccountingPoliciesByPolicy" roleURI="http://www.biomerica.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_INTANGIBLEASSETSNETTables" roleURI="http://www.biomerica.com/role/INTANGIBLEASSETSNETTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SHAREHOLDERSEQUITYTables" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_INCOMETAXESTables" roleURI="http://www.biomerica.com/role/INCOMETAXESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_GEOGRAPHICINFORMATIONTables" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_InventoriesTable" roleURI="http://www.biomerica.com/role/InventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SharebasedcompensationassumptionsTable" roleURI="http://www.biomerica.com/role/SharebasedcompensationassumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_RevenuefromcontractswithcustomersTable" roleURI="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_IntangibleassetsnetTable" roleURI="http://www.biomerica.com/role/IntangibleassetsnetTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ExpectedamortizationofintangibleassetsTable" roleURI="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_AccountspayableandaccruedexpensebalancesTable" roleURI="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_OutstandingStockOptionsActivityTable" roleURI="http://www.biomerica.com/role/OutstandingStockOptionsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_NonvestedStockOptionsActivityTable" roleURI="http://www.biomerica.com/role/NonvestedStockOptionsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_StockOptionsSummaryTable" roleURI="http://www.biomerica.com/role/StockOptionsSummaryTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_IncometaxexpenseTable" roleURI="http://www.biomerica.com/role/IncometaxexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_IncomeTaxRateReconciliationTable" roleURI="http://www.biomerica.com/role/IncomeTaxRateReconciliationTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_DeferredTaxTable" roleURI="http://www.biomerica.com/role/DeferredTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_GeographicinformationregardingnetsalesTable" roleURI="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ThematurityofleaseliabilitiesTable" roleURI="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails" roleURI="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SHAREHOLDERSEQUITYDetails" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_INCOMETAXESDetails" roleURI="http://www.biomerica.com/role/INCOMETAXESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_GEOGRAPHICINFORMATIONDetails" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#bmra_r_SUBSEQUENTEVENTSDetails" roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20200531.xsd#DocumentAndEntityInformation" roleURI="http://www.biomerica.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20200531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="A5PercentConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_PreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquipmentGross" xlink:href="bmra-20200531.xsd#bmra_EquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="EquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FurnitureFixturesAndLeaseholdImprovementsGross" xlink:href="bmra-20200531.xsd#bmra_FurnitureFixturesAndLeaseholdImprovementsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="FurnitureFixturesAndLeaseholdImprovementsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Investments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20200531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="A5PercentConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_PreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNoParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockNoParValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PreferredStockUndesignatedShares" xlink:href="bmra-20200531.xsd#bmra_PreferredStockUndesignatedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="PreferredStockUndesignatedShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionsReceivableMember" xlink:href="bmra-20200531.xsd#bmra_SubscriptionsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="SubscriptionsReceivableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20200531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="A5PercentConvertiblePreferredStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="6.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValuePreferredStock" xlink:href="bmra-20200531.xsd#bmra_StockIssuedDuringPeriodValuePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValuePreferredStock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesPreferredStock" xlink:href="bmra-20200531.xsd#bmra_StockIssuedDuringPeriodSharesPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesPreferredStock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable" xlink:href="bmra-20200531.xsd#bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_0" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInDeferredRentLiability" xlink:href="bmra-20200531.xsd#bmra_IncreaseDecreaseInDeferredRentLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInDeferredRentLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseRightofUseAssetAmortization" xlink:href="bmra-20200531.xsd#bmra_OperatingLeaseRightofUseAssetAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OperatingLeaseRightofUseAssetAmortization" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20200531.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromCommonStockSubscribed" xlink:href="bmra-20200531.xsd#bmra_ProceedsFromCommonStockSubscribed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromCommonStockSubscribed" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidDuringTheYearForAbstract" xlink:href="bmra-20200531.xsd#bmra_CashPaidDuringTheYearForAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="CashPaidDuringTheYearForAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringTheYearForAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringTheYearForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EstablishmentOfRightOfUseAsset" xlink:href="bmra-20200531.xsd#bmra_EstablishmentOfRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="EstablishmentOfRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="EstablishmentOfLeaseLiability" xlink:href="bmra-20200531.xsd#bmra_EstablishmentOfLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="EstablishmentOfLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ORGANIZATION">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INTANGIBLEASSETSNET">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITY">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXES">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATION">
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureAbstract" xlink:href="bmra-20200531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureTextBlock" xlink:href="bmra-20200531.xsd#bmra_GeographicInformationDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationDisclosureAbstract" xlink:to="GeographicInformationDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:href="bmra-20200531.xsd#bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConcentrationRiskGeographicPolicyPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INTANGIBLEASSETSNETTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables">
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureAbstract" xlink:href="bmra-20200531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationDisclosureAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:href="bmra-20200531.xsd#bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/InventoriesTable">
    <loc xlink:type="locator" xlink:label="InventoriesAbstract" xlink:href="bmra-20200531.xsd#bmra_InventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SharebasedcompensationassumptionsTable">
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationAssumptionsAbstract" xlink:href="bmra-20200531.xsd#bmra_ShareBasedCompensationAssumptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:href="bmra-20200531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable"/>
    <loc xlink:type="locator" xlink:label="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:href="bmra-20200531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAssumptionsAbstract" xlink:to="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsTable" xlink:to="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable">
    <loc xlink:type="locator" xlink:label="RevenueFromContractsWithCustomersAbstract" xlink:href="bmra-20200531.xsd#bmra_RevenueFromContractsWithCustomersAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractsWithCustomersAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClinicalLabMember" xlink:href="bmra-20200531.xsd#bmra_ClinicalLabMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="ClinicalLabMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OTCMember" xlink:href="bmra-20200531.xsd#bmra_OTCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="OTCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PhysiciansOfficeMember" xlink:href="bmra-20200531.xsd#bmra_PhysiciansOfficeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="PhysiciansOfficeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContractManufacturingMember" xlink:href="bmra-20200531.xsd#bmra_ContractManufacturingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="ContractManufacturingMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IntangibleassetsnetTable">
    <loc xlink:type="locator" xlink:label="IntangibleAssetsNetAbstract" xlink:href="bmra-20200531.xsd#bmra_IntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedLicenseAgreementsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedPatentsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FiniteLivedLicenseAccumulatedAmortization" xlink:href="bmra-20200531.xsd#bmra_FiniteLivedLicenseAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetAbstract" xlink:to="FiniteLivedLicenseAccumulatedAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FiniteLivedPatentsAccumulatedAmortization" xlink:href="bmra-20200531.xsd#bmra_FiniteLivedPatentsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetAbstract" xlink:to="FiniteLivedPatentsAccumulatedAmortization" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:href="bmra-20200531.xsd#bmra_ExpectedAmortizationOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpectedAmortizationOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable">
    <loc xlink:type="locator" xlink:label="AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:href="bmra-20200531.xsd#bmra_AccountsPayableAndAccruedExpenseBalancesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedExpenseBalancesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/OutstandingStockOptionsActivityTable">
    <loc xlink:type="locator" xlink:label="OutstandingStockOptionsActivityAbstract" xlink:href="bmra-20200531.xsd#bmra_OutstandingStockOptionsActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:href="bmra-20200531.xsd#bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:href="bmra-20200531.xsd#bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OutstandingStockOptionsActivityAbstract" xlink:to="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare071390Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare071390Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare071390Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare225362Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare225362Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare225362Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare071104Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare071104Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare071104Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare071362Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare071362Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare071362Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare082390Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare082390Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare082390Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare268818Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare268818Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare268818Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare085818Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare085818Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare085818Member" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangePerShare082818Member" xlink:href="bmra-20200531.xsd#bmra_ExercisePriceRangePerShare082818Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangePerShare082818Member" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityTable" xlink:to="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/NonvestedStockOptionsActivityTable">
    <loc xlink:type="locator" xlink:label="NonVestedStockOptionsActivityAbstract" xlink:href="bmra-20200531.xsd#bmra_NonVestedStockOptionsActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonVestedStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/StockOptionsSummaryTable">
    <loc xlink:type="locator" xlink:label="StockOptionsSummaryAbstract" xlink:href="bmra-20200531.xsd#bmra_StockOptionsSummaryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsSummaryAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RangeOfExercisePrice082104Member" xlink:href="bmra-20200531.xsd#bmra_RangeOfExercisePrice082104Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="RangeOfExercisePrice082104Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RangeOfExercisePrice120281Member" xlink:href="bmra-20200531.xsd#bmra_RangeOfExercisePrice120281Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="RangeOfExercisePrice120281Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RangeOfExercisePrice362818Member" xlink:href="bmra-20200531.xsd#bmra_RangeOfExercisePrice362818Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="RangeOfExercisePrice362818Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMasDJzLBFPhcZ39E819xIH5B6s9+QqmUnZaYcTPdiZJQG4iHDdujDjCMFWAPlk1IXbu5qod0zXC71jDSSWZ68hzrssnC2jdQRCahfF4171SwV1eWMDeSOEOT3PjeTUhuzAY=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IncometaxexpenseTable">
    <loc xlink:type="locator" xlink:label="IncomeTaxExpenseAbstract" xlink:href="bmra-20200531.xsd#bmra_IncomeTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/IncomeTaxRateReconciliationTable">
    <loc xlink:type="locator" xlink:label="IncomeTaxRateReconciliationAbstract" xlink:href="bmra-20200531.xsd#bmra_IncomeTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:href="bmra-20200531.xsd#bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxRateReconciliationAbstract" xlink:to="IncreaseReductionInIncomeTaxesResultingFromAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DeferredTaxTable">
    <loc xlink:type="locator" xlink:label="DeferredTaxAbstract" xlink:href="bmra-20200531.xsd#bmra_DeferredTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="bmra-20200531.xsd#bmra_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:href="bmra-20200531.xsd#bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsAccumulatedDepreciationAndAmortization" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable">
    <loc xlink:type="locator" xlink:label="GeographicInformationRegardingNetSalesAbstract" xlink:href="bmra-20200531.xsd#bmra_GeographicInformationRegardingNetSalesAbstract"/>
    <loc xlink:type="locator" xlink:label="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:href="bmra-20200531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
    <loc xlink:type="locator" xlink:label="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:href="bmra-20200531.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationRegardingNetSalesAbstract" xlink:to="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_EuropeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_AsiaMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_AsiaMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_SouthAmericaMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SouthAmericaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SouthAmericaMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MiddleEastMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MiddleEastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="us-gaap_MiddleEastMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherForeignMember" xlink:href="bmra-20200531.xsd#bmra_OtherForeignMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="OtherForeignMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="bmra-20200531.xsd#bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="TheMaturityOfLeaseLiabilitiesAbstract" xlink:href="bmra-20200531.xsd#bmra_TheMaturityOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:href="bmra-20200531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20200531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="A5PercentConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ThreeDistributorsMember" xlink:href="bmra-20200531.xsd#bmra_ThreeDistributorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="ThreeDistributorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoDistributorsMember" xlink:href="bmra-20200531.xsd#bmra_TwoDistributorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="TwoDistributorsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OneDistributorsMember" xlink:href="bmra-20200531.xsd#bmra_OneDistributorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="OneDistributorsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DistributorsInEcuadorMember" xlink:href="bmra-20200531.xsd#bmra_DistributorsInEcuadorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="DistributorsInEcuadorMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MX"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_MX" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DistributionRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DistributionRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DistributionRightsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasedTechnologyRightsMember" xlink:href="bmra-20200531.xsd#bmra_PurchasedTechnologyRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="PurchasedTechnologyRightsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_RangeAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsProductLineMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_CostOfGoodsProductLineMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" order="9.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashUninsuredAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CashUninsuredAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OtherReceivablesGrossCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AdvertisingExpense" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:href="bmra-20200531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TwoVendorsMember" xlink:href="bmra-20200531.xsd#bmra_TwoVendorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="TwoVendorsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OneVendorMember" xlink:href="bmra-20200531.xsd#bmra_OneVendorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="OneVendorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsPayableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsTable" xlink:to="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsTable" xlink:href="bmra-20200531.xsd#bmra_SHAREHOLDERSEQUITYDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_SHAREHOLDERSEQUITYDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="SHAREHOLDERSEQUITYDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="A5PercentConvertiblePreferredStockMember" xlink:href="bmra-20200531.xsd#bmra_A5PercentConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="A5PercentConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_CommonStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_PreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AtMarketIssuanceSalesAgreementMember" xlink:href="bmra-20200531.xsd#bmra_AtMarketIssuanceSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="AtMarketIssuanceSalesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RegistrationRightsAgreementMember" xlink:href="bmra-20200531.xsd#bmra_RegistrationRightsAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RegistrationRightsAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_CostOfSalesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="A2010PlanMember" xlink:href="bmra-20200531.xsd#bmra_A2010PlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="A2010PlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="A2014PlanMember" xlink:href="bmra-20200531.xsd#bmra_A2014PlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="A2014PlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="A2017PlanMember" xlink:href="bmra-20200531.xsd#bmra_A2017PlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="A2017PlanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="A2020PlanMember" xlink:href="bmra-20200531.xsd#bmra_A2020PlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="A2020PlanMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MX"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_MX" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="srt_RangeAxis" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="SHAREHOLDERSEQUITYDetailsLineItems" order="11.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ConversionOfStockDescription" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_DividendsPreferredStock" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/INCOMETAXESDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="INCOMETAXESDetailsTable" xlink:href="bmra-20200531.xsd#bmra_INCOMETAXESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="INCOMETAXESDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_INCOMETAXESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="INCOMETAXESDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CaliforniaStateIncomeTaxMember" xlink:href="bmra-20200531.xsd#bmra_CaliforniaStateIncomeTaxMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="CaliforniaStateIncomeTaxMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsTable" xlink:to="INCOMETAXESDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INCOMETAXESDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails">
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureAbstract" xlink:href="bmra-20200531.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationDisclosureAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:href="bmra-20200531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="COMMITMENTSANDCONTINGENCIESDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RoyaltyAgreementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TelconAgreementMember" xlink:href="bmra-20200531.xsd#bmra_TelconAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="TelconAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MountSinaiLicenseAgreementsMember" xlink:href="bmra-20200531.xsd#bmra_MountSinaiLicenseAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="MountSinaiLicenseAgreementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UCLicenseAgreementsMember" xlink:href="bmra-20200531.xsd#bmra_UCLicenseAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="UCLicenseAgreementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniversityOfSouthernCaliforniaMember" xlink:href="bmra-20200531.xsd#bmra_UniversityOfSouthernCaliforniaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="UniversityOfSouthernCaliforniaMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MaxHealthMember" xlink:href="bmra-20200531.xsd#bmra_MaxHealthMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MaxHealthMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniversityOFMichiganMember" xlink:href="bmra-20200531.xsd#bmra_UniversityOFMichiganMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="UniversityOFMichiganMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeaconessMedicalCenterMember" xlink:href="bmra-20200531.xsd#bmra_DeaconessMedicalCenterMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="DeaconessMedicalCenterMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchManagementInstitutionMember" xlink:href="bmra-20200531.xsd#bmra_ResearchManagementInstitutionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ResearchManagementInstitutionMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BiomericaInfoodsProductMember" xlink:href="bmra-20200531.xsd#bmra_BiomericaInfoodsProductMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BiomericaInfoodsProductMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BiomericaInfoodsIBSProductMember" xlink:href="bmra-20200531.xsd#bmra_BiomericaInfoodsIBSProductMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BiomericaInfoodsIBSProductMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BiomericaHPyloriProductMember" xlink:href="bmra-20200531.xsd#bmra_BiomericaHPyloriProductMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BiomericaHPyloriProductMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HoustonMethodistResearchInstituteMember" xlink:href="bmra-20200531.xsd#bmra_HoustonMethodistResearchInstituteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="HoustonMethodistResearchInstituteMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MayoClinicArizonaMember" xlink:href="bmra-20200531.xsd#bmra_MayoClinicArizonaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MayoClinicArizonaMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MayoClinicJacksonvilleMember" xlink:href="bmra-20200531.xsd#bmra_MayoClinicJacksonvilleMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MayoClinicJacksonvilleMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:href="bmra-20200531.xsd#bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="PropertySubjectToOrAvailableForOperatingLease_Domain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BuildingInIrvineCaliforniaMember" xlink:href="bmra-20200531.xsd#bmra_BuildingInIrvineCaliforniaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="BuildingInIrvineCaliforniaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyAvailableForOperatingLeaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseAmendmentAxis" xlink:href="bmra-20200531.xsd#bmra_LeaseAmendmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="LeaseAmendmentAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseAmendmentDomain" xlink:href="bmra-20200531.xsd#bmra_LeaseAmendmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseAmendmentAxis" xlink:to="LeaseAmendmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstAmendmentToLeaseMember" xlink:href="bmra-20200531.xsd#bmra_FirstAmendmentToLeaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseAmendmentAxis" xlink:to="FirstAmendmentToLeaseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EZDetectProductMember" xlink:href="bmra-20200531.xsd#bmra_EZDetectProductMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="EZDetectProductMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonexclusiveDistributorAgreementMember" xlink:href="bmra-20200531.xsd#bmra_NonexclusiveDistributorAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="NonexclusiveDistributorAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MX"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_MX" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="srt_RangeAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsTable" xlink:to="COMMITMENTSANDCONTINGENCIESDetailsLineItems" order="10.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RentalExpenseIncreaseDuringPeriod" xlink:href="bmra-20200531.xsd#bmra_RentalExpenseIncreaseDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="RentalExpenseIncreaseDuringPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseDepositLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseDepositLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_LeaseDepositLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseExpirationPeriod" xlink:href="bmra-20200531.xsd#bmra_LeaseExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="LeaseExpirationPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyExpensePercentageOfSales" xlink:href="bmra-20200531.xsd#bmra_RoyaltyExpensePercentageOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="RoyaltyExpensePercentageOfSales" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedFeesAndOtherRevenueReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedFeesAndOtherRevenueReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_AccruedFeesAndOtherRevenueReceivable" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromFeesReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromFeesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromFeesReceived" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPercentage" xlink:href="bmra-20200531.xsd#bmra_RoyaltyPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="RoyaltyPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContractTerm" xlink:href="bmra-20200531.xsd#bmra_ContractTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="ContractTerm" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SuccessFeesPercentage" xlink:href="bmra-20200531.xsd#bmra_SuccessFeesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="SuccessFeesPercentage" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_PaymentsForFees" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseMaintenanceFee" xlink:href="bmra-20200531.xsd#bmra_LicenseMaintenanceFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="LicenseMaintenanceFee" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalTrialAgreementMaximumBudgetedCosts" xlink:href="bmra-20200531.xsd#bmra_ClinicalTrialAgreementMaximumBudgetedCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="ClinicalTrialAgreementMaximumBudgetedCosts" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BilledCommitmentPercentage" xlink:href="bmra-20200531.xsd#bmra_BilledCommitmentPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="BilledCommitmentPercentage" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COMMITMENTSANDCONTINGENCIESDetailsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SUBSEQUENTEVENTSDetailsTable" xlink:href="bmra-20200531.xsd#bmra_SUBSEQUENTEVENTSDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SUBSEQUENTEVENTSDetailsLineItems" xlink:href="bmra-20200531.xsd#bmra_SUBSEQUENTEVENTSDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SUBSEQUENTEVENTSDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeesMember" xlink:href="bmra-20200531.xsd#bmra_EmployeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="EmployeesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeesAndConsultantsMember" xlink:href="bmra-20200531.xsd#bmra_EmployeesAndConsultantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="EmployeesAndConsultantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultantMember" xlink:href="bmra-20200531.xsd#bmra_ConsultantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ConsultantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniversityOfTexasHealthScienceCenterMember" xlink:href="bmra-20200531.xsd#bmra_UniversityOfTexasHealthScienceCenterMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="UniversityOfTexasHealthScienceCenterMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeAndBoardMemberMember" xlink:href="bmra-20200531.xsd#bmra_EmployeeAndBoardMemberMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="EmployeeAndBoardMemberMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="SUBSEQUENTEVENTSDetailsLineItems" order="6.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalTrialAgreementMaximumBudgetedCosts" xlink:href="bmra-20200531.xsd#bmra_ClinicalTrialAgreementMaximumBudgetedCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="ClinicalTrialAgreementMaximumBudgetedCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="bmra-20200531.xsd#bmra_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560337834104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOMERICA INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--05-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,752,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,397,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000073290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560339562072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,641,027<span></span>
</td>
<td class="nump">$ 686,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, less allowance for doubtful accounts of $70,981 and $73,110, respectively</a></td>
<td class="nump">1,765,871<span></span>
</td>
<td class="nump">1,454,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">2,850,836<span></span>
</td>
<td class="nump">2,151,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">1,509,083<span></span>
</td>
<td class="nump">202,402<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">14,766,817<span></span>
</td>
<td class="nump">4,494,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_EquipmentGross', window );">Equipment</a></td>
<td class="nump">1,921,833<span></span>
</td>
<td class="nump">1,891,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_FurnitureFixturesAndLeaseholdImprovementsGross', window );">Furniture, fixtures and leasehold improvements</a></td>
<td class="nump">225,189<span></span>
</td>
<td class="nump">222,033<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">2,147,022<span></span>
</td>
<td class="nump">2,113,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(1,867,643)<span></span>
</td>
<td class="num">(1,762,344)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net property and equipment</a></td>
<td class="nump">279,379<span></span>
</td>
<td class="nump">351,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">INTANGIBLE ASSETS, net of accumulated amortization</a></td>
<td class="nump">168,655<span></span>
</td>
<td class="nump">107,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">RIGHT OF USE ASSETS, net of accumulated amortization</a></td>
<td class="nump">1,711,510<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">INVESTMENTS</a></td>
<td class="nump">165,324<span></span>
</td>
<td class="nump">165,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">OTHER ASSETS</a></td>
<td class="nump">168,193<span></span>
</td>
<td class="nump">126,832<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">17,259,878<span></span>
</td>
<td class="nump">5,245,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">986,711<span></span>
</td>
<td class="nump">1,037,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">278,627<span></span>
</td>
<td class="nump">226,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">211,809<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,477,147<span></span>
</td>
<td class="nump">1,264,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">1,569,678<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,046,825<span></span>
</td>
<td class="nump">1,264,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (NOTE 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, Series A 5%, convertible, $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding at May 31, 2020 and no shares authorized, issued and outstanding at May 31, 2019 and Preferred stock, undesignated, no par value, authorized 4,428,571 and 5,000,000 shares, at May 31, 2020 and May 31, 2019, respectively and none issued and outstanding at May 31, 2020 and May 31, 2019</a></td>
<td class="nump">25,714<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.08 par value; 25,000,000 shares authorized; 11,740,089 and 9,677,188 shares issued and outstanding at May 31, 2020 and 2019, respectively</a></td>
<td class="nump">939,205<span></span>
</td>
<td class="nump">774,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">35,213,707<span></span>
</td>
<td class="nump">22,830,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(39,841)<span></span>
</td>
<td class="num">(36,531)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(21,925,732)<span></span>
</td>
<td class="num">(19,586,678)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">14,213,053<span></span>
</td>
<td class="nump">3,980,970<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">17,259,878<span></span>
</td>
<td class="nump">5,245,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember', window );">5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, Series A 5%, convertible, $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding at May 31, 2020 and no shares authorized, issued and outstanding at May 31, 2019 and Preferred stock, undesignated, no par value, authorized 4,428,571 and 5,000,000 shares, at May 31, 2020 and May 31, 2019, respectively and none issued and outstanding at May 31, 2020 and May 31, 2019</a></td>
<td class="nump">25,714<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, Series A 5%, convertible, $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding at May 31, 2020 and no shares authorized, issued and outstanding at May 31, 2019 and Preferred stock, undesignated, no par value, authorized 4,428,571 and 5,000,000 shares, at May 31, 2020 and May 31, 2019, respectively and none issued and outstanding at May 31, 2020 and May 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_EquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of long-lived, depreciable equipment used in the production process to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_EquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_FurnitureFixturesAndLeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases and of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_FurnitureFixturesAndLeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560337665688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts (in Dollars)</a></td>
<td class="nump">$ 70,981<span></span>
</td>
<td class="nump">$ 73,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">11,740,089<span></span>
</td>
<td class="nump">9,677,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">11,740,089<span></span>
</td>
<td class="nump">9,677,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember', window );">5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par Value (in Dollars per share)</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="nump">571,429<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">321,429<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">321,429<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred Stock, No Par Value (in Dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_PreferredStockUndesignatedShares', window );">Preferred Stock, undesignated shares</a></td>
<td class="nump">4,428,571<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_PreferredStockUndesignatedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of preferred shares undesignated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_PreferredStockUndesignatedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560344961448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 6,692,711<span></span>
</td>
<td class="nump">$ 5,200,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="num">(4,910,935)<span></span>
</td>
<td class="num">(3,908,668)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">1,781,776<span></span>
</td>
<td class="nump">1,292,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,274,415<span></span>
</td>
<td class="nump">2,025,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,910,209<span></span>
</td>
<td class="nump">1,679,098<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,184,624<span></span>
</td>
<td class="nump">3,704,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(2,402,848)<span></span>
</td>
<td class="num">(2,412,790)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest and dividend income</a></td>
<td class="nump">71,193<span></span>
</td>
<td class="nump">44,014<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">71,184<span></span>
</td>
<td class="nump">43,967<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(2,331,664)<span></span>
</td>
<td class="num">(2,368,823)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAX EXPENSE</a></td>
<td class="num">(7,390)<span></span>
</td>
<td class="num">(24,237)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (2,339,054)<span></span>
</td>
<td class="num">$ (2,393,060)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC NET LOSS PER COMMON SHARE (in Dollars per share)</a></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED NET LOSS PER COMMON SHARE (in Dollars per share)</a></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE NUMBER OF COMMON AND COMMON EQUIVALENT SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in Shares)</a></td>
<td class="nump">10,166,296<span></span>
</td>
<td class="nump">9,212,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in Shares)</a></td>
<td class="nump">10,166,296<span></span>
</td>
<td class="nump">9,212,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (2,339,054)<span></span>
</td>
<td class="num">$ (2,393,060)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>OTHER COMPREHENSIVE LOSS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(3,310)<span></span>
</td>
<td class="num">(10,395)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE LOSS</a></td>
<td class="num">$ (2,342,364)<span></span>
</td>
<td class="num">$ (2,403,455)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560339384776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS` EQUITY - USD ($)<br></strong></div></th>
<th class="th">
<div>Series A Preferred Stock [Member] </div>
<div>5% Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Subscriptions Receivable [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at May. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 711,040<span></span>
</td>
<td class="nump">$ 20,843,550<span></span>
</td>
<td class="num">$ (9,062)<span></span>
</td>
<td class="num">$ (26,136)<span></span>
</td>
<td class="num">$ (17,193,618)<span></span>
</td>
<td class="nump">$ 4,325,774<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balances (in Shares) at May. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,888,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,080<span></span>
</td>
<td class="nump">108,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,053<span></span>
</td>
<td class="nump">1,726,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,776,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from ATM (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable', window );">Stock subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense in connection with options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,393,060)<span></span>
</td>
<td class="num">(2,393,060)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at May. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 774,173<span></span>
</td>
<td class="nump">22,830,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,531)<span></span>
</td>
<td class="num">(19,586,678)<span></span>
</td>
<td class="nump">3,980,970<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balances (in Shares) at May. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,677,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,037<span></span>
</td>
<td class="nump">212,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,995<span></span>
</td>
<td class="nump">10,098,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,232,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from ATM (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,674,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_StockIssuedDuringPeriodValuePreferredStock', window );">Issuance of preferred stock</a></td>
<td class="nump">$ 45,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,871,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,917,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_StockIssuedDuringPeriodSharesPreferredStock', window );">Issuance of preferred stock (in Shares)</a></td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred to common stock</a></td>
<td class="num">$ (20,000)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of preferred to common stock (in Shares)</a></td>
<td class="num">(250,000)<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense in connection with options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,339,054)<span></span>
</td>
<td class="num">(2,339,054)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at May. 31, 2020</a></td>
<td class="nump">$ 25,714<span></span>
</td>
<td class="nump">$ 939,205<span></span>
</td>
<td class="nump">$ 35,213,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39,841)<span></span>
</td>
<td class="num">$ (21,925,732)<span></span>
</td>
<td class="nump">$ 14,213,053<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balances (in Shares) at May. 31, 2020</a></td>
<td class="nump">321,429<span></span>
</td>
<td class="nump">11,740,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_AdjustmentsToSubscriptionsReceivableStockSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_StockIssuedDuringPeriodSharesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of preferred stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_StockIssuedDuringPeriodSharesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_StockIssuedDuringPeriodValuePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of preferred stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_StockIssuedDuringPeriodValuePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560339328808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,339,054)<span></span>
</td>
<td class="num">$ (2,393,060)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">129,172<span></span>
</td>
<td class="nump">162,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Change in provision for allowance for doubtful accounts</a></td>
<td class="num">(2,129)<span></span>
</td>
<td class="nump">15,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Inventory reserve</a></td>
<td class="nump">17,714<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option expense</a></td>
<td class="nump">200,470<span></span>
</td>
<td class="nump">151,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_IncreaseDecreaseInDeferredRentLiability', window );">Reduction (increase) in deferred rent liability</a></td>
<td class="num">(37,971)<span></span>
</td>
<td class="nump">6,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Decrease in deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_OperatingLeaseRightofUseAssetAmortization', window );">Amortization of right-of-use asset</a></td>
<td class="nump">269,460<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(309,090)<span></span>
</td>
<td class="num">(670,126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(717,460)<span></span>
</td>
<td class="nump">21,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="num">(1,306,681)<span></span>
</td>
<td class="nump">98,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_IncreaseDecreaseInLeaseLiability', window );">Reduction in lease liability</a></td>
<td class="num">(199,483)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(41,361)<span></span>
</td>
<td class="num">(13,677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(12,883)<span></span>
</td>
<td class="nump">343,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">51,798<span></span>
</td>
<td class="nump">16,977<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,297,498)<span></span>
</td>
<td class="num">(2,244,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Increase in intangibles</a></td>
<td class="num">(85,319)<span></span>
</td>
<td class="num">(69,974)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(33,608)<span></span>
</td>
<td class="num">(101,137)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(118,927)<span></span>
</td>
<td class="num">(171,111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ProceedsFromCommonStockSubscribed', window );">Common stock subscribed</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from sale of convertible preferred stock, net</a></td>
<td class="nump">1,917,586<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sales of common stock, net</a></td>
<td class="nump">10,232,857<span></span>
</td>
<td class="nump">1,776,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">223,534<span></span>
</td>
<td class="nump">121,790<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,373,977<span></span>
</td>
<td class="nump">1,907,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(3,310)<span></span>
</td>
<td class="num">(10,395)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">7,954,242<span></span>
</td>
<td class="num">(518,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, beginning of year</a></td>
<td class="nump">686,785<span></span>
</td>
<td class="nump">1,204,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, end of year</a></td>
<td class="nump">8,641,027<span></span>
</td>
<td class="nump">686,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_CashPaidDuringTheYearForAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">7,390<span></span>
</td>
<td class="nump">14,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_EstablishmentOfRightOfUseAsset', window );">Establishment of Right-of-use asset per ASC 842</a></td>
<td class="nump">1,942,999<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_EstablishmentOfLeaseLiability', window );">Establishment of Lease liability per ASC 842</a></td>
<td class="nump">$ 1,980,970<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_CashPaidDuringTheYearForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_CashPaidDuringTheYearForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_EstablishmentOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in Establishment Of Lease Liability Per ASC 842</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_EstablishmentOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_EstablishmentOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in Establishment Of Right Of Use Asset Per ASC 842</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_EstablishmentOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncreaseDecreaseInDeferredRentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncreaseDecreaseInDeferredRentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in LeaseLiability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_OperatingLeaseRightofUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of Right of Use Asset for Operating Lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_OperatingLeaseRightofUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ProceedsFromCommonStockSubscribed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the common stock subscription.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ProceedsFromCommonStockSubscribed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e99989-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560417699192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">1. &#xa0;&#xa0;&#xa0;ORGANIZATION </font></b></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: justify; margin: 0in 0in 0pt;"><font style="font-size: 10pt;">Biomerica Inc. and Subsidiaries (collectively the &#x201c;Company&#x201d;, &#x201c;we&#x201d;, &#x201c;us&#x201d;, or &#x201c;our&#x201d;) develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care </font><font style="font-size: 10pt; color: black;">(physicians' offices and over-the-counter through drugstores and online) </font><font style="font-size: 10pt;">and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. </font><font style="font-size: 10pt; color: black;">Our diagnostic test kits are used to analyze blood, urine or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The </font><font style="font-size: 10pt;">Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in"><font style="FONT-SIZE:10pt">Our primary focus is the research and development of revolutionary, patented diagnostic guided therapy (&#x201c;DGT&#x201d;) products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. If these DGT products prove effective in their clinical trials, and are ultimately cleared for sale by the U.S. Food and Drug Administrations (&#x201c;FDA&#x201d;), the revenues potential to the Company is significant.&#xa0; </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in"><font style="FONT-SIZE:10pt">Due to the global 2019 SARS-CoV-2 novel coronavirus (&#x201c;COVID-19&#x201d;) pandemic, in March 2020 we began redirecting and focused a majority of our resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been exposed to COVID-19. </font></p><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560341885976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">2. &#xa0;&#xa0;&#xa0;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">PRINCIPLES OF CONSOLIDATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The enclosed consolidated financial statements for the years ended May 31, 2020 and 2019 include the accounts of Biomerica, Inc. ("Biomerica") as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">ACCOUNTING ESTIMATES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; and inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, likelihood of lease extensions to occur, asset valuation, among other things; (and other items that may be necessary to estimate using current, historical and judgment based). Actual results could materially differ from those estimates. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">FAIR VALUE OF FINANCIAL INSTRUMENTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company's financial instruments consist of its cash and cash equivalents, accounts receivable,&#xa0;and accounts payable. The carrying amounts of the Company's financial instruments approximate their fair values.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">CONCENTRATION OF CREDIT RISK</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.&#xa0; As of May 31, 2020, the Company had approximately $8,595,241 of uninsured cash.</font> <font style="FONT-SIZE:10pt; COLOR:black">The Company does not believe it is exposed to any significant credit risks.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets.&#xa0; The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. </font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: justify; margin: 0in 0in 0pt;"><font style="font-size: 10pt; color: black;">For the years ended May 31, 2020 and 2019, the Company had three distributors and two distributors which accounted for a total of 57.2% and 46.3% of our net consolidated sales, respectively. Of this, for the years ended May 31, 2020 and 2019 one of the distributors mentioned above accounted for 25.7% and 36.3%, respectively, of net consolidated sales.&#xa0; At May 31, 2020 and 2019, the Company had three distributors and two distributors which accounted for a total of 80.0% and 68.1%, respectively, of gross accounts receivable. Of the 80.0% as of May 31, 2020, 43.9% was owed by a distributor in Ecuador. Total gross receivables at May 31, 2020 and 2019 were $1,836,852 and $1,527,762, respectively.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">For the year ended May 31, 2020, one vendor accounted for 59.3% of the purchases of raw materials. For the year ended May 31, 2019, two vendors accounted for a total of 23.8 % of the purchases of raw materials.</font><font style="FONT-SIZE:10pt">&#xa0;</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">GEOGRAPHIC CONCENTRATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">As of May 31, 2020 and 2019, approximately $613,000 and $665,000 of Biomerica's gross inventory and approximately $31,000 and $39,000, of Biomerica's property and equipment, net of accumulated depreciation, was located in Mexicali, Mexico, respectively.</font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: justify; margin: 0in 0in 0pt;"><strong><font style="font-size: 10pt;">CASH AND </font></strong><font style="font-size: 10pt;"><strong><font style="color: black;">CASH EQUIVALENTS</font></strong></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">ACCOUNTS RECEIVABLE</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company extends unsecured credit to its customers on a regular basis. &#xa0;International accounts are required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. &#xa0;Based on various criteria,&#xa0;initial credit levels for individual distributors are approved by designated officers and managers of the company. All increases in credit limits are also approved by designated upper level management. &#xa0;Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. &#xa0;Balances over ninety days old are usually reserved for unless collection is reasonably assured. &#xa0; </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. &#xa0; Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">INVENTORIES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Inventories approximate the following at May 31:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td colspan="2" style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt">2020</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td colspan="2" style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style="HEIGHT:16.6pt"> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Raw materials</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; BACKGROUND:aqua">$</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; BACKGROUND:aqua">1,635,000</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt">&#xa0;&#xa0; </font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt">$</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,208,000</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Work in progress</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt">&#xa0;&#xa0; 988,000</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt">&#xa0;&#xa0; 771,000</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Finished products </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; BACKGROUND:aqua">&#xa0;&#xa0; 228,000</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt">&#xa0;&#xa0; 172,000</font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; BORDER-LEFT:0px; PADDING-RIGHT:0in"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt">2,851,000</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,151,000</font></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of May 31, 2020 and 2019, inventory reserves were approximately $67,000 and $49,000, respectively.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">PROPERTY AND EQUIPMENT</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $105,299 and $101,216 for the years ended May 31, 2020 and 2019, respectively. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">INTANGIBLE ASSETS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#x201c;ASC&#x201d;), ASC 350 Intangibles &#x2013; Goodwill and Other (&#x201c;ASC 350&#x201d;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to $23,873 and $61,689 for the years ended May 31, 2020 and 2019, respectively.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset's balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of May 31, 2020 or 2019.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">INVESTMENTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">From time-to-time, the Company makes investments in privately-held companies. &#xa0;The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee&#x2019;s industry), a write-down to estimated fair value is recorded. Investments represent the Company&#x2019;s investment in a Polish distributor which is primarily engaged in distributing medical products and devices. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value of the investment to be greater than the fair value. The Company owns approximately 6% of the investee and, accordingly, applies the cost method to account for the investment. &#xa0;Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">SHARE-BASED COMPENSATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company follows the guidance of the accounting provisions of ASC 718<a name="_Hlk17621381">, </a>Share-based Compensation (&#x201c;ASC 718&#x201d;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#x2019;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#x201c;simplified method&#x201d; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company has not paid dividends historically and does not expect to pay them in the foreseeable future.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">In applying the Black-Scholes options-pricing model, assumptions used were as follows: &#xa0;</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.94%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:143.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Dividend yield</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 0%</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">0%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Expected volatility</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;55.52-72.62%</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">57.90-60.41%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:143.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Risk free interest rate</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;&#xa0;0.43-1.80%</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2.33-2.85%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Expected life</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.75-6.25 years</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.75-6.25 years</font></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">REVENUE RECOGNITION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company has various contracts with customers.&#xa0; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of May 31, 2020 and does not believe that any additional discounts will be given through the end of the contract periods. </font><font style="FONT-SIZE:10pt">Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. <font style="COLOR:black">The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. &#xa0;Physicians&#x2019; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. </font><a name="_Hlk49511094"></a></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Disaggregation of revenue:</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The following is a breakdown of revenues according to markets to which the products are sold:</font></p><br/><table width="733" style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:550pt; BORDER-COLLAPSE:collapse; BORDER-BOTTOM:0px;  BORDER-LEFT:0px; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:165pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">Year Ended</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;&#xa0;&#xa0; </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2019</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Clinical Lab</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,922,425 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">4,043,993 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">OTC</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,269,535 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">868,605 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Physicians&#x2019; Office</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,194,991 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">170,871 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Contract Manufacturing</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">305,760 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">117,213 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6,692,711 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">5,200,682 </font></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">See Note 7 for additional information regarding revenue concentrations.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">SHIPPING AND HANDLING FEES </font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company includes shipping and handling fees billed to customers in net sales. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">RESEARCH AND DEVELOPMENT</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Research and development costs are expensed as incurred. The Company expensed $1,910,209 and $1,679,098 of research and development costs during the years ended May 31, 2020 and 2019, respectively.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">INCOME TAXES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. At May 31, 2020 and 2019, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its deferred tax assets.&#xa0;&#xa0; During the fiscal year ended May 31, 2020, this valuation allowance was increased to approximately </font><font style="FONT-SIZE:9pt; COLOR:black">$</font><font style="FONT-SIZE:10pt; COLOR:black">3,175,000, which fully covers the net tax asset of $3,175,000</font><font style="FONT-SIZE:9pt; COLOR:black">.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company&#x2019;s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. Upon adopting the revisions in ASC 740, the Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the &#x201c;Interest expense&#x201d; line and penalties related to liabilities for income taxes within the &#x201c;Other expense&#x201d; line of the consolidated statements of operations and comprehensive loss. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">ADVERTISING COSTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately <font style="BACKGROUND:white">$174</font> and $0 for the years ended May 31, 2020 and 2019, respectively. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">FOREIGN CURRENCY TRANSLATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the years ended May 31, 2020 and 2019.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">RIGHT-OF-USE ASSETS AND LEASE LIABILITY</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">Incentive payments received from landlords are recorded as deferred lease incentives and are amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. When the terms of an operating lease provide for periods of free rent, rent concessions, and/or rent escalations, the Company establishes a deferred rent liability for the difference between the scheduled rent payment and the straight-line rent expense recognized. This deferred rent liability was amortized over the underlying lease term on a straight-line basis as a reduction of rent expense.<font style="COLOR:black">&#xa0;During the year ended May 31, 2020, the Company adopted ASC 842, Leases.&#xa0; As a result, the existing deferred rent liability was netted against the Right-of-Use Asset which was capitalized at that time.</font></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&#xa0; Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&#xa0; Right-of-Use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&#xa0; Leases will be classified as financing or operating which will drive the expense recognition pattern.&#xa0; For lessees, the statement of operations presentation and expense recognition pattern for financing and operating leases is similar to the current model for capital and operating leases, respectively.&#xa0; The Company has elected to exclude short-term leases.&#xa0; The update also requires additional disclosures that will better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases.&#xa0; The Company adopted this guidance as of June 1, 2019, the required effective date, using the effective date transition method.&#xa0; As permitted under the effective date transition method, financial information and disclosure for periods prior to the date of initial application will not be updated. An adjustment to opening accumulated deficit was not required in conjunction with adoption. The adoption of this statement resulted in a right-of-use asset being recorded in the amount of $1,942,999 and a lease liability being recorded in the amount of $1,980,970. Both will be amortized over the life of the underlying leases. For additional information, see Note 8-Commitments and Contingencies. The Company has elected not to reassess whether expired or existing contracts contain leases, or reassess the classification of existing leases as of the adoption date. The Company leases office space and copy machines, all of which are operating leases.&#xa0; Most leases include the option to renew and the exercise of the renewal options is at the Company&#x2019;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&#xa0; The leases do not include the options to purchase the leased property.&#xa0; The depreciable life of assets and leasehold improvements are limited by the expected lease term.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">NET LOSS PER SHARE</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2020 and 2019 were 1,789,251 and 1,476,209, respectively. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company also has outstanding 321,429 of Series A 5% Convertible Preferred Stock, which may be converted at any time to common stock.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">SEGMENT REPORTING</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">ASC 280, Segment Reporting (&#x201c;ASC 280&#x201d;), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company&#x2019;s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing and sales of diagnostic kits.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">REPORTING COMPREHENSIVE LOSS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders&#x2019; equity. Accumulated other comprehensive loss consists solely of foreign currency translation adjustments. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">RECENT ACCOUNTING PRONOUNCEMENTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On February 15, 2018, the FASB issued ASU 2018-02, &#x201c;Reclassification of Certain Tax Effects From Accumulated Comprehensive Income&#x201d; (&#x201c;ASU 2018-02&#x201d;).&#xa0; ASU 2018-02 will give companies the option to reclassify stranded tax effects caused by the newly-enacted U.S. Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) from accumulated other comprehensive income (&#x201c;ASCI&#x201d;) to retained earnings.&#xa0; ASU 2018-02 was effective for all companies for the fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.&#xa0; Management is taking the provisions of this statement into account in the preparation of the consolidated financial statements for the year ended May 31, 2020.&#xa0; The adoption of this standard has not had a significant impact on the Company&#x2019;s consolidated financial statements.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">On June 20, 2018, the FASB issued ASU 2018-07,&#xa0;&#x201c;Compensation&#x2014;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&#x201d; (&#x201c;ASU 2018-07&#x201d;). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for share-based payments to nonemployees (service providers, external legal counsel, and suppliers). ASU 2018-07 was effective </font><font style="FONT-SIZE:10pt">for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.&#xa0;During the year ended May 31, 2020, the Company adopted the provisions of this statement and is taking them into account in the preparation of the consolidated financial statements for the year ended May 31, 2020. The adoption of this standard has not had a significant impact on the Company&#x2019;s consolidated financial statements.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0pt 0in"><font style="FONT-SIZE:10pt; COLOR:black">Other recent ASU's issued by the FASB and guidance issued by the Securities and Exchange Commission (&#x201c;SEC&#x201d;) did not, or are not believed by management to, have a material effect on the Company&#x2019;s present or future consolidated financial statements. </font></p><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560341746760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">3. &#xa0;&#xa0;&#xa0;INTANGIBLE ASSETS, NET</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets, net of accumulated amortization, consist of the following at May 31:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:193.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:193.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Licenses</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">551,397 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">510,600 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:193.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Patents</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">113,382 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">68,860 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:193.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-<br/>licenses</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(487,989)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(471,530)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:193.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-<br/>patents</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(8,135)</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(721)</font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:193.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets, net</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">168,655 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">107,209 </font></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Expected amortization of intangible assets for the years ending May 31:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:123.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:123.85pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">18,112 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:123.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2022</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">8,503 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:123.85pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2023</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6,211 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:123.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2024</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6,136 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:123.85pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2025</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">5,219 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:123.85pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Thereafter</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:16%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">124,474 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:123.85pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:20pt; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:16%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">168,655 </font></p></td></tr></table><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560345958920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">4.&#xa0;&#xa0;&#xa0; ACCOUNTS PAYABLE AND ACCRUED EXPENSES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company&#x2019;s accounts payable and accrued expense balances consist of the following at May 31:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:205.9pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:205.9pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Accounts payable and accrued expenses</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">986,711 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">999,594 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:205.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Deferred rent</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">-</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">37,971 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:205.9pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">986,711 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,037,565 </font></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">As of May 31, 2020 and 2019 the Company had two vendors and one vendor which accounted for 26.9% and 32.1%, respectively, of accounts payable.</font></p><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560342015944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">5. &#xa0;&#xa0;&#xa0;SHAREHOLDERS' EQUITY</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">On February 24, 2020, the Company filed with the Secretary of State of Delaware a certificate of designation to authorize for issuance 571,429 shares of Series A 5% Convertible Preferred Stock.&#xa0; On February 26, 2020, the Company filed with the Secretary of State of Delaware a certificate of correction, correcting certain language defects in the previously filed certificate of designation.&#xa0; Please see below a description of the Series A 5% Convertible Preferred Stock shares that were issued in February 2020.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">STOCK OPTION AND RESTRICTED STOCK PLANS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">In August 2010, the Company adopted a stock option and restricted stock plan (the "2010 Plan") which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company's unissued common stock may be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2010. &#xa0;The 2010 Plan expires in December 2020. Options granted under the 2010 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">In December 2014, the Company adopted a stock option and restricted stock plan (the "2014 Plan") which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company's unissued common stock may be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2014. &#xa0;The 2014 Plan expires in December 2024. Options granted under the 2014 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">In December 2017, the Company adopted a stock option and restricted stock plan (the &#x201c;2017 Plan&#x201d;) which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 900,000 shares of the Company&#x2019;s unissued common stock may be granted to affiliates, employees or consultants of the Company.&#xa0; This plan was approved by shareholders in December 2017.&#xa0; The 2017 Plan expires in December 2027.&#xa0; Options granted under the 2017 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.</font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: justify; margin: 0in 0in 0pt;"><font style="font-size: 10pt; color: black;">In February 2020, the Board approved the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;), which will be presented to the Company&#x2019;s shareholders for final approval and adoption at the Company&#x2019;s annual meeting to be held in December 2020. The 2020 Plan authorizes the issuance of an </font><font style="font-size: 10pt; color: black;">aggregate number of common stock options and/or restricted common shares to be issued in an amount not to exceed 900,000. &#xa0;The 2020 Plan authorizes the issuance of common stock options and restricted common shares to employees, directors and consultants of the Company. During fiscal 2020, certain common stock options were granted under this plan, the actual vesting of which is subject to the plan being approved and adopted by shareholders at our upcoming annual meeting of shareholders.&#xa0;&#xa0; </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">Stock option expense during fiscal 2020 was $200,470. This included, by department, $17,892 for research and development, $156,750 in administrative, $2,933 in sales and marketing, $22,895 for production and $0 in Mexico. In fiscal 2019, stock option expense was $151,224. This included $3,714 in research and development, $143,299 in administrative, $4,163 in sales and marketing and $48 in Mexico.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Activity as to aggregate stock options outstanding is as follows: </font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:39pt"> <td style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">NUMBER OF STOCK OPTIONS</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">EXERCISE PRICE&#xa0; RANGE PER SHARE</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">WEIGHTED AVERAGE EXERCISE PRICE</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options outstanding at May 31, 2018</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,138,625 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$0.71-$3.90</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1.65 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:175.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options granted</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">558,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$2.25-$3.62</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2.60 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options exercised</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(163,500)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$0.71-$1.04</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">0.76 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options canceled or expired</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(56,916)</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$0.71-$3.62</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2.49 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options outstanding at May 31, 2019</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,476,209 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$3.90</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2.07 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:175.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options granted</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">517,500 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$2.68-$8.18</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">4.47 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options exercised</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(137,958)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$3.90</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1.64 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options canceled or expired</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(66,500)</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$0.85-$8.18</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.43 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options outstanding at May 31, 2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,789,251 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$8.18</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2.75 </font></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The weighted average fair value of options granted during 2020 and 2019 was $4.47 and $2.60, respectively. The aggregate intrinsic value of options exercised during 2020 and 2019 was approximately $589,000 and $364,000, respectively. The aggregate intrinsic value of options outstanding at May 31, 2020 and 2019 was approximately $6,923,000 and $808,000, respectively. The aggregate intrinsic value of options vested and exercisable at May 31, 2020 and 2019 was approximately $4,442,000 and $685,000, respectively.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">Number of non-vested stock options included in table above is as follows:</font>&#xa0;&#xa0; </p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:82.5pt"> <td style="HEIGHT:82.5pt; WIDTH:167.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:82.5pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">NUMBER OF SHARES</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:82.5pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:82.5pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">STOCK OPTIONS WEIGHTED AVERAGE AVERAGE GRANT DATE FAIR VALUE</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:167.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2019</font></p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">769,584 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2.49 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:167.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Granted</font></p></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">517,500 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">4.47 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:167.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Vested</font></p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(407,750)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2.25 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:167.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Forfeited</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(56,750)</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.55 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:167.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">822,584 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.78 </font></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">At May 31, 2020, total compensation cost related to non-vested stock option awards not yet recognized totaled approximately $663,000. The weighted-average period over which this amount is expected to be recognized is 3.67 years. The weighted average remaining contractual term of options that were exercisable at May 31, 2020 was 6.19 years.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The following summarizes information about all of the Company's stock options outstanding at May 31, 2020. These options are comprised of those granted under the 2010, 2014, 2017 and 2020 plans.</font></p><br/><table style="width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0">
<tr style="height: 64.5pt;">
<td style="border-top: 0px; height: 64.5pt; border-right: 0px; width: 17%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">RANGE OF EXERCISE PRICES</font></p>
</td>
<td style="border-top: 0px; height: 64.5pt; border-right: 0px; width: 17%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">&#xa0;NUMBER OUTSTANDING May 31, 2020</font></p>
</td>
<td style="border-top: 0px; height: 64.5pt; border-right: 0px; width: 17%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">&#xa0;WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE IN YEARS</font></p>
</td>
<td style="border-top: 0px; height: 64.5pt; border-right: 0px; width: 16%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">WEIGHTED AVERAGE EXERCISE PRICE</font></p>
</td>
<td style="border-top: 0px; height: 64.5pt; border-right: 0px; width: 15.78%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">&#xa0;NUMBER EXERCISABLE AT MAY 31, 2020</font></p>
</td>
<td style="border-top: 0px; height: 64.5pt; border-right: 0px; width: 16%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">&#xa0;WEIGHTED AVERAGE EXERCISE PRICE</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$ 0.82-$1.04</font></p>
</td>
<td style="height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">276,000</font></p>
</td>
<td style="height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">4.44</font></p>
</td>
<td style="height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$0.84 </font></p>
</td>
<td style="height: 15pt; width: 15.78%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">276,000</font></p>
</td>
<td style="height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$0.84 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 17%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$ 1.20-$ 2.81</font></p>
</td>
<td style="height: 15pt; width: 17%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">1,072,500</font></p>
</td>
<td style="height: 15pt; width: 17%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">7.57</font></p>
</td>
<td style="height: 15pt; width: 16%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$2.17 </font></p>
</td>
<td style="height: 15pt; width: 15.78%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">506,000</font></p>
</td>
<td style="height: 15pt; width: 16%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$1.71 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$ 3.62-$ 8.18</font></p>
</td>
<td style="height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">440,751</font></p>
</td>
<td style="height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">7.62</font></p>
</td>
<td style="height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$5.38 </font></p>
</td>
<td style="height: 15pt; width: 15.78%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">184,667</font></p>
</td>
<td style="height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$3.87 </font></p>
</td>
</tr>
</table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">COMMON STOCK ACTIVITY</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">During the year ended May 31, 2020, options to purchase 137,958 shares of common stock were exercised at prices ranging from $0.82 to $3.90.&#xa0; Total net proceeds to the Company were $223,534.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">During the year ended May 31, 2019, options to purchase 163,500 shares of common stock were exercised at prices ranging from $0.71 to $1.04.&#xa0; <a name="_Hlk17185589">Total net proceeds to the Company were $121,790.</a></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">On December 1, 2017, the Company entered into an At Market Issuance Sales Agreement (or &#x201c;ATM Agreement&#x201d;) with an agent, and filed a prospectus supplement with the SEC pursuant to which the Company could offer and sell from time to time up to an aggregate of $7,000,000 of shares of the Company&#x2019;s common stock, par value $0.08 per share (the &#x201c;Placement Shares&#x201d;), through the agent. From December 1, 2017 to March 19, 2020, the Company sold common stock resulting in $6,997,935 of gross proceeds under this ATM Agreement, of which $3,771,048 were sold during the year ended May 31, 2020. </font><font style="FONT-SIZE:10pt">This At Market Issuance Agreement expired on July 20, 2020 upon the expiration of the Company&#x2019;s S-3 registration statement base prospectus dated July 20, 2017. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 12pt"><font style="FONT-SIZE:10pt; COLOR:black">The Placement Shares sold and issued under the ATM Agreement have been registered under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), pursuant to the Registration Statement on Form S-3 (File No. 333-219130) (the &#x201c;Registration Statement&#x201d;), which was originally filed with the SEC on June 30, 2017 and declared effective by the SEC on July 20, 2017, the base prospectus contained within the Registration Statement, and the prospectus supplement related to the sale of shares under the ATM Agreement was filed with the SEC on December 1, 2017.&#xa0;</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">On March 20, 2020, the Company filed a new prospectus supplement to the S-3 registration statement base prospectus dated July 20, 2017 for purposes of raising up to $12,500,000 from time to time pursuant to the terms of the ATM Agreement. </font><a name="_Hlk47966232"><font style="FONT-SIZE:10pt">This ATM Agreement expired on July 20, 2020 upon the expiration of the Company&#x2019;s S-3 registration statement base prospectus dated July 20, 2017. Gross proceeds for the year ended May 31, 2020, were $6,817,330.</font></a></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">Please refer to &#x201c;Subsequent Events&#x201d; for a description of the Form S-3 filed with the Securities and Exchange Commission on July 20, 2020.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Combined Placement Shares sold under the ATM during the twelve months ended May 31, 2020 under the two prospectus supplements dated December 1, 2017 and March 20, 2020 totaled 1,674,943 shares. Total net proceeds from the sale of Placement Shares under the two prospectus supplements during the twelve months ended May 31, 2020 were $10,232,857 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3.&#xa0; These shares were sold at prices ranging from $2.33 to $9.08 per share. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Under an ATM Agreement, sales of the Placement Shares are deemed to be &#x201c;at the market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act.&#xa0; The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company&#x2019;s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement.&#xa0; </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">During the year ended May 31, 2020, 250,000 shares of common stock were converted from Preferred Stock as described below in &#x201c;Preferred Stock Activity&#x201d;.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">During the year ended May 31, 2020, the Company sold 1,674,943 shares of its common stock at prices ranging from $2.33 to $9.08 under its S-3 Registration Statement which resulted in gross proceeds of $10,588,378 and net proceeds to the Company of $10,232,857 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">During the year ended May 31, 2019, the Company sold 625,677 shares of its common stock at prices ranging from $2.59 to $4.16 under its S-3 Registration Statement which resulted in gross proceeds of $1,847,662 and net proceeds to the Company of $1,776,575 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt">PREFERRED STOCK ACTIVITY</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">On February 24, 2020, the Company entered into and closed on a Stock Purchase Agreement (the &#x201c;Stock Purchase Agreement&#x201d;) with </font><font style="FONT-SIZE:10pt">Palm Global Small Cap Master Fund LP (&#x201c;Palm&#x201d;) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed to purchase from the Company, 571,429 shares of the Company&#x2019;s Series A 5% Convertible Preferred Stock, $0.08 par value per share for a purchase price of approximately $2 million, or $3.50 per Series A Convertible Preferred Stock. Under the terms of the Stock Purchase Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company&#x2019;s common stock, subject to certain adjustments. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Series A 5% Convertible Preferred Stock shares are convertible at the option of the holder at any time into an equal number of common stock shares (&#x201c;Conversion Shares&#x201d;). The conversion price may be adjusted for stock splits or other common stock issuances. The Company may require the conversion of all of the outstanding Series A 5% Convertible Preferred Stock shares if the closing sale price of the Company&#x2019;s common stock equals or exceeds $9.00 for a period of five consecutive trading days with a minimum average trading volume of 35,000 shares per day over such period; provided, that, on such date, the Conversion Shares are registered for resale. </font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: justify; margin: 0in 0in 0pt;"><font style="font-size: 10pt; color: black;">The Series A 5% Convertible Preferred Stock shares accrue annual preferred dividends at a rate of $0.175 per Series A 5% Convertible Preferred Stock share. The shares of Series A 5% Convertible Preferred Stock are also entitled to receive participating dividends. The shares of Series A 5% Convertible Preferred Stock have no voting rights. Accruing dividends are payable only when, as, and if declared by the Board and the Company has no obligation to pay such accruing dividends. As such, since the dividend payment is conditional on events that are deemed unlikely at this time, a liability has not been recorded at year-end for these dividends. Dividends that have &#xa0;accumulated through May 31, 2020 total approximately $18,000.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">The 5% dividend is a cumulative dividend, and is only payable if the Board elects to pay a dividend on the Company&#x2019;s common shares, at which point the accrued cumulative dividend must be paid current. At the conversion of any preferred shares into common shares, all accrued, unpaid dividends on the converted preferred shares are canceled and forgiven by Palm. As part of the purchase, Palm was given the right to appoint a Board Observer to the Board. The preferred shares have many material preferential rights over common shareholders in the event of a filing for bankruptcy or dissolution of the Company. For further details on the rights of these preferred shares, please refer to the Company&#x2019;s disclosures filed under an SEC 8-K on February 26, 2020. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On March 24, 2020, Palm converted 250,000 shares of Convertible Preferred Stock into 250,000 shares of unregistered common stock. On July 21, 2020, the Company filed with the SEC a registration statement on Form S-3 that among other things registered all of the common shares issued, or to be issued, to Palm upon conversion of the Convertible Preferred Stock into common shares. The Company anticipates the registration statement shall become effective promptly following the filing of this annual report on Form 10-K with the SEC. The Company incurred approximately $82,000 in issuance costs associated with this stock issuance.</font></p><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560341725976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">6. &#xa0;&#xa0;&#xa0;INCOME TAXES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Income tax expense from continuing operations for the years ended May 31, 2020 and 2019 consists of the following:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;Years ended May 31,</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Current:</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">U.S. Federal</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;-- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;-- </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Foreign Taxes Subsidiaries</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(6,590)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(13,437)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">State and local</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(800)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(800)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total current</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(7,390)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(14,237)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Deferred:</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">U.S. Federal&#xa0;</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;-- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(10,000)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">State and local</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;-- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;-- </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total deferred</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;-- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(10,000)</font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Income tax expense</font></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(7,390)</font></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(24,237)</font></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Income tax expense from continuing operations differs from the amounts computed by applying the U.S. Federal income tax rate applicable for each year (21% for 2020 and 2019) to pretax income as a result of the following:</font></p><br/><table style="width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0">
<tr style="height: 15pt;">
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 3.5in; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Years ended May 31,</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">2020</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">2019</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 3.5in; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Computed "expected" tax benefit </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">489,651 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">497,453 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 3.5in; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Increase (reduction) in income taxes resulting from:</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 3.5in; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Change in valuation allowance</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(716,000)</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(910,000)</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 3.5in; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">State income taxes, net of federal benefit</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">154,254 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">89,267 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 3.5in; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Research and development tax credits</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">49,770 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">55,908 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 3.5in; white-space: nowrap; padding: 0in 0in 0in 0pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Permanent tax differences and other</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">21,525 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(256,572)</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 3.5in; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 0in 0in 0pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Foreign taxes of subsidiaries</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(6,590)</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(13,437)</font></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 3.5in; white-space: nowrap; padding: 0in 0in 0in 0pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Income tax expense</font></p>
</td>
<td style="height: 15.75pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(7,390)</font></p>
</td>
<td style="height: 15.75pt; width: 2%; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(24,237)</font></p>
</td>
</tr>
</table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The tax effect of significant temporary differences&#xa0;is presented below:</font>&#xa0;</p><br/><table style="width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0">
<tr style="height: 15pt;">
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 301.7pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">As of May 31,</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">2020</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">2019</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Deferred tax assets:</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Accounts receivable, principally due to allowance for doubtful accounts</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">17,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">18,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Inventory valuation&#xa0;&#xa0;&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">16,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">12,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Compensated absences</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">64,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">48,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Net operating loss carryforwards&#xa0;&#xa0;&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">2,286,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">1,735,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Tax credit carryforwards</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">599,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">467,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Deferred rent expense/Capitalized leases</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">17,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">9,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Other</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">171,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">176,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Accumulated depreciation and amortization</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">5,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 0pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(6,000)</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Total deferred tax assets&#xa0;&#xa0;&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">3,175,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">2,459,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 301.7pt; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Less valuation allowance</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(3,175,000)</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(2,459,000)</font></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 301.7pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Net deferred tax asset</font></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">&#xa0;-- </font></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">&#xa0;-- </font></p>
</td>
</tr>
</table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company has provided a valuation allowance of approximately $3,175,000 and $2,459,000 as of May 31, 2020 and 2019, respectively. The net change in the valuation allowance for the years ended May 31, 2020 and 2019 was an increase of $716,000 and $900,000, respectively.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">At May 31, 2020, the Company has Federal income tax NOL carryforwards of approximately $9,213,000. &#xa0;At May 31, 2020, the Company has California state income tax net operating loss carryforwards of approximately $5,025,000.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">At May 31, 2020, the Company has Federal research and development tax credit carryforward of approximately $438,000. &#xa0;The Federal credits begin to expire in 2027. &#xa0;The Company also had similar credit carryforwards for state purposes of $160,000 at May 31, 2020.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Pursuant to Internal Revenue Code (&#x201c;IRC&#x201d;) Sections 382 and 383, annual use of the Company's net operating loss ("NOL") and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections 382 and 383 of the IRC, the annual use of the Company's NOLs and credit carryforwards would be limited if there is a cumulative change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period. Management has not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">For the year ended May 31, 2020, the Company did an analysis of its ASC 740 position and has not identified any uncertain tax positions as defined under ASC 740. Should such position be identified in the future and should the Company owe interest and penalties as a result of this, these would be recognized as interest expense and other expense, respectively, in the consolidated financial statements. The Company is no longer subject to any significant U.S. federal tax examinations by tax authorities for years before fiscal year 2016.</font></p><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560341824264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_GeographicInformationDisclosureAbstract', window );"><strong>Geographic Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_GeographicInformationDisclosureTextBlock', window );">Geographic Information Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt">&#xa0;<b><font style="FONT-SIZE:10pt; COLOR:black">7. &#xa0;&#xa0;&#xa0;GEOGRAPHIC INFORMATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt">&#xa0;<font style="FONT-SIZE:10pt; COLOR:black">The Company operates as one segment. Geographic information regarding net sales is approximately as follows: </font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Years ended May 31,</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Net sales:</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Europe</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,434,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,694,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">United States &#xa0;</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">445,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">523,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Asia</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,867,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,514,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">South America</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,615,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">256,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Middle East</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">314,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">214,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Other foreign</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">18,000 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;-- </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.25in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total net sales</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6,693,000 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">5,201,000 </font></p></td></tr></table><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GeographicInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GeographicInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GeographicInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments according to the geographic areas.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GeographicInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560341905992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">8. &#xa0;&#xa0;&#xa0;COMMITMENTS AND CONTINGENCIES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">OPERATING LEASES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">On June 18, 2009, the Company entered into an agreement to lease a building in Irvine, California. The lease commenced September 1, 2009 and ended August 31, 2016. </font><font style="FONT-SIZE:10pt">&#xa0;On November 30, 2015, the Company entered into the First Amendment to Lease wherein it exercised its option to extend its lease until August 31, 2021. The initial base rent for the lease extension was $21,000 per month, increasing to $23,637 through August 31, 2021. The monthly rent is currently $22,948. The security deposit of $22,080 remains the same.<font style="COLOR:black">&#xa0;</font></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">In November 2016, the Company&#x2019;s subsidiary, Biomerica de Mexico, entered into a ten-year lease for approximately 8,104 square feet at a monthly rent of $2,926. The Company has one 10-year option to renew at the end of the initial lease period. The yearly rate is subject to an annual adjustment for inflation according to the United States Bureau of Labor Statistics Consumer Price Index for All Urban Consumers. The monthly rate is currently $3,239. &#xa0;Biomerica, Inc. is not a guarantor of such lease.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Total gross rent expense in the U.S. for fiscal 2020 was $300,267 and 2019 was $268,550.&#xa0; Rent expense for the Mexico facility for fiscal 2020 and 2019 was $43,481 and $46,040, respectively. </font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: justify; margin: 0in 0pt 0pt 0in;"><font style="font-size: 10pt;">For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company&#x2019;s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included in the measurement of the right-of-use asset and related lease liability.&#xa0; Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss when they are incurred.&#xa0; </font></p><br/><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Courier New&quot;; MARGIN:0in 0in 0pt"><font style="FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;">Supplemental cash flow information related to leases for the year ended May 31, 2020:&#xa0; </font></p><br/><table style="width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0">
<tr style="height: 15pt;">
<td style="height: 15pt; width: 365.05pt; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Operating cash flows from operating leases&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15pt; width: 12%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">311,742 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 365.05pt; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">&#xa0;</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 365.05pt; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Right-of-use assets obtained in exchange for <br/>&#xa0;&#xa0; new operating lease liabilities</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">&#xa0;-- </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 365.05pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Weighted average remaining lease term (in years)</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">6.27</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 365.05pt; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Weighted average discount rate</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">6.5%</font></p>
</td>
</tr>
</table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The maturity of lease liabilities as of May 31, 2020 are as follows:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Years ending May 31,</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">211,808 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2022</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">236,391 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2023</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">262,810 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2024</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">291,329 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2025</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">322,098 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Thereafter</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">457,051 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total</font></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,781,487 </font></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">According to the terms of the lease in Irvine, the Company is also responsible for routine repairs of the building and for certain increases in property tax. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company also has various insignificant leases for office equipment.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">RETIREMENT SAVINGS PLAN</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Effective September 1, 1986, the Company established a 401(k) plan for the benefit of its employees. The plan permits eligible employees to contribute to the plan up to the maximum percentage of total annual compensation allowable under the limits of IRC Sections 415, 401(k) and 404. The Company, at the discretion of its Board of Directors, may make contributions to the plan in amounts determined by the Board each year. No contributions by the Company have been made since the plan's inception.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">LITIGATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. While the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that exist. Therefore, it is possible the outcome of such legal proceedings, claims and litigation could have a material effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows. There were no legal proceedings pending as of May 31, 2020.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On July 2, 2020, we received a notice of investigation and subpoena to produce information and documents from the Division of Enforcement of the SEC. The subpoena seeks information and documents related to events and circumstances leading up to our March 17, 2020 announcement that we had commenced shipping samples of our COVID-19 IgG/IgM Rapid Test to countries outside of the United States, and had initiated the application process with the United States Food and Drug Administration under the COVID-19 Emergency Use Authorization for approval to market and sell the test in the United States. The subpoena also seeks information and documents about the identity of any persons who were aware of the substance of the March 17, 2020 announcement prior to that date. We are cooperating and intends to continue cooperating fully with the SEC&#x2019;s investigation. At this time, we are unable to predict the duration, scope or outcome of this investigation.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">CONTRACTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt">Contracts and Licensing Agreements</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company has one royalty agreement in which it has obtained rights to manufacture and market certain products for the life of the products. Royalty expense of approximately $15,000 and $19,000 is included in cost of sales for the agreement for each of the years ended May 31, 2020 and 2019, respectively. Sales of products manufactured under these agreements comprise approximately 1.8% and 2.9% of total sales for the years ended May 31, 2020 and 2019, respectively. The Company may license other products or technology in the future as it deems necessary for conducting business.&#xa0; The Company has other royalty agreements, however they are not considered material.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On May 25, 2016, the Company entered into an Exclusive Marketing License Agreement (&#x201c; Telcon Agreement&#x201d;) with Celtis Pharm Co., Ltd., who subsequently changed their name to Telcon Pharmaceutical Co., LTD (&#x201c;Telcon&#x201d;), a medical company in the South Korea. The Telcon Agreement grants to Telcon an exclusive license to market and sell Biomerica&#x2019;s new InFoods&#xae; IBS products (&#x201c;IBS Products&#x201d;) in South Korea. The term of the agreement is for a period of five years following Korean FDA clearance of the product and provides an additional two years for Telcon to attain such Korean FDA clearance. The sequential two-year and five-year terms do not begin until after Biomerica first receives final clearance for sale of the IBS Products in the United States from the FDA. Telcon, at its sole cost and expense, must use its commercially reasonable good faith efforts to obtain Korean FDA for the IBS Product to be sold in South Korea. The agreement may be cancelled if Biomerica has not obtained final USFDA clearance for sale of the IBS Products on or before December 31, 2019. Biomerica is also obligated to maintain a full quality assurance system for the IBS Products following the harmonized standards according to Annex IV of Directive 98/79/EC. We are working with Telcon management to extend the term of the Telcon Agreement. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">The terms of the Telcon Agreement provide up to $1.25 million in exclusivity fees based on certain milestones including Biomerica&#x2019;s starting clinical trials in the United States, receipt of US FDA clearance and Telcon&#x2019;s first sales of IBS Products in Korea. If Biomerica commences FDA Trials and Telcon pays the initial $250,000 milestone-based exclusivity fees, and the Agreement is subsequently terminated by either party for lack of performance, then Biomerica shall issue to Telcon 83,333 shares of Biomerica common in consideration for the $250,000 of paid exclusivity fee. No exclusivity fees have yet been paid.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">Additionally, the Telcon Agreement provides for&#xa0;a royalty of 15% paid to Biomerica on all sales in Korea of the IBS Product, and further sets the pricing of IBS Products sold to Telcon.&#xa0; In order to retain the exclusivity within South Korean, Telcon must meet certain annual minimum royalty payments to Biomerica following Telcon&#x2019;s receipt of Korean FDA approval or clearance for the IBS Product to be sold in Korea, which in no case will be later than May 31, 2019.<b> </b>&#xa0;&#xa0;In September 2017, an agreement to extend this date was signed extending the date until April 30, 2020. We are working with Telcon management to extend the date for the completion of this obligation.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><a name="_Hlk48120529"><font style="FONT-SIZE:10pt; COLOR:black">In October 2018, the Company entered into an agreement with a customer for the sale of its EZ Detect product in the United States. The term of the Agreement is for three years and is renewable for one-year terms upon written notice.&#xa0; The agreement defines the price and rebate to the customer. There were no sales under this agreement in fiscal 2020.</font></a></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">In December 2018, the Company entered into an agreement with a company for the purpose of procuring and assisting in transactions related to its EZ Detect product with China.&#xa0; The contract is for a period of twelve months and is cancellable by either party with forty-five days written notice.&#xa0; The contract specifies 2.5-6% success fees and milestone payments upon certain events transpiring. During fiscal 2019, the Company incurred $27,579 in expenses for this contract. There were no expenses incurred in fiscal 2020.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">In April 2019, the Company entered into a consulting agreement with the former, retired president of the Company. The agreement stipulates that he shall be available by consultation if needed for the period of April 8, 2019 through April 7, 2020.&#xa0; In return, the Company has agreed to allow his stock options in the Company to continue to vest and be exercisable until April 7, 2020. At that time, no options will vest and any vested, unexercised options must be exercised by July 2, 2020 at which time they will be forfeited. All options that were eligible to vest according to this agreement were vested and exercised.&#xa0; There were no fees incurred for this agreement for consultation services.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">In May 2019, the Company entered into an agreement with MaxHealth Medical International Limited and MaxHealth China (&#x201c;MaxHealth&#x201d;) giving MaxHealth exclusive distribution rights to Biomerica&#x2019;s EZ Detect Product in China.&#xa0; Among other things, the Agreement called for MaxHealth to deposit $100,000 upon execution of the agreement, and an additional $900,000 (for a total of $1,000,000 USD) upon clearance of Chinese customs of the initial order of $100,000. The $1,000,000 was to be used as a prepayment for the first $1,000,000 of purchase orders for the product. While the Company received the first deposit of $100,000, and shipped $100,000 of product to Maxhealth, the Company has not received the second deposit, and has not shipped any further product, which has placed MaxHealth in Default of the agreement.&#xa0; MaxHealth and the Company have been negotiating a possible remedy for the default. There is no assurance these negotiations will be successful or that the default will be rectified.&#xa0; </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">On April 1, 2020, the Company entered into two separate non-exclusive license agreements (the &#x201c;Mount Sinai License Agreements&#x201d;) with the Mount Sinai Icahn School of Medicine in New York (&#x201c;Mount Sinai&#x201d;) to license technology from Mount Sinai that the Company intends to use to scale up and manufacture a laboratory version serological test for SARS-CoV-2 coronavirus.&#xa0; This test uses the ELISA microplate format that can run on existing open system equipment found in most hospitals and clinical laboratories in the United States.&#xa0; The non-exclusive Mount Sinai License Agreements provide for royalty payments to Mount Sinai based on a percentage of gross sales of commercial products manufactured and sold by Biomerica that incorporate the Mount Sinai technology licensed under the Mount Sinai License Agreement. On June 20, 2020, the Company filed for EUA with the FDA based on this on this technology. The Company purchased materials in the amount of $5,100 during fiscal 2020 and subsequently to that another $2,850.&#xa0; No royalty fees have been paid yet on these agreements.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">On May 7, 2020, the Company entered into an exclusive license agreement (the &#x201c;UC License Agreements&#x201d;) with The Regents of the University of California (&#x201c;UC&#x201d;) to license all patent rights pertaining to certain licensed technology from UC. This technology is being developed at the University by one of the professors and his team utilizing CRISPR technology. This group is developing a viral detection test for SARS-CoV-2 coronavirus.&#xa0;If this technology development is successful, the Company will work with the University to transfer the technology to Biomerica where the CRISPR based product will need to be further developed, validated and cleared with regulatory agencies for commercial sale into the market.&#xa0; The exclusive UC License Agreements provide for an initial and annual license fee, and a royalty payment on all commercial revenues, to the UC Regents. The UC License Agreement also includes certain investment requirements and milestones the Company will need to meet for the launch of a commercial product based on the licensed technology. The Company paid an initial license fee of $5,000 with the execution of the agreement. An additional $5,000 is due in September 2020.&#xa0; No royalties have been paid yet on this agreement. A license maintenance fee of $10,000 is due annually. This is creditable against earned royalties due each year in the amount of five percent on net sales of licensed products.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><a name="_Hlk48645104"><font style="FONT-SIZE:10pt">On May 18, 2020, the Company signed a non-exclusive distributor agreement with a company in Russia for the distribution of COVID-19 tests. The term of the agreement is for an initial two years, however, the agreement may be terminated for breach of contract. The agreement allows for quantity discounts based on certain milestones.</font></a></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0pt 0in"><b><font style="FONT-SIZE:10pt">Clinical Trial Agreements</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">In September 2017, the Company signed a Clinical Samples Agreement with the University of Southern California for the purpose of providing clinical samples for use by the Company in conducting future clinical trials for one of the products which the Company is developing.&#xa0; The initial budget was estimated to be $82,472. The work started in October 2017 with charges for work performed being invoiced and paid monthly.&#xa0; This study ended in February 2020. The Company incurred $2,200 in fiscal 2020 and $12,567 in expenses previously invoiced for a total of $14,767. In addition, $17,064 in fees has been accrued for unbilled charges as of May 31, 2020.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">In November 2017, the Company entered into a Clinical Trial Agreement with the University of Michigan to perform an InFoods 24 Endpoint Determination Study.&#xa0; The Company will be invoiced monthly for work performed the previous month. The maximum budget for the study is $181,015. The Company incurred $30,900 and $40,885 in expenses for this study during fiscal 2020 and 2019, respectively. This commitment is approximately 47% billed.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">In January 2018, the Company entered into a Clinical Trial Agreement with Beth Israel Deaconess Medical Center for the purposes of conducting an Antibody Guided Restriction Trial Using Biomerica InFoods 24G Test in patients with a previous diagnosis of Irritable Bowel Syndrome (&#x201c;IBS&#x201d;).&#xa0; The study began in the first quarter of fiscal 2019. The Company was invoiced monthly for work performed the previous month.&#xa0; The total cost of the study was initially estimated to be $142,000, however the study was expanded and total costs of the trial was approximately $305,000. The Company incurred $141,640 and $146,760 in expenses for this study during fiscal 2020 and 2019, respectively. This study was closed in February 2020 and no additional costs are expected.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On July 12, 2019, the Company entered into a Clinical Trial Agreement with a research management institution for the purpose of conducting a clinical trial of the Biomerica HP Stool Antigen test.&#xa0; The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month.&#xa0; The maximum budgeted costs was approximately $117,200.&#xa0; During fiscal 2020, $13,111 in charges were billed and the Company accrued $6,670 in charges as of May 31, 2020. This study is now closed so no further charges will be incurred.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On July 22, 2019, the Company entered into a Clinical Trial Agreement with a research institution, for the purpose of conducting a clinical trial of the Biomerica Infoods product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be approximately $107,000.&#xa0; The Company incurred $20,875 in charges during fiscal 2020. This commitment is approximately 19% billed. In addition, the Company accrued $2,650 in unbilled charges as of May 31, 2020.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On September 25, 2019, the Company entered into a Clinical Trial Agreement with a medical practice for the purpose of conducting a clinical trial of the Biomerica Infoods IBS product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $136,000. During fiscal 2020, the Company was invoiced $45,250 in expenses. This commitment is approximately 33% billed. In addition, the Company accrued $5,975 in unbilled charges as of May 31, 2020.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On September 25, 2019, the Company entered into a Clinical Trial Agreement with a research institution for the purpose of conducting a clinical trial of the Biomerica H. pylori product.&#xa0; The term of the agreement shall be until completion of the work outlined and the charges were invoiced monthly for work performed in the previous month.&#xa0; The maximum budgeted costs will be approximately $57,800. The Company was invoiced $41,845 in charges during the year ended May 31, 2020. At May 31, 2020, the commitment was approximately 72% billed and the study has been closed so no further charges will be incurred.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">In December 2019, the Company entered into a Clinical Trial Agreement with Houston Methodist Research Institute for the purpose of conducting a clinical trial of the Biomerica InFoods&#xae; IBS product.&#xa0; The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month.&#xa0; The maximum budgeted costs will be approximately $133,000. During the year ended May 31, 2020, the Company was invoiced $4,000 in charges. This commitment is approximately 3% billed.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On May 28, 2020, the Company entered into a Clinical Trial Agreement with the Mayo Clinic Arizona for the purpose of participating in the ongoing end point clinical trial of the Biomerica Infoods IBS product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $135,515. &#xa0;At May 31, 2020, $17,390 had been invoiced to the Company. This commitment is approximately 13% billed.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On May 28, 2020, the Company entered into a Clinical Trial Agreement with the Mayo Clinic Jacksonville for the purpose of participating in the ongoing end point clinical trial of the Biomerica Infoods IBS product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $135,515. The Company has not received any billings as of May 31, 2020, however accrued $17,390 in charges as of that date.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">The addition of both Mayo Clinic sites and other major medical centers were brought into the Infoods&#xae; IBS clinicals studies in order to accelerate patient enrollment.</font></p><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560341897688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0pt 0in"><b><font style="FONT-SIZE:10pt; COLOR:black">9.&#xa0;&#xa0;&#xa0; SUBSEQUENT EVENTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">Subsequent to May 31, 2020 and through August 31, 2020, 12,500 stock options were exercised at $1.20 per share.&#xa0; Net proceeds to the Company were approximately $14,900.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On June 15, 2020, the Board approved the grant of 52,000 stock options to certain employees.&#xa0; The options vest one-quarter on June 15, 2021 and then one-quarter per year thereafter.&#xa0; The options have an exercise price of $5.46 per share and have a ten-year life.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On July 13, 2020, the Board approved the grant of 76,000 stock options to certain employees and consultants.&#xa0; The options vest one-quarter on July 13, 2021 and then one-quarter per year thereafter.&#xa0; The options have an exercise price of $8.70 per share and have a ten-year life.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On July 13, 2020, the approved the grant of 7,500 stock options to a consultant.&#xa0; The options vest one-half on January 13, 2021 and one-half on July 13, 2021.&#xa0; The options have an exercise price of $8.70 per share and have a ten-year life.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On June 25, 2020, the Company entered into a Clinical Trial Agreement with the University of Texas Health Science Center for the purpose of conducting a clinical trial of the Biomerica Infoods product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $139,850.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On July 20, 2020, the Company filed with the SEC a new Form S-3 &#x201c;Shelf&#x201d; registration statement to replace the registration statement that expired on that day.&#xa0; The new registration statement registers common shares to be issued in a maximum aggregate of $90,000,000.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On August 27, 2020, the Board approved the grant of 33,000 stock options to an employee and a board member. The options vest one-quarter on August 27, 2021 and then one-quarter per year thereafter.&#xa0; The options have an exercise price of $7.47 per share and have a ten-year life.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On August 27, 2020, the Board approved the grant of 2,500 stock options to a consultant. The options vest one-half on January 13, 2021 and 50% on July 13, 2021. The options have an exercise price of $7.47 per share and have a ten-year life.</font></p><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560337852088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">PRINCIPLES OF CONSOLIDATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The enclosed consolidated financial statements for the years ended May 31, 2020 and 2019 include the accounts of Biomerica, Inc. ("Biomerica") as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">ACCOUNTING ESTIMATES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; and inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, likelihood of lease extensions to occur, asset valuation, among other things; (and other items that may be necessary to estimate using current, historical and judgment based). Actual results could materially differ from those estimates.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">FAIR VALUE OF FINANCIAL INSTRUMENTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company's financial instruments consist of its cash and cash equivalents, accounts receivable,&#xa0;and accounts payable. The carrying amounts of the Company's financial instruments approximate their fair values.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">CONCENTRATION OF CREDIT RISK</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.&#xa0; As of May 31, 2020, the Company had approximately $8,595,241 of uninsured cash.</font> <font style="FONT-SIZE:10pt; COLOR:black">The Company does not believe it is exposed to any significant credit risks.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets.&#xa0; The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. </font></p><br/><p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: justify; margin: 0in 0in 0pt;"><font style="font-size: 10pt; color: black;">For the years ended May 31, 2020 and 2019, the Company had three distributors and two distributors which accounted for a total of 57.2% and 46.3% of our net consolidated sales, respectively. Of this, for the years ended May 31, 2020 and 2019 one of the distributors mentioned above accounted for 25.7% and 36.3%, respectively, of net consolidated sales.&#xa0; At May 31, 2020 and 2019, the Company had three distributors and two distributors which accounted for a total of 80.0% and 68.1%, respectively, of gross accounts receivable. Of the 80.0% as of May 31, 2020, 43.9% was owed by a distributor in Ecuador. Total gross receivables at May 31, 2020 and 2019 were $1,836,852 and $1,527,762, respectively.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">For the year ended May 31, 2020, one vendor accounted for 59.3% of the purchases of raw materials. For the year ended May 31, 2019, two vendors accounted for a total of 23.8 % of the purchases of raw materials.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock', window );">Concentration Risk Geographic Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">GEOGRAPHIC CONCENTRATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">As of May 31, 2020 and 2019, approximately $613,000 and $665,000 of Biomerica's gross inventory and approximately $31,000 and $39,000, of Biomerica's property and equipment, net of accumulated depreciation, was located in Mexicali, Mexico, respectively.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: justify; margin: 0in 0in 0pt;"><strong><font style="font-size: 10pt;">CASH AND </font></strong><font style="font-size: 10pt;"><strong><font style="color: black;">CASH EQUIVALENTS</font></strong></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">ACCOUNTS RECEIVABLE</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company extends unsecured credit to its customers on a regular basis. &#xa0;International accounts are required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. &#xa0;Based on various criteria,&#xa0;initial credit levels for individual distributors are approved by designated officers and managers of the company. All increases in credit limits are also approved by designated upper level management. &#xa0;Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. &#xa0;Balances over ninety days old are usually reserved for unless collection is reasonably assured. &#xa0; </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. &#xa0; Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">INVENTORIES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Inventories approximate the following at May 31:</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td colspan="2" style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt">2020</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td colspan="2" style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style="HEIGHT:16.6pt"> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Raw materials</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; BACKGROUND:aqua">$</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; BACKGROUND:aqua">1,635,000</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt">&#xa0;&#xa0; </font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt">$</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,208,000</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Work in progress</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt">&#xa0;&#xa0; 988,000</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt">&#xa0;&#xa0; 771,000</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Finished products </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; BACKGROUND:aqua">&#xa0;&#xa0; 228,000</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt">&#xa0;&#xa0; 172,000</font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; BORDER-LEFT:0px; PADDING-RIGHT:0in"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt">2,851,000</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,151,000</font></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of May 31, 2020 and 2019, inventory reserves were approximately $67,000 and $49,000, respectively.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">PROPERTY AND EQUIPMENT</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $105,299 and $101,216 for the years ended May 31, 2020 and 2019, respectively.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">INTANGIBLE ASSETS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#x201c;ASC&#x201d;), ASC 350 Intangibles &#x2013; Goodwill and Other (&#x201c;ASC 350&#x201d;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to $23,873 and $61,689 for the years ended May 31, 2020 and 2019, respectively.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset's balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of May 31, 2020 or 2019.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">INVESTMENTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">From time-to-time, the Company makes investments in privately-held companies. &#xa0;The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee&#x2019;s industry), a write-down to estimated fair value is recorded. Investments represent the Company&#x2019;s investment in a Polish distributor which is primarily engaged in distributing medical products and devices. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value of the investment to be greater than the fair value. The Company owns approximately 6% of the investee and, accordingly, applies the cost method to account for the investment. &#xa0;Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">SHARE-BASED COMPENSATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company follows the guidance of the accounting provisions of ASC 718<a name="_Hlk17621381">, </a>Share-based Compensation (&#x201c;ASC 718&#x201d;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#x2019;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#x201c;simplified method&#x201d; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company has not paid dividends historically and does not expect to pay them in the foreseeable future.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">In applying the Black-Scholes options-pricing model, assumptions used were as follows: &#xa0;</font></p><br/><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.94%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:143.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Dividend yield</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 0%</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">0%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Expected volatility</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;55.52-72.62%</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">57.90-60.41%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:143.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Risk free interest rate</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;&#xa0;0.43-1.80%</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2.33-2.85%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Expected life</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.75-6.25 years</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.75-6.25 years</font></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">REVENUE RECOGNITION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company has various contracts with customers.&#xa0; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of May 31, 2020 and does not believe that any additional discounts will be given through the end of the contract periods. </font><font style="FONT-SIZE:10pt">Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. <font style="COLOR:black">The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. &#xa0;Physicians&#x2019; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. </font><a name="_Hlk49511094"></a></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Disaggregation of revenue:</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The following is a breakdown of revenues according to markets to which the products are sold:</font></p><br/><table width="733" style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:550pt; BORDER-COLLAPSE:collapse; BORDER-BOTTOM:0px;  BORDER-LEFT:0px; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:165pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">Year Ended</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;&#xa0;&#xa0; </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2019</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Clinical Lab</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,922,425 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">4,043,993 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">OTC</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,269,535 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">868,605 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Physicians&#x2019; Office</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,194,991 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">170,871 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Contract Manufacturing</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">305,760 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">117,213 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6,692,711 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">5,200,682 </font></p></td></tr></table><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">See Note 7 for additional information regarding revenue concentrations.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods and Service [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">SHIPPING AND HANDLING FEES </font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company includes shipping and handling fees billed to customers in net sales.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">RESEARCH AND DEVELOPMENT</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Research and development costs are expensed as incurred. The Company expensed $1,910,209 and $1,679,098 of research and development costs during the years ended May 31, 2020 and 2019, respectively.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">INCOME TAXES</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. At May 31, 2020 and 2019, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its deferred tax assets.&#xa0;&#xa0; During the fiscal year ended May 31, 2020, this valuation allowance was increased to approximately </font><font style="FONT-SIZE:9pt; COLOR:black">$</font><font style="FONT-SIZE:10pt; COLOR:black">3,175,000, which fully covers the net tax asset of $3,175,000</font><font style="FONT-SIZE:9pt; COLOR:black">.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company&#x2019;s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. Upon adopting the revisions in ASC 740, the Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the &#x201c;Interest expense&#x201d; line and penalties related to liabilities for income taxes within the &#x201c;Other expense&#x201d; line of the consolidated statements of operations and comprehensive loss.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Cost [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">ADVERTISING COSTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately <font style="BACKGROUND:white">$174</font> and $0 for the years ended May 31, 2020 and 2019, respectively.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions and Translations Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">FOREIGN CURRENCY TRANSLATION</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the years ended May 31, 2020 and 2019.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">RIGHT-OF-USE ASSETS AND LEASE LIABILITY</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">Incentive payments received from landlords are recorded as deferred lease incentives and are amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. When the terms of an operating lease provide for periods of free rent, rent concessions, and/or rent escalations, the Company establishes a deferred rent liability for the difference between the scheduled rent payment and the straight-line rent expense recognized. This deferred rent liability was amortized over the underlying lease term on a straight-line basis as a reduction of rent expense.<font style="COLOR:black">&#xa0;During the year ended May 31, 2020, the Company adopted ASC 842, Leases.&#xa0; As a result, the existing deferred rent liability was netted against the Right-of-Use Asset which was capitalized at that time.</font></font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.&#xa0; Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&#xa0; Right-of-Use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&#xa0; Leases will be classified as financing or operating which will drive the expense recognition pattern.&#xa0; For lessees, the statement of operations presentation and expense recognition pattern for financing and operating leases is similar to the current model for capital and operating leases, respectively.&#xa0; The Company has elected to exclude short-term leases.&#xa0; The update also requires additional disclosures that will better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases.&#xa0; The Company adopted this guidance as of June 1, 2019, the required effective date, using the effective date transition method.&#xa0; As permitted under the effective date transition method, financial information and disclosure for periods prior to the date of initial application will not be updated. An adjustment to opening accumulated deficit was not required in conjunction with adoption. The adoption of this statement resulted in a right-of-use asset being recorded in the amount of $1,942,999 and a lease liability being recorded in the amount of $1,980,970. Both will be amortized over the life of the underlying leases. For additional information, see Note 8-Commitments and Contingencies. The Company has elected not to reassess whether expired or existing contracts contain leases, or reassess the classification of existing leases as of the adoption date. The Company leases office space and copy machines, all of which are operating leases.&#xa0; Most leases include the option to renew and the exercise of the renewal options is at the Company&#x2019;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&#xa0; The leases do not include the options to purchase the leased property.&#xa0; The depreciable life of assets and leasehold improvements are limited by the expected lease term.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">NET LOSS PER SHARE</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2020 and 2019 were 1,789,251 and 1,476,209, respectively. </font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">The Company also has outstanding 321,429 of Series A 5% Convertible Preferred Stock, which may be converted at any time to common stock.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">SEGMENT REPORTING</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">ASC 280, Segment Reporting (&#x201c;ASC 280&#x201d;), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company&#x2019;s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing and sales of diagnostic kits.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">REPORTING COMPREHENSIVE LOSS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders&#x2019; equity. Accumulated other comprehensive loss consists solely of foreign currency translation adjustments.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; ">
<p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b><font style="FONT-SIZE:10pt; COLOR:black">RECENT ACCOUNTING PRONOUNCEMENTS</font></b></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt">On February 15, 2018, the FASB issued ASU 2018-02, &#x201c;Reclassification of Certain Tax Effects From Accumulated Comprehensive Income&#x201d; (&#x201c;ASU 2018-02&#x201d;).&#xa0; ASU 2018-02 will give companies the option to reclassify stranded tax effects caused by the newly-enacted U.S. Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) from accumulated other comprehensive income (&#x201c;ASCI&#x201d;) to retained earnings.&#xa0; ASU 2018-02 was effective for all companies for the fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.&#xa0; Management is taking the provisions of this statement into account in the preparation of the consolidated financial statements for the year ended May 31, 2020.&#xa0; The adoption of this standard has not had a significant impact on the Company&#x2019;s consolidated financial statements.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:10pt; COLOR:black">On June 20, 2018, the FASB issued ASU 2018-07,&#xa0;&#x201c;Compensation&#x2014;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&#x201d; (&#x201c;ASU 2018-07&#x201d;). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for share-based payments to nonemployees (service providers, external legal counsel, and suppliers). ASU 2018-07 was effective </font><font style="FONT-SIZE:10pt">for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.&#xa0;During the year ended May 31, 2020, the Company adopted the provisions of this statement and is taking them into account in the preparation of the consolidated financial statements for the year ended May 31, 2020. The adoption of this standard has not had a significant impact on the Company&#x2019;s consolidated financial statements.</font></p><br/><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0pt 0in"><font style="FONT-SIZE:10pt; COLOR:black">Other recent ASU's issued by the FASB and guidance issued by the Securities and Exchange Commission (&#x201c;SEC&#x201d;) did not, or are not believed by management to, have a material effect on the Company&#x2019;s present or future consolidated financial statements.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the description of risks that arise due to concentrations of operating facilities, revenues, assets, customers, vendors or the like in a certain geographic area, either domestic or foreign. The description may address risks inherent in the geographic area, and, at a minimum, informs users of the general nature of the risk, but excludes "Information about Geographic Areas" that may be disclosed elsewhere.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ConcentrationRiskGeographicPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560341968584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td colspan="2" style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt">2020</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td colspan="2" style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style="HEIGHT:16.6pt"> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Raw materials</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; BACKGROUND:aqua">$</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; BACKGROUND:aqua">1,635,000</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt">&#xa0;&#xa0; </font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt">$</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.6pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,208,000</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Work in progress</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt">&#xa0;&#xa0; 988,000</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt">&#xa0;&#xa0; 771,000</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Finished products </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; BACKGROUND:aqua">&#xa0;&#xa0; 228,000</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt">&#xa0;&#xa0; 172,000</font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; BORDER-LEFT:0px; PADDING-RIGHT:0in"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt">2,851,000</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:black 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,151,000</font></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.94%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:143.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Dividend yield</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 0%</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">0%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Expected volatility</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;55.52-72.62%</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">57.90-60.41%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:143.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Risk free interest rate</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;&#xa0;0.43-1.80%</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.94%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2.33-2.85%</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:143.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Expected life</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.75-6.25 years</font></p></td> <td style="HEIGHT:15pt; WIDTH:1.94%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.75-6.25 years</font></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text"><table width="733" style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:550pt; BORDER-COLLAPSE:collapse; BORDER-BOTTOM:0px;  BORDER-LEFT:0px; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:165pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">Year Ended</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;&#xa0;&#xa0; </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:77pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">May 31, 2019</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Clinical Lab</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,922,425 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">4,043,993 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">OTC</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,269,535 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">868,605 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Physicians&#x2019; Office</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,194,991 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">170,871 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:374pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Contract Manufacturing</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">305,760 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">117,213 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:374pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6,692,711 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">5,200,682 </font></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560341913848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:193.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:193.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Licenses</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">551,397 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">510,600 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:193.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Patents</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">113,382 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">68,860 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:193.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-<br/>licenses</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(487,989)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(471,530)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:193.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Less accumulated amortization-<br/>patents</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(8,135)</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(721)</font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:193.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Intangible assets, net</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">168,655 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">107,209 </font></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:123.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:123.85pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">18,112 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:123.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2022</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">8,503 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:123.85pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2023</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6,211 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:123.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2024</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6,136 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:123.85pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2025</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:16%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">5,219 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:123.85pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Thereafter</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:16%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">124,474 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:123.85pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:20pt; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:16%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 16%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">168,655 </font></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560341832232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:205.9pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:205.9pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Accounts payable and accrued expenses</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">986,711 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">999,594 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:205.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Deferred rent</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">-</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">37,971 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:205.9pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">986,711 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,037,565 </font></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560344696200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:39pt"> <td style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">NUMBER OF STOCK OPTIONS</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">EXERCISE PRICE&#xa0; RANGE PER SHARE</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:39pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">WEIGHTED AVERAGE EXERCISE PRICE</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options outstanding at May 31, 2018</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,138,625 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$0.71-$3.90</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1.65 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:175.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options granted</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">558,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$2.25-$3.62</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2.60 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options exercised</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(163,500)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$0.71-$1.04</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">0.76 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options canceled or expired</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(56,916)</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$0.71-$3.62</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2.49 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options outstanding at May 31, 2019</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,476,209 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$3.90</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2.07 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:175.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options granted</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">517,500 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$2.68-$8.18</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">4.47 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:175.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options exercised</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(137,958)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$3.90</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1.64 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options canceled or expired</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(66,500)</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$0.85-$8.18</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.43 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:175.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Options outstanding at May 31, 2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,789,251 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">$0.82-$8.18</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2.75 </font></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Nonvested Share Activity [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:82.5pt"> <td style="HEIGHT:82.5pt; WIDTH:167.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:82.5pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">NUMBER OF SHARES</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:82.5pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:82.5pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">STOCK OPTIONS WEIGHTED AVERAGE AVERAGE GRANT DATE FAIR VALUE</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:167.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2019</font></p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">769,584 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2.49 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:167.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Granted</font></p></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">517,500 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">4.47 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:167.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Vested</font></p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(407,750)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2.25 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:167.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Forfeited</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(56,750)</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.55 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:167.75pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Non-vested shares at May 31, 2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">822,584 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1.5pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">3.78 </font></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</a></td>
<td class="text"><table style="width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0">
<tr style="height: 64.5pt;">
<td style="border-top: 0px; height: 64.5pt; border-right: 0px; width: 17%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">RANGE OF EXERCISE PRICES</font></p>
</td>
<td style="border-top: 0px; height: 64.5pt; border-right: 0px; width: 17%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">&#xa0;NUMBER OUTSTANDING May 31, 2020</font></p>
</td>
<td style="border-top: 0px; height: 64.5pt; border-right: 0px; width: 17%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">&#xa0;WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE IN YEARS</font></p>
</td>
<td style="border-top: 0px; height: 64.5pt; border-right: 0px; width: 16%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">WEIGHTED AVERAGE EXERCISE PRICE</font></p>
</td>
<td style="border-top: 0px; height: 64.5pt; border-right: 0px; width: 15.78%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">&#xa0;NUMBER EXERCISABLE AT MAY 31, 2020</font></p>
</td>
<td style="border-top: 0px; height: 64.5pt; border-right: 0px; width: 16%; border-bottom: windowtext 0pt solid; border-left: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">&#xa0;WEIGHTED AVERAGE EXERCISE PRICE</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$ 0.82-$1.04</font></p>
</td>
<td style="height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">276,000</font></p>
</td>
<td style="height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">4.44</font></p>
</td>
<td style="height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$0.84 </font></p>
</td>
<td style="height: 15pt; width: 15.78%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">276,000</font></p>
</td>
<td style="height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$0.84 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 17%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$ 1.20-$ 2.81</font></p>
</td>
<td style="height: 15pt; width: 17%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">1,072,500</font></p>
</td>
<td style="height: 15pt; width: 17%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">7.57</font></p>
</td>
<td style="height: 15pt; width: 16%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$2.17 </font></p>
</td>
<td style="height: 15pt; width: 15.78%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">506,000</font></p>
</td>
<td style="height: 15pt; width: 16%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$1.71 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$ 3.62-$ 8.18</font></p>
</td>
<td style="height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">440,751</font></p>
</td>
<td style="height: 15pt; width: 17%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">7.62</font></p>
</td>
<td style="height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$5.38 </font></p>
</td>
<td style="height: 15pt; width: 15.78%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">184,667</font></p>
</td>
<td style="height: 15pt; width: 16%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$3.87 </font></p>
</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560342057032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;Years ended May 31,</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Current:</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">U.S. Federal</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;-- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;-- </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Foreign Taxes Subsidiaries</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(6,590)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(13,437)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">State and local</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(800)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(800)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total current</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(7,390)</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(14,237)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Deferred:</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">U.S. Federal&#xa0;</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;-- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(10,000)</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">State and local</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;-- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;-- </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:218.15pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total deferred</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;-- </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(10,000)</font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:218.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Income tax expense</font></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(7,390)</font></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">(24,237)</font></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><table style="width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0">
<tr style="height: 15pt;">
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 3.5in; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Years ended May 31,</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">2020</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">2019</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 3.5in; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Computed "expected" tax benefit </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">489,651 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">497,453 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 3.5in; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Increase (reduction) in income taxes resulting from:</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 3.5in; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Change in valuation allowance</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(716,000)</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(910,000)</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 3.5in; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">State income taxes, net of federal benefit</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">154,254 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">89,267 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 3.5in; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Research and development tax credits</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">49,770 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">55,908 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 3.5in; white-space: nowrap; padding: 0in 0in 0in 0pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Permanent tax differences and other</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">21,525 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(256,572)</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 3.5in; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 0in 0in 0pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Foreign taxes of subsidiaries</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(6,590)</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(13,437)</font></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="height: 15.75pt; width: 3.5in; white-space: nowrap; padding: 0in 0in 0in 0pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Income tax expense</font></p>
</td>
<td style="height: 15.75pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(7,390)</font></p>
</td>
<td style="height: 15.75pt; width: 2%; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(24,237)</font></p>
</td>
</tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><table style="width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0">
<tr style="height: 15pt;">
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 301.7pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">As of May 31,</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">2020</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" colspan="2" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: center; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">2019</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Deferred tax assets:</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Accounts receivable, principally due to allowance for doubtful accounts</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">17,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">18,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Inventory valuation&#xa0;&#xa0;&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">16,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">12,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Compensated absences</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">64,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">48,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Net operating loss carryforwards&#xa0;&#xa0;&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">2,286,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">1,735,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Tax credit carryforwards</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">599,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">467,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Deferred rent expense/Capitalized leases</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">17,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 10%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">9,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Other</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">171,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">176,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; background: #80ffff; white-space: nowrap; padding: 0in 0in 0in 0.1in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Accumulated depreciation and amortization</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">5,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 0pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(6,000)</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 301.7pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Total deferred tax assets&#xa0;&#xa0;&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">3,175,000 </font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">2,459,000 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 301.7pt; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Less valuation allowance</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(3,175,000)</font></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #80ffff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">(2,459,000)</font></p>
</td>
</tr>
<tr style="height: 15.75pt;">
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 301.7pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Net deferred tax asset</font></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">&#xa0;-- </font></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">&#xa0;-- </font></p>
</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560417750520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_GeographicInformationDisclosureAbstract', window );"><strong>Geographic Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Years ended May 31,</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2020</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: center;"><font style="FONT-SIZE:10pt; COLOR:black">2019</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Net sales:</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Europe</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,434,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,694,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">United States &#xa0;</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">445,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">523,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Asia</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,867,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">2,514,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">South America</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,615,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">256,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:157.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Middle East</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">314,000 </font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">214,000 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.15in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Other foreign</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">18,000 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">&#xa0;-- </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:157.7pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.25in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total net sales</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">6,693,000 </font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">5,201,000 </font></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GeographicInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GeographicInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560341882664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock', window );">Schedule Of Cash Flow Supplemental Disclosures Related To Lease [Table Text Block]</a></td>
<td class="text"><table style="width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0">
<tr style="height: 15pt;">
<td style="height: 15pt; width: 365.05pt; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Operating cash flows from operating leases&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">$</font></p>
</td>
<td style="height: 15pt; width: 12%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">311,742 </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 365.05pt; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">&#xa0;</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 365.05pt; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Right-of-use assets obtained in exchange for <br/>&#xa0;&#xa0; new operating lease liabilities</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #80ffff; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">&#xa0;-- </font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 365.05pt; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Weighted average remaining lease term (in years)</font></p>
</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#xa0;</td>
<td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">6.27</font></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 365.05pt; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">Weighted average discount rate</font></p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 2%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p>
</td>
<td style="height: 15pt; width: 12%; background: #80ffff; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman','serif'; text-align: right; margin: 0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt; color: black;">6.5%</font></p>
</td>
</tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text"><table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Years ending May 31,</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2021</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">211,808 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2022</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">236,391 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2023</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">262,810 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2024</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">291,329 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">2025</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">322,098 </font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:148.3pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.1in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Thereafter</font></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">457,051 </font></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:148.3pt; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.2in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">Total</font></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#80ffff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;">&#xa0;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto;"><font style="FONT-SIZE:10pt; COLOR:black">$</font></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#80ffff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; margin-left: auto; margin-right: auto; text-align: right;"><font style="FONT-SIZE:10pt; COLOR:black">1,781,487 </font></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information related to lease for the periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560334479128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="nump">$ 8,595,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesGrossCurrent', window );">Other Receivables, Gross, Current</a></td>
<td class="nump">1,836,852<span></span>
</td>
<td class="nump">$ 1,527,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">$ 279,379<span></span>
</td>
<td class="nump">351,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable', window );">Threshold Period Past Due for Write-off of Trade Accounts Receivable</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory Valuation Reserves</a></td>
<td class="nump">$ 67,000<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, Depletion and Amortization</a></td>
<td class="nump">105,299<span></span>
</td>
<td class="nump">101,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 23,873<span></span>
</td>
<td class="nump">61,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">$ 1,910,209<span></span>
</td>
<td class="nump">1,679,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">3,175,000<span></span>
</td>
<td class="nump">2,459,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross</a></td>
<td class="nump">3,175,000<span></span>
</td>
<td class="nump">2,459,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Expense</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 1,711,510<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)</a></td>
<td class="nump">1,789,251<span></span>
</td>
<td class="nump">1,476,209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmra_PurchasedTechnologyRightsMember', window );">Purchased Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">MEXICO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross</a></td>
<td class="nump">$ 613,000<span></span>
</td>
<td class="nump">$ 665,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">31,000<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">1,942,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 1,980,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=bmra_ThreeDistributorsMember', window );">Three Distributors [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">57.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=bmra_ThreeDistributorsMember', window );">Three Distributors [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=bmra_TwoDistributorsMember', window );">Two Distributors [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=bmra_TwoDistributorsMember', window );">Two Distributors [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=bmra_OneDistributorsMember', window );">One Distributors [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">25.70%<span></span>
</td>
<td class="nump">36.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=bmra_DistributorsInEcuadorMember', window );">Distributors in Ecuador [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">43.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Cost of Goods and Service, Product and Service Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">59.30%<span></span>
</td>
<td class="nump">23.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember', window );">5% Convertible Preferred Stock [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)</a></td>
<td class="nump">321,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period past due for trade accounts receivable to write off as uncollectible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmra_PurchasedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmra_PurchasedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=bmra_ThreeDistributorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=bmra_ThreeDistributorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=bmra_TwoDistributorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=bmra_TwoDistributorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=bmra_OneDistributorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=bmra_OneDistributorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=bmra_DistributorsInEcuadorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=bmra_DistributorsInEcuadorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560340746040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_InventoriesAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,635,000<span></span>
</td>
<td class="nump">$ 1,208,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">988,000<span></span>
</td>
<td class="nump">771,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished products</a></td>
<td class="nump">228,000<span></span>
</td>
<td class="nump">172,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 2,850,836<span></span>
</td>
<td class="nump">$ 2,151,090<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_InventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_InventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560339618744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">55.52%<span></span>
</td>
<td class="nump">57.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.43%<span></span>
</td>
<td class="nump">2.33%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">3 years 9 months<span></span>
</td>
<td class="text">3 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">72.62%<span></span>
</td>
<td class="nump">60.41%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.85%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsSharebasedcompensationassumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560339243016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">$ 6,692,711<span></span>
</td>
<td class="nump">$ 5,200,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ClinicalLabMember', window );">Clinical Lab [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">2,922,425<span></span>
</td>
<td class="nump">4,043,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_OTCMember', window );">OTC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">1,269,535<span></span>
</td>
<td class="nump">868,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_PhysiciansOfficeMember', window );">Physicians Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">2,194,991<span></span>
</td>
<td class="nump">170,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ContractManufacturingMember', window );">Contract Manufacturing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">$ 305,760<span></span>
</td>
<td class="nump">$ 117,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ClinicalLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_ClinicalLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_OTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_OTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_PhysiciansOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_PhysiciansOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560439334504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Details) - Intangible assets, net - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_IntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedLicenseAgreementsGross', window );">Licenses</a></td>
<td class="nump">$ 551,397<span></span>
</td>
<td class="nump">$ 510,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patents</a></td>
<td class="nump">113,382<span></span>
</td>
<td class="nump">68,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_FiniteLivedLicenseAccumulatedAmortization', window );">Less accumulated amortization- licenses</a></td>
<td class="num">(487,989)<span></span>
</td>
<td class="num">(471,530)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_FiniteLivedPatentsAccumulatedAmortization', window );">Less accumulated amortization- patents</a></td>
<td class="num">(8,135)<span></span>
</td>
<td class="num">(721)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 168,655<span></span>
</td>
<td class="nump">$ 107,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_FiniteLivedLicenseAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of licenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_FiniteLivedLicenseAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_FiniteLivedPatentsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_FiniteLivedPatentsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedLicenseAgreementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedLicenseAgreementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560418946632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Details) - Expected amortization of intangible assets<br></strong></div></th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ExpectedAmortizationOfIntangibleAssetsAbstract', window );"><strong>Expected amortization of intangible assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 18,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">8,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">6,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">6,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">5,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">124,474<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 168,655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ExpectedAmortizationOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ExpectedAmortizationOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560337753176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts Payable [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=bmra_TwoVendorsMember', window );">Two Vendors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">26.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=bmra_OneVendorMember', window );">One Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=bmra_TwoVendorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=bmra_TwoVendorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=bmra_OneVendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=bmra_OneVendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560344676072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense balances - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_AccountsPayableAndAccruedExpenseBalancesAbstract', window );"><strong>Accounts payable and accrued expense balances [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 986,711<span></span>
</td>
<td class="nump">$ 999,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,971<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 986,711<span></span>
</td>
<td class="nump">$ 1,037,565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_AccountsPayableAndAccruedExpenseBalancesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_AccountsPayableAndAccruedExpenseBalancesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560328760760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">28 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 24, 2020</div></th>
<th class="th"><div>Feb. 24, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 01, 2017</div></th>
<th class="th"><div>Jul. 20, 2017</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Aug. 31, 2010</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Mar. 19, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Feb. 26, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,534<span></span>
</td>
<td class="nump">$ 121,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,232,857<span></span>
</td>
<td class="nump">$ 1,776,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,958<span></span>
</td>
<td class="nump">163,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,470<span></span>
</td>
<td class="nump">$ 151,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.47<span></span>
</td>
<td class="nump">$ 2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 589,000<span></span>
</td>
<td class="nump">$ 364,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,923,000<span></span>
</td>
<td class="nump">808,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,442,000<span></span>
</td>
<td class="nump">685,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 663,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 244 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 69 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | MEXICO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | 2010 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | 2014 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | 2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | 2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,892<span></span>
</td>
<td class="nump">3,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,750<span></span>
</td>
<td class="nump">143,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Selling and Marketing Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,933<span></span>
</td>
<td class="nump">$ 4,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember', window );">5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in Shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Preferred Stock, Dividends Per Share, Declared (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends, Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember', window );">5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of Stock, Amount Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Conversion of Stock, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may require the conversion of all of the outstanding Series A 5% Convertible Preferred Stock shares if the closing sale price of the Company&#x2019;s common stock equals or exceeds $9.00 for a period of five consecutive trading days with a minimum average trading volume of 35,000 shares per day over such period; provided, that, on such date, the Conversion Shares are registered for resale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in Shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="nump">$ 82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,232,857<span></span>
</td>
<td class="nump">$ 1,776,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,588,378<span></span>
</td>
<td class="nump">$ 1,847,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,674,943<span></span>
</td>
<td class="nump">625,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.08<span></span>
</td>
<td class="nump">$ 4.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="nump">$ 2.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,958<span></span>
</td>
<td class="nump">163,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.90<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,534<span></span>
</td>
<td class="nump">$ 121,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | At Market Issuance Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,232,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,771,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,997,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,674,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | At Market Issuance Sales Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | At Market Issuance Sales Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | At Market Issuance Sales Agreement [Member] | Registration Rights Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,817,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | At Market Issuance Sales Agreement [Member] | Registration Rights Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SHAREHOLDERSEQUITYDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bmra_A2010PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bmra_A2010PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bmra_A2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bmra_A2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bmra_A2017PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bmra_A2017PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bmra_A2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bmra_A2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bmra_A5PercentConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bmra_AtMarketIssuanceSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bmra_AtMarketIssuanceSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_RegistrationRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_RegistrationRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560328666312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare071390Member', window );">Exercise Price Range Per Share $0.71 - $3.90 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,138,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare225362Member', window );">Exercise Price Range Per Share $2.25 - $3.62 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, number of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">558,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare071104Member', window );">Exercise Price Range Per Share $0.71 - $1.04 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, number of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare071362Member', window );">Exercise Price Range Per Share $0.71 - $3.62 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options canceled or expired, number of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled or expired, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082390Member', window );">Exercise Price Range Per Share $0.82 - $3.90 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number of stock options</a></td>
<td class="nump">1,476,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, number of stock options</a></td>
<td class="num">(137,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, weighted average exercise price</a></td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,476,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare268818Member', window );">Exercise Price Range Per Share $2.68 - $8.18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, number of stock options</a></td>
<td class="nump">517,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted average exercise price</a></td>
<td class="nump">$ 4.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare085818Member', window );">Exercise Price Range Per Share $0.85 - $8.18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options canceled or expired, number of stock options</a></td>
<td class="num">(66,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled or expired, weighted average exercise price</a></td>
<td class="nump">$ 3.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082818Member', window );">Exercise Price Range Per Share $0.82 - $8.18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number of stock options</a></td>
<td class="nump">1,789,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SHAREHOLDERSEQUITYDetailsOutstandingStockOptionsActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare071390Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare071390Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare225362Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare225362Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare071104Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare071104Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare071362Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare071362Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082390Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082390Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare268818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare268818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare085818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare085818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_ExercisePriceRangePerShare082818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560340507528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) - Non-vested Stock Options Activity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_NonVestedStockOptionsActivityAbstract', window );"><strong>Non-vested Stock Options Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested shares, number of shares | shares</a></td>
<td class="nump">769,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested shares, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 2.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, number of shares | shares</a></td>
<td class="nump">517,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 4.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested, number of shares | shares</a></td>
<td class="num">(407,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 2.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited, number of shares | shares</a></td>
<td class="num">(56,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 3.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested shares, number of shares | shares</a></td>
<td class="nump">822,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested shares, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 3.78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_NonVestedStockOptionsActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_NonVestedStockOptionsActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560339285448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) - Stock Options Summary<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice082104Member', window );">Range Of Exercise Price $0.82 - $1.04 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, Minimum</a></td>
<td class="nump">$ 0.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, Maximum</a></td>
<td class="nump">$ 1.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number (in Shares) | shares</a></td>
<td class="nump">276,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">4 years 160 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number (in Shares) | shares</a></td>
<td class="nump">276,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice120281Member', window );">Range Of Exercise Price $1.20 - $2.81 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, Minimum</a></td>
<td class="nump">1.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, Maximum</a></td>
<td class="nump">$ 2.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number (in Shares) | shares</a></td>
<td class="nump">1,072,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 208 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number (in Shares) | shares</a></td>
<td class="nump">506,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice362818Member', window );">Range Of Exercise Price $3.62 - $8.18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, Minimum</a></td>
<td class="nump">3.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, Maximum</a></td>
<td class="nump">$ 8.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number (in Shares) | shares</a></td>
<td class="nump">440,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 226 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number (in Shares) | shares</a></td>
<td class="nump">184,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice082104Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice082104Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice120281Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice120281Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice362818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bmra_RangeOfExercisePrice362818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560345022232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">$ 3,175,000<span></span>
</td>
<td class="nump">$ 2,459,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">716,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">9,213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=bmra_CaliforniaStateIncomeTaxMember', window );">California State Income Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">5,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">438,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member] | State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_INCOMETAXESDetailsLineItems', window );"><strong>INCOME TAXES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_INCOMETAXESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_INCOMETAXESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=bmra_CaliforniaStateIncomeTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=bmra_CaliforniaStateIncomeTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560328708168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - Income tax expense - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign Taxes Subsidiaries</a></td>
<td class="num">(6,590)<span></span>
</td>
<td class="num">(13,437)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(800)<span></span>
</td>
<td class="num">(800)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="num">(7,390)<span></span>
</td>
<td class="num">(14,237)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">$ (7,390)<span></span>
</td>
<td class="num">$ (24,237)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560340529352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - Income Tax Rate Reconciliation - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_IncomeTaxRateReconciliationAbstract', window );"><strong>Income Tax Rate Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Computed "expected" tax benefit</a></td>
<td class="nump">$ 489,651<span></span>
</td>
<td class="nump">$ 497,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract', window );"><strong>Increase (reduction) in income taxes resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(716,000)<span></span>
</td>
<td class="num">(910,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">154,254<span></span>
</td>
<td class="nump">89,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">49,770<span></span>
</td>
<td class="nump">55,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent tax differences and other</a></td>
<td class="nump">21,525<span></span>
</td>
<td class="num">(256,572)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign taxes of subsidiaries</a></td>
<td class="num">(6,590)<span></span>
</td>
<td class="num">(13,437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">$ (7,390)<span></span>
</td>
<td class="num">$ (24,237)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncomeTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncomeTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncreaseReductionInIncomeTaxesResultingFromAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560334458920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details) - Deferred Tax - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Accounts receivable, principally due to allowance for doubtful accounts</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory valuation</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Compensated absences</a></td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">2,286,000<span></span>
</td>
<td class="nump">1,735,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">599,000<span></span>
</td>
<td class="nump">467,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent expense/Capitalized leases</a></td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">171,000<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization', window );">Accumulated depreciation and amortization</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">3,175,000<span></span>
</td>
<td class="nump">2,459,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(3,175,000)<span></span>
</td>
<td class="num">(2,459,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accumulated depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_DeferredTaxAssetsAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560426130696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_GeographicInformationDisclosureAbstract', window );"><strong>Geographic Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GeographicInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GeographicInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560340226088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 6,692,711<span></span>
</td>
<td class="nump">$ 5,200,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">2,434,000<span></span>
</td>
<td class="nump">1,694,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">445,000<span></span>
</td>
<td class="nump">523,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaMember', window );">Asia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">1,867,000<span></span>
</td>
<td class="nump">2,514,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_SouthAmericaMember', window );">South America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">1,615,000<span></span>
</td>
<td class="nump">256,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_MiddleEastMember', window );">Middle East [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">314,000<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bmra_OtherForeignMember', window );">Other Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_SouthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_SouthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_MiddleEastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_MiddleEastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bmra_OtherForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bmra_OtherForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560324374088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 18, 2020</div></th>
<th class="th"><div>May 07, 2020</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>May 25, 2016</div></th>
<th class="th"><div>Jun. 18, 2009</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>May 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 25, 2019</div></th>
<th class="th"><div>Jul. 22, 2019</div></th>
<th class="th"><div>Jul. 12, 2019</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,910,209<span></span>
</td>
<td class="nump">$ 1,679,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">MEXICO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,481<span></span>
</td>
<td class="nump">46,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,267<span></span>
</td>
<td class="nump">268,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=bmra_EZDetectProductMember', window );">EZ Detect Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ContractTerm', window );">Contract Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other Nonoperating Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=bmra_EZDetectProductMember', window );">EZ Detect Product [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SuccessFeesPercentage', window );">Success Fees Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=bmra_EZDetectProductMember', window );">EZ Detect Product [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SuccessFeesPercentage', window );">Success Fees Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=bmra_NonexclusiveDistributorAgreementMember', window );">Non-exclusive Distributor Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ContractTerm', window );">Contract Term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=bmra_BuildingInIrvineCaliforniaMember', window );">Building In Irvine California [Member] | First Amendment To Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Operating Leases, Rent Expense, Minimum Rentals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RentalExpenseIncreaseDuringPeriod', window );">Rental Expense, Increase During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseDepositLiability', window );">Lease Deposit Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertyAvailableForOperatingLeaseMember', window );">Property Available for Operating Lease [Member] | MEXICO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Operating Leases, Rent Expense, Minimum Rentals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_LeaseExpirationPeriod', window );">Lease Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MaxHealthMember', window );">MaxHealth [Member] | EZ Detect Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related Party Transaction, Purchases from Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty', window );">Related Party Transaction, Due from (to) Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related Party Transaction, Description of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The $1,000,000 was to be used as a prepayment for the first $1,000,000 of purchase orders for the product. While the Company received the first deposit of $100,000, and shipped $100,000 of product to Maxhealth, the Company has not received the second deposit, and has not shipped any further product, which has placed MaxHealth in Default of the agreement<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOFMichiganMember', window );">University OF Michigan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,900<span></span>
</td>
<td class="nump">40,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_BilledCommitmentPercentage', window );">Billed Commitment, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_DeaconessMedicalCenterMember', window );">Deaconess Medical Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 305,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,640<span></span>
</td>
<td class="nump">146,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_ResearchManagementInstitutionMember', window );">Research Management Institution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaInfoodsProductMember', window );">Biomerica Infoods Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_BilledCommitmentPercentage', window );">Billed Commitment, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaInfoodsIBSProductMember', window );">Biomerica Infoods IBS Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_BilledCommitmentPercentage', window );">Billed Commitment, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaHPyloriProductMember', window );">Biomerica H. Pylori Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_BilledCommitmentPercentage', window );">Billed Commitment, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_HoustonMethodistResearchInstituteMember', window );">Houston Methodist Research Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_BilledCommitmentPercentage', window );">Billed Commitment, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MayoClinicArizonaMember', window );">Mayo Clinic Arizona [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_BilledCommitmentPercentage', window );">Billed Commitment, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MayoClinicJacksonvilleMember', window );">Mayo Clinic Jacksonville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RoyaltyExpensePercentageOfSales', window );">Royalty Expense Percentage Of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_TelconAgreementMember', window );">Telcon Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedFeesAndOtherRevenueReceivable', window );">Accrued Fees and Other Revenue Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Proceeds from Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_RoyaltyPercentage', window );">Royalty Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_MountSinaiLicenseAgreementsMember', window );">Mount Sinai License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related Party Transaction, Purchases from Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_MountSinaiLicenseAgreementsMember', window );">Mount Sinai License Agreements [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related Party Transaction, Purchases from Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_UCLicenseAgreementsMember', window );">UC License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_LicenseMaintenanceFee', window );">License Maintenance Fee, Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_UCLicenseAgreementsMember', window );">UC License Agreements [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_UniversityOfSouthernCaliforniaMember', window );">University Of Southern California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedFeesAndOtherRevenueReceivable', window );">Accrued Fees and Other Revenue Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_UniversityOfSouthernCaliforniaMember', window );">University Of Southern California [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_BilledCommitmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the commitment billed during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_BilledCommitmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_COMMITMENTSANDCONTINGENCIESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum budgeted costs related to clinical trial agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ClinicalTrialAgreementMaximumBudgetedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of the contract in which it expires.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_LeaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of years in which the lease expires.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_LeaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_LicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of license maintenance fee payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_LicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_RentalExpenseIncreaseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rental expense increase during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_RentalExpenseIncreaseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_RoyaltyExpensePercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty expenses expressed as a percentage of sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_RoyaltyExpensePercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SuccessFeesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of success related to the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SuccessFeesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedFeesAndOtherRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the amount of fees and other revenue, excluding investment income receivable, earned but not yet received, which were recognized in conformity with revenue recognition criteria based on estimates or specific contractual terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedFeesAndOtherRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121604594&amp;loc=SL77919106-209958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121595440&amp;loc=d3e34039-112682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for fees during the current period. This element excludes cash proceeds from license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919370-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121603689&amp;loc=d3e36975-112693<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918703-209980<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121606570&amp;loc=SL77919784-209982<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bmra_EZDetectProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bmra_EZDetectProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bmra_NonexclusiveDistributorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bmra_NonexclusiveDistributorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=bmra_BuildingInIrvineCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=bmra_BuildingInIrvineCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_LeaseAmendmentAxis=bmra_FirstAmendmentToLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_LeaseAmendmentAxis=bmra_FirstAmendmentToLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertyAvailableForOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertyAvailableForOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MaxHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MaxHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOFMichiganMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOFMichiganMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_DeaconessMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_DeaconessMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_ResearchManagementInstitutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_ResearchManagementInstitutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaInfoodsProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaInfoodsProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaInfoodsIBSProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaInfoodsIBSProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaHPyloriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_BiomericaHPyloriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_HoustonMethodistResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_HoustonMethodistResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MayoClinicArizonaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MayoClinicArizonaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MayoClinicJacksonvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_MayoClinicJacksonvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_TelconAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_TelconAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_MountSinaiLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_MountSinaiLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_UCLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_UCLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_UniversityOfSouthernCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_UniversityOfSouthernCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560338991368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - Supplemental cash flow information related to leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract', window );"><strong>Supplemental cash flow information related to leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 311,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">6 years 98 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560417618024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - The maturity of lease liabilities<br></strong></div></th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_TheMaturityOfLeaseLiabilitiesAbstract', window );"><strong>The maturity of lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 211,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">236,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">262,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">291,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">322,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">457,051<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 1,781,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_TheMaturityOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_TheMaturityOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140560339034840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 27, 2020</div></th>
<th class="th"><div>Jul. 20, 2020</div></th>
<th class="th"><div>Jul. 13, 2020</div></th>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jun. 25, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOfTexasHealthScienceCenterMember', window );">University Of Texas Health Science Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts', window );">Clinical Trial Agreement Maximum Budgeted Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Employees and Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Employee and Board Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmra_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ClinicalTrialAgreementMaximumBudgetedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum budgeted costs related to clinical trial agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ClinicalTrialAgreementMaximumBudgetedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SUBSEQUENTEVENTSDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SUBSEQUENTEVENTSDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOfTexasHealthScienceCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_UniversityOfTexasHealthScienceCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_EmployeesAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_EmployeesAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_EmployeeAndBoardMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_EmployeeAndBoardMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" !NB!]1([X@S@<$   I#P  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;*5778_B-A1]WOX**^I#*RV3Q($!5H#$Q[!%VV$1='<UCY[$0#2)36UG&/Y]
MKYV0L--@HG8>ACCQ.??8]_HD=W#DXD7N*57H+4V8'#I[I0Z?7%>&>YH2><</
ME,&3+1<I43 4.U<>!"61 :6)BSWOWDU)S)S1P-Q;B=& 9RJ)&5T))+,T)>(T
MH0D_#AW?.=]8Q[N]TC?<T>! =G1#U;?#2L#(+5FB.*5,QIPA0;=#9^Q_FF$#
M,#.^Q_0H+ZZ17LHSYR]ZL(B&CJ<5T82&2E,0^'FE4YHDF@ET_%V0.F5,#;R\
M/K//S>)A,<]$TBE/?L21V@^=GH,BNB59HM;\^ <M%M31?"%/I/F/COG<-G90
MF$G%TP(,"M*8Y;_DK=B("P"^!L % +\#^.TK@*  !$T![0+0-CN3+\7LPXPH
M,AH(?D1"SP8V?6$VTZ!A^3'3>=\H 4]CP*G1C(<9I%&A,8O0 U.Q.J$%R^M)
MYZ6%OFUFZ+=??Q^X"L)ID!L6U).<&E^A]C%ZY$SM)?!&-/J9P 6=I5A\%CO!
M5L9'<D*!_Q%A#WLU>J9V]#C;W=G@,SM\R5\![FFXW[<L)BAW/C!\P:V=O]SN
M/V$26BB:2DN$=AFA;2*TKT0HTKFFNU@J02#4DJ2T+I%VGLGBZ^/#>C$=H\5R
M:M'5*75UK'SERO\Z'6KEV.&^U_IB47%?JKBWTDPS(;2(>2Q#DJ G2H0N5 3'
MJ%:4G:W5\CJMP+?HZI:ZNDVR-N5I"@6Q43Q\^8@V>R*H1%\S)15A4<QV=?6?
M$W<,L3;\UY'O=SNXTX-Z?:V1U"LE]9I(6F7/21RB><*)JCL_.<G]17@<!/UN
MK^O5A^^7X?O6\&,HEL@4S#PA=0N?V/%;DDAJR8SO56;I-<H-:!%0,POPM3?T
MA9YJS=%.Y>F_;H#[GDW9A8W[C9051;VF!RX4E D4$%&9K!5H9WRB-@_R<:4,
M-U'VG2<94_!I 0<NH:)>D9WIAJ+*>/V@B2*C TWAN.^XJ$^AG6?)68N$(7S#
M""")<D*;PLJX_4;._0,^AUHOC!_!!RB1G$&0A939^RB%6COGDMND5=[M-S3O
M%14QCZR6>8.J>)W_\N'#O]_(/ZNK/-VWVW"I[M+5YW"SOM[L9+=458[NVRW]
MO:IBZZ[KLM/-GVRJ*E/W&[GZ)B5)@B:9A,>R7HZ=1XG,ZJZ5S?MVGRX$/:14
M[+1U?08&M==OP@-A]0?T_QD_KHP?-S+^S1Y.I$W0#9J;@BJ_QXW\?L$4F(_I
MG?0I).<70*VV_^3W[D5OH1-C>C2)0@YNGK<9Y=VR#QR;[L>MIN=-Y"/1>94H
MH5N >G==L >1]V7Y0/&#Z52>N8*^QUSNH9>E0D^ YUO.U7F@ Y3=\>@?4$L#
M!!0    ( &Z('U%@I$#VO <   TB   8    >&PO=V]R:W-H965T<R]S:&5E
M=#(N>&UL[5IM;^)&$/XK*Y2JK>0[O+M^O2:1".$N2 FDP+6JJG[8P!*L\PNU
MU^12]<=WUCC8V.L-:?NE4C^0&#P[?F9V9IZ9A?.G)/V2;3@7Z&L4QME%;R/$
M]D._GRTW/&+9^V3+8[BS3M*("7B;/O:S;<K9JE@4A7UBFDX_8D'<NSPO/KM/
M+\^37(1!S.]3E.51Q-+G*QXF3Q<]W'OY8!8\;H3\H']YOF6/?,[%Y^U]"N_Z
M!RVK(.)Q%B0Q2OGZHC? 'X:6*1<4$C\%_"FK72-IRD.2?)%OQJN+GBD1\9 O
MA53!X-^.#WD82DV X_=2:>_P3+FP?OVB_6-A/!CSP#(^3,*?@Y787/2\'EKQ
M-<M#,4N>;GAID"WU+9,P*_ZBIU+6[*%EGHDD*A<#@BB(]__9U](1M068=BP@
MY0)RZ@):+J"%H7MDA5G73+#+\S1Y0JF4!FWRHO!-L1JL"6*YC7.1PMT UHG+
MX70RG]Z.KP>+T36Z&MP.)L,1FM^,1HLY>H<^SZ_1=V??G_<%/$HNZ"]+M5=[
MM:1#[1U[1A0;B)C$5*P>GKH:^\>K^V#>P49RL)$4ZFB7C9]GL]%D@0;S.9CU
M0:.1'C320J/5I9%E&\3B%5K*"_Y['NQ8R&.1J3RU5^44JF16[2X]Q\(F<<_[
MN[I/VG*.Y[B>?1 [@FH=H%I:J(/E,LD!&>3<D@/,AY ;*.19AE@(.<SB)4=0
M#= JR1_$.@\AL<H%R1J=N:;A>[@P]<RE!L:F 8JR+2^R+WQ6V;O'8]?LP*YC
M>RYNV*N0LVS+L8G:8/M@L*TU>!SO8">2-."9@6(N5!#MUJ.)9YL>=1H0%7+8
MQJ9OJB$Z!XB.%N)]RK<L6"'^%:IQQK/"OXG8\%0%UFG[R08('FV ;<M!]EEF
MASO= U97BW61"!9")4I3\"IB6<;54>XJ=M-U' \WP[PM:%F^Y1-?C=,[X/2T
M27X_F]Z/9HM?T&!RC48_?A[?WT'.ZY+=/VCVM1X807IO@;F4D>2WS?8)]FAS
M<Q1RGH^IA]568[.JWZ86W<<\C0.1IY#5Z^"KO-B'4\B!W#9)N$)!M$V3'8^Z
MZE/Y@*/ (3; :YB@E"-FS=1C$VH4A$\(,0"YY:EX+M!SG<]+=<=I:;DF(4W$
M*D%,+6QU0*X8!9/7JFH>Y2$3? 5- S10RX#)MD0)E[10O,-0V1VK&21*2=<A
MU.H"7!$6UC/6!#K"-WB8MAWG^M1MA41;CD)]=#OJ(ZY("^M9:SQ9#":?QE>W
MHY*UBU(N*8G5/,^B)!7!']V>5U ,<*IM-\U0R)DN,3M*$JZH".NY:#;^=+-
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ME>>AS&.?R/-$?B('WR+;LJT.[^FYWGAPZ&TJO;5HNQ9M%^%Z)\)-8K5Z21H
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MQ>&^6G=:KHMZUH4(+$G.CPP$>8SC7PT,A1.U)^CLR11I+2ZC'\"$GP RD*'
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MENQWQW?'X[V3,CR(]'.VY5R"YSA*LHO>5LK=N\$@6VUY'&1OQ8XGZI>-2.-
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MBKH%]3K+]OGYRK=]5ST2%@5@?08U]=2A##EZIDU%16H6])B1: O01TSUF);
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M7%QN>;#F:0Y0OV^$D"\W^>OBZF\BH_\ 4$L#!!0    ( &Z('U'/'4-JI0<
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M[+=2>5!F&7,V*?,_L[1>7PW" 4K9*M[E]6/Y\@=K%?+$?$F9<_D_>FED W^
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M6''-NFGCB#W_J$(([@K0)CI-9G?\!QRX^9% CCX4,<  5()S"\^ 3/"/@#Y
M\>)P!U\ _L6-5*8BS"ZY'+9#54:"&^6I360F2&EH0* 6&-<;@E5@^B/0(1(S
M^-;BOQ1PR"&BA9BC"A%5C)AR!5@'(FHT%MLTA$V V&(8!GB;1B3 >LIN5)FE
MC$?X?'*@L]!@*$#?49J1-^5^Y]%@/:A@0F)"=I61CDLD&4N06X)242E+/? 0
M(LXER'@-G2Q6 AD",V0H%P(F,J=0>*$1N"FS3K9;_"'3C^SB9<.@JE>_@DVZ
MGDTGS:B'<;EO;!D=PMF+[N1@I][%&D1EDR "X1@N1"E>))G+[:!)1 0+3P*@
MBQ&P()[E[+1D(99)8<K#!&PL?T(HNM$0N<7F)Z"43#.<?IK\B>QDVAH\Y40$
MFF.2I =,8WNT(W,%^H-T P4NV^*'[R\HB/<$I@/@J4!MUSM#$1D8;%!,#H5Q
M,SI:9_3#LLHBMG\4PQLY7'"BF*< <N&D(F.CX@283CD"A":P6I1L29.M[%IO
M@!NQN1!0_;B*Q#/@P<H7F,/C3PB\&:F+<J$6L2K[F0+*"F@OJ+<)E+Q CY:S
M&E&,054)R>I(PH^]E<6-"XDYO. PB5,,CR/.9MA\$AQU0<6#@%B:DJ;F1K8#
MKA9)M"!#/$>40S#T)X)=4W.!3I[XNI(SM48J<C*X3)XHL+!<(6NTU@!?$\\S
M^"%3".>!Y%KX4S\J.Z'X<"H21M+4C&_AJ-!.DDI8Y/B!,1"AQIF/H=0;U0M.
MCACTX.=^]Y0^_Y87]\AFF'I5H/B>G?(/PR$#G4OP3F9=;\ZH?I]'](9]^I?Q
M[!O5!W#:DP7Z04\^SU@PK#_;E]5RS*>4!+"^D<(!*US!&'Z@U-X<7GXGWJO!
MJ-DPR!H(WPL0.?OF7(L9LF8*\]6(4TH*-S!TAB/;%[A[R+.>KK"[)PS?1J3#
M&DH>"Y1L(KR;V?7-9';[.Z$\!'@WF#U2-WL!)K&14K"$7E#6.VJ"VA!3-I*/
M((S9G%B \ <>RX:\O*11*-VW34KD)7K &6"HQ $*X@<Y9U&F0HMN$.)"PB0@
MQXI"1EH$D_RVUMD+P)CI!F^-NR\)NN'98'KO,3':LAVA32#980;/9!HDC[07
M4>,\8">*$H2"W0$)VH80C>3NM)<@QKE6E/F!!\$K(C:B82[*1O*$39Q))^S,
MVT5&$(KB#7A, 3: C>VH"Y\V(KQ-G.198D8S2%TMX971"(/2Y$$[0&=983.V
M19BMT"(0U0-<N]?EZ#\0]XE/826.\KU8^A(_V%%?$0RN$34]DP>ATZ<+X1/[
MZ1>H7+J$ N=T)69$;VY_H#SP]]@B]EPRW7OE9R,!)FSW3:\["/IG9Q(D=\'2
M]4Y^/ _25L#IU>WHZO,4@Y?1?#Z!< 8B#^0QVABIE[@:1!&B$RWN@=?64U):
M'?XFMYVG^6HG7]&*Z(*=X!&?&[&R\QM>C7..H#,LP""- 8XXG&.K2Z/YV!:7
M J!XK(X&78]DH_#77N^C^ISG,4%17/J:4NG>'/B8G0>=D,T:KV!E-&]M%M#/
M!&HA8M%+#&AT4UYQ=YB+K"4)0AGZ%A"06"P4!U3HC%'QDBT3V!Z&GP4 6QB_
M1& *7\"(!!#I PDIZUNVDF#&S^91$!6QTQ3;S@*YP8.PV"@A*_7\<*G2HB4;
M+92_KDBUBGBJ$-#FT6$!2(0I>J<BB[A)#K=I#38J'.A1?X;(C]5B&F]3);$O
M5EBWL:-9FOTG6-# ;34,CJ\W_:/@='@DV1' "J=G?UUK?)B/?"1#RN8J0N[8
MPA.; :/W2!3%FXS\D3&/:RT5(-VT#KZ)^9N+F_@,$LKBH<O"*<@B8<UZX>C0
ML4U->T6T*L,"J57#BNIXE$99 MIJY:4KW!@%M+ ?CM-XO[:2ZZ(7?P<P(69Z
M"%TX^>ZHJ]P7=T;1]!$'NZS&\^PC"C^> H=:\ULN,%V2>TLV^K#,#UT2PRMR
MW$OPQ8L8!H$03B(V.5SK-)9L >'01EW![LDTCL4KME"6B[#3:]-K&_20X8AU
ME%*4M\".)BG@N%(0PSE8+M-XLF$,_\>BV_]4^QW*%$(Q.N(222V;F/"=-DI.
MG#6+.:NRXW!&Z,5#AH=M?1+38'JSS0OJB%BT<SX [3$P#\1GX,Z\XEM=59*Z
M8UU%)\HP<0 (%W-Q3![S5VLRZL./M%D0FF('QC]4CYA@.HSSQZR)E.N#XIP'
M<X1C#7M:A:;6EZR!A;UE[$CD=TB--Z @?L+;U=KAT,&^)6"M=;8*5QS4U38.
M.+#1,1?9_7 SAA [:DN>A&0IETSQW'"/F*S@73J6L 9AU)I;&2$AHR(S:A&3
MQS523T)T6^(:C+9*#><-L1*&5C;QZ4M_DV2@R[1P_\G;]ODI"OF]M!8EK]-$
MK";A7'$N6+5C-.#,<TU<1]V!D2[:#P4-16P&6QPG2$3.V)=:!!C\-B-BH1K!
M,'6#!%*[0W!;3XE**JDIE*KYE]%L<G@^FD\NU/CZV\WD:E[W05DN<2C+NUU5
M2<PV?.G#\T:&@#MK *<,P9$&SXKI*!E@2-&7(IK&\*U6,\ETN>HHXLN(SA53
MQ;#BQE8W,;-EM*9XDAT!82$\FIU% .=I&-T?SJ-U3CDO;H,X!*&/2+3S6*=!
MHT.B0I/ T:"Q^_;#]@LA6>T2-)+=M_C?A&A$LY5C.I"<YV#0&?0/A_W.2?\M
ME@O/NH<GW<YQ[ZV:)>8>89+F9BLX>>K"4/#KT6&O<PH3]CM'1X?]SNG FYL<
MY%%G.#@\Z?0'XO7;?\\FOTZN[B:8U;_^?#5]=I+(?I?ASC-J^9,"@DN3<OJY
M;B6201RF[ZRAEA8ABF0LG.;,8CM7PT8*?9R?2D'C0VE)#0K :[,=NKP^K_.5
MVSS!THPS5R2]-!UVHRUM)A(37D3R"G"SH5TZ6R+5 IZ"Y@-:RA13KZA$+Q3E
M*<E-.@Q1955DAJ#AUI76R6QQF6;)R JT&7$?PA-M'4/!Z==:F.OR1M;*H\LR
M+,*QS2F6K;-[Z<RX%85IVUGU=DA46<@D.89HG8#]!O9*ZL76?5%^JTV;)S83
M&@NF#LO*U-BPIF@/]&EHLNUSX!8QQ)ZR32Z?N&(6"!^:<-A YO ?L3R+VU(I
MV3\@>*X+\DBT0>X9L&.P09J$4K+BL;0>. G%1VB0Q$F&.QNEJX&-JT@N@E"7
MC&LSRN@TQ7Q]PAG@-%S43A/!)E"%25\QRWZ%S*\>-=!';BC3PU;?GQD@#.<=
M ^>@T1J&!>J)U_12_VS ".8RTW8=%ILPTC"&D]@.25[?CCU/+YD?H _8A8X=
MMU%4*^RH*VR#X"$\CK*O_>:.ND^O;#8"=-0-Y<X3T%]!+%(4V[,N6GTWNAE^
M$:="-E2/:S!"G!@K]0K8\J<#JLYKNPK-;DN^RRUF%T+7TE&_265M$V85PD$*
M+Z2LA&S*,X:T&>7'1<*X3L;5L!?/V)L1N7"1F'"UPIC=!DIB4S^03-798TS9
MJP4 FGM"48W^3']STIF#']G6><:V9ND']3MV!4R>1XM^BX :6U'["D*,^>*S
M?C\X!C?S1AT'W>.CX.SLB&2E%_1/SH+!T4"=GIP&)]W!GN.]YN/M![VS8WBP
MIWK#+D2S/5 <8> WQQO<S%%W$ Q/NJK7&P;]WI'+8)\$)V?]8-CKP>=!T.]V
M(0SN@^9KB,W ?PX;"51J_N+K&WR3 I,CU/'(W,/3BS2N+V62^9?IS0UV*F,R
M]PO\[RO^<3EIU<4DG61J'T5MG;:$L=18=0,;QG%[K1$@/Y@#ESK);#*?C&9C
M[@^X *?]]9ISQS.KQ(*R08@YBU:G<R7C%C<SN,WBO8QXTPO.>EU@E4VX!2?#
MLZ![=LIB].I27K_O7\C+ 9:<J-O1?[2XYXK$7&X@:%J&3QP9LCB31R3O1@CR
MN$M]\3CPE@;Z>3#XM<Z#78 G)H\/$[[8+%V@=^;<L@L$;0LF%TS+1VTQ!LRS
ML#TOKW1L<S#\K)-:D,+W^]K)[9#?X\"2G@R?"-BB3=%4>J+L2SVUI#[X:&P<
MNH  ?)EPV8W:63C=C^D5:I[*F#G234#!%!S$(R8L28*,?H$M_PL+<%>X#KD?
MDI-T.N.J)SY3<'?NJ.XN]A"2%PE[1:=XSXF+F:=&D-)V'KNJ;ITIX&Y+2EE2
M]_..@T7* Q) V3,['Y)+2-@*#" V/QF&R^_90Q/,U81(TL'U9G,B#A,HW(?E
MR*C5Q=43ZK28E1<>5&<F7+V9*K'M&=R!;=,P(^(Q90H^E+M?)6TC/#7:T2J1
M.16M6P6&?:?GQ:&XF)BGU[H,7[,&;4P<[EV3<&"UP#Q3R4WA A90>O<(#MB/
MVN M 8X"]U_LT</VS;VK/K)-IL8=S@8T:XKJ*.@-!UQ+9"^]K*AS!3-(?/:H
M5K7$ <%OW#.J\XHQ+;%9RT(5.M,Z'%_L7'=&^9@?FE)OF;(0<4+NP+!U9ZRF
M^%=K2EM.8T*H64/1; EIG@T5G/FT#TB(0ZO0WZT$<L*X_I$Z LC</H1)2A*M
M*>".M$L$O::[@51EL' ,7TM1O^[*P"9 *OC86H,CT,8=!CQV2)E.E$'X#Y!X
MZ6-RL-$0)=6@32I\$,@B3L?*)$PHJ XX'%&@$. .J;4+^68TMHWXC!.[R!D5
M/)AMD2 ?V>#;L$>LKW]BDL^JQ^T;0]RREE=,S"8$J:PV]DD78>^WB'G3XMVV
MCS=!G?)"*HK3^9BRG/JQ=+%_:NRT($>WE$*..P (1O@&&Q>4&N)3"ZG<ROJK
M._+3%!JU@=TX$D(WJL0MOY9N76 &QQK P 6NNH$_:WD._5MA=AT,9<JU"W7S
MJB1K*>?>9C4E*!8DAH00$%6D'76WQ85BS'*YBUK6 H P[S6@=%&8316''"3S
M7DX/+VU2W!>E8)$P 02_%I6.O>R5Z  ,\J'1,XB'9EQ D6"XJ9U"7(* .46I
M>PI4 2&D--M?7X3+I_M6V'==SL-EV-3O]4MD7'(I]!KO13UH@CS@Q"Y^G<QN
MIW.,%L;7\];E(3YF+U&,M@T#8RR1E D;9>.JZ$*Y-#7!7S:4RXW?T5'#_I$W
M#_^^KY6E-SQ6E]>SR?3SE1K?S6:3J_'OZG8VNII_K;.]WF71=I>S;1S1?L&@
MKK/:ZZ9;,(V=5^;BVZN[UR>[Z\P[$$>G:5C83C00^DW="E:;1/]&*N?[R&6Y
MJ?!>;(?*\W7B?C^,=^DL1W@BF4Q:))7>"<*L3X**> MXJ8CO>HIB>VDJQ ^!
M9)N\*Y7U.3Z;/,1"TDJW%_%+O:ZA#R(%>L15(LF3O!CXT*5;-&+L T+P0G0%
M5]=YC7;[.Y?-]@G]+95)N6N@38&]*L3EH&C'H8&[&.IW#_ZX]OUPL1MBZ^GG
M+[>'UY>'=W/7%H)A]M?)"+[X.AV=3[].;W_'J!)KG ]>$ZZMBW"$F&)0G]O0
MQ>^ <_B1KTHF=B93MXH\;\FIL/C#I0E^C'MM,)/4;%20MFM#??6N8Q&Q1E;6
MX/DWEPK7=/4*\84?C]$2TK#$70:<*Z5^2*P^\%7+0L(BQ"F<,(0MO">TAJLA
M#@XED]CP&S:3315VQP]ZJ+ZZ:D^M#B4; 3:^;".N4ON<[62VL4N3*_[N/<>-
MLIB8%RF@2OX__2PNFKF2%V(&#[FCDX81Z))/C_L!-W?QA<-0=#N0.%9:NE_;
M((0,I-54(&0K-+,7AN]@<R,.7LF5X'BO?[!QD8)"V4N]*"HTW*!-)TS$I<M:
M[&UU.L_A'Y>7N1S-S]T-^L28BA+N/J8P[LEJRR"+*',=[=2[IDT3PF[0>:9\
M(4)@O>TFX?>X[&U:?GYONE.SIKY+_1V$1[,@.?1$YDL/1VE6SCU9>GZ3FU&,
M70>O"^:@01(IV-<*B-I:@X3Y*M<PZ%;H-(_7-_G/5MQ?C>-QE+@'#I+6T4DT
M>J'KH-X2[:KNW%#=(M9K/K1LD+;%NJPC*#)A.RKI,+Q!7GBV2R05'XD+NEVQ
MUFW5Y_@J+#'%SE?>1&P"5Z;2]EZ$YT=D)W4SXRO3TK'6)-)U@:9]-53%3#8)
MWGV2S)-M3*?B,C?LL[KMG>"UWBQ,;GCX'# !-3*:-9BS0Q*R5,P&/B6Z1-6+
M^EYML\3&[Y7P,XX+-!UHL"@V ?GFVTC[\Y2YM$]QF$HX+$## =MAF..R!=P]
M5O=E-079)[MM$BFUXIH,N*;X]PHL<7U[<>W=(F/LA3+"850-_IJ_,-3BX[4=
MM6!LMYB!**6OS+;T?N?!H'&_W OQFB_O\%TNX-S<"8A]4X>]5T:])-(HZB<8
M^4"1SLQO-^,N;LJ:-!NKETF4<#<:3N XQ&]-^4.NHXB9C+D50I('\A?#5I1H
MISSLBB09LL>:2LSNL)%@NAJC8P4"'-R9M/R&S]YN\2,3G':#LV&W XZF7#M+
MLJ_IV>MJ;GMXN1>[OSP4 !B6*M+I(4@DR$3=1CZVKV")GO7:^1HJ605,_9&.
MV.8[,#"V:=XY\[IHCI_HRII8 P)>GI99>UG?97&3B 6J.W_<.:+<- FUCI,K
M<?3Z) E%MMAL&*VQ7]"KI]H7B[3-54=]\_RP_WH769HX@)>1+(C33[J($N/.
MA7[%S+8TW"3N#39MKXLY/%(H[.M'6;VV+]C)Y9XG-:U3#I$LG\@6%8(EO5Y+
ME.>:]Y0(O!TT+QK:["<QGG?"G!46Q#D=_'-.$)FN <-1$+LN>9[&WH= ZVO%
MM^W/]S?]TUU033?&K'OD/B'/^5Y-;M77Z_E<W4QFW.J%%UWI+IXAXP?.A&(R
M0U%>5=H+/B6/X 8MMP:G9W&,A*G>35I0&KQ*AM,9S%^YZY<6&]EW!5TD*:W3
M(J'02U0DZ;3(\6@2\EJ2:Z5CXKH#A?KL29K+(MHD3MJV$?_%/WBY,RS F MK
M;7";40(%GZ*;SHR::C=2%I1FW,E<UG=0!I3JTOY;G8#F0Z;X03<7]Z6DELDF
M"^Q;?&R^_(?B7<[W](+AZ5G0'_3H^UYP/#S!JN^KG=\(%*A3RCNLHSX\VS_#
MS<PUY4!&:O 63:#CTDUA(Y$Y;M#6,>0BH_"3D28NPWU?N3LI?*:CYI//7.Z>
MW%S/Z/U@& KUP=##NORNGYE+D/H57QA2WZ#P@] ZJ.!2@SP<H.QN*Q@5U6\_
MP21(L<52,'7;>"Y\@3=/:Z-GF);ZQ@B+CI%FHT"M=+XJPNT:.SY04 +OVI;7
M4'>[Q[SYJ45,&(!+VOW)NN85+*ETAGYBG>BE1UD,1H,N8V+44- [G<B1;L."
MTS@*)9@*@MQS;/?R@3$(718/_+)_T+KH(->$EZ""X2K+J:OE/BFI><$>&G:,
MSB9?)E?SZ:\3MC3C9]FB.NCQ+ N! <J/<F(L\"Z&/NMS1=T/!*'A"]H"Z8,0
M;2)+T)C9"WA<ZQ+%\(U4%VD=&E<X(]NK@J@);?/H!])@]FT-QI6;EL^37S;%
M1^)5)\HZ].*%UOL)9]=7\'D\X2L"UUXLWAL0^CV5>!Q";!M:C^9W],MAMQ_8
MC/=,/X<-8W%DM^&3FA#"-7P)P=]I\_"X[<)FS&LM= O6O1?>EPS0L I2]Y4]
M0PBNF(#9%C)N5!@6NJ*0VG#%ZP!>2'>'ME6 TL.XB7$EVOCW?&'PC6".PMOQ
MWT<N T'"\;VDIE00/$,S=1,0O5(2!&.,P-NT-HPHT 4-U(24>DUUSI9[5654
MUU7")?=PB1'8A88X')UI?=2NARS9N$C"E3>P(.!/V+B\CD7%\-ZZL&9?=@OA
MPP)US[HM/_R5MS/Z'FN/PWHYU""S[1K#Z95:S5=2<IN!)"7:9O2[A%$9D2)(
MS,)]3XF&3HEP(1 /X@*MUO](#D_Y/ZAWM_D6#..P=_K3!S7U,1JP]0I,S6:;
MYCL(+N9H; [Y-2,WDNBLLVDO*]EPGY(-\83YZG.C(<9=N47A2R%2D,N896[Q
M8^,6BW6PU"M!]''^QV5T2D2W;@]&O1//9_/*!=EMZG), 7BN^&5C8,53EEY3
MT3V)PK2H?ZXQ_V3=^*L)VN^J#]'A:]OF_X5&D0W%:@E*\?SN;\9JDMAL4BZZ
MKVTS.<W?YS74QE$36^ZBV)L*$4X5YA-W9Q:<><Q='FACY<JJM)6W@5.9!WRI
M**S?(B&%NA?V[3*SA;M7^'U.['M=\GOOQ=2 _U;T^FUJFLI*?D>U^U;9-WR/
M^,76]7!^/?BWL%@A&$KU$A[M=H:# \["V#_*?$NON5[D)8!-^HCOM= %#H#?
MESF$4O('+N#>>_[IOP%02P,$%     @ ;H@?4><\R1S^ @  :08  !@   !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6R%55%OVS@,_BN$L8<KX*LM.TZ<(@F0
M;+E=@;8HEFQ[&/:@V$PL5)9RDK*T]^N/DM-<-C39BTU2Y,>/E$F/]MH\V0;1
MP7,KE1U'C7/;FR2Q58,MM]=ZBXI.UMJTW)%J-HG=&N1U"&IEDJ5I/VFY4-%D
M%&R/9C+2.R>%PD<#=M>VW+S,4.K].&+1J^&3V#3.&Y+):,LWN$#W>?MH2$N.
M*+5H45FA%1A<CZ,INYGUO']P^")P;T]D\)6LM'[RRFT]CE)/""56SB-P>OW
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ME7:TFH+8T+\ C7>@\[76[E7Q"8Y_E\E_4$L#!!0    ( &Z('U'HUZ3#U@(
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M'REBWW"T_]:O^;\K%)YT:H%ZX^>1JR9%5DU[W#V.O*3J]"?W:EY>,;WATH#
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M[%%PK/S,?"CEAGY,N9!E*5/Z<RTX. QN@/6EE*7Y@ CJ7]>^_U]02P,$%
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M^T_&+?&C8R?/6L!R4M.-1SJ+'..\Q')M#Q2&SMQ^A(XP^I>OOQR6VI$X@:/
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MZ]*6J*D23=TL(>[[S=-3>%26B:/Z3Z!+,ML[R9T65>;MSUY.>-2=)*KP,\A
MIM;2-HUZV#V,N4G3W1_AS8Q<,%UP:4#@BJ#16:\3@&[F3N-85?M>?U&6)H<W
M2QK5J%T G:^4LGO')3@,__%?4$L#!!0    ( &Z('U'^M^1?D1H  ,!1   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;.U<^V_C1I+^??X*8M:SEP <
M64]+S@O0>)Q$>_."/9/%WF%_:),MB1F*U+))>YR__KZJZFXV*=F3;((]+.Z
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M+Y\CN5EM?CA=;5Y'5VJ?I=%[;6K!\(90BL8W-3F:.VDGHXQYT[2@)+1\($(
M,"P$,SXVZY3H6%9OC^2DWY=ERK.\K)H-V#6Q>TJ6^-D6[OUV+Y%24K'J/OH
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M^P@TG,0,/K60/P7H>80 ,>;H7$05,P^Y GA; AGP^"8-81$@MIC.@(B0GDB
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M]3 %')#-@]5,M-C;1V(C-#XY5MSA&\^D.8#[N1#Z=6(,M/\:QG\#4$L#!!0
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M-HQ5S<KIJ=SP;%-,+'<9Q_FG6*YPX*1,".#](L,/=K41!NH1MO,O4$L#!!0
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M=KG!\16D$<#S7 B]VQ@'W4 \^P]02P,$%     @ ;H@?4:]_<5#! @  HP4
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ML@YTOY'2'!6;X+27^W\!4$L#!!0    ( &Z('U$U\&:R+P,  +$&   9
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M\VKK"\47Y9&O)ZX43\N?<TIB*HH&^O\IY^KUHGC ]M3@Q;]02P,$%     @
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M5)F\.H:KB62E.<GF3*IST0S7ZN8"K@7J^Y(Q^3[1AV-S%Z;_ %!+ P04
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M"8NF[S43Q6O;:V9<Z<YEAX7^58 P 7H_YUSM)J9]M3^?[ ]02P,$%     @
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M<VAE970S,2YX;6RE5&MOVC 4_2M6M ^MM#4O J4*D5)@VJ25H5+VT+0/)KE
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M>KI^_8A9[FV6T*<^I<N.;B^.;TXO/E].3F]N_P%.__EU^N7?X-V$9-@/TI_
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M%K'B2Q8O\M<RW<59%H?YQSG!=+VP!O3Y?1QGJR_L34_KE[D=_0]02P,$%
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MT"=@@FQ..,T&II"H5&YS4B(("@2H 0%$X(ZE8IZ!ZS2DX78"4TZGFA-:SRE
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M&U4[C/6W! JS03]?<ZZ>)L9!]74R_0]02P,$%     @ ;H@?4>M;ZI[^ @
M;0H  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULK5;;;N(P$/T5*]J'
M5MJ2&W=!I *MM@_L5J7=W5>3#&#5L5G;7/KWM9V00@EI4?<EL9V9,^>,/?'T
M-EP\RP6 0MN4,MEW%DHMNZXKXP6D6-;X$IC^,N,BQ4I/Q=R52P$XL4XI=0//
M:[HI)LR)>G;M7D0]OE*4,+@72*[2%(N7 5"^Z3N^LUMX(/.%,@MNU%OB.4Q
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M64$B>,(*1JW\=^3+^HG<_'8[<S72,&!NTH1\K$,&5T+Z 7D57.>*//,4TE,
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MF&R&O6:C15G/2TNA<?JJEQL<D$$: 7R_$D(_;LP(UH[<\[]02P,$%     @
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MZ#%O!2951G*"<E0&BMUWR.'N/_(=OUVCQWX@\?#A=P-7'HJ;372F/Y(B-$Q
ML. X92H+Q-X)*E/Y*?;?H8Q?8T:X[DW9#R2>?UB8RE%QLZ5.61C&@,94JJ-D
MJ>P0=TY0ELI=<?<=LG3W3MO%-7\E-7&DX74AE;N29G>]51$(I#_%]8=V>HPN
MI+)&@D]/%U+Y+"%OUZ7 ^CM&MB]+\Q:F][N02QI W]+-G03Q M8 U;&WMUH'
M;5V+K*.2*."K5.6?VN5JV;4-LU[EU?JE[N;RWJM*D[>"4RH6+)4HAKE.Z7QN
MZX=)Y-U5/E%\F34H3USI=B<;1KHC!6$"]/TYYVHS,1N4/>[@'U!+ P04
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M8]71%"3"]S6J#@:9PC:L"C_+^%E-J\I'M.8YRQBMWJ#=<UMX1CHFY K;L"S
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MK.]:K_[Z-T^[QK4JFZ,_Z_ZES3\!4$L! A0#%     @ ;H@?40=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " !NB!]13:_EKN\    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " !NB!]1F5R<(Q &  "<)P  $P
M        @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &Z(
M'U$COB#.!P0  "D/   8              " @0X(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " !NB!]18*1 ]KP'   -(@  &
M        @(%+#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ ;H@?41W0I%Z9 P  # X  !@              ("!/10  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( &Z('U$KF'QV8 4  ' 3   8
M              " @0P8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " !NB!]10TJWU>\%   ?&0  &               @(&B'0  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ ;H@?4<\=0VJE!P
M:1X  !@              ("!QR,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( &Z('U&LG)?^IP4  )H+   8              " @:(K
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !NB!]17\L*
M%/<@   #70  &               @(%_,0  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ ;H@?4><\R1S^ @  :08  !@
M ("!K%(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( &Z(
M'U'HUZ3#U@(  !0&   9              " @>!5  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ ;H@?47@ 8M)I$@  :3L  !D
M         ("![5@  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " !NB!]1X6!1TX\'  "'$@  &0              @(&-:P  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( &Z('U%G(S8AU0(   @&
M   9              " @5-S  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ ;H@?4?ZWY%^1&@  P%$  !D              ("!7W8
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !NB!]1AY4J
MOY$$  # #   &0              @($GD0  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( &Z('U'H[VGX]"(   )K   9
M  " @>^5  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
M;H@?4:J9"X3- P  00@  !D              ("!&KD  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " !NB!]1#\.#\?H"  "R!@  &0
M            @($>O0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( &Z('U'I-+R^=0(  !T%   9              " @4_   !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ ;H@?43MDPC1X!
MS@H  !D              ("!^\(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " !NB!]1.X'[7L\$   <"P  &0              @(&J
MQP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &Z('U&O
M?W%0P0(  *,%   9              " @;#,  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ ;H@?437P9K(O P  L08  !D
M     ("!J,\  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &Z('U&.JI$.DP(  !<'   9              "
M@:_D  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ ;H@?
M46*Z#S=J @  B 8  !D              ("!>><  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    " !NB!]14/CQ-W<"  #X!@  &0
M        @($:Z@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( &Z('U'H&DO;60(  -(%   9              " @<CL  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ ;H@?43J4Q*;U"P  V$T
M !D              ("!6.\  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    " !NB!]1ZO7X29($  "O&0  &0              @(&$^P
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( &Z('U%X@PTI
M @,  #(*   9              " @4T  0!X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ ;H@?40>4_Y5 !   A1,  !D
M ("!A@,! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !N
MB!]1PG0.&YH#  "I#   &0              @(']!P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( &Z('U'K6^J>_@(  &T*   9
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M970T,2YX;6Q02P$"% ,4    " !NB!]1)L!9MFX,  "F2P  &0
M    @(%B' $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M &Z('U&T'5B+R (  .<&   9              " @0<I 0!X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ ;H@?43OGYD]P @  AP8  !D
M             ("!!BP! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    " !NB!]1%1@O_[\$    &@  &0              @(&M+@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( &Z('U'1*K2I-P(
M ( *   -              "  :,S 0!X;"]S='EL97,N>&UL4$L! A0#%
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K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     U #4 :@X  ,8^ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>201</ContextCount>
  <ElementCount>387</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>91</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS` EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS` EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedCashFlow</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ORGANIZATION</Role>
      <ShortName>ORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - INTANGIBLE ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/INTANGIBLEASSETSNET</Role>
      <ShortName>INTANGIBLE ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SHAREHOLDERSEQUITY</Role>
      <ShortName>SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - GEOGRAPHIC INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GEOGRAPHICINFORMATION</Role>
      <ShortName>GEOGRAPHIC INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/INTANGIBLEASSETSNETTables</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INTANGIBLEASSETSNET</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITY</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INCOMETAXES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - GEOGRAPHIC INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/GEOGRAPHICINFORMATION</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/InventoriesTable</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SharebasedcompensationassumptionsTable</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - INTANGIBLE ASSETS, NET (Details) - Intangible assets, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/IntangibleassetsnetTable</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Details) - Intangible assets, net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INTANGIBLEASSETSNETTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - INTANGIBLE ASSETS, NET (Details) - Expected amortization of intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ExpectedamortizationofintangibleassetsTable</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Details) - Expected amortization of intangible assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INTANGIBLEASSETSNETTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense balances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/AccountspayableandaccruedexpensebalancesTable</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense balances</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - SHAREHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/OutstandingStockOptionsActivityTable</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Non-vested Stock Options Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/NonvestedStockOptionsActivityTable</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details) - Non-vested Stock Options Activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - SHAREHOLDERS' EQUITY (Details) - Stock Options Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/StockOptionsSummaryTable</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details) - Stock Options Summary</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITYTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INCOMETAXESTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - INCOME TAXES (Details) - Income tax expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/IncometaxexpenseTable</Role>
      <ShortName>INCOME TAXES (Details) - Income tax expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INCOMETAXESTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - INCOME TAXES (Details) - Income Tax Rate Reconciliation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/IncomeTaxRateReconciliationTable</Role>
      <ShortName>INCOME TAXES (Details) - Income Tax Rate Reconciliation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INCOMETAXESTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - INCOME TAXES (Details) - Deferred Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/DeferredTaxTable</Role>
      <ShortName>INCOME TAXES (Details) - Deferred Tax</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/INCOMETAXESTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - GEOGRAPHIC INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - Supplemental cash flow information related to leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details) - Supplemental cash flow information related to leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) - The maturity of lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details) - The maturity of lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="bmra-20200531.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bmra-20200531.xml</File>
    <File>bmra-20200531.xsd</File>
    <File>bmra-20200531_cal.xml</File>
    <File>bmra-20200531_def.xml</File>
    <File>bmra-20200531_lab.xml</File>
    <File>bmra-20200531_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001513162-20-000185-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001513162-20-000185-xbrl.zip
M4$L#!!0    ( &^('U& K!EG#Q\! &3Z#P 1    8FUR82TR,#(P,#4S,2YX
M;6SL?6MSVT:RZ/?S*W!S=D\E=2F9 -]VXENT'HZRLJ05Y3SVUBT71 Q)Q"#
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M.K,0;/INXK+13]\A+1R%&#_^YAG?O7E/XPP=VV???,4T?OIN6/]R[CI3]9?
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MD_ZGXU*"5=( R5OU04:[\F.O-X$[G.@>,^[8<&([EC-^2M/ @1$ N?-+EGV
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MWY@[-+WEDJ2=)]X*\+':;K3J:2Y9";H,P3/_/F5L+%E<QNYOM+)&O;M\8?F
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M]!8S15'0KYA_HGL3B@P8S/CP!"8DV,DQ.PU]\Z%,7FAJO4Y3WO;B$&2>&I0
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M=>OI;P8O.XY14_ 2(4.: J,5H)P"R;@@K9412& D().\.M@(Q+H8W/1P80]
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MQ]H_Z<UF^[CQS_ @P :S(N':X2$2Z&W Z2Q,V#A6KE'YFG2&731DY=B1I9(
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M7=@-L ((Z1P7U&3 *W(P2!]<O)J(WJV\Z2*\AZGTBFV"A0#@ZT_PA252+[V
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M)XQ23YD_<0SO![R3@KX72$C+_)L2^@FV8YG1>!H(^ELD;1],]BC#CAPGCE=
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M ZDW@W"DYD/Q)^4TUH@CT\,Z>LAP&7H1P3*]3$@>N=(&>O$X]>HSP-LWVB\
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MY?@N0IS>%'!F1ZML/-IMEU7/-)7_O!-X-QV=EF=TZ?$ED?-V.,LU1?A(6AT
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MZ$:)MXD<$IXV$EYLP2.?K?&8#>1P%"+A^NKVL_B!Y]RYEA/(<5XV3\[EC_-
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M_#?&:*,T_E0\)!U92)X3QNU4Q[3?_BMLS$3.&<]^PHC-L\6&B>$APG!4PUT
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M*RU,I1(/D3[@$Y*K<P<$$7-[X&])+1#2 FR8)S$SODHUZ0KG,$LUG 00!M8
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M1.,[YQ%TM-.>EL^=['#EYS@+/<L!7AK5XD@B'2P^WC02?A)WB($"*;@#NVO
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M._==@I)39*OUH 2<;C#)HM71%OCL^0"F/(R@GCPGY :8?W)2=R^ESA_=^PY
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M354:&1TZ<3-Y58)5,7/+2#4HZFW?Q^/#KB1NR.]H)6?FMN.5C%(B$NU6PYR
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M-UQTWP*V\@$*)QBT+CU,*/>Z/MB(< ;@Y=C W(,;^Y[O$#J[RUZ* V\_(Q\
MU8GKT6=F!-;A&81.KJ$A\DV/L;#ATH6#N(6BXQ#=?K1H52EX/!R(5YVB ]HH
M4\$W24>O%L"HPV)Q;XO>1(3U@IMI@&13$X("X#+W- #:0"2"W@(F!COC#_\#
M ]+.R/";"\$0K%]'1?*C_E"7QMS@(6;)"\19EL:0"XJ+)N]];V([!ETRVBWF
MU0[)&+73V'!U>)?R >C<]HHB\6%D/.'GWS[X[NFCILW.KJGK--!>+F%$T+A
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M*Z_FW@>+2KKXZ->>NL;?,#3S\>D78VUJF*]GTO_59K8[[^#CES7V'^[8X\>
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MG'V0F;39S+%?P$7Q")"X6Y,;+<G]KZ\Y\#,AGJ3!_Y(\00E=ZREMQ@B!D$R
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MYNI2/QG)J<'AR9%/W:_X'I22;1N,!88AGKZ N4) Z6$18K&]-@ZTW(C/S9C
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MW M=RF1XE2EP2JVM4H$3<=6<X,12'&H)TA-<$IYAMLZ(W>785'!BUWOW7GC
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M>H-^,00R8[\#:W0F_9]N8PS_?,2#"!XY17@!$Y;][&BSCQ('\@SO" :+Q;X
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M*=L3QN?(=<7%,)NU^89O>;7XT0?H4%&_0:DWF_-?*9SFS)(QX"9",CL2+=
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M[:SW"1ZI<4[QYBM[U1FT7373[JAM[:E)"@])[QB"('FVW<&41<*@>37)>%S
MIN.\!(>HB&"M=8V@EE")0:\*J1P?KZ%E\7U8[YBAQ=>NS0FR$76X@!D,!"B9
M\A>3K-V6A(PF(DE!&"66NP\@A:P?O,B^RRS9PE[1@T+"L@7JS3X+D92#F)+5
M_J?)B%)'$!.S(42L=CQ.1<)!9PZ*#>Y$BM$)Z]$J6=$';..D*@J'MUA8]?V4
MIZ('O\6>[4#"/N$C$,V0R9)CM>4@8K&ZYRNYW*87CV3@*#&VA.TK-+=E$5O&
MQQ(^4NM0G[S.&5.1S0>93BY3*_ W;'[X#HXP"1:Z;L <TDMD8WY -&88R5;\
MZ>TE=,;85%Z,59_ZFE=2-#"5&H#B<2J[PN0G1"EC9 MW7RI%:^BHS?:2 K1/
MC%+[F_22-?(N-?H%^@1V\H[-ZA2MG(E$;0NY*2#)38%3=G94[I9EB=,<:PH@
MD?!Z20(E#@_1CML9&\KHWO8KAHR%=TD5,(+S/-Z_?,3. ;*Y4FV"*/,&79>P
M__8A0=A426T=:NN-LR4MI!8>,Q95-.RG1/<]5;-\?D$":Z%/,)]SF>\6MY3O
MT41I6)NA-%-6/5A"^C\Y3/$P5Y+1>GQL_%CDTFE(%:QDB=,<]M9C*!-'R;57
MGHK\7D?F0+O8'3HCUPK/!J@I/\R0M^4C*QM+B;>F1->Q7/3.KO@& 9E!/X9U
MQH#<*UKZRI&YU4,N'U'Q12K5*Y2OIMY)<0O8*K<LTR5M-5TB](156!7N-F%!
MDO!Z]2[T?_;L\.Z] 3.5J(H]29G@4I.B;>E-Q:MQ4@XLX5'&\@2E' 3&T4%@
M<?(AH*AX:UIW^=;@J 1> 4M':\0J@5DDCX!4'#Q+C6RE*RN(3\#$:SE7VBU+
M*W(*5-$*8A5-MM$]K@M^8 #':@Q ?)ZT'MHSY#\OLK. #J?@NU)V=,2A.+9E
M40^[:8+]?GEW^O_Y^?+3X5]_?C&F[ORK?7AL/A[-[K\N[-NN^W!^1(Z/_K?_
M[?9F0:VCF?&X:_WA_+KWZ<?!XWA\:XVZL-\:?+Q]O+U#X^[5:_/"^4@N[RX_
MP)?.JVD;S?J[8#XRS^ZF],(<&)U7GWX=70+:_>/QXMU9?VS<'1R?OMX[GO?>
M'[Y[18]__?AC<FO?@:_&3=]$=W]\/'^)WG=-]UOW6^?R['.[;WW?ZWT9NH<_
ML+G[^*5SM/>M>WW]^>[5Z_$CH=3N['\S/PXZ7]^?OF^?6P=W^_M?R<=3<GW>
M@\.COQJ=ZT'PF,$SLNA4JPI->4]638' 9S[=_UIO>(K)W<(TL!RN(9=22HQ7
M1<:>#JB'P[C YQ5<$E"&M!VL[F5*8BZX>#9T *D7T-9#:2%-GA?7Q< /C>"E
M,B/PQ#WUHD;24R5O^=)Q47Q#7@\EU>JF*^W7J.C:&TR37KF';'+EU=K<X+;Q
MPT6\;B=YL9^238Y<H9MJKAG,)W8Z\E%=W5=<(Q%<D5?KC;<EI&_F4E155BO<
M82O1"YTA&]B&+B^4)KVT%_(6^5C+!H1F4$\8W:5Q[0ZI0= 0+ITF$*R"YK>R
MJ3XE@\=H(;0 1E+O>HG+ZU'J\E>"KD8=S 8*<;@;2UXWHV@GO)0*F^E:<LBM
MC+?\,H=4^9&EU<GPD] M';(E4)7Z5LR3M-@&,#V=0V(@NNQ'Y7.8+O09<2A
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M*E\OK<//PWC.X065C"L_M5!-D9^"^\+'%@0SIS<M+GK(6N?!\/]02P,$%
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MM#* THFMJZ$-_,9;%(0X^BO)_J"C[EBU/,$F ^3[!9M*_K5O3_D$P'R2VN8
M$(N&ZD,-H */8*3%EZI$D99P(7XQ\3$)P+F4W +Z0DJ[%08;GB:%(52'7H<X
MC!21UR,1H4+NLA+IQSA8HZJ:T>HB*(UI(-HHM.QSN,L Z+W#2VX&\>:ON^DA
MM&$^N1#9WRR"AXOLPRF\V3_VT2T,:.*\*@QL<>+:5;83NI9>A2V,>-*P[L]>
M>W'RA),@CI:=]%"B%^:*D8T<&:7PKH(#Z.[HUG4<#_6M,!+&7?K@?D"C^>L
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MR&NAJH3B6X45_;9%*_IMU8K6GQ"&L(O"3GTO3TV'0@XY$]6,ZY\]E Z!/+#
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M-BW@7$WU7Z]IM/-[)ZL)HL@35Z,;T"9>=A1;W@SAU:GOW,+3:)O2&A%UKKD
MEPW4D*>WHKV8.!B+=.VDUQU%*Y\?M& "O?)<M$YO%(#.Q<Z-^FL\N.Y?<MWY
MA'Z!-YJ'ON4ON:Q($FYN@D>$TY_<E0MWRP3%KXG\.^WG5UVRRW5.\W6!5J;O
MUNM6*=P^OU^SPAW(+E<XS?<98QS8"#GA%9E]8_M8/='6W4H)X)A+4'<UR,*3
M-^(2A2ZADCZO039R'Y S\@O/<D",@!0#K?-(Y.#-I<P-HA\KY\1.$,\H,2[
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M*W5VUXPE,!X?'[^YS]]R?V,'JXL$BNG=Y;3_ZQV9:O\W.M]L?B_5;B2J!SL
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M]REPOKD).U9J2[+;;L_,[D5)*G77K*325)7\&,>$@R)1$MTLLDRRU"I_^@/
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M?6%[QRVAS\;%5L$T:&< P35$)LE;II'[<;""!30V)H_R*/S95T*REB#!38_
M$N(;6F "WOY?Y"M'X3-$BQ*YQ/JGDS<G[\#6B<$S)G@$WGY[>O3UV7<@>7)(
MLO N?8IB_W?H'8&OSK(_^4F"MW7DGLDNQ?5[\&DM<%)PX^S!5Z='6:TA_/<P
MHA&2(7#Z'?E[:RB[T(.)_QCBK=@1IE^3O>(!OD:2OCM"@R%4WAZ=G)S@_\^E
M.:(*6V?>O*&;CR6$*F.OD[-\%8?U>1Q<O:'"J\.Y.T[[2?>S,(5H,M,9F;IY
MC/^+ S?G^Q6B,7GQ![']TKS-;G=EQ>+<]DCWH.@/<'/P,^[P+ZL>IJJF&_$5
ME2G1W0>7E70N B=)YFL"\J&PQV9F%FQ,.5A.!VZ&-R^DX2&N;-9-8FF-6BR)
M.MH.-U1K9O'.B><Q8>01"WD'XR5>48;W-YB<#>^3Y:02.B;+;#5'_0'I6"\^
M -#.,UNHO[!JU-14SUY+N9-D(T%95CAZJC)%A5$,,A*Y,A$10*@(U?I'U6N7
M4Z<F%T(RF92N[?"FIL71^%5XCC"REJ6U[;!^LT%&J6RP4>>A[^VGHNV@R21E
M,[*.H.I)[$3VVS'9_'[4=-+EJFF;>.8AFS(#.3>#&6UL*12__6RO/IZM-TU]
M(B35!M[O@C*OHA>FH%1G:1E/-5$4056+^HP-6125BN!U. ]]8>PV0LZ1H4AL
MC9>]<&PEA"R>;B/YW8]U@+7UR4;6P51HQ ])18<FT?M:V#>#;A-8C-H>0B)&
MCH&D1)'%33T GALEJZ5?9/54ENJ0FH@.46=\RA2%PYX%M7@87,\.>;.">:19
M<6SRI\8QSU_!V>&12&VG]%=P>GKT[=?HK^^R0YCOCK[Y]MNCTW?OFIZ5U"E(
M^S#%\D:,!8_#@\K6%'<[]L[)F0P@RK UN[67D$@"S16.Q>$EVQ!3B2[)SHYN
M*+M&WT10B<?.>/8%0Q IV\D+)=E%ETQ\0C1ZS:2+%MGAPA(L5H9//AABJ$#H
M(")AWSR)0A*\,6L'M5I$!XY%</G9!I$X$D%%$BT,,18X">(0PBG0KR#O>>1I
M'">X<WQO%EXX6S]U!JD&PV)E^F8?70S6A9RR-<!5=H^1\^1F'6S?".,KKG'[
MBS-B?>!452W(A6/\)%\,GV"8H!W++'2C#;R.$ER<9+Y>.2^# $I1!*,>E*)P
M$O7Q2(%J<C.LI ,"1&(TM?)4<, HB2<]59HNV *FCA]";^K$^,6BI%&-;^V[
M_B W-R2XF@S#BL61JM9(6MH%G[PZZWB3''^'>!I9J7$971@G6:[>$+"B<+%Q
MA:PM!O<*!_'&\N9_=K91\E=22C&U'>1BZZR9,4<=;.]+B^2;;G1Q: D%YTZ
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MQ>.,W? AMRT1SENOIG6ZV0;1'L(%#(@!,HUJ#O\18)DM'1O!!*QN[:;&Z,*
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MWU.00V(;MBLZO6K,G RPVT1+PD-D!3>GM*,73.<X>QJAS@S4N.$WX.OM<HZ
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M:8"]O.9=F"-PXX?^9K<9PSYN8"SV5 M53@/CN+_<WX!$,?\REE^MA$5$_^@
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MJ)VV)!>(:(S?@/;@RW_#_C:EAW3M'(D<2"%P/K/&@+0&J+G=T 1#,P?>)66
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MJ'&,Z\UB#_E\7S6Y<_8DDQ_?V+C=X7I8\W4F67X;Z'?H#9("V+N0IK^5WD?
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M(2-U'CFQEY'46'.H!(R[F3QI!(L.67-()Y"U'P6"9/336G*8H]?-;9O^MD-
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MFO9!$6-H1BURL@M2)TSY4WO8SJKK>"@,S4!31F6RXAGK[):VXE$;V\T3Z'9
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M&3:+S)J]/>/>3H0LTJ]Z#[1R*&8KVRJD*HX01O<_MV$*W$5>[&#T;%3)J7S
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MG^M.?+'ZTQ7VPGLN7I8^/,&;CWDIL8X-ZH^PE8>KJ*#]1]X^0AX9P,#)LR.
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M.WT'+9T.Z.44T<2)]+YX$"L'KP@8E#SU S;AN@-Z*FBS (PO(#(<ZBB"FT7
M;4B*+_"9R-0V+3H[O_4]WWAKH?I&J+VKW\Q)?( X:<'X'B \08D;>GQAB":S
M+<F?<')[2:8];CXW_'9]V;3Y-FO=R;UB%+STW;@9AXZ'!&'<QTBF=*]:]C$@
M8\45H R<$!(\S%5\DLAZ]5*%6K41?" YB/H"/EE F4F\SXNLS0+5<[I*T9H$
M":W9J( N2;DB3LJ^LA,FF_##D*$0=32>E2M]- ;!)%1H2-\*$F==3T2!(%+%
MA9QD.6-" 4:07M&?:LC0;%\^"<Y#=3'4$\L0E;>&P<P2EP7,ZT#PY<S]NH9$
MW9H\9&&2B6$$<;5I!X\92ESML4'1O-5$Y6Z#S>.^'Y1"RN0[I]1#9Y/W"Y@/
M4$V0ODF? M87E^(*U]>6\MU"AE6@(,5@?&EGM<S)&A>ED/LF7&3L7]U^<DD/
M(5VC*)$FO@E5HLR*\UW3BNNK;MZ__,RK39T]/>;+,VA5%1>F,Q6=$F[$+,JZ
M52'HW*_+Y,(S!,]]!6-P;\DK^4R;1++;[F2KD0O^5/.EPLH7?RZX1G"U#0#G
M:>)).C'K,_L!T+E%/T+U)[8> @V1!@?R8G@B)U5&CL4P1V[+$85!F_>^%_E1
M:84ZZU '?S W$1H&TPF9W>R4SM$@95&!,)P=U,W'=?5O9"V"5=L<XT5*6?$<
M46[@IYXR;RR3W23@K0#8E7RE\:),7]G;,J(C%BQB?3"#A;H6NTS\&6N(E2;S
M90K9F  /X-MWA2!N8*.;ZU)E-#Q4;59<EVV="VJ74$OBU)%/D  HSM^\U*DA
M@ BGMR%K6A)G\%)P&GT#R21,[)OH"DZCJ]14=>W/5;52^"[WO'[.EWQV-X2;
M-OS:]G.".(WB9UY"NRK0^E;;O,S!7@?G;U0AKIZLE.O!='<I;@(!1=&(R6H"
M<]+T](II238]%S:V+=Q<$U\/X0MZ%K^:SZ1GK#L;]W/#U[OB0[YV7N[>].<%
M4PLP6"&Q?S*&2$R6\<PA/H =/5@_B6<\ AH\>'CL,6XOF;-_;;>6<J$-1B86
MYU3J<5?8(1RDMHN7M4J=5/^_+B^W3T7UPKG>602JFEF#O3&KO 7UV2S4R15#
M7TN3 Q--LB,Q9B++* ULI&6CK; K7\S9KGVLZOQ/OOI<"E/2ZN,([K3F_<N@
MC<\=J/CABQHSKWKSP!A9B[TF3$RN'O"+)[VS3\5(_\U^6O'1'C*6]T+N2!B
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M47:F+4UFZMPCD%SOV(G"G*FI.*NT$WL&*54)912JF"MTZ5C)!NN??@TL-&F
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M<9K12A)"(F,"+ *IIT/T1]S-04H9:F8>5&W$LNP(#>S*TD-K61U!/XJRX*=
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M2XP,L[*@UK?A6$"4:E&-=WM7]13*B(ZYVUU0&4\35/^61$MI"EA+F9$!5.&
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M5PTD]5AEC< )*YK3QXVZ]IR<F7F;E[:;#3!QJ[B33)8(<?PFS3&A#6,@@@G
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MHJ^<<B(,KY7$2!");153G0'RTQO,$,Y%P?_Z_U!+ 0(4 Q0    ( &^('U&
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G+3(P,C P-3,Q7W!R92YX;6Q02P4&      8 !@"* 0  ;F\"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
